Original Article
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
N Engl J Med 1999; 341:709-717September 2, 1999
- Abstract
Background and Methods
Aldosterone is important in the pathophysiology of heart failure. In a double-blind study, we enrolled 1663 patients who had severe heart failure and a left ventricular ejection fraction of no more than 35 percent and who were being treated with an angiotensin-converting–enzyme inhibitor, a loop diuretic, and in most cases digoxin. A total of 822 patients were randomly assigned to receive 25 mg of spironolactone daily, and 841 to receive placebo. The primary end point was death from all causes.
Results
The trial was discontinued early, after a mean follow-up period of 24 months, because an interim analysis determined that spironolactone was efficacious. There were 386 deaths in the placebo group (46 percent) and 284 in the spironolactone group (35 percent; relative risk of death, 0.70; 95 percent confidence interval, 0.60 to 0.82; P<0.001). This 30 percent reduction in the risk of death among patients in the spironolactone group was attributed to a lower risk of both death from progressive heart failure and sudden death from cardiac causes. The frequency of hospitalization for worsening heart failure was 35 percent lower in the spironolactone group than in the placebo group (relative risk of hospitalization, 0.65; 95 percent confidence interval, 0.54 to 0.77; P<0.001). In addition, patients who received spironolactone had a significant improvement in the symptoms of heart failure, as assessed on the basis of the New York Heart Association functional class (P<0.001). Gynecomastia or breast pain was reported in 10 percent of men who were treated with spironolactone, as compared with 1 percent of men in the placebo group (P<0.001). The incidence of serious hyperkalemia was minimal in both groups of patients.
Conclusions
Blockade of aldosterone receptors by spironolactone, in addition to standard therapy, substantially reduces the risk of both morbidity and death among patients with severe heart failure. (N Engl J Med 1999:341:709-17.)
Media in This Article
Figure 1
Kaplan–Meier Analysis of the Probability of Survival among Patients in the Placebo Group and Patients in the Spironolactone Group.Figure 2
Relative Risks of Death from All Causes and According to Demographic and Clinical Characteristics.Article Activity
- Article
Aldosterone has an important role in the pathophysiology of heart failure.1-4 Aldosterone promotes the retention of sodium, the loss of magnesium and potassium, sympathetic activation, parasympathetic inhibition, myocardial and vascular fibrosis, baroreceptor dysfunction, and vascular damage and impairs arterial compliance.4-8 Many physicians have assumed that inhibition of the renin–angiotensin–aldosterone system by an angiotensin-converting–enzyme (ACE) inhibitor will suppress the formation of aldosterone. In addition, treatment with an aldosterone-receptor blocker in conjunction with an ACE inhibitor has been considered relatively contraindicated because of the potential for serious hyperkalemia.9,10
Consequently, aldosterone-receptor blockers are used infrequently in patients with heart failure.11,12 There is increasing evidence to suggest, however, that ACE inhibitors only transiently suppress the production of aldosterone.7,13-16 Furthermore, treatment with the aldosterone-receptor blocker spironolactone at a daily dose of 12.5 to 25 mg in conjunction with standard doses of an ACE inhibitor, a loop diuretic, and in most cases digoxin is pharmacologically effective and well tolerated, decreases atrial natriuretic peptide concentrations, and does not lead to serious hyperkalemia (defined as a serum potassium concentration of at least 6.0 mmol per liter).17 On the basis of this information, we designed the Randomized Aldactone Evaluation Study (RALES) to test the hypothesis that daily treatment with 25 mg of spironolactone would significantly reduce the risk of death from all causes among patients who had severe heart failure as a result of systolic left ventricular dysfunction and who were receiving standard therapy, including an ACE inhibitor, if tolerated.
Methods
Patients
Patients were eligible for enrollment if they had had New York Heart Association (NYHA) class IV heart failure within the six months before enrollment and were in NYHA class III or IV at the time of enrollment, had been given a diagnosis of heart failure at least six weeks before enrollment, were being treated with an ACE inhibitor (if tolerated) and a loop diuretic, and had a left ventricular ejection fraction of no more than 35 percent within the six months before enrollment (with no clinically significant intercurrent event). Treatment with digitalis and vasodilators was allowed, but potassium-sparing diuretics were not permitted. Oral potassium supplements were not recommended unless hypokalemia (defined as a serum potassium concentration of less than 3.5 mmol per liter) developed.
Patients were excluded from the study if they had primary operable valvular heart disease (other than mitral or tricuspid regurgitation with clinical symptoms due to left ventricular systolic heart failure), congenital heart disease, unstable angina, primary hepatic failure, active cancer, or any life-threatening disease (other than heart failure). Patients who had undergone heart transplantation or were awaiting the procedure were also ineligible. Other criteria for exclusion were a serum creatinine concentration of more than 2.5 mg per deciliter (221 μmol per liter) and a serum potassium concentration of more than 5.0 mmol per liter. The institutional review boards or ethics committees of all participating institutions approved the protocol, and all patients gave written informed consent.
Procedures
After the initial evaluation, patients were randomly assigned in a double-blind fashion to receive either 25 mg of spironolactone (Aldactone, Searle, Skokie, Ill.) once daily or a matching placebo. After eight weeks of treatment, the dose could be increased to 50 mg once daily if the patient showed signs or symptoms of progression of heart failure without evidence of hyperkalemia. If hyperkalemia developed at any time, the dose could be decreased to 25 mg every other day; however, the investigator was encouraged first to adjust the doses of concomitant medications. Follow-up evaluations and laboratory measurements, including measurements of serum potassium, were conducted every 4 weeks for the first 12 weeks, then every 3 months for up to 1 year and every 6 months thereafter until the end of the study. Additional clinical laboratory tests were also performed at weeks 1 and 5. Serum potassium was also measured at week 9 in patients for whom the dose was increased to 50 mg. Study medication could be withheld in the event of serious hyperkalemia, a serum creatinine concentration of more than 4.0 mg per deciliter (354 μmol per liter), intercurrent illness, or any condition in which such a course was deemed medically necessary to protect the patient's best interests. However, all patients remained in the study so that we could track hospitalizations and deaths.
An independent data and safety monitoring board periodically reviewed the results in a blinded fashion. Event committees whose members were unaware of the patients' treatment assignments assessed the causes of death and reasons for hospitalization.
End Points
The primary end point of the study was death from any cause. Secondary end points included death from cardiac causes, hospitalization for cardiac causes, the combined incidence of death from cardiac causes or hospitalization for cardiac causes, and a change in the NYHA class. The effect of spironolactone was also assessed with the use of six prerandomization variables: left ventricular ejection fraction, the cause of heart failure, the serum creatinine concentration, age, the use of ACE inhibitors, and the use of digitalis.
Statistical Analysis
The analysis of death from all causes (the primary end point) included all patients, according to the intention-to-treat principle. Kaplan–Meier18 methods were used to construct cumulative survival curves for the two groups. The primary comparison between the two groups was based on a log-rank test.19 Cox proportional-hazards regression models20 were developed to explore the effects of base-line variables on the estimated effect of spironolactone. Formal assessment of efficacy used a group sequential monitoring plan with a Lan–DeMets21 stopping boundary and an O'Brien–Fleming22 spending function.
The sample size was calculated on the basis of the following assumptions: the mortality rate in the placebo group would be 38 percent, the risk of death would be 17 percent lower in the spironolactone group than in the placebo group, and approximately 5 percent of the patients in the spironolactone group would discontinue treatment during each year of the study.23 The power of the study to detect a difference between treatment groups was set at 90 percent (with a two-tailed α level of 0.05).
At each of its meetings, the data and safety monitoring board evaluated the available data for evidence of efficacy and safety and calculated the cumulative type I error with respect to efficacy. In two large studies of patients with heart failure,24,25 the distributions of the time to death were nonexponential; therefore, the computations for group sequential monitoring of mortality from all causes were based on life-table calculations of event rates. The critical z value required to establish that treatment with spironolactone was efficacious was 2.02, corresponding to a P value of 0.043.
Results
Randomization was begun on March 24, 1995; recruitment was completed on December 31, 1996, with follow-up scheduled to continue through December 31, 1999. However, at the fifth planned interim analysis, the observed effect of spironolactone on the risk of death from all causes exceeded the prespecified critical z value. Hence, the trial was stopped on August 24, 1998, after a mean follow-up of 24 months, on the recommendation of the data and safety monitoring board. The analysis includes all events through midnight on August 24, 1998.
A total of 1663 patients from 195 centers in 15 countries underwent randomization: 841 were assigned to receive placebo and 822 were assigned to receive spironolactone. As shown in Table 1Table 1
Base-Line Characteristics of the Patients., the two groups had similar characteristics at base line. Seven patients (three in the placebo group and four in the spironolactone group) who had a history of NYHA class IV heart failure were in NYHA class II at the time of randomization. During the study, 414 patients (200 in the placebo group and 214 in the spironolactone group) discontinued treatment because of a lack of response, because of adverse events, or for administrative reasons. Treatment was stopped in an additional 19 patients (11 in the placebo group and 8 in the spironolactone group) because of the need for heart transplantation; 2 patients, both of whom were in the placebo group, died after heart transplantation. Patients who discontinued treatment were followed by means of regularly scheduled telephone calls to determine their vital status. After 24 months of follow-up, the mean daily dose of study medication for the patients who continued to receive treatment was 31 mg in the placebo group and 26 mg in the spironolactone group.Survival
There were 386 deaths in the placebo group (46 percent) and 284 deaths in the spironolactone group (35 percent), representing a 30 percent reduction in the risk of death (relative risk of death among the patients in the spironolactone group, 0.70 by a Cox proportional-hazards model; 95 percent confidence interval, 0.60 to 0.82; P<0.001) (Figure 1Figure 1
Kaplan–Meier Analysis of the Probability of Survival among Patients in the Placebo Group and Patients in the Spironolactone Group. and Table 2Table 2
Relative Risks of Death and Hospitalization.). A total of 314 deaths in the placebo group (37 percent) and 226 deaths in the spironolactone group (27 percent) were attributed to cardiac causes, representing a 31 percent reduction in the risk of death from cardiac causes (relative risk, 0.69; 95 percent confidence interval, 0.58 to 0.82; P<0.001). The reduction in the risk of death among the patients in the spironolactone group was attributed to significantly lower risks of both death from progressive heart failure and sudden death from cardiac causes (Table 2).The reduction in the risk of death among patients in the spironolactone group was similar in analyses of all six prespecified subgroups as well as in retrospective analyses performed according to sex, NYHA class, base-line serum potassium concentration, use of potassium supplements, and use of beta-blockers (Figure 2Figure 2
Relative Risks of Death from All Causes and According to Demographic and Clinical Characteristics.). The estimated beneficial effect was similar across geographic regions.Death from Cardiac Causes and Hospitalization for Cardiac Causes
During the trial, 336 patients in the placebo group and 260 patients in the spironolactone group were hospitalized at least once for cardiac reasons (Table 2). In total, there were 753 hospitalizations for cardiac causes in the placebo group and 515 in the spironolactone group, representing a 30 percent reduction in the risk of hospitalization for cardiac causes among patients in the spironolactone group (relative risk, 0.70; 95 percent confidence interval, 0.59 to 0.82; P<0.001) (Table 2). Analysis of the combined end point of death from cardiac causes or hospitalization for cardiac causes revealed a 32 percent reduction in the risk of this end point among patients in the spironolactone group as compared with those in the placebo group (relative risk, 0.68; 95 percent confidence interval, 0.59 to 0.78; P<0.001) (Table 3Table 3
Relative Risks of the Combined End Points of Death or Hospitalization in the Spironolactone Group.).Changes in NYHA Class
Three categories were used to assess changes in the symptoms of heart failure: improvement, no change, and worsening or death. The condition of patients who were in NYHA class III at base line was considered to have improved if they were in NYHA class I or II at the end of the study and considered to have worsened if they were in NYHA class IV (or had died). The condition of patients who were in NYHA class IV at base line was considered to have improved if they were in NYHA class I, II, or III at the end of the study; other patients in NYHA class IV at base line either had no change at the end of the study or died. In the placebo group, the condition of 33 percent of the patients improved; it did not change in 18 percent, and it worsened in 48 percent. In the spironolactone group, the condition of 41 percent of the patients improved; it did not change in 21 percent, and it worsened in 38 percent. The difference between groups was significant (P<0.001 by the Wilcoxon test).
Safety
There were no significant differences between the two groups in serum sodium concentration, blood pressure, or heart rate during the study. The median creatinine and potassium concentrations did not change in the placebo group during the first year of follow-up, the period for which the data were most complete. During the same period, however, the median creatinine concentration in the spironolactone group increased by approximately 0.05 to 0.10 mg per deciliter (4 to 9 μmol per liter) and the median potassium concentration increased by 0.30 mmol per liter. The differences between the two groups were significant (P<0.001) but were not clinically important.
Table 4Table 4
Adverse Events. lists the adverse reactions in the two groups. Serious hyperkalemia occurred in 10 patients in the placebo group (1 percent) and 14 patients in the spironolactone group (2 percent, P=0.42). Gynecomastia or breast pain was reported by 10 percent of the men in the spironolactone group and 1 percent of the men in the placebo group (P<0.001), causing more patients in the spironolactone group than in the placebo group to discontinue treatment (10 vs. 1, P=0.006).Discussion
We found that treatment with spironolactone reduced the risk of death from all causes, death from cardiac causes, hospitalization for cardiac causes, and the combined end point of death from cardiac causes or hospitalization for cardiac causes among patients who had severe heart failure as a result of left ventricular systolic dysfunction and who were receiving standard therapy including an ACE inhibitor. Spironolactone also improved the symptoms of heart failure, as measured by changes in the NYHA functional class. The reductions in the risk of death and hospitalization were observed after 2 to 3 months of treatment and persisted throughout the study (mean follow-up, 24 months). The results were consistent among subgroups. Serious hyperkalemia requiring the discontinuation of treatment was uncommon, occurring in one patient in the placebo group and three in the spironolactone group.
The patients in our study were at higher risk than those in studies of the effects of bisoprolol,26 digoxin,27 amlodipine,28 or carvedilol29 on heart failure resulting from systolic left ventricular dysfunction and treated with standard therapy, including an ACE inhibitor, but they were at lower risk than patients in a study of the effects of enalapril.25 The reduction in the risk of death with spironolactone treatment was due to significant decreases in the risk of both death from progressive heart failure and sudden death from cardiac causes. These results are consistent with the current understanding of the effect of aldosterone in patients with heart failure.30-32
Aldosterone was originally thought to be important in the pathophysiology of heart failure only because of its ability to increase sodium retention and potassium loss. However, in the past several years, research has shown that aldosterone also causes myocardial and vascular fibrosis,33,34 direct vascular damage,8 and baroreceptor dysfunction6 and prevents the uptake of norepinephrine by myocardium.4,32 The reduction in the risk of death in our study does not appear to be due entirely to an effect of spironolactone on sodium retention or potassium loss; instead, it is likely that spironolactone is also cardioprotective. In our previous dose-finding study,17 a dose of 25 mg of spironolactone daily had no apparent diuretic effect — that is, there was no change in total body weight, the sodium-retention score, or urinary sodium excretion. In the present study, spironolactone (mean dose, 26 mg daily) did not have a clinically significant hemodynamic effect. Although we cannot rule out the possibility that spironolactone had some effect on sodium excretion in the present study, this effect would most likely be minor, as compared with the effect of the high doses of loop diuretics used. Also, although there was a significant increase from base line in serum potassium concentrations in the patients in the spironolactone group, this change was not clinically important.
The 35 percent reduction in the risk of hospitalization for worsening heart failure may be attributable to the ability of spironolactone to reduce myocardial and vascular fibrosis. Although the exact cause of the reduction in the risk of death in our study remains speculative, we postulate that an aldosterone-receptor blocker can prevent progressive heart failure by averting sodium retention and myocardial fibrosis and prevent sudden death from cardiac causes by averting potassium loss and by increasing the myocardial uptake of norepinephrine. Spironolactone may prevent myocardial fibrosis by blocking the effects of aldosterone on the formation of collagen,5,35,36 which in turn could play a part in reducing the risk of sudden death from cardiac causes, since myocardial fibrosis could predispose patients to variations in ventricular-conduction times and, hence, to reentry ventricular arrhythmias.32,35-37
Few patients (11 percent) in the spironolactone group were receiving a beta-blocker at base line, and the reduction in the risk of death did not differ significantly between those who were treated with a beta-blocker and those who were not so treated. Since our patients were at higher risk than patients who were evaluated in recent studies of beta-blockers in heart failure,26,29 studies are needed to examine both the tolerability and the effectiveness of beta-blockers in such a high-risk population as well as the effects of the concomitant use of an aldosterone-receptor blocker and a beta-blocker.
Our finding that an aldosterone-receptor blocker reduced the risk of both morbidity and death among patients who were receiving an ACE inhibitor emphasizes the point that standard doses of an ACE inhibitor do not effectively suppress the production of aldosterone.7,14 Although higher doses of ACE inhibitors may be more effective than lower doses in reducing the risk of morbidity and death among patients with heart failure,38 there is no evidence that higher doses suppress aldosterone production more effectively in the long term. ACE inhibitors cannot totally suppress the production of aldosterone, because other factors in addition to angiotensin II (e.g., serum potassium) are important in the production of aldosterone and may override the effects of angiotensin II.39-41 Since aldosterone remains in the circulation, only the presence of an aldosterone-receptor blocker will completely suppress the effects of this hormone.
The fact that spironolactone significantly reduced the risk of both morbidity and death among the high-risk patients in our study with only a very low incidence of serious hyperkalemia can be attributed to our previous efforts in determining an effective and safe dose of spironolactone when used in conjunction with an ACE inhibitor.17 We found that spironolactone at a dose of 12.5 to 25 mg daily was pharmacologically effective in blocking the aldosterone receptors and decreasing atrial natriuretic peptide concentrations and that serious hyperkalemia occurred most frequently with daily doses of 50 mg or greater.17 In the present study, therefore, spironolactone therapy was initiated at a daily dose of 25 mg, and physicians were given the option of reducing the dose to 25 mg every other day if serum potassium concentrations started to rise to a hyperkalemic level or of increasing the dose to 50 mg daily after eight weeks in patients who had symptoms or signs of worsening heart failure but no evidence of hyperkalemia. It should be emphasized, however, that a serum creatinine concentration of more than 2.5 mg per deciliter and a serum potassium concentration of more than 5.0 mmol per liter were exclusion criteria. In addition, the long-term use of agents known to interact with spironolactone, increase the risk of hyperkalemia, or do both was not allowed. Although potassium supplements were used by 29 percent of the patients in the spironolactone group, the benefit of spironolactone in these patients was similar to that in patients who did not use potassium supplements.
Overall, spironolactone therapy was tolerated well: 8 percent of the patients in the spironolactone group discontinued treatment because of adverse events, as compared with 5 percent of the patients in the placebo group. This difference was due in part to a significant incidence of gynecomastia or breast pain among men in the spironolactone group (P<0.001). The rate of discontinuation of treatment because of this event was higher in the spironolactone group than in the placebo group (2 percent vs. 0.2 percent, P=0.006). Gynecomastia has previously been observed in patients who were treated with spironolactone.42,43 Specifically, gynecomastia has been reported to occur in 6.9 percent of men who received daily doses of spironolactone of 50 mg or less for hypertension.43 The use of a selective aldosterone-receptor antagonist such as eplerenone, which has a lower affinity for androgen and progesterone receptors than does spironolactone,44 may minimize the risk of gynecomastia. The risk of gynecomastia should not, however, be an argument against the use of spironolactone in men with severe heart failure, since spironolactone reduces the risk of both morbidity and death. The effectiveness and risks of treatment with spironolactone in patients at lower risk than those in our study, such as those with less severe heart failure, will require further prospective study.
Our finding that an aldosterone-receptor antagonist, when used in conjunction with an ACE inhibitor, reduces the risk of both death from progressive heart failure and sudden death from cardiac causes contributes to our understanding of the pathophysiology of heart failure and has implications for the treatment of patients with other conditions in which ACE inhibitors are beneficial, such as patients with hypertension and those who have had a myocardial infarction.
Preliminary data were presented at the American Heart Association meeting, Dallas, November 8–11, 1998.
Supported by a grant from Searle, Skokie, Ill.
We are indebted to Lorraine R. Baer, Pharm.D., for editorial contributions and assistance in the preparation of the manuscript.
Source Information
From the Department of Internal Medicine, Division of Cardiology, University of Michigan, Ann Arbor (B.P., R.C.); the Centre d'Investigation, Clinique de Nancy, Nancy, France (F.Z.); STICARES, Cardiovascular Research Foundation, Rotterdam, the Netherlands (W.J.R.); the Service de Cardiologie, Hôpital Henri Mondor, Creteil, France (A.C.); Global Medical Operations, Searle, Skokie, Ill. (A.P.); and the Statistics Collaborative, Washington, D.C. (J.P., J.W.).
Address reprint requests to Dr. Pitt at the Division of Cardiology, University of Michigan Medical Center, 3910 Taubman, 1500 E. Medical Center Dr., Ann Arbor, MI 48109-0366.
Other investigators are listed in the Appendix.
Appendix
In addition to the authors, the following persons participated in the study: Data and Safety Monitoring Board — D. Julian (chair), J.-P. Boissel, C. Furberg, H. Kulbertus, S. Pocock; Primary End-Point Committee — J. Blumenfeld, J.A. Ramires; Nonfatal Hospitalization End-Point Committee — S. Sasayama (chair), C. Brilla, D. Duprez, R. Muñoz; Medical Monitors — D. Asner, B. Roniker; Investigators: Belgium — P. Block, G. Boxho, J.-M. Chaudron, V. Conraads, J. Creplet, P. De Salle, F. Deman, D. Duprez, O. Gurnee, G. Heyndrickx, S. Janssens, G. Jouret, C. Mortier, L. Pierard, P. Timmermans, J.L. Vandenbossche, W. Van Mieghem, J. Vanwelden, J. Vincke; Brazil — F.M. Albanesi Filho, F.A. de Almeida, J.C.A. Ayoub, E.T. Barbosa, M. Batlouni, L.C. Bodanese, R.M. Carrasco, A.C. de C. Carvalho, I. Castro, O.R. Coelho, D. Dauar, C. Drumond Neto, G.S. Feitosa, R.A. Franken, P.C.B.V. Jardim, C. Mady, M.F. de C. Maranhão, J.A. Marin Neto, L.F. de Miranda, J.C. Nicolau, W. Oigman, W.A. de Oliveira Júnior, W.C. Pereira Filho, J.A.F. Ramires, J.J.F. Rapozo Filho, S. Rassi, J.M. Ribeiro, J.P. Ribeiro, P.R.F. Rossi, J.F.K. Saraiva, A.S. Sbissa, M.A.D. da Silva, J.E. de Sigueira, J. Souza Filho; Canada — I.M. Arnold, D. Beanlands, C. Koilppillai, S. Lepage, A. Morris, M. White; France — F. Albert, G. Amat, F. Apffel, M.C. Aumont, S. Baleynaud, P. Battistella, J. Beaune, L. Bonnefoy, A. Bonneau, J. Bonnet, M. Bory, J.P. Bousser, J.A. Boutarin, B. Charbonnier, A. Cohen, A. Cohen-Solal, M.T. Courbet-Andrejak, A. Cribier, F. Delahaye, C. D'Ivernois, J.P. Doazan, V. Dormagen, H. Douard, F. Dravet, A. Dutoit, J.M. Fayard, M. Ferriere, C. Fournier, Y. Frances, F. Funck, M. Galinier, L.F. Garnier, P. Gibelin, P. Gosse, B. Grivet, L. Guize, B. d'Hautefeuille, A. Heraudeau, J.F. Huret, L. Janin-Manificat, G. Jarry, Y. Jobic, E. Jullien, J.C. Kahn, K. Khalife, A. Koenig, F. Latour, C. Leclercq, F. Leclercq, L. Ledain, H. Le Marec, S. Levy, J.M. Mallion, P. Maribas, G. Mialet, P.L. Michel, J.P. Millet, B. Moquet, J.P. Normand, T. Olive, P. Poncelet, J. Ponsonnaille, J. Puel, A. Rifai, P. Sans, J.P. Simon, M. Toussaint, A. Verdun, B. Veyre, S. Werquin; Germany — C. Brilla, G. Riegger, M. Zehender; Japan — Y. Aizawa, M. Hori, H. Inoue, H. Kasanuki, A. Kitabatake, M. Matsuzaki, S. Ogawa, M. Omata, S. Sasayama, A. Takeshita, Y. Yazaki, M. Yokoyama; Mexico — L. Avila, F.J. Guerrero, H. Gutiérrez-Leonard, J.L. Leyva-Garza; the Netherlands — P.J.L.M. Bernink, H. Fintelman, J.A. Kragten, J.B.L. ten Kate, D.J.A. Lok, A.R. Ramdat Misier, G.P. Molhoek, G.M.G. Paulussen, L.H.J. van Kempen, D.J. van Veldhuisen, L.G.P.M. van Zeijl, A.J.A.M. Withagen; New Zealand — H. Ikram; South Africa — J.D. Marx, D.P. Naidoo; Spain — J.M. Aguirre, S. Alcasena, M. Artaza, J. Azpitarte, J.R. Berrazueta, A. Castro-Beiras, P. Conthe, A. Cortina, J.M. Cruz-Fernández, J. Farré, I. Ferreira, M. García-Moll, V. López-García-de-Aranda, J.L. López-Sendón, R. Muñoz, F. Navarro, J. Palomo, J.M. Ribera-Casado, J.L. Rodríguez-Lambert, J. Soler-Soler, E. de-Teresa, J.A. de-Velasco; Switzerland — P. Delafontaine, O.M. Hess, L. Kappenberger, G. Noll, W. Rutishauser, J. Sztajzel; United Kingdom — A.J.S. Coats, T.S. Callaghan, A.D. Struthers; United States — G.W. Dec, P. Deedwania, J. Nicklas, K.T. Weber; Venezuela — N. Lopez, S. Waich.
- References
References
1
Dzau VJ ,Colucci WS ,Hollenberg NK ,Williams GH . Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure. Circulation 1981;63:645-651
CrossRef | Web of Science | Medline2
Swedberg K ,Eneroth P ,Kjekshus J ,Wilhelmsen L . Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation 1990;82:1730-1736
CrossRef | Web of Science | Medline3
Weber KT ,Villarreal D . Aldosterone and antialdosterone therapy in congestive heart failure. Am J Cardiol 1993;71:Suppl:3A-11A
CrossRef | Web of Science | Medline4
Barr CS ,Lang CC ,Hanson J ,Arnott M ,Kennedy N ,Struthers AD . Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1995;76:1259-1265
CrossRef | Web of Science | Medline5
MacFadyen RJ ,Barr CS ,Struthers AD . Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res 1997;35:30-34
CrossRef | Web of Science | Medline6
Wang W . Chronic administration of aldosterone depresses baroreceptor reflex function in the dog. Hypertension 1994;24:571-575
Web of Science | Medline7
Duprez DA ,De Buyzere ML ,Rietzschel ER , et al. Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients. Eur Heart J 1998;19:1371-1376
CrossRef | Web of Science | Medline8
Rocha R ,Chander PN ,Khanna K ,Zuckerman A ,Stier CT Jr . Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998;31:451-458
Web of Science | Medline9
Capoten tablets: captopril tablets. In: Physicians' desk reference. 52nd ed. Montvale, N.J.: Medical Economics, 1998:784-7.
10
Vasotec tablets: enalapril maleate. In: Physicians' desk reference. 52nd ed. Montvale, N.J.: Medical Economics, 1998:1771-4.
11
Cleland JG ,Swedberg K ,Poole-Wilson PA . Successes and failures of current treatment of heart failure. Lancet 1998;352:Suppl 1:SI19-SI28
CrossRef | Medline12
Cohn JN . The management of chronic heart failure. N Engl J Med 1996;335:490-498
Full Text | Web of Science | Medline13
Borghi C ,Boschi S ,Ambrosioni E ,Melandri G ,Branzi A ,Magnani B . Evidence of a partial escape of renin-angiotensin-aldosterone blockade in patients with acute myocardial infarction treated with ACE inhibitors. J Clin Pharmacol 1993;33:40-45
Web of Science | Medline14
Cleland JGF ,Dargie HJ ,Hodsman GP , et al. Captopril in heart failure: a double blind controlled trial. Br Heart J 1984;52:530-535
CrossRef | Web of Science | Medline15
Biollaz J ,Brunner HR ,Gavras I ,Waeber B ,Gavras H . Antihypertensive therapy with MK 421: angiotensin II-renin relationships to evaluate efficacy of converting enzyme blockade. J Cardiovasc Pharmacol 1982;4:966-972
CrossRef | Web of Science | Medline16
Staessen J ,Lijnen P ,Fagard R ,Verschueren LJ ,Amery A . Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol 1981;91:457-465
CrossRef | Web of Science | Medline17
The RALES Investigators
CrossRef | Web of Science | Medline18
Kaplan EL ,Meier P . Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481
CrossRef | Web of Science19
Mantel N . Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-170
Medline20
Cox DR . Regression models and life-tables. J R Stat Soc [B] 1972;34:187-20221
Lan KKG ,DeMets DL . Discrete sequential boundaries for clinical trials. Biometrika 1983;70:659-663
CrossRef | Web of Science22
O'Brien PC ,Fleming TR . A multiple testing procedure for clinical trials. Biometrics 1979;35:549-556
CrossRef | Web of Science | Medline23
Lakatos E . Sample sizes based on the log-rank statistic in complex clinical trials. Biometrics 1988;44:229-241[Erratum, Biometrics 1988;44:923.]
CrossRef | Web of Science | Medline24
The SOLVD Investigators
Full Text | Web of Science | Medline25
The CONSENSUS Trial Study Group
Full Text | Web of Science | Medline26
The CIBIS-II Investigators and Committees
CrossRef | Web of Science | Medline27
The Digitalis Investigation Group
Full Text | Web of Science | Medline28
Packer M ,O'Connor CM ,Ghali JK , et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996;335:1107-1114
Full Text | Web of Science | Medline29
Packer M ,Bristow MR ,Cohn JN , et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-1355
Full Text | Web of Science | Medline30
Zannad F . Angiotensin-converting enzyme inhibitor and spironolactone combination therapy: new objectives in congestive heart failure treatment. Am J Cardiol 1993;71:Suppl:34A-39A
CrossRef | Web of Science | Medline31
Pitt B . “Escape“ of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy. Cardiovasc Drugs Ther 1995;9:145-149
CrossRef | Web of Science | Medline32
Struthers AD . Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure. J Card Fail 1996;2:47-54
CrossRef | Medline33
Weber KT ,Brilla CG . Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation 1991;83:1849-1865
Web of Science | Medline34
Brilla CG ,Pick R ,Tan LB ,Janicki JS ,Weber KT . Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res 1990;67:1355-1364
Web of Science | Medline35
Klug D ,Robert V ,Swynghedauw B . Role of mechanical and hormonal factors in cardiac remodeling and the biologic limits of myocardial adaptation. Am J Cardiol 1993;71:Suppl:46A-54A
CrossRef | Web of Science | Medline36
Brilla CG ,Matsubara LS ,Weber KT . Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol 1993;25:563-575
CrossRef | Web of Science | Medline37
Barr CS ,Naas A ,Freeman M ,Lang CC ,Struthers AD . QT dispersion and sudden unexpected death in chronic heart failure. Lancet 1994;343:327-329
CrossRef | Web of Science | Medline38
Hobbs RE . Results of the ATLAS study -- high or low doses of ACE inhibitors for heart failure? Cleve Clin J Med 1998;65:539-542
Web of Science | Medline39
Hajnoczky G ,Varnai P ,Hollo Z , et al. Thapsigargin-induced increase in cytoplasmic Ca2+ concentration and aldosterone production in rat adrenal glomerulosa cells: interaction with potassium and angiotensin-II. Endocrinology 1991;128:2639-2644
CrossRef | Web of Science | Medline40
Szalay KS ,Beck M ,Toth M ,de Chatel R . Interactions between ouabain, atrial natriuretic peptide, angiotensin-II and potassium: effects on rat zona glomerulosa aldosterone production. Life Sci 1998;62:1845-1852
CrossRef | Web of Science | Medline41
Okubo S ,Niimura F ,Nishimura H , et al. Angiotensin-independent mechanism for aldosterone synthesis during chronic extracellular fluid volume depletion. J Clin Invest 1997;99:855-860
CrossRef | Web of Science | Medline42
Aldactone: spironolactone. In: Physicians' desk reference. 53rd ed. Montvale, N.J.: Medical Economics, 1999:2928-9.
43
Jeunemaitre X ,Chatellier G ,Kreft-Jais C , et al. Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol 1987;60:820-825
CrossRef | Web of Science | Medline44
de Gasparo M ,Joss U ,Ramjoue HP , et al. Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro. J Pharmacol Exp Ther 1987;240:650-656
Web of Science | Medline
- Citing Articles (1828)
Citing Articles
1
Rajaa F Faris, Marcus Flather, Henry Purcell, Philip A Poole-Wilson, Andrew JS Coats, Rajaa F Faris. 2012. Diuretics for heart failure. .
CrossRef2
Robert Rosenson, John Horowitz, Juan-Carlos Kaski, Henry Krum, Willem Remme. (2012) Clinical Trials Update Esc Congress 2011. Cardiovascular Drugs and Therapy
CrossRef3
Beth D. Kaufman, Kimberly Y. Lin, Akash R. Patel, Maryam Y. Naim, Maully J. Shah, Robert E. Shaddy. 2012. Cardiac Failure. , 1021-1031.
CrossRef4
Anastasia S. Mihailidou. (2012) Aldosterone in Heart Disease. Current Hypertension Reports
CrossRef5
Massimo Volpe, Silvia Mennuni. (2012) Eplerenone works. Does it matter how?. Expert Review of Cardiovascular Therapy 10:2, 131-133
CrossRef6
Adonis Saremi, Dipika Gopal, Alan S Maisel. (2012) Brain natriuretic peptide-guided therapy in the inpatient management of decompensated heart failure. Expert Review of Cardiovascular Therapy 10:2, 191-203
CrossRef7
R. V. Pruijsten, S. I. Lok, H. H. Kirkels, C. Klopping, J. R. Lahpor, N. de Jonge. (2012) Functional and haemodynamic recovery after implantation of continuous-flow left ventricular assist devices in comparison with pulsatile left ventricular assist devices in patients with end-stage heart failure. European Journal of Heart Failure
CrossRef8
Jing-yi Li, Shao-ling Zhang, Meng Ren, Yan-ling Wen, Li Yan, Hua Cheng. (2012) High-sodium intake aggravates myocardial injuries induced by aldosterone via oxidative stress in Sprague-Dawley rats. Acta Pharmacologica Sinica
CrossRef9
Hirotaka Shibata, Hiroshi Itoh. (2012) Mineralocorticoid Receptor-Associated Hypertension and Its Organ Damage: Clinical Relevance for Resistant Hypertension. American Journal of Hypertension
CrossRef10
Craig R. Butler, Bodh I. Jugdutt. (2012) The paradox of left ventricular assist device unloading and myocardial recovery in end-stage dilated cardiomyopathy: implications for heart failure in the elderly. Heart Failure Reviews
CrossRef11
S. Laribi, A. Aouba, M. Nikolaou, J. Lassus, A. Cohen-Solal, P. Plaisance, G. Pavillon, P. Jois, G. C. Fonarow, E. Jougla, A. Mebazaa, . (2012) Trends in death attributed to heart failure over the past two decades in Europe. European Journal of Heart Failure
CrossRef12
Evangelos P. Daskalopoulos, Ben J.A. Janssen, W. Matthijs Blankesteijn. (2012) Myofibroblasts in the Infarct Area: Concepts and Challenges. Microscopy and Microanalysis1-15
CrossRef13
John D. Bonagura, Linda B. Lehmkuhl, Helio Autran de Morais. 2012. Fluid and Diuretic Therapy in Heart Failure. , 514-543.
CrossRef14
Jerry M Buysse, I-Zu Huang, Bertram Pitt. (2012) PEARL-HF: prevention of hyperkalemia in patients with heart failure using a novel polymeric potassium binder, RLY5016. Future Cardiology 8:1, 17-28
CrossRef15
Shu Kasama, Takuji Toyama, Hiroyuki Sumino, Hisao Kumakura, Yoshiaki Takayama, Kazutomo Minami, Shuichi Ichikawa, Naoya Matsumoto, Yuichi Sato, Masahiko Kurabayashi. (2012) Effects of mineralocorticoid receptor antagonist spironolactone on cardiac sympathetic nerve activity and prognosis in patients with chronic heart failure. International Journal of Cardiology
CrossRef16
Alexandra A. dos Santos, Izo Helber, Ednei L. Antonio, Marcelo F. Franco, Paulo J.F. Tucci. (2012) Severity of the cardiac impairment determines whether digitalis prolongs or reduces survival of rats with heart failure due to myocardial infarction. International Journal of Cardiology
CrossRef17
J. David Spence. (2012) Lessons From Africa: The Importance of Measuring Plasma Renin and Aldosterone in Resistant Hypertension. Canadian Journal of Cardiology
CrossRef18
Peter Greaves. 2012. Mammary Gland. , 69-97.
CrossRef19
Andrew S Levey, Josef Coresh. (2012) Chronic kidney disease. The Lancet 379:9811, 165-180
CrossRef20
Luis Almenar Bonet, Josep Comín Colet, Enrique Pérez de la Sota, Beatriz Díaz Molina. (2012) Insuficiencia cardiaca y trasplante. Revista Española de Cardiología 65, 35-41
CrossRef21
Haissam Haddad, Lisa Mielniczuk, Ross A. Davies. (2012) Recent advances in the management of chronic heart failure. Current Opinion in Cardiology1
CrossRef22
Aurelie Nguyen Dinh Cat, Frederic Jaisser. (2012) Extrarenal effects of aldosterone. Current Opinion in Nephrology and Hypertension1
CrossRef23
Tetsuro Nariai, Katsuya Fujita, Masaya Mori, Seiji Katayama, Seiji Hori, Kazuki Matsui. (2012) Antihypertensive and Cardiorenal Protective Effects of SM-368229, a Novel Mineralocorticoid Receptor Antagonist, in Aldosterone/Salt-Treated Rats. Pharmacology 89:1-2, 44-52
CrossRef24
Gail B. Rattinger, Sarah K. Dutcher, Pankdeep T. Chhabra, Christine S. Franey, Linda Simoni-Wastila,, Stephen S. Gottlieb, Bruce Stuart, Ilene H. Zuckerman. (2012) The Effect of Dementia on Medication Use and Adherence Among Medicare Beneficiaries With Chronic Heart Failure. The American Journal of Geriatric Pharmacotherapy
CrossRef25
N Fujimura, K Noma, T Hata, J Soga, T Hidaka, N Idei, Y Fujii, S Mikami, T Maruhashi, Y Iwamoto, Y Kihara, K Chayama, H Kato, J K Liao, Y Higashi. (2011) Mineralocorticoid Receptor Blocker Eplerenone Improves Endothelial Function and Inhibits Rho-Associated Kinase Activity in Patients With Hypertension. Clinical Pharmacology & Therapeutics
CrossRef26
Catherine L. Tacon, John McCaffrey, Anthony Delaney. (2011) Dobutamine for patients with severe heart failure: a systematic review and meta-analysis of randomised controlled trials. Intensive Care Medicine
CrossRef27
Osamu Tsukamoto, Masafumi Kitakaze. (2011) It is Time to Reconsider the Cardiovascular Protection Afforded by RAAS Blockade - Overview of RAAS Systems. Cardiovascular Drugs and Therapy
CrossRef28
Daniel B. Kramer, Mark E. Josephson. (2011) Expanding the Use of Cardiac Resynchronization Therapy: Words of Caution. Cardiac Electrophysiology Clinics 3:4, 529-537
CrossRef29
Cécile Walczak, Fanny Gaignier, Alexandre Gilet, Feng Zou, Simon N. Thornton, Armelle Ropars. (2011) Aldosterone increases VEGF-A production in human neutrophils through PI3K, ERK1/2 and p38 pathways. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1813:12, 2125-2132
CrossRef30
E. Franco, I.J. Núñez-Gil, D. Vivas, B. Ruiz Mateos, B. Ibañez, N. Gonzalo, C. Macaya, A. Fernández Ortiz. (2011) Heart failure and non-ST-segment elevation myocardial infarction: A review for a widespread situation. European Journal of Internal Medicine 22:6, 533-540
CrossRef31
B. Pitt, M. Gheorghiade. (2011) Vasopressin V1 receptor-mediated aldosterone production as a result of selective V2 receptor antagonism: a potential explanation for the failure of tolvaptan to reduce cardiovascular outcomes in the EVEREST trial. European Journal of Heart Failure 13:12, 1261-1263
CrossRef32
Alejandro de la Sierra. (2011) Renin–angiotensin system blockade and reduction of cardiovascular risk: future perspectives. Expert Review of Cardiovascular Therapy 9:12, 1585-1591
CrossRef33
Stefano Muzzarelli, Micha Tobias Maeder, Stefan Toggweiler, Hans Rickli, Fabian Nietlispach, Barbara Julius, Thilo Burkard, Matthias Emil Pfisterer, Hans-Peter Brunner-La Rocca. (2011) Frequency and Predictors of Hyperkalemia in Patients ≥60 Years of Age With Heart Failure Undergoing Intense Medical Therapy. The American Journal of Cardiology
CrossRef34
Bertram Pitt. (2011) The Role of Mineralocorticoid Receptor Antagonists in Patients with American College of Cardiology/American Heart Association StageB Heart Failure. Heart Failure Clinics
CrossRef35
Massimo Zecchin, Marco Merlo, Alberto Pivetta, Giulia Barbati, Cristina Lutman, Dario Gregori, Laura Vitali Serdoz, Stefano Bardari, Silvia Magnani, Andrea Di Lenarda, Alessandro Proclemer, Gianfranco Sinagra. (2011) How Can Optimization of Medical Treatment Avoid Unnecessary Implantable Cardioverter-Defibrillator Implantations in Patients With Idiopathic Dilated Cardiomyopathy Presenting With “SCD-HeFT Criteria?”. The American Journal of Cardiology
CrossRef36
Andrew L. Clark. (2011) Almanac 2011: heart failure. The national society journals present selected research that has driven recent advances in clinical cardiology. Revista Portuguesa de Cardiologia 30:12, 941-948
CrossRef37
Farzin Beygui, Jean-Philippe Labbé, Guillaume Cayla, Pierre-Vladimir Ennezat, Pascal Motreff, François Roubille, Johanne Silvain, Olivier Barthélémy, Nicolas Delarche, Eric Van Belle, Jean-Philippe Collet, Gilles Montalescot. (2011) Early mineralocorticoid receptor blockade in primary percutaneous coronary intervention for ST-elevation myocardial infarction is associated with a reduction of life-threatening ventricular arrhythmia. International Journal of Cardiology
CrossRef38
Patrick Collier, Kenneth M. McDonald. (2011) The Role of Renin Angiotensin System Intervention in Stage B Heart Failure. Heart Failure Clinics
CrossRef39
E. de Teresa Galván, J.M. García Pinilla, R. de Teresa Herrera. (2011) Tratamiento de la insuficiencia cardiaca. Medicine - Programa de Formación Médica Continuada Acreditado 10:92, 6240-6248
CrossRef40
Tomoaki Hasui, Nobuyuki Matsunaga, Taiichi Ora, Norio Ohyabu, Nobuhiro Nishigaki, Yoshimi Imura, Yumiko Igata, Hideki Matsui, Takashi Motoyaji, Toshimasa Tanaka, Noriyuki Habuka, Satoshi Sogabe, Midori Ono, Christopher S. Siedem, Tony P. Tang, Cassandra Gauthier, Lisa A. De Meese, Steven A. Boyd, Shoji Fukumoto. (2011) Identification of Benzoxazin-3-one Derivatives as Novel, Potent, and Selective Nonsteroidal Mineralocorticoid Receptor Antagonists. Journal of Medicinal Chemistry111129111224002
CrossRef41
Arthur Mark Richards. (2011) Mineralocorticoid receptor antagonists for heart failure. Expert Opinion on Pharmacotherapy1-15
CrossRef42
B Julie He, Mei-ling A Joiner, Madhu V Singh, Elizabeth D Luczak, Paari Dominic Swaminathan, Olha M Koval, William Kutschke, Chantal Allamargot, Jinying Yang, Xiaoqun Guan, Kathy Zimmerman, Isabella M Grumbach, Robert M Weiss, Douglas R Spitz, Curt D Sigmund, W Matthijs Blankesteijn, Stephane Heymans, Peter J Mohler, Mark E Anderson. (2011) Oxidation of CaMKII determines the cardiotoxic effects of aldosterone. Nature Medicine
CrossRef43
T. Unger, L. Paulis, D. A. Sica. (2011) Therapeutic perspectives in hypertension: novel means for renin-angiotensin-aldosterone system modulation and emerging device-based approaches. European Heart Journal 32:22, 2739-2747
CrossRef44
M. Albaghdadi, M. Gheorghiade, B. Pitt. (2011) Mineralocorticoid receptor antagonism: therapeutic potential in acute heart failure syndromes. European Heart Journal 32:21, 2626-2633
CrossRef45
Angela Brown, Becky Captain. (2011) 50 Years of Thiazides: Should Thiazide Diuretics Be Considered Third-Line Hypertension Treatment?. American Journal of Therapeutics 18:6, e244-e254
CrossRef46
Michael Böhm, Adriaan A. Voors, Jean-Marie Ketelslegers, Stephan H. Schirmer, Eva Turgonyi, Peter Bramlage, Faiez Zannad. (2011) Biomarkers: optimizing treatment guidance in heart failure. Clinical Research in Cardiology 100:11, 973-981
CrossRef47
Prajwal A. Deshmukh, Sripad R. Bellary, Frank T. Schwender, German Kamalov, Minoti Magotra, Amy L. de Jongh Curry, Yao Sun, Karl T. Weber. (2011) Spironolactone Prevents the Inducibility of Ventricular Tachyarrhythmia in Rats With Aldosteronism. Journal of Cardiovascular Pharmacology 58:5, 487-491
CrossRef48
Alexander A. Leung, Adam Wright, Valeria Pazo, Andrew Karson, David W. Bates. (2011) Risk of Thiazide-induced Hyponatremia in Patients with Hypertension. The American Journal of Medicine 124:11, 1064-1072
CrossRef49
Christopher M. O'Connor, Mona Fiuzat, JoAnn Lindenfeld, Alan Miller, Carlo Lombardi, Peter Carson, Linda K. Shaw, Li-Joy Wang, Patricia Connolly, Roger Mills, Clyde Yancy, Kenneth Mahaffey. (2011) Mode of Death and Hospitalization from the Second Follow-Up Serial Infusions of Nesiritide (FUSION II) Trial and Comparison of Clinical Events Committee Adjudicated Versus Investigator Reported Outcomes. The American Journal of Cardiology 108:10, 1449-1457
CrossRef50
Daniel Jacoby, Oltjan Albajrami, Lavanya Bellumkonda. (2011) Natural History of End-stage LV Dysfunction: Has It Improved from the Classic Franciosa and Cohn Graph?. Cardiology Clinics 29:4, 485-495
CrossRef51
Michele Emdin, Luigi Emilio Pastormerlo, Claudio Passino. (2011) The Month After. Journal of the American College of Cardiology 58:19, 1967-1969
CrossRef52
Anand Vaidya, Jonathan S. Williams. (2011) The relationship between vitamin D and the renin-angiotensin system in the pathophysiology of hypertension, kidney disease, and diabetes. Metabolism
CrossRef53
U. Kintscher, R. Kreutz. (2011) Neue Medikamente in der Hypertensiologie. Der Nephrologe 6:6, 504-509
CrossRef54
Patrick Rossignol, Joël Ménard, Renaud Fay, Finn Gustafsson, Bertram Pitt, Faiez Zannad. (2011) Eplerenone Survival Benefits in Heart Failure Patients Post-Myocardial Infarction Are Independent From its Diuretic and Potassium-Sparing Effects. Journal of the American College of Cardiology 58:19, 1958-1966
CrossRef55
Robert W. Schrier. (2011) Use of Diuretics in Heart Failure and Cirrhosis. Seminars in Nephrology 31:6, 503-512
CrossRef56
Akshay S. Desai, Eldrin F. Lewis, Rebecca Li, Scott D. Solomon, Susan F. Assmann, Robin Boineau, Nadine Clausell, Rafael Diaz, Jerome L. Fleg, Ivan Gordeev, Sonja McKinlay, Eileen O'Meara, Tamaz Shaburishvili, Bertram Pitt, Marc A. Pfeffer. (2011) Rationale and design of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial: A randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. American Heart Journal
CrossRef57
John B. Kostis. (2011) Atrial Fibrillation Registries, Administrative Databases, Clinical Trials, and Outcomes. The American Journal of Cardiology
CrossRef58
K.-C. Yang, P. Y. Jay, J. R. McMullen, J. M. Nerbonne. (2011) Enhanced cardiac PI3K signalling mitigates arrhythmogenic electrical remodelling in pathological hypertrophy and heart failure. Cardiovascular Research
CrossRef59
Jonathan P. Man, Bodh I. Jugdutt. (2011) Systolic heart failure in the elderly: optimizing medical management. Heart Failure Reviews
CrossRef60
Bertram Pitt. (2011) The role of mineralocorticoid receptor antagonists (MRAs) in very old patients with heart failure. Heart Failure Reviews
CrossRef61
Domenic A. Sica. (2011) What is the Role of Aldosterone Excess in Resistant Hypertension and How Should It Be Investigated and Treated?. Current Cardiology Reports
CrossRef62
Gregory Egnaczyk, Carmelo A. Milano, Joseph G. Rogers. (2011) Clinical Trials in Mechanical Circulatory Support. Heart Failure Clinics 7:4, 457-466
CrossRef63
Marieke A. Hillaert, Eef G. Lentjes, Farzin Beygui, Hans Kemperman, Folkert W. Asselbergs, Hendrik M. Nathoe, Pierfrancesco Agostoni, Michiel Voskuil, Fabrice Ivanes, Brigitte Jude, Michel E. Bertrand, Gerard Pasterkamp, Yolanda van der Graaf, Pieter A. Doevendans, Gilles Montalescot, Eric Van Belle. (2011) Measuring and targeting aldosterone and renin in atherosclerosis—A review of clinical data. American Heart Journal 162:4, 585-596
CrossRef64
, Simone Birocchi, Giulia Carla Luisa Cernuschi. (2011) Eplerenone, an aldosterone antagonist, reduces hospitalization and death in heart failure patients with nyha class II and an ejection fraction of less than 30%. Internal and Emergency Medicine 6:5, 453-454
CrossRef65
Samir Parikh, Lee Hebert, Brad Rovin. (2011) Protecting the kidneys in lupus nephritis. International Journal of Clinical Rheumatology 6:5, 529-546
CrossRef66
Rachel B Rapkin, Mitchell D Creinin. (2011) The combined oral contraceptive pill containing drospirenone and ethinyl estradiol plus levomefolate calcium. Expert Opinion on Pharmacotherapy 12:15, 2403-2410
CrossRef67
Mustafa Dohadwala, N. A. Mark Estes, Mark S. Link. (2011) New Paradigms in the Prevention of Sudden Cardiac Arrest and Heart Failure Treatment. Current Cardiology Reports 13:5, 377-386
CrossRef68
V. Ricchiuti, N. Lapointe, L. Pojoga, T. Yao, L. Tran, G. H. Williams, G. K. Adler. (2011) Dietary sodium intake regulates angiotensin II type 1, mineralocorticoid receptor, and associated signaling proteins in heart. Journal of Endocrinology 211:1, 47-54
CrossRef69
Andrew Plump, Jeffrey Madwed. (2011) Heart failure drug discovery: Scarred or ready for remodeling?. Journal of Molecular and Cellular Cardiology 51:4, 444-448
CrossRef70
Agata Bielecka-Dabrowa, Jacek Rysz, Dimitri P Mikhailidis, Maciej Banach. (2011) What is the risk of hyperkalaemia in heart failure?. Expert Opinion on Pharmacotherapy 12:15, 2329-2338
CrossRef71
Anjay Rastogi, Mohamad Rashid, Richard F. Wright. (2011) Reducing Cardiorenal Risk Through Combination Therapy With a Direct Renin Inhibitor. The Journal of Clinical Hypertensionno-no
CrossRef72
José Luis Górriz Teruel, Sandra Beltrán Catalán. (2011) Assessment of Renal Function, Iatrogenic Hyperkalemia and Acute Renal Dysfunction in Cardiology. Contrast-Induced Nephropathy. Revista Española de Cardiología (English Edition)
CrossRef73
José Luis Górriz Teruel, Sandra Beltrán Catalán. (2011) Valoración de afección renal, disfunción renal aguda e hiperpotasemia por fármacos usados en cardiología y nefrotoxicidad por contrastes. Revista Española de Cardiología
CrossRef74
P. Collier, C.J. Watson, M.H. van Es, D. Phelan, C. McGorrian, M. Tolan, M.T. Ledwidge, K.M. McDonald, J.A. Baugh. (2011) Getting to the heart of cardiac remodeling; how collagen subtypes may contribute to phenotype. Journal of Molecular and Cellular Cardiology
CrossRef75
Finn Gustafsson, Michel Azizi, Johann Bauersachs, Frederic Jaisser, Patrick Rossignol. (2011) Targeting the aldosterone pathway in cardiovascular disease. Fundamental & Clinical Pharmacologyno-no
CrossRef76
Yonghong Huan, Stephanie DeLoach, Scott W. Keith, Theodore L. Goodfriend, Bonita Falkner. (2011) Aldosterone and aldosterone: renin ratio associations with insulin resistance and blood pressure in African Americans. Journal of the American Society of Hypertension
CrossRef77
T. A. McDonagh, M. Komajda, A. P. Maggioni, F. Zannad, M. Gheorghiade, M. Metra, H. J. Dargie. (2011) Clinical trials in acute heart failure: simpler solutions to complex problems. Consensus document arising from a European Society of Cardiology cardiovascular round-table think tank on acute heart failure, 12 May 2009. European Journal of Heart Failure
CrossRef78
Ulrike Muscha Steckelings, Ludovit Paulis, Thomas Unger, Michael Bader. (2011) Emerging drugs which target the renin–angiotensin–aldosterone system. Expert Opinion on Emerging Drugs1-12
CrossRef79
Sean Balmain, Michael A McDonald. (2011) Cardiac resynchronization therapy in mildly symptomatic heart failure: the earlier the better. Expert Review of Cardiovascular Therapy 9:9, 1147-1153
CrossRef80
J.-J. Perrenoud. (2011) Heart Failure (Part 2). European Geriatric Medicine 2:4, 237-244
CrossRef81
J. J. V. McMurray. (2011) CONSENSUS to EMPHASIS: the overwhelming evidence which makes blockade of the renin-angiotensin-aldosterone system the cornerstone of therapy for systolic heart failure. European Journal of Heart Failure 13:9, 929-936
CrossRef82
Marla J. De Jong, Misook L. Chung, Jia-Rong Wu, Barbara Riegel, Mary Kay Rayens, Debra K. Moser. (2011) Linkages between anxiety and outcomes in heart failure. Heart & Lung: The Journal of Acute and Critical Care 40:5, 393-404
CrossRef83
Esteban López-de-Sá, Angel Martínez, Manuel Anguita, David Dobarro, Manuel Jiménez-Navarro. (2011) Aldosterone Receptor Antagonist Use After Myocardial Infarction. Data From the REICIAM Registry. Revista Española de Cardiología (English Edition)
CrossRef84
Esteban López-de-Sá, Angel Martínez, Manuel Anguita, David Dobarro, Manuel Jiménez-Navarro. (2011) Uso de antagonistas de los receptores de aldosterona tras el infarto de miocardio. Datos del registro REICIAM. Revista Española de Cardiología
CrossRef85
Nadia Aspromonte, Dinna N Cruz, Roberto Valle, Monica Bonello, Marco Tubaro, Giovanni Gambaro, Giuseppe Marchese, Massimo Santini, Claudio Ronco. (2011) Metabolic and toxicological considerations for diuretic therapy in patients with acute heart failure. Expert Opinion on Drug Metabolism & Toxicology 7:9, 1049-1063
CrossRef86
Robert Gros, Qingming Ding, Mark Davis, Rasha Shaikh, Bonan Liu, Jozef Chorazyczewski, J. Geoffrey Pickering, Ross D. Feldman. (2011) Delineating the receptor mechanisms underlying the rapid vascular contractile effects of aldosterone and estradiol. Canadian Journal of Physiology and Pharmacology 89:9, 655-663
CrossRef87
István Késői, Balázs Sági, Tibor Vas, Tünde Pintér, Tibor Kovács, István Wittmann, Judit Nagy. (2011) Cardiorenalis szindrómák. Orvosi Hetilap 152:38, 1520-1527
CrossRef88
Marco A. Caccamo, Peter M. Eckman. (2011) Pharmacologic Therapy for New York Heart Association Class IV Heart Failure. Congestive Heart Failure 17:5, 213-219
CrossRef89
Murray Epstein, David A. Calhoun. (2011) Aldosterone Blockers (Mineralocorticoid Receptor Antagonism) and Potassium-Sparing Diuretics. The Journal of Clinical Hypertension 13:9, 644-648
CrossRef90
Kevin Damman, Adriaan A. Voors, Gerjan Navis, Dirk J. van Veldhuisen, Hans L. Hillege. (2011) The Cardiorenal Syndrome in Heart Failure. Progress in Cardiovascular Diseases 54:2, 144-153
CrossRef91
Mariusz K. Szymanski, Kevin Damman, Dirk J. van Veldhuisen, Wiek H. van Gilst, Hans L. Hillege, Rudolf A. de Boer. (2011) Prognostic value of renin and prorenin in heart failure patients with decreased kidney function. American Heart Journal 162:3, 487-493
CrossRef92
Jessi Khangura, Sarah J Goodlin. (2011) Heart failure treatment in the elderly. Expert Review of Cardiovascular Therapy 9:9, 1171-1179
CrossRef93
F. Verbeke, W. Van Biesen, R. Vanholder. (2011) The role of collagen metabolism in CKD-associated arterial senescence: underestimated and underappreciated. Nephrology Dialysis Transplantation 26:9, 2726-2728
CrossRef94
Morag J. Young, Amanda J. Rickard. (2011) Mechanisms of mineralocorticoid salt-induced hypertension and cardiac fibrosis. Molecular and Cellular Endocrinology
CrossRef95
F. Edelmann, A. Tomaschitz, R. Wachter, G. Gelbrich, M. Knoke, H.-D. Dungen, S. Pilz, L. Binder, R. Stahrenberg, A. Schmidt, W. Marz, B. Pieske. (2011) Serum aldosterone and its relationship to left ventricular structure and geometry in patients with preserved left ventricular ejection fraction. European Heart Journal
CrossRef96
Arihiro Kiyosue, Daisuke Nagata, Masahiro Myojo, Tomohiko Sato, Masao Takahashi, Hiroshi Satonaka, Ryozo Nagai, Yasunobu Hirata. (2011) Aldosterone-induced osteopontin gene transcription in vascular smooth muscle cells involves glucocorticoid response element. Hypertension Research
CrossRef97
R. Lowrie, F. S. Mair, N. Greenlaw, P. Forsyth, A. McConnachie, J. Richardson, N. Khan, D. Morrison, C.-M. Messow, B. Rae, J. J. V. McMurray. (2011) The Heart failure and Optimal Outcomes from Pharmacy Study (HOOPS): rationale, design, and baseline characteristics. European Journal of Heart Failure 13:8, 917-924
CrossRef98
Barry A. Borlaug, David A. Kass. (2011) Ventricular–Vascular Interaction in Heart Failure. Cardiology Clinics 29:3, 447-459
CrossRef99
Novalia P. Sidik, Scott D. Solomon, Roberto Latini, Aldo P. Maggioni, Melanie Wright, Claudio R. Gimpelewicz, Bertram Pitt, John J. V. McMurray. (2011) Effect of Aliskiren in Patients with Heart Failure According to Background Dose of ACE Inhibitor: A Retrospective Analysis of the Aliskiren Observation of Heart Failure Treatment (ALOFT) Trial. Cardiovascular Drugs and Therapy 25:4, 315-321
CrossRef100
Charles F. Jackson, Nanette K. Wenger. (2011) Cardiovascular Disease in the Elderly. Revista Española de Cardiología (English Edition) 64:8, 697-712
CrossRef101
Sorel Goland, Vladimir Naugolny, Zila Korbut, Izabella Rozen, Abraham Caspi, Steven Malnick. (2011) Appropriateness and complications of the use of spironolactone in patients treated in a heart failure clinic. European Journal of Internal Medicine 22:4, 424-427
CrossRef102
Charles F. Jackson, Nanette K. Wenger. (2011) Enfermedad cardiovascular en el anciano. Revista Española de Cardiología 64:8, 697-712
CrossRef103
S. Hisatake, S. Nanjo, S. Fujimoto, S. Yamashina, H. Yuzawa, A. Namiki, H. Nakano, J. Yamazaki. (2011) Comparative analysis of the therapeutic effects of long-acting and short-acting loop diuretics in the treatment of chronic heart failure using 123I-metaiodobenzylguanidine scintigraphy. European Journal of Heart Failure 13:8, 892-898
CrossRef104
Jesus Herreros, Juan Bustamante. (2011) Myocardial regeneration in heart failure: integrated development of biological therapeutic approaches. Expert Review of Cardiovascular Therapy 9:8, 1027-1039
CrossRef105
B. J. Borkowski, Y. Cheema, A. U. Shahbaz, S. K. Bhattacharya, K. T. Weber. (2011) Cation dyshomeostasis and cardiomyocyte necrosis: the Fleckenstein hypothesis revisited. European Heart Journal 32:15, 1846-1853
CrossRef106
Henry Krum, John R Teerlink. (2011) Medical therapy for chronic heart failure. The Lancet 378:9792, 713-721
CrossRef107
Daniel P. Judge, David A. Kass, W. Reid Thompson, Kathryn R. Wagner. (2011) Pathophysiology and Therapy of Cardiac Dysfunction in Duchenne Muscular Dystrophy. American Journal Cardiovascular Drugs1
CrossRef108
Matthew J. Volk, Andrew S. Bomback, Philip J. Klemmer. (2011) Mineralocorticoid Receptor Blockade in Chronic Kidney Disease. Current Hypertension Reports 13:4, 282-288
CrossRef109
S. SCHULLER, N. VAN ISRAËL, S. VANBELLE, C. CLERCX, K. McENTEE. (2011) Lack of efficacy of low-dose spironolactone as adjunct treatment to conventional congestive heart failure treatment in dogs. Journal of Veterinary Pharmacology and Therapeutics 34:4, 322-331
CrossRef110
Martin Stockburger, Alice Krebs, Oezlem Celebi, Aischa Nitardy, Dirk Habedank, Thomas Knaus, Mathias Rauchhaus, Rainer Dietz. (2011) Long-Term Survival of Routine Implantable Cardioverter/Defibrillator Recipients Appears to be Significantly Impaired with Concomitant Diuretics and Improved with Aldosterone Antagonists. Cardiovascular Therapeutics 29:4, 243-250
CrossRef111
Katrin Kliche, Pia Jeggle, Hermann Pavenstädt, Hans Oberleithner. (2011) Role of cellular mechanics in the function and life span of vascular endothelium. Pflügers Archiv - European Journal of Physiology 462:2, 209-217
CrossRef112
Andrés A. Herrada, Carmen Campino, Cristián A. Amador, Luis F. Michea, Carlos E. Fardella, Alexis M. Kalergis. (2011) Aldosterone as a modulator of immunity. Journal of Hypertension1
CrossRef113
Cao Thach Tran, Keld Kjeldsen. (2011) Protection against β adrenoceptor agonist reduction of plasma potassium in severe but not in moderate hypokalemia. Fundamental & Clinical Pharmacology 25:4, 452-461
CrossRef114
Juan A. Sanchez, Lise L. Sanchez, Stanley J. Dudrick. (2011) Nutritional Considerations in Adult Cardiothoracic Surgical Patients. Surgical Clinics of North America 91:4, 857-875
CrossRef115
Bruce J. Kimura, Norihiro Yogo, Charles W. O'Connell, James N. Phan, Brian K. Showalter, Tanya Wolfson. (2011) Cardiopulmonary Limited Ultrasound Examination for “Quick-Look” Bedside Application. The American Journal of Cardiology 108:4, 586-590
CrossRef116
Jennifer Franke, Christian Zugck, Jan Sebastian Wolter, Lutz Frankenstein, Matthias Hochadel, Philipp Ehlermann, Ralph Winkler, Manfred Nelles, Ralf Zahn, Hugo A. Katus, Jochen Senges. (2011) A decade of developments in chronic heart failure treatment: a comparison of therapy and outcome in a secondary and tertiary hospital setting. Clinical Research in Cardiology
CrossRef117
Tomohiro Hanazawa, Taku Obara, Kei Ogasawara, Takahiro Shinki, Sakiko Katada, Ryusuke Inoue, Hirohito Metoki, Kei Asayama, Masahiro Kikuya, Takayoshi Ohkubo, Nariyasu Mano, Yutaka Imai. (2011) Low-Dose and Very Low-Dose Spironolactone in Combination Therapy for Essential Hypertension: Evaluation by Self-Measurement of Blood Pressure at Home. Clinical and Experimental Hypertension1-10
CrossRef118
Gregory Giamouzis, Javed Butler, Filippos Triposkiadis. (2011) Renal Function in Advanced Heart Failure. Congestive Heart Failure 17:4, 180-188
CrossRef119
I. Sudano, F. Ruschitzka, G. Noll, T. F. Luscher. (2011) Endothelial function and the effects of aldosterone blockade. European Heart Journal Supplements 13:Suppl B, B21-B26
CrossRef120
L. M. Ruilope. (2011) Safety aspects of aldosterone-blocking drugs. European Heart Journal Supplements 13:Suppl B, B40-B42
CrossRef121
J. Winter, K. E. Brack, G. A. Ng. (2011) Cardiac contractility modulation in the treatment of heart failure: initial results and unanswered questions. European Journal of Heart Failure 13:7, 700-710
CrossRef122
A. D. Struthers, T. Unger. (2011) Physiology of aldosterone and pharmacology of aldosterone blockers. European Heart Journal Supplements 13:Suppl B, B27-B30
CrossRef123
Theresa Dartsch, Robert Fischer, Andrej Gapelyuk, Marco Weiergraeber, Dennis Ladage, Toni Schneider, Alexander Schirdewan, Hannes Reuter, Jochen Mueller-Ehmsen, Carsten Zobel. (2011) Aldosterone induces electrical remodeling independent of hypertension. International Journal of Cardiology
CrossRef124
Ross D. Feldman, Robert Gros. (2011) Unraveling the mechanisms underlying the rapid vascular effects of steroids: sorting out the receptors and the pathways. British Journal of Pharmacology 163:6, 1163-1169
CrossRef125
S. Yagi, M. Sata. (2011) Pre-clinical data on the role of mineralocorticoid receptor antagonists in reversing vascular inflammation. European Heart Journal Supplements 13:Suppl B, B15-B20
CrossRef126
S. Messaoudi, F. Jaisser. (2011) Aldosterone and the mineralocorticoid receptor. European Heart Journal Supplements 13:Suppl B, B4-B9
CrossRef127
Omar F. AbouEzzeddine, Margaret M. Redfield. (2011) Who Has Advanced Heart Failure? Definition and Epidemiology. Congestive Heart Failure 17:4, 160-168
CrossRef128
F. Zannad, J.-M. Ketelslegers, P. Bramlage. (2011) Role of biomarkers in guiding treatment with aldosterone-blocking agents. European Heart Journal Supplements 13:Suppl B, B31-B35
CrossRef129
Daniela Giannessi. (2011) Multimarker approach for heart failure management: Perspectives and limitations. Pharmacological Research 64:1, 11-24
CrossRef130
Lynn R. Punnoose, Michael M. Givertz, Eldrin F. Lewis, Parakash Pratibhu, Lynne W. Stevenson, Akshay S. Desai. (2011) Heart Failure With Recovered Ejection Fraction: A Distinct Clinical Entity. Journal of Cardiac Failure 17:7, 527-532
CrossRef131
Qian Li, Robert J. Glynn, Nancy A. Dreyer, Jun Liu, Helen Mogun, Soko Setoguchi. (2011) Validity of claims-based definitions of left ventricular systolic dysfunction in Medicare patients. Pharmacoepidemiology and Drug Safety 20:7, 700-708
CrossRef132
D. J. van Veldhuisen, K. Swedberg. (2011) Treatment of chronic heart failure with aldosterone-blocking agents. European Heart Journal Supplements 13:Suppl B, B43-B45
CrossRef133
B. Pitt, R. Latini, A. P. Maggioni, S. D. Solomon, B. A. Smith, M. Wright, M. F. Prescott, J. J. V. McMurray. (2011) Neurohumoral effects of aliskiren in patients with symptomatic heart failure receiving a mineralocorticoid receptor antagonist: the Aliskiren Observation of Heart Failure Treatment study. European Journal of Heart Failure 13:7, 755-764
CrossRef134
Shahriar Iravanian, Ali A. Sovari, Harvey A. Lardin, Hong Liu, Hong D. Xiao, Elena Dolmatova, Zhe Jiao, Brett S. Harris, Emily A. Witham, Robert G. Gourdie, Heather S. Duffy, Kenneth E. Bernstein, Samuel C. Dudley. (2011) Inhibition of renin-angiotensin system (RAS) reduces ventricular tachycardia risk by altering connexin43. Journal of Molecular Medicine 89:7, 677-687
CrossRef135
Frederick E Dewey, Matthew T Wheeler, Euan A Ashley. (2011) Systems biology of heart failure, challenges and hopes. Current Opinion in Cardiology 26:4, 314-321
CrossRef136
Pernelle Noize, Haleh Bagheri, Geneviève Durrieu, Françoise Haramburu, Nicholas Moore, Patrick Giraud, Michel Galinier, Jacques Pourrat, Jean-Louis Montastruc. (2011) Life-threatening drug-associated hyperkalemia: a retrospective study from laboratory signals. Pharmacoepidemiology and Drug Safety 20:7, 747-753
CrossRef137
Hanna B. Slim, Henry R. Black, Paul D. Thompson. (2011) Older Blood Pressure Medications—Do They Still Have a Place?. The American Journal of Cardiology 108:2, 308-316
CrossRef138
P. Bramlage, E. Turgonyi, G. Montalescot. (2011) Aldosterone blockade: current research and future trends. European Heart Journal Supplements 13:Suppl B, B46-B50
CrossRef139
M. Bohm, J. C. Reil, P. Bramlage, B. Pitt, F. Zannad. (2011) Clinical efficacy of aldosterone-blocking agents. European Heart Journal Supplements 13:Suppl B, B36-B39
CrossRef140
Taishi Nakamura, Masaya Fukuda, Keiichiro Kataoka, Hisato Nako, Yoshiko Tokutomi, Yi-Fei Dong, Eiichiro Yamamoto, Osamu Yasuda, Hisao Ogawa, Shokei Kim-Mitsuyama. (2011) Eplerenone potentiates protective effects of amlodipine against cardiovascular injury in salt-sensitive hypertensive rats. Hypertension Research 34:7, 817-824
CrossRef141
Agata Bielecka-Dabrowa, Dimitri P. Mikhailidis, Linda Jones, Jacek Rysz, Wilbert S. Aronow, Maciej Banach. (2011) The meaning of hypokalemia in heart failure. International Journal of Cardiology
CrossRef142
B. Pitt. (2011) Introduction. European Heart Journal Supplements 13:Suppl B, B1-B3
CrossRef143
Salvatore Paterna, Sergio Fasullo, Gaspare Parrinello, Sergio Cannizzaro, Ivana Basile, Gabriella Vitrano, Gabriella Terrazzino, Giorgio Maringhini, Filippo Ganci, Sebastiano Scalzo, Filippo M. Sarullo, Gennaro Cice, Pietro Di Pasquale. (2011) Short-Term Effects of Hypertonic Saline Solution in Acute Heart Failure and Long-Term Effects of a Moderate Sodium Restriction in Patients With Compensated Heart Failure With New York Heart Association Class III (Class C) (SMAC-HF Study). The American Journal of the Medical Sciences 342:1, 27-37
CrossRef144
Peter Kolkhof, Steffen A. Borden. (2011) Molecular pharmacology of the mineralocorticoid receptor: Prospects for novel therapeutics. Molecular and Cellular Endocrinology
CrossRef145
Alex Odermatt, Denise V. Kratschmar. (2011) Tissue-specific modulation of mineralocorticoid receptor function by 11β-hydroxysteroid dehydrogenases: An overview. Molecular and Cellular Endocrinology
CrossRef146
Smail Messaoudi, Feriel Azibani, Claude Delcayre, Frederic Jaisser. (2011) Aldosterone, mineralocorticoid receptor, and heart failure. Molecular and Cellular Endocrinology
CrossRef147
Jessica Huyet, Grégory Maurice Pinon, Michel Raymond Fay, Marie-Edith Rafestin-Oblin, Jérôme Fagart. (2011) Structural determinants of ligand binding to the mineralocorticoid receptor. Molecular and Cellular Endocrinology
CrossRef148
Shigeru Shibata, Toshiro Fujita. (2011) Mineralocorticoid receptors in the pathophysiology of chronic kidney diseases and the metabolic syndrome. Molecular and Cellular Endocrinology
CrossRef149
Jun Yang, Peter J. Fuller. (2011) Interactions of the mineralocorticoid receptor – Within and without. Molecular and Cellular Endocrinology
CrossRef150
Scott M. MacKenzie, John M.C. Connell, Eleanor Davies. (2011) Non-adrenal synthesis of aldosterone: A reality check. Molecular and Cellular Endocrinology
CrossRef151
Damien Le Menuet, Mathilde Munier, Giulia Campostrini, Marc Lombès. (2011) Mineralocorticoid receptor and embryonic stem cell models: Molecular insights and pathophysiological relevance. Molecular and Cellular Endocrinology
CrossRef152
Claudia Grossmann, Michael Gekle. (2011) Interaction between mineralocorticoid receptor and epidermal growth factor receptor signaling. Molecular and Cellular Endocrinology
CrossRef153
Simona Maule, Chiara Bertello, Franco Rabbia, Alberto Milan, Paolo Mulatero, Valeria Milazzo, Grazia Papotti, Franco Veglio. (2011) Ventricular repolarization before and after treatment in patients with secondary hypertension due to renal-artery stenosis and primary aldosteronism. Hypertension Research
CrossRef154
Raúl Quirós López, Javier García Alegría, María Dolores Martín Escalante, Javier Trujillo Santos, María Ángeles Villena Ruiz, Emilio Perea Milla. (2011) Factores pronósticos y supervivencia a largo plazo tras el diagnóstico inicial de insuficiencia cardiaca. Medicina Clínica
CrossRef155
Ryan P. Morrissey, Lawrence Czer, Prediman K. Shah. (2011) Chronic Heart Failure. American Journal Cardiovascular Drugs 11:3, 153-171
CrossRef156
, Friedrich M. Fruhwald, Hanno Ulmer, Richard Pacher, Gerhard Pölzl, Claudia Dornaus, Manfred Wieser, Christian Ebner, Susanne Reiter, Lalit Kaltenbach, Johann Altenberger. (2011) Ruhepuls und funktionelle Einschränkungen als prognostische Parameter bei herzinsuffizienten Patienten im tatsächlichen Leben. Daten aus dem Herzinsuffizienz-Register der ÖKG. Wiener klinische Wochenschrift 123:11-12, 378-383
CrossRef157
P. Friocourt. (2011) Traitement de l’insuffisance cardiaque du sujet âgé. NPG Neurologie - Psychiatrie - Gériatrie 11:63, 114-123
CrossRef158
Somya A. Chandrasekaran, Hector O. Ventura, Carl J. Lavie, Ileana Pina. (2011) Disparities in Women with Heart Failure. Current Cardiovascular Risk Reports 5:3, 261-265
CrossRef159
Luis M Ruilope, Julian Segura, Jose L Zamorano. (2011) New clinical concepts after the ONTARGET trial. Expert Review of Cardiovascular Therapy 9:6, 685-689
CrossRef160
Gregg C. Fonarow, Clyde W. Yancy, Adrian F. Hernandez, Eric D. Peterson, John A. Spertus, Paul A. Heidenreich. (2011) Potential impact of optimal implementation of evidence-based heart failure therapies on mortality. American Heart Journal 161:6, 1024-1030.e3
CrossRef161
Georgios Dimitriadis, Vasileios Papadopoulos, Konstantinos Mimidis. (2011) Eplerenone reverses spironolactone-induced painful gynaecomastia in cirrhotics. Hepatology International 5:2, 738-739
CrossRef162
Alex Reyentovich, Stuart D. Katz. (2011) Mineralocorticoid-receptor Antagonists in Heart Failure: A Tale of Serendipity and Success. Current Heart Failure Reports 8:2, 87-90
CrossRef163
Yanping Fu, Gang Shi, Yong Wu, Yasuyuki Kawai, Qing Tian, Linlin Yue, Qinjie Xia, Isamu Miyamori, Chunyuan Fan. (2011) The mitochondria mediate the induction of NOX1 gene expression by aldosterone in an ATF-1-dependent manner. Cellular & Molecular Biology Letters 16:2, 226-235
CrossRef164
Dagmara Hering, Murray D Esler, Henry Krum, Felix Mahfoud, Michael Böhm, Paul A Sobotka, Markus P Schlaich. (2011) Recent advances in the treatment of hypertension. Expert Review of Cardiovascular Therapy 9:6, 729-744
CrossRef165
Sanne de Jong, Toon A B van Veen, Harold V M van Rijen, Jacques M T de Bakker. (2011) Fibrosis and Cardiac Arrhythmias. Journal of Cardiovascular Pharmacology 57:6, 630-638
CrossRef166
Niloofar Nobakht, Mohammad Kamgar, Anjay Rastogi, Robert W. Schrier. (2011) Limitations of angiotensin inhibition. Nature Reviews Nephrology 7:6, 356-359
CrossRef167
Redi Pecini, Daniel Vega Møller, Christian Torp-Pedersen, Christian Hassager, Lars Køber. (2011) Heart failure etiology impacts survival of patients with heart failure. International Journal of Cardiology 149:2, 211-215
CrossRef168
Sandhya Murthy, Hannah I. Lipman. (2011) Management of End-Stage Heart Failure. Primary Care: Clinics in Office Practice 38:2, 265-276
CrossRef169
Jean-Philippe Bertocchio, Frédéric Jaisser. (2011) Aldostérone et pathologies rénales : une notion émergente avec des implications thérapeutiques importantes. Néphrologie & Thérapeutique 7:3, 139-147
CrossRef170
Dennis Ladage, Nora Schützeberg, Theresa Dartsch, Benjamin Krausgrill, Marcel Halbach, Carsten Zobel, Jochen Müller-Ehmsen. (2011) Hyperaldosteronism is associated with a decrease in number and altered growth factor expression of endothelial progenitor cells in rats. International Journal of Cardiology 149:2, 152-156
CrossRef171
Louise A Burton, Marion ET McMurdo, Allan D Struthers. (2011) Mineralocorticoid antagonism: a novel way to treat sarcopenia and physical impairment in older people?. Clinical Endocrinologyno-no
CrossRef172
JoAnn Lindenfeld. (2011) Impressive Results for Aldosterone Antagonists in Mild Heart Failure. Current Cardiology Reports 13:3, 167-169
CrossRef173
G. O. Oghlakian, I. Sipahi, J. C. Fang. (2011) Treatment of Heart Failure With Preserved Ejection Fraction: Have We Been Pursuing the Wrong Paradigm?. Mayo Clinic Proceedings 86:6, 531-539
CrossRef174
Amy McCurley, Iris Z. Jaffe. (2011) Mineralocorticoid receptors in vascular function and disease. Molecular and Cellular Endocrinology
CrossRef175
Elise P. Gomez-Sanchez, Celso E. Gomez-Sanchez. (2011) Central regulation of blood pressure by the mineralocorticoid receptor. Molecular and Cellular Endocrinology
CrossRef176
Michael A. Steinman, John B. Harlow, Barry M. Massie, Peter J. Kaboli, Kathy Z. Fung, Paul A. Heidenreich. (2011) Age and Receipt of Guideline-Recommended Medications for Heart Failure: A Nationwide Study of Veterans. Journal of General Internal Medicine
CrossRef177
Masatsugu Hori. (2011) Tolvaptan for Heart Failure Patients with Volume Overload. Cardiovascular Drugs and Therapy
CrossRef178
T. Thum, K. Schmitter, F. Fleissner, V. Wiebking, B. Dietrich, J. D. Widder, V. Jazbutyte, S. Hahner, G. Ertl, J. Bauersachs. (2011) Impairment of endothelial progenitor cell function and vascularization capacity by aldosterone in mice and humans. European Heart Journal 32:10, 1275-1286
CrossRef179
Nicholas B Norgard, Gina M Prescott. (2011) Future of personalized pharmacotherapy in chronic heart failure patients. Future Cardiology 7:3, 357-379
CrossRef180
Jean L. Rouleau. (2011) New and Emerging Drugs and Device Therapies for Chronic Heart Failure in Patients With Systolic Ventricular Dysfunction. Canadian Journal of Cardiology 27:3, 296-301
CrossRef181
O. R. de Peuter, G. Y. H. Lip, P. C. Souverein, O. H. Klungel, A. de Boer, H. R. Buller, P. W. Kamphuisen. (2011) Time-trends in treatment and cardiovascular events in patients with heart failure: a pharmacosurveillance study. European Journal of Heart Failure 13:5, 489-495
CrossRef182
Tarek Hakki, Katja Hübel, Herbert Waldmann, Rita Bernhardt. (2011) The development of a whole-cell based medium throughput screening system for the discovery of human aldosterone synthase (CYP11B2) inhibitors: Old drugs disclose new applications for the therapy of congestive heart failure, myocardial fibrosis and hypertension. The Journal of Steroid Biochemistry and Molecular Biology 125:1-2, 120-128
CrossRef183
Fadi G Hage, Sulaf J Mansur, Suzanne Oparil. (2011) Rationale for the use of multiple blockers of the renin–angiotensin–aldosterone system in specific patient populations. Therapy 8:3, 227-236
CrossRef184
David N. Rosenthal, Gregory B. Hammer. (2011) Cardiomyopathy and heart failure in children: anesthetic implications. Pediatric Anesthesia 21:5, 577-584
CrossRef185
Robert J. Mentz, Eldrin F. Lewis. (2011) Epidemiology of Cardiorenal Syndrome. Cardiology Clinics 29:2, 301-314
CrossRef186
Sanne de Jong, Toon A B van Veen, Jacques M T de Bakker, Marc A Vos, Harold V M van Rijen. (2011) Biomarkers of Myocardial Fibrosis. Journal of Cardiovascular Pharmacology 57:5, 522-535
CrossRef187
Hari K Parthasarathy, Joel Ménard, William B White, William F Young, Gordon H Williams, Bryan Williams, Luis Miguel Ruilope, Gordon T McInnes, John M Connell, Thomas M MacDonald. (2011) A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. Journal of Hypertension 29:5, 980-990
CrossRef188
Krystallenia I. Alexandraki, Gregory A. Kaltsas, Apostolos-Ilias Vouliotis, Theodoros G. Papaioannou, Lauren Trisk, Athanasios Zilos, Márta Korbonits, G. Michael Besser, Aris Anastasakis, Ashley B. Grossman. (2011) Specific electrocardiographic features associated with Cushing’s disease. Clinical Endocrinology 74:5, 558-564
CrossRef189
Jean-Philippe Bertocchio, David G Warnock, Frederic Jaisser. (2011) Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease. Kidney International 79:10, 1051-1060
CrossRef190
R. Scott Wright, Jeffrey L. Anderson, Cynthia D. Adams, Charles R. Bridges, Donald E. Casey, Steven M. Ettinger, Francis M. Fesmire, Theodore G. Ganiats, Hani Jneid, A. Michael Lincoff, Eric D. Peterson, George J. Philippides, Pierre Theroux, Nanette K. Wenger, James Patrick Zidar. (2011) 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction. Journal of the American College of Cardiology 57:19, e215-e367
CrossRef191
Ali Ahmed. (2011) Chronic Heart Failure in Older Adults. Medical Clinics of North America 95:3, 439-461
CrossRef192
Shinpei Kimura, Masahiro Ito, Makoto Tomita, Makoto Hoyano, Hiroaki Obata, Limin Ding, Masaomi Chinushi, Haruo Hanawa, Makoto Kodama, Yoshifusa Aizawa. (2011) Role of mineralocorticoid receptor on atrial structural remodeling and inducibility of atrial fibrillation in hypertensive rats. Hypertension Research 34:5, 584-591
CrossRef193
Barbara Schreier, Sindy Rabe, Bettina Schneider, Stefanie Ruhs, Claudia Grossmann, Steffen Hauptmann, Manfred Blessing, Joachim Neumann, Michael Gekle. (2011) Aldosterone/NaCl-induced renal and cardiac fibrosis is modulated by TGF-β responsiveness of T cells. Hypertension Research 34:5, 623-629
CrossRef194
Angela Yee-Moon Wang, John E. Sanderson. (2011) Treatment of Heart Failure in Long-term Dialysis Patients: A Reappraisal. American Journal of Kidney Diseases 57:5, 760-772
CrossRef195
Simon Lucas, Matthias Negri, Ralf Heim, Christina Zimmer, Rolf W. Hartmann. (2011) Fine-Tuning the Selectivity of Aldosterone Synthase Inhibitors: Structure−Activity and Structure−Selectivity Insights from Studies of Heteroaryl Substituted 1,2,5,6-Tetrahydropyrrolo[3,2,1- ij ]quinolin-4-one Derivatives. Journal of Medicinal Chemistry 54:7, 2307-2319
CrossRef196
(2011) Eplerenone in Mild Heart Failure. New England Journal of Medicine 364:14, 1370-1372
Full Text197
Daniel Kurnik, Janet Vesterman-Landes, Martin Bialik, Itzhak Katzir, Yosef Lomnicky, Hillel Halkin, Ronen Loebstein. (2011) Hyperkalemia and Renal Function During Monotherapy and Dual Renin-Angiotensin Blockade in the Community Setting. Clinical Therapeutics 33:4, 456-464
CrossRef198
Kosaku Nitta. (2011) Pathogenesis and therapeutic implications of cardiorenal syndrome. Clinical and Experimental Nephrology 15:2, 187-194
CrossRef199
Shigeru Shibata, Toshiro Fujita. (2011) The Kidneys and Aldosterone/Mineralocorticoid Receptor System in Salt-Sensitive Hypertension. Current Hypertension Reports 13:2, 109-115
CrossRef200
Willa A. Hsueh, Kathleen Wyne. (2011) Renin-Angiotensin-Aldosterone System in Diabetes and Hypertension. The Journal of Clinical Hypertension 13:4, 224-237
CrossRef201
T.H. Fischer, A.G. Rokita, L.S. Maier. (2011) Schlüsselrolle des Ca2+ in der Herzinsuffizienz und mögliche neue therapeutische Ansatzpunkte. Der Kardiologe 5:2, 80-90
CrossRef202
B. Pitt, S. D. Anker, D. A. Bushinsky, D. W. Kitzman, F. Zannad, I.-Z. Huang, . (2011) Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. European Heart Journal 32:7, 820-828
CrossRef203
K. Damman, A. H. Maass, P. van der Meer. (2011) Heart failure highlights in 2010. European Journal of Heart Failure 13:4, 358-363
CrossRef204
Marie Briet, Ernesto L. Schiffrin. (2011) The Role of Aldosterone in the Metabolic Syndrome. Current Hypertension Reports 13:2, 163-172
CrossRef205
L. Björck, S. Capewell, K. Bennett, G. Lappas, A. Rosengren. (2011) Increasing evidence-based treatments to reduce coronary heart disease mortality in Sweden: quantifying the potential gains. Journal of Internal Medicine 269:4, 452-467
CrossRef206
P. van der Meer, D. J. van Veldhuisen. (2011) To bind or not to bind: potassium-lowering drugs in heart failure. European Heart Journal 32:7, 791-792
CrossRef207
John Warren. (2011) Drug discovery: lessons from evolution. British Journal of Clinical Pharmacology 71:4, 497-503
CrossRef208
J. G. F. Cleland, A. P. Coletta, L. Buga, R. Antony, P. Pellicori, N. Freemantle, A. L. Clark. (2011) Clinical trials update from the American Heart Association Meeting 2010: EMPHASIS-HF, RAFT, TIM-HF, Tele-HF, ASCEND-HF, ROCKET-AF, and PROTECT. European Journal of Heart Failure 13:4, 460-465
CrossRef209
(2011) Cardiac-Resynchronization Therapy. New England Journal of Medicine 364:13, 1277-1278
Full Text210
Andreas Tomaschitz, Stefan Pilz, Eberhard Ritz, Tanja Grammer, Christiane Drechsler, Bernhard O. Boehm, Winfried März. (2011) Association of Plasma Aldosterone With Cardiovascular Mortality in Patients With Low Estimated GFR: The Ludwigshafen Risk and Cardiovascular Health (LURIC) Study. American Journal of Kidney Diseases 57:3, 403-414
CrossRef211
J. M. Ritter. (2011) Dual blockade of the renin-angiotensin system with angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs). British Journal of Clinical Pharmacology 71:3, 313-315
CrossRef212
Fabiano E. Xavier, Javier Blanco-Rivero, María Soledad Avendaño, Esther Sastre, Rubén Yela, Kyra Velázquez, Mercedes Salaíces, Gloria Balfagón. (2011) Aldosterone alters the participation of endothelial factors in noradrenaline vasoconstriction differently in resistance arteries from normotensive and hypertensive rats. European Journal of Pharmacology 654:3, 280-288
CrossRef213
VASSILIS DIMAS, COLBY AYERS, JAMES DANIELS, JOSE A. JOGLAR, JOSEPH A. HILL, R. HARIS NASEEM. (2011) Spironolactone Therapy is Associated with Reduced Ventricular Tachycardia Rate in Patients with Cardiomyopathy. Pacing and Clinical Electrophysiology 34:3, 309-314
CrossRef214
Youhua Zhang, Todor N. Mazgalev. (2011) Arrhythmias and vagus nerve stimulation. Heart Failure Reviews 16:2, 147-161
CrossRef215
Saurabh Malhotra, Mithilesh K Das. (2011) Delayed and indirect effects of antiarrhythmic drugs in reducing sudden cardiac death. Future Cardiology 7:2, 203-217
CrossRef216
Soo S. Rhee, Elizabeth N. Pearce. (2011) Sistema endocrino y corazón: una revisión. Revista Española de Cardiología 64:3, 220-231
CrossRef217
Yohann Rautureau, Pierre Paradis, Ernesto L. Schiffrin. (2011) Cross-talk between aldosterone and angiotensin signaling in vascular smooth muscle cells. Steroids
CrossRef218
Buddha Basnyat, Peter S. Holck, Matiram Pun, Stephen Halverson, Piotr Szawarski, Jeffrey Gertsch, Mike Steif, Skip Powell, Subhash Khanal, Anip Joshi, Ravi Shankar, Jamie Karambay, Hattie D. Alexander, Allyson Stone, Candice Morrissey, Beth H. Thompson, Jeremy Farrar. (2011) Spironolactone Does Not Prevent Acute Mountain Sickness: A Prospective, Double-Blind, Randomized, Placebo-Controlled Trial by SPACE Trial Group (Spironolactone and Acetazolamide Trial in the Prevention of Acute Mountain Sickness Group). Wilderness & Environmental Medicine 22:1, 15-22
CrossRef219
Miriam S. Jacob, W. H. Wilson Tang. (2011) Aldosterone-Receptor Antagonists in Heart Failure: Insights After EMPHASIS-HF. Current Heart Failure Reports 8:1, 7-13
CrossRef220
Markus Haass. (2011) Highlights of the latest clinical trials from the 2010 Scientific Sessions of the American Heart Association. Future Cardiology 7:2, 163-167
CrossRef221
Christopher Adlbrecht, Martin Huelsmann, Rudolf Berger, Deddo Moertl, Guido Strunk, August Oesterle, Roozbeh Ahmadi, Thomas Szucs, Richard Pacher. (2011) Cost analysis and cost-effectiveness of NT-proBNP-guided heart failure specialist care in addition to home-based nurse care. European Journal of Clinical Investigation 41:3, 315-322
CrossRef222
Masanori Abe, Kazuyoshi Okada, Noriaki Maruyama, Shiro Matsumoto, Takashi Maruyama, Takayuki Fujita, Koichi Matsumoto, Masayoshi Soma. (2011) Benidipine reduces albuminuria and plasma aldosterone in mild-to-moderate stage chronic kidney disease with albuminuria. Hypertension Research 34:2, 268-273
CrossRef223
Mihai Gheorghiade, Andrew Ambrosy. (2011) Heart failure in 2010: One step forward, two steps back. Nature Reviews Cardiology 8:2, 72-73
CrossRef224
Y. Hori, H. Tada, K. Nakamura, S. Naito, Y. Nakata, K. Goto, J. Imamoto, M. Yokokawa, Y. Tanaka, N. Funabashi, K. Aonuma, I. Komuro, K. Taniguchi, S. Oshima. (2011) Presence of structural heart disease and left ventricular dysfunction predict hospitalizations for new-onset heart failure after right ventricular apical pacing. Europace 13:2, 230-236
CrossRef225
K. Graf. (2011) Aldosteronblockade bei gering symptomatischer Herzinsuffizienz. Der Kardiologe 5:1, 43-44
CrossRef226
Turgay Celık, U. Cagdas Yuksel. (2011) The small intestine in cardiac cachexia: A forgotten player of the game. International Journal of Cardiology 147:1, 186-187
CrossRef227
Cheng-Shi Jiang, Rong Zhou, Jing-Xu Gong, Li-Li Chen, Tibor Kurtán, Xu Shen, Yue-Wei Guo. (2011) Synthesis, modification, and evaluation of (R)-de-O-methyllasiodiplodin and analogs as nonsteroidal antagonists of mineralocorticoid receptor. Bioorganic & Medicinal Chemistry Letters 21:4, 1171-1175
CrossRef228
E. E. Creemers, Y. M. Pinto. (2011) Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heart. Cardiovascular Research 89:2, 265-272
CrossRef229
Luis M. Ruilope. (2011) On the Need to Reissue Renin-Angiotensin-Aldosterone System Suppression in Chronic Kidney Disease. Current Cardiovascular Risk Reports 5:1, 5-6
CrossRef230
Pierre Meneton, Philippe Ricordeau, Alain Weill, Philippe Tuppin, Solène Samson, Hubert Allemand, Pierre Durieux, Joël Ménard. (2011) Evaluation of the agreement between guidelines and initial antihypertensive drug treatment using a national health care reimbursement database. Journal of Evaluation in Clinical Practiceno-no
CrossRef231
John D. Horowitz, Robert S. Rosenson, John J. V. McMurray, Nikolaus Marx, Willem J. Remme. (2011) Clinical Trials Update AHA Congress 2010. Cardiovascular Drugs and Therapy 25:1, 69-76
CrossRef232
Robert W. Schrier, Mihai Gheorghiade. (2011) Challenge of rehospitalizations for heart failure: Potential of natriuretic doses of mineralocorticoid receptor antagonists. American Heart Journal 161:2, 221-223
CrossRef233
2011. Part Introduction. , 33-280.
CrossRef234
Armstrong, Paul W., . (2011) Aldosterone Antagonists — Last Man Standing?. New England Journal of Medicine 364:1, 79-80
Full Text235
Zannad, Faiez, McMurray, John J.V., Krum, Henry, van Veldhuisen, Dirk J., Swedberg, Karl, Shi, Harry, Vincent, John, Pocock, Stuart J., Pitt, Bertram, . (2011) Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. New England Journal of Medicine 364:1, 11-21
Full Text236
Laura A. Johnson, Shail M. Govani, Joel C. Joyce, Akbar K. Waljee, Brenda W. Gillespie, Peter D.R. Higgins. (2011) Spironolactone and colitis: Increased mortality in rodents and in humans. Inflammatory Bowel Diseasesn/a-n/a
CrossRef237
Andrew A. House, Mikko Haapio, Johan Lassus, Rinaldo Bellomo, Claudio Ronco. (2011) Pharmacological Management of Cardiorenal Syndromes. International Journal of Nephrology 2011, 1-8
CrossRef238
M. Gheorghiade, M. Albaghdadi, F. Zannad, G. C. Fonarow, M. Bohm, C. Gimpelewicz, J. Botha, S. Moores, E. F. Lewis, H. Rattunde, A. Maggioni, , M. Gheorghiade, A. Maggioni, G. C. Fonarow, M. Bohm, F. Zannad, S. Solomon, E. Lewis, P. Finn, H. Hartley, L. Weinrach, E. Barkoudah, C. Duong, A. Rogers, K. Swedberg, S. Pocock, B. Pitt, J. S. Borer, J. Rouleau, M. Wibberg. (2011) Rationale and design of the multicentre, randomized, double-blind, placebo-controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT). European Journal of Heart Failure 13:1, 100-106
CrossRef239
Adam Romanovsky, Sean Bagshaw, Mitchell H. Rosner. (2011) Hyponatremia and Congestive Heart Failure: A Marker of Increased Mortality and a Target for Therapy. International Journal of Nephrology 2011, 1-7
CrossRef240
Katerina Leftheris, Yajun Zheng, Deepak S. Lala. 2011. Recent Advances in Mineralocorticoid Receptor Antagonists. , 89-102.
CrossRef241
Jean Lachaine, Catherine Beauchemin, Elodie Ramos. (2011) Use, tolerability and compliance of spironolactone in the treatment of heart failure. BMC Clinical Pharmacology 11:1, 4
CrossRef242
Neil Smart. (2011) Exercise Training for Heart Failure Patients with and without Systolic Dysfunction: An Evidence-Based Analysis of How Patients Benefit. Cardiology Research and Practice 2011, 1-7
CrossRef243
Jason J. Gajarsa, Robert A. Kloner. (2011) Left ventricular remodeling in the post-infarction heart: a review of cellular, molecular mechanisms, and therapeutic modalities. Heart Failure Reviews 16:1, 13-21
CrossRef244
Anastasios Lymperopoulos, Giuseppe Rengo, Carmela Zincarelli, Jihee Kim, Walter J. Koch. (2011) Adrenal Beta-Arrestin 1 Inhibition In Vivo Attenuates Post-Myocardial Infarction Progression to Heart Failure and Adverse Remodeling Via Reduction of Circulating Aldosterone Levels. Journal of the American College of Cardiology 57:3, 356-365
CrossRef245
LEONARDO CALÒ, ANNAMARIA MARTINO, LUIGI SCIARRA, ANTONIO CICCAGLIONI, ERMENEGILDO DE RUVO, LUCIA DE LUCA, ANTONELLA SETTE, GIUSEPPE GIUNTA, ERNESTO LIOY, FRANCESCO FEDELE. (2011) Upstream Effect for Atrial Fibrillation: Still a Dilemma?. Pacing and Clinical Electrophysiology 34:1, 111-128
CrossRef246
Eric E. Essick, Flora Sam. (2011) Cardiac Hypertrophy and Fibrosis in the Metabolic Syndrome: A Role for Aldosterone and the Mineralocorticoid Receptor. International Journal of Hypertension 2011, 1-12
CrossRef247
Finn Gustafsson, Michel Azizi, Johann Bauersachs, Frederic Jaisser, Patrick Rossignol. (2011) Targeting the aldosterone pathway in cardiovascular disease : Aldosterone in cardiovascular disease. Fundamental and Clinical Pharmacologyno
CrossRef248
Jerome L. Fleg, Wilbert S. Aronow, William H. Frishman. (2011) Cardiovascular drug therapy in the elderly: benefits and challenges. Nature Reviews Cardiology 8:1, 13-28
CrossRef249
(2011) Erratum. Journal of Cardiac Failure 17:1, 90-90.e4
CrossRef250
Joshua M. Hauser, Robert O. Bonow. 2011. Heart Failure and Palliative Care. , 391-404.
CrossRef251
Lutz Frankenstein, Andrew L. Clark, Jorge P. Ribeiro. (2011) Influence of Sex on Treatment and Outcome in Chronic Heart Failure. Cardiovascular Therapeuticsno-no
CrossRef252
Sandeep Talwar, Leslie A. Saxon. 2011. Clinical Trials of Cardiac Resynchronization Therapy. , 279-299.
CrossRef253
Gil Chernin, Amir Gal-Oz, Eyal Ben-Assa, Idit F. Schwartz, Talia Weinstein, Doron Schwartz, Donald S. Silverberg. (2011) Secondary Prevention of Hyperkalemia With Sodium Polystyrene Sulfonate in Cardiac and Kidney Patients on Renin-Angiotensin-Aldosterone System Inhibition Therapy. Clinical Cardiologyn/a-n/a
CrossRef254
Jalal K. Ghali, Barry M. Massie, Douglas L. Mann, Michael W. Rich. (2010) Heart Failure Guidelines, Performance Measures, and the Practice of MedicineMind the Gap. Journal of the American College of Cardiology 56:25, 2077-2080
CrossRef255
W.C. De Mello, Y. Gerena. (2010) Further studies on the effects of intracrine and extracellular angiotensin II on the regulation of heart cell volume. On the influence of aldosterone and spironolactone. Regulatory Peptides 165:2-3, 200-205
CrossRef256
Lionel D. Edwards. 2010. Drug Research in Older Patients. , 197-206.
CrossRef257
U.C. Hoppe, E. Erdmann. (2010) Herzinsuffizienz Update 2010 und aktuelle ESC-Leitlinien. Herz 35:8, 535-541
CrossRef258
Mehmet Kayrak, Ahmet Bacaksiz, Mehmet A. Vatankulu, Selim S. Ayhan, Hatem Ari, Zeynettin Kaya, Kurtulus Ozdemir. (2010) The effects of spironolactone on atrial remodeling in patients with preserved left ventricular function after an acute myocardial infarction. Coronary Artery Disease 21:8, 477-485
CrossRef259
John W. Funder, Martin Reincke. (2010) Aldosterone: A cardiovascular risk factor?. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1802:12, 1188-1192
CrossRef260
F. Braunschweig, G. Boriani, A. Bauer, R. Hatala, C. Herrmann-Lingen, J. Kautzner, S. S. Pedersen, S. Pehrson, R. Ricci, M. J. Schalij. (2010) Management of patients receiving implantable cardiac defibrillator shocks: Recommendations for acute and long-term patient management. Europace 12:12, 1673-1690
CrossRef261
Shinsuke Harasawa, Yuji Otsuka, Katsuaki Okubo, Miyuki Koike, Hirotaka Fujita, Toshio Kushiro, Ken Nagao, Atsushi Hirayama. (2010) Amlodipine suppressed cardiac gene expression of brain natriuretic peptide, transforming growth factor-β1 and fibronectin mediated by aldosterone in male stroke-prone spontaneously hypertensive rats. Journal of Pharmacy and Pharmacology 62:12, 1740-1745
CrossRef262
Leonardo A. Sechi, GianLuca Colussi, Alessandro Di Fabio, Cristiana Catena. (2010) Cardiovascular and Renal Damage in Primary Aldosteronism: Outcomes After Treatment. American Journal of Hypertension 23:12, 1253-1260
CrossRef263
Marcus Quinkler, Paul M. Stewart. (2010) Treatment of primary aldosteronism. Best Practice & Research Clinical Endocrinology & Metabolism 24:6, 923-932
CrossRef264
Keith A Thompson, Parag Bharadwaj, Kiran J Philip, Ernst R Schwarz. (2010) Heart failure therapy: beyond the guidelines. Journal of Cardiovascular Medicine 11:12, 919-927
CrossRef265
Kodlipet Dharmashankar, Michael E. Widlansky. (2010) Vascular Endothelial Function and Hypertension: Insights and Directions. Current Hypertension Reports 12:6, 448-455
CrossRef266
Victoria Cachofeiro, Natalia López-Andrés, Maria Miana, Beatriz Martín-Fernández, Natalia de las Heras, Ernesto Martínez, Vicente Lahera, María Antonia Fortuño. (2010) Aldosterone and the cardiovascular system: a dangerous association. Hormone Molecular Biology and Clinical Investigation 4:2, 539-548
CrossRef267
Kimiaki Komukai, Seibu Mochizuki, Michihiro Yoshimura. (2010) Gender and the renin-angiotensin-aldosterone system. Fundamental & Clinical Pharmacology 24:6, 687-698
CrossRef268
Yen-Hung Lin, Chen Lin, Men-Tzung Lo, Hung-Ju Lin, Yen-Wen Wu, Ron-Bin Hsu, Chia-Lun Chao, Hsiu-Ching Hsu, Pa-Chun Wang, Vin-Cent Wu, Shoei-Shen Wang, Chi-Ming Lee, Kuo-Liong Chien, Yi-Lwun Ho, Ming-Fong Chen, Chung-Kang Peng. (2010) The relationship between aminoterminal propeptide of type III procollagen and heart rate variability parameters in heart failure patients: a potential serum marker to evaluate cardiac autonomic control and sudden cardiac death. Clinical Chemistry and Laboratory Medicine 48:12, 1821-1827
CrossRef269
Rongqin Ren, John A. Cidlowski. (2010) Glucocorticoid signaling in cardiac disease. Hormone Molecular Biology and Clinical Investigation 4:2, 559-564
CrossRef270
Sanae Hamaguchi, Shintaro Kinugawa, Miyuki Tsuchihashi-Makaya, Kazutomo Goto, Daisuke Goto, Takashi Yokota, Satoshi Yamada, Hisashi Yokoshiki, Akira Takeshita, Hiroyuki Tsutsui. (2010) Spironolactone use at discharge was associated with improved survival in hospitalized patients with systolic heart failure. American Heart Journal 160:6, 1156-1162
CrossRef271
Paul Wojciechowski. (2010) Perioperative Optimization of the Heart Failure Patient. International Anesthesiology Clinics 47:4, 121-135
CrossRef272
Jodi Heshka, Marcel Ruzicka, Swapnil Hiremath, Brendan B. McCormick. (2010) Spironolactone for difficult to control hypertension in chronic kidney disease: an analysis of safety and efficacy. Journal of the American Society of Hypertension 4:6, 295-301
CrossRef273
Iris Z. Jaffe, Brenna G. Newfell, Mark Aronovitz, Najwa N. Mohammad, Adam P. McGraw, Roger E. Perreault, Peter Carmeliet, Afshin Ehsan, Michael E. Mendelsohn. (2010) Placental growth factor mediates aldosterone-dependent vascular injury in mice. Journal of Clinical Investigation 120:11, 3891-3900
CrossRef274
Nina Queisser, Gholamreza Fazeli, Nicole Schupp. (2010) Superoxide anion and hydrogen peroxide-induced signaling and damage in angiotensin II and aldosterone action. Biological Chemistry 391:11, 1265-1279
CrossRef275
Fabian Hammer, Nicola C. Edwards, Beverly A. Hughes, Richard P. Steeds, Charles J. Ferro, Jonathan N. Townend, Paul M. Stewart. (2010) The effect of spironolactone upon corticosteroid hormone metabolism in patients with early stage chronic kidney disease. Clinical Endocrinology 73:5, 566-572
CrossRef276
Sulaf J. Mansur, Fadi G. Hage, Suzanne Oparil. (2010) Have the Renin-Angiotensin-Aldosterone System Perturbations in Cardiovascular Disease Been Exhausted?. Current Cardiology Reports 12:6, 450-463
CrossRef277
Masayuki Yamaji, Takayoshi Tsutamoto, Chiho Kawahara, Keizo Nishiyama, Takashi Yamamoto, Masanori Fujii, Minoru Horie. (2010) Effect of eplerenone versus spironolactone on cortisol and hemoglobin A1c levels in patients with chronic heart failure. American Heart Journal 160:5, 915-921
CrossRef278
J. G. F. Cleland, A. P. Coletta, A. Torabi, D. Ahmed, A. L. Clark. (2010) Clinical trials update from the European Society of Cardiology Meeting 2010: SHIFT, PEARL-HF, STAR-heart, and HEBE-III. European Journal of Heart Failure 12:11, 1261-1264
CrossRef279
Jacob C. Jentzer, Tracy A. DeWald, Adrian F. Hernandez. (2010) Combination of Loop Diuretics With Thiazide-Type Diuretics in Heart Failure. Journal of the American College of Cardiology 56:19, 1527-1534
CrossRef280
Yoshiko Mizuno, Robert F. Jacob, R. Preston Mason. (2010) Advances in Pharmacologic Modulation of Nitric Oxide in Hypertension. Current Cardiology Reports 12:6, 472-480
CrossRef281
A. JANSSON, A. JOHANNISSON, C. KVART. (2010) Plasma aldosterone concentration and cardiovascular response to low sodium intake in horses in training. Equine Veterinary Journal 42, 329-334
CrossRef282
Mette Engbaek, Mette Hjerrild, Jesper Hallas, Ib A. Jacobsen. (2010) The effect of low-dose spironolactone on resistant hypertension. Journal of the American Society of Hypertension 4:6, 290-294
CrossRef283
G. K. Adler, I. Bonyhay, V. Curren, E. Waring, R. Freeman. (2010) Hypoglycaemia increases aldosterone in a dose-dependent fashion. Diabetic Medicine 27:11, 1250-1255
CrossRef284
Enrico Vizzardi, Antonio D'Aloia, Raffaele Giubbini, Tania Bordonali, Silvia Bugatti, Natalia Pezzali, Alessia Romeo, Alessandra Dei Cas, Marco Metra, Livio Dei Cas. (2010) Effect of Spironolactone on Left Ventricular Ejection Fraction and Volumes in Patients With Class I or II Heart Failure. The American Journal of Cardiology 106:9, 1292-1296
CrossRef285
Gennaro Cice, Attilio Di Benedetto, Salvatore D'Isa, Antonello D'Andrea, Daniele Marcelli, Emanuele Gatti, Raffaele Calabrò. (2010) Effects of Telmisartan Added to Angiotensin-Converting Enzyme Inhibitors on Mortality and Morbidity in Hemodialysis Patients With Chronic Heart Failure. Journal of the American College of Cardiology 56:21, 1701-1708
CrossRef286
Justin A. Ezekowitz, Michael A. McDonald. 2010. Management of Comorbidity in Chronic Heart Failure. , 137-156.
CrossRef287
Ronald Freudenberger. 2010. Management of Advanced Heart Failure. , 357-383.
CrossRef288
Vijay U. Rao, John R. Teerlink. 2010. Treating Systolic Heart Failure. , 287-326.
CrossRef289
Ruchika Dutta, Barry H. Greenberg. 2010. Neurohormonal Blocking Agents in the Treatment of Patients with Left Ventricular Dysfunction and Heart Failure. , 83-116.
CrossRef290
Nico R. Van de Veire, Jeroen J. Bax. 2010. Imaging the Failing Heart. , 45-81.
CrossRef291
Dawn Lombardo. 2010. Digoxin, Diuretics, and Vasodilators in Heart Failure. , 117-135.
CrossRef292
Melissa H. Kong, Eric D. Peterson, Gregg C. Fonarow, Gillian D. Sanders, Clyde W. Yancy, Andrea M. Russo, Anne B. Curtis, Samuel F. Sears Jr., Kevin L. Thomas, Susan Campbell. (2010) Addressing disparities in sudden cardiac arrest care and the underutilization of effective therapies. American Heart Journal 160:4, 605-618.e1
CrossRef293
Farzin Beygui, Eric Vicaut, Patrick Ecollan, Jacques Machecourt, Eric Van Belle, Faiez Zannad, Gilles Montalescot. (2010) Rationale for an early aldosterone blockade in acute myocardial infarction and design of the ALBATROSS trial. American Heart Journal 160:4, 642-648.e1
CrossRef294
Arjun D. Sinha, Rajiv Agarwal. (2010) Should All Hypertensive Dialysis Patients Receive a Blocker of the Renin-Angiotensin System?. Current Hypertension Reports 12:5, 356-363
CrossRef295
Ingegerd Östman-Smith. (2010) Hypertrophic cardiomyopathy in childhood and adolescence - strategies to prevent sudden death. Fundamental & Clinical Pharmacology 24:5, 637-652
CrossRef296
Andrew A. House, Mikko Haapio, Johan Lassus, Rinaldo Bellomo, Claudio Ronco. (2010) Therapeutic Strategies for Heart Failure in Cardiorenal Syndromes. American Journal of Kidney Diseases 56:4, 759-773
CrossRef297
Doson Chua, Anita Lo, Chris Lo. (2010) Spironolactone Use in Heart Failure Patients With End-Stage Renal Disease on Hemodialysis: Is It Safe?. Clinical Cardiology 33:10, 604-608
CrossRef298
Patricia Gangoiti, Luz Camacho, Lide Arana, Alberto Ouro, Maria H. Granado, Leyre Brizuela, Josefina Casas, Gemma Fabriás, José Luis Abad, Antonio Delgado, Antonio Gómez-Muñoz. (2010) Control of metabolism and signaling of simple bioactive sphingolipids: Implications in disease. Progress in Lipid Research 49:4, 316-334
CrossRef299
Guido Lastra, Sonal Dhuper, Megan S. Johnson, James R. Sowers. (2010) Salt, aldosterone, and insulin resistance: impact on the cardiovascular system. Nature Reviews Cardiology 7:10, 577-584
CrossRef300
Giuseppe Boriani, Igor Diemberger, Cinzia Valzania, Mauro Biffi, Cristian Martignani, Emanuel Raschi, Valentina Mantovani, Matteo Ziacchi, Matteo Bertini, Fabrizio De Ponti, Angelo Branzi. (2010) Role of drugs and devices in patients at risk of sudden cardiac death. Fundamental & Clinical Pharmacology 24:5, 575-594
CrossRef301
Matthew J. O'Connor, David N. Rosenthal, Robert E. Shaddy. (2010) Outpatient Management of Pediatric Heart Failure. Heart Failure Clinics 6:4, 515-529
CrossRef302
Stephen A. Douglas, Giora Z. Feuerstein. 2010. The Role of Translational Medicine and Predictive Biomarkers in the Development of Novel, Innovative Treatments for the Management of Chronic Heart Failure: A Pharmaceutical Industry Perspective. .
CrossRef303
F. H. Messerli, J. A. Staessen, F. Zannad. (2010) Of fads, fashion, surrogate endpoints and dual RAS blockade. European Heart Journal 31:18, 2205-2208
CrossRef304
Justin A. Ezekowitz, Padma Kaul. (2010) The epidemiology and management of elderly patients with myocardial infarction or heart failure. Heart Failure Reviews 15:5, 407-413
CrossRef305
Jay Margolis, Robert A Gerber, Craig Roberts, Mihai Gheorghiade. (2010) Adherence to Aldosterone-Blocking Agents in Patients with Heart Failure. American Journal of Therapeutics 17:5, 446-454
CrossRef306
Elisa Pereira, Agustín Carreño, Mazine Bennouna, Isabel Ferreras. (2010) La sombra del RALES es alargada. Atención Primaria 42:9, 487-488
CrossRef307
Judith Z. Goldfinger, Eric D. Adler. (2010) End-of-Life Options for Patients with Advanced Heart Failure. Current Heart Failure Reports 7:3, 140-147
CrossRef308
German Kamalov, Syamal K Bhattacharya, Karl T Weber. (2010) Congestive Heart Failure: Where Homeostasis Begets Dyshomeostasis. Journal of Cardiovascular Pharmacology 56:3, 320-328
CrossRef309
Aviva Gamliel-Lazarovich, Anna Gantman, Raymond Coleman, Arco Y Jeng, Marielle Kaplan, Shlomo Keidar. (2010) FAD286, an aldosterone synthase inhibitor, reduced atherosclerosis and inflammation in apolipoprotein E-deficient mice. Journal of Hypertension 28:9, 1900-1907
CrossRef310
Douglas L. Mann, Ronald J. Krone. (2010) Cardiac Disease in Cancer Patients: An Overview. Progress in Cardiovascular Diseases 53:2, 80-87
CrossRef311
Antonio Cherubini, Susanna Del Signore, Joe Ouslander, Todd Semla, Jean-Pierre Michel. (2010) Fighting Against Age Discrimination in Clinical Trials. Journal of the American Geriatrics Society 58:9, 1791-1796
CrossRef312
Robert D Toto. (2010) Aldosterone blockade in chronic kidney disease: can it improve outcome?. Current Opinion in Nephrology and Hypertension 19:5, 444-449
CrossRef313
Michael G. Usher, Sheng Zhong Duan, Christine Y. Ivaschenko, Ryan A. Frieler, Stefan Berger, Günther Schütz, Carey N. Lumeng, Richard M. Mortensen. (2010) Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice. Journal of Clinical Investigation 120:9, 3350-3364
CrossRef314
Michael R Lattanzio, Matthew R Weir. (2010) Have we fallen off target with concerns surrounding dual RAAS blockade?. Kidney International 78:6, 539-545
CrossRef315
John W Funder. (2010) Aldosterone, hypertension and heart failure: insights from clinical trials. Hypertension Research 33:9, 872-875
CrossRef316
Jiafu Wei, Juan Ni, Dejia Huang, Mao Chen, Shaodi Yan, Yong Peng. (2010) The Effect of Aldosterone Antagonists for Ventricular Arrhythmia: A Meta-Analysis. Clinical Cardiology 33:9, 572-577
CrossRef317
Amanda J Edgley, Henry Krum, Darren J Kelly. (2010) Targeting Fibrosis for the Treatment of Heart Failure: A Role for Transforming Growth Factor-β. Cardiovascular Therapeuticsno-no
CrossRef318
Josh Batterink, Sarah N Stabler, Aaron M Tejani, Curt T Fowkes, Aaron M Tejani. 2010. Spironolactone for hypertension. .
CrossRef319
F. Edelmann, A. G. Schmidt, G. Gelbrich, L. Binder, C. Herrmann-Lingen, M. Halle, G. Hasenfuss, R. Wachter, B. Pieske. (2010) Rationale and design of the 'aldosterone receptor blockade in diastolic heart failure' trial: a double-blind, randomized, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure (Aldo-DHF). European Journal of Heart Failure 12:8, 874-882
CrossRef320
Kristina Kusche-Vihrog, Chiara Callies, Johannes Fels, Hans Oberleithner. (2010) The epithelial sodium channel (ENaC): Mediator of the aldosterone response in the vascular endothelium?. Steroids 75:8-9, 544-549
CrossRef321
Finn Gustafsson, Julian Segura, Luis M Ruilope. (2010) How should we manage heart failure developing in patients already treated with angiotensin-converting enzyme inhibitors and beta-blockers for hypertension, diabetes or coronary disease?. Journal of Hypertension 28:8, 1595-1598
CrossRef322
Miki Nagase. (2010) Activation of the aldosterone/mineralocorticoid receptor system in chronic kidney disease and metabolic syndrome. Clinical and Experimental Nephrology 14:4, 303-314
CrossRef323
D. Le Menuet, M. Munier, G. Meduri, S. Viengchareun, M. Lombes. (2010) Mineralocorticoid receptor overexpression in embryonic stem cell-derived cardiomyocytes increases their beating frequency. Cardiovascular Research 87:3, 467-475
CrossRef324
Felipe A. Martinez. (2010) Aldosterone Inhibition and Cardiovascular Protection: More Important Than it Once Appeared. Cardiovascular Drugs and Therapy 24:4, 345-350
CrossRef325
Ludovit Paulis, Thomas Unger. (2010) Novel therapeutic targets for hypertension. Nature Reviews Cardiology 7:8, 431-441
CrossRef326
Claudia Grossmann, Stefanie Ruhs, Anja Seiferth, Michael Gekle. (2010) Interaction between mineralocorticoid receptor and cAMP/CREB signaling. Steroids 75:8-9, 539-543
CrossRef327
Meng-Ting Wang, Chen-Yi Su, Agnes L. F. Chan, Pei-Wen Lian, Hsin-Bang Leu, Yu-Juei Hsu. (2010) Risk of digoxin intoxication in heart failure patients exposed to digoxin-diuretic interactions: a population-based study. British Journal of Clinical Pharmacology 70:2, 258-267
CrossRef328
Yee Lu, Elaine Ku, Vito M. Campese. (2010) Aldosterone in the Pathogenesis of Chronic Kidney Disease and Proteinuria. Current Hypertension Reports 12:4, 303-306
CrossRef329
Shin-ichiro Miura, Keijiro Saku. (2010) Is a blood pressure rise the only deleterious off-target effect of cholesterol ester transfer protein inhibitors?. Journal of Hypertension 28:8, 1614-1616
CrossRef330
Christopher M. Adams, Chii-Whei Hu, Arco Y. Jeng, Rajeshri Karki, Gary Ksander, Dan LaSala, Jennifer Leung-Chu, Guiqing Liang, Qian Liu, Erik Meredith, Chang Rao, Dean F. Rigel, Jie Shi, Sherri Smith, Clayton Springer, Chun Zhang. (2010) The discovery of potent inhibitors of aldosterone synthase that exhibit selectivity over 11-β-hydroxylase. Bioorganic & Medicinal Chemistry Letters 20:15, 4324-4327
CrossRef331
Akira Sezai, Kazutomo Minami, Mitsumasa Hata, Isamu Yoshitake, Shinji Wakui, Ayako Takasaka, Tomohiko Murakami, Motomi Shiono, Tadateru Takayama, Atsushi Hirayama. (2010) Long-Term Results (Three-Year) of Emergency Coronary Artery Bypass Grafting for Patients With Unstable Angina Pectoris. The American Journal of Cardiology 106:4, 511-516
CrossRef332
Filippo Brandimarte, Gian Francesco Mureddu, Alessandro Boccanelli, Giuseppe Cacciatore, Camillo Brandimarte, Francesco Fedele, Mihai Gheorghiade. (2010) Diuretic therapy in heart failure: current controversies and new approaches for fluid removal. Journal of Cardiovascular Medicine 11:8, 563-570
CrossRef333
Puneeta Tandon, Juan G. Abraldes, Annalisa Berzigotti, Juan Carlos Garcia-Pagan, Jaime Bosch. (2010) Renin–angiotensin–aldosterone inhibitors in the reduction of portal pressure: A systematic review and meta-analysis. Journal of Hepatology 53:2, 273-282
CrossRef334
Thomas J Povsic, Christopher M O’Connor. (2010) Cell therapy for heart failure: the need for a new therapeutic strategy. Expert Review of Cardiovascular Therapy 8:8, 1107-1126
CrossRef335
Amir Tirosh, Rajesh Garg, Gail K. Adler. (2010) Mineralocorticoid Receptor Antagonists and the Metabolic Syndrome. Current Hypertension Reports 12:4, 252-257
CrossRef336
Raimund H. Pichler, Ian H. de Boer. (2010) Dual Renin-Angiotensin-Aldosterone System Blockade for Diabetic Kidney Disease. Current Diabetes Reports 10:4, 297-305
CrossRef337
Christopher M. O'Connor, Mona Fiuzat. (2010) Is Rehospitalization After Heart Failure Admission a Marker of Poor Quality?Time for Re-Evaluation
. Journal of the American College of Cardiology 56:5, 369-371
CrossRef338
Jaroslav Kalvoda, Marc de Gasparo. 2010. Eplerenone: Selective Aldosterone Antagonist. , 359-381.
CrossRef339
Inga S. Thrainsdottir, Lars Rydén. 2010. Congestive Heart Failure. , 684-697.
CrossRef340
Jesús Sánchez-Más, María C. Turpín, Antonio Lax, Juan A. Ruipérez, Mariano Valdés Chávarri, Domingo A. Pascual-Figal. (2010) Efecto diferencial de espironolactona frente a eplerenona sobre el papel protector in vitro de testosterona en la apoptosis de cardiocitos. Revista Española de Cardiología 63:7, 779-787
CrossRef341
K. Schmidt, R. Tissier, B. Ghaleh, T. Drogies, S. B. Felix, T. Krieg. (2010) Cardioprotective effects of mineralocorticoid receptor antagonists at reperfusion. European Heart Journal 31:13, 1655-1662
CrossRef342
A. Davenport, S. D. Anker, A. Mebazaa, A. Palazzuoli, G. Vescovo, R. Bellomo, P. Ponikowski, I. Anand, N. Aspromonte, S. Bagshaw, T. Berl, I. Bobek, D. N. Cruz, L. Daliento, M. Haapio, H. Hillege, A. House, N. Katz, A. Maisel, S. Mankad, P. McCullough, F. Ronco, A. Shaw, G. Sheinfeld, S. Soni, N. Zamperetti, P. Zanco, C. Ronco, . (2010) ADQI 7: the clinical management of the Cardio-Renal syndromes: work group statements from the 7th ADQI consensus conference. Nephrology Dialysis Transplantation 25:7, 2077-2089
CrossRef343
Philip A. Kithas, Mark A. Supiano. (2010) Spironolactone and Hydrochlorothiazide Decrease Vascular Stiffness and Blood Pressure in Geriatric Hypertension. Journal of the American Geriatrics Society 58:7, 1327-1332
CrossRef344
G. Michael Felker. (2010) Diuretic Management in Heart Failure. Congestive Heart Failure 16, S68-S72
CrossRef345
Heather Haley, David W. Ploth. (2010) Dyshomeostasis of Serum Sodium Concentration in Congestive Heart Failure. The American Journal of the Medical Sciences 340:1, 42-47
CrossRef346
Barry Greenberg. (2010) Managing hyponatremia in patients with heart failure. Journal of Hospital Medicine 5:S3, S33-S39
CrossRef347
Christian Werner, Janine Pöss, Michael Böhm. (2010) Optimal Antagonism of the Renin-Angiotensin-Aldosterone System. Drugs 70:10, 1215-1230
CrossRef348
Daniel G. Kramer, Thomas A. Trikalinos, David M. Kent, George V. Antonopoulos, Marvin A. Konstam, James E. Udelson. (2010) Quantitative Evaluation of Drug or Device Effects on Ventricular Remodeling as Predictors of Therapeutic Effects on Mortality in Patients With Heart Failure and Reduced Ejection Fraction. Journal of the American College of Cardiology 56:5, 392-406
CrossRef349
Hani M. Wadei, Stephen C. Textor. (2010) Hypertension in the kidney transplant recipient. Transplantation Reviews 24:3, 105-120
CrossRef350
Wilfried Mullens, Leonardo P. J. Oliveira, Tanya Verga, Bruce L. Wilkoff, Wai Hong Wilson Tang. (2010) Insights From Internet-Based Remote Intrathoracic Impedance Monitoring as Part of a Heart Failure Disease Management Program. Congestive Heart Failure 16:4, 159-163
CrossRef351
Heart Failure Society of America. (2010) Executive Summary: HFSA 2010 Comprehensive Heart Failure Practice Guideline. Journal of Cardiac Failure 16:6, 475-539
CrossRef352
A Sato, S Fukuda. (2010) Clinical effects of eplerenone, a selective aldosterone blocker, in Japanese patients with essential hypertension. Journal of Human Hypertension 24:6, 387-394
CrossRef353
Li Liu, Fandian Zeng, Xiaohua Zeng, Qingmei Xue, Shaoping Nie, Cailian Kang, Jianhong Wu, Qingyun Kang, Xingao Wang, Xiaoqing Liu, Tao Li, Jun Chen, Qing Li, Rong Xu, Xiaoyan Yang, Hui Kang, Fagang Jiang, Zongtao Li, Xuwu Wang, Li Zhang, Yu Long. (2010) Revaluation of clopidogrel: let the data speak for themselves. Journal of Huazhong University of Science and Technology [Medical Sciences] 30:3, 299-306
CrossRef354
D. Castagno, P. S. Jhund, J. J. V. McMurray, J. D. Lewsey, E. Erdmann, F. Zannad, W. J. Remme, J. L. Lopez-Sendon, P. Lechat, F. Follath, C. Hoglund, V. Mareev, Z. Sadowski, R. J. Seabra-Gomes, H. J. Dargie. (2010) Improved survival with bisoprolol in patients with heart failure and renal impairment: an analysis of the cardiac insufficiency bisoprolol study II (CIBIS-II) trial. European Journal of Heart Failure 12:6, 607-616
CrossRef355
Robert M Carey. (2010) Aldosterone and cardiovascular disease. Current Opinion in Endocrinology, Diabetes and Obesity 17:3, 194-198
CrossRef356
G. de Simone, M. Chinali, G.F. Mureddu, G. Cacciatore, D. Lucci, R. Latini, S. Masson, M. Vanasia, A.P. Maggioni, A. Boccanelli. (2010) Effect of canrenone on left ventricular mechanics in patients with mild systolic heart failure and metabolic syndrome: The AREA-in-CHF study. Nutrition, Metabolism and Cardiovascular Diseases
CrossRef357
J. GUYONNET, J. ELLIOTT, V. KALTSATOS. (2010) A preclinical pharmacokinetic and pharmacodynamic approach to determine a dose of spironolactone for treatment of congestive heart failure in dog. Journal of Veterinary Pharmacology and Therapeutics 33:3, 260-267
CrossRef358
(2010) Section 15: Management of Heart Failure in Special Populations. Journal of Cardiac Failure 16:6, e169-e175
CrossRef359
Hiromichi Kosaka, Kazunori Hirayama, Nobuyuki Yoda, Katsutoshi Sasaki, Tetsuya Kitayama, Hideaki Kusaka, Masahiro Matsubara. (2010) The L-, N-, and T-type triple calcium channel blocker benidipine acts as an antagonist of mineralocorticoid receptor, a member of nuclear receptor family. European Journal of Pharmacology 635:1-3, 49-55
CrossRef360
Katsuyuki Ando, Hiroshi Ohtsu, Yoshihiro Arakawa, Kiyoshi Kubota, Takuhiro Yamaguchi, Miki Nagase, Akira Yamada, Toshiro Fujita. (2010) Rationale and design of the Eplerenone combination Versus conventional Agents to Lower blood pressure on Urinary Antialbuminuric Treatment Effect (EVALUATE) trial: a double-blinded randomized placebo-controlled trial to evaluate the antialbuminuric effects of an aldosterone blocker in hypertensive patients with albuminuria. Hypertension Research 33:6, 616-621
CrossRef361
(2010) Section 7: Heart Failure in Patients With Reduced Ejection Fraction. Journal of Cardiac Failure 16:6, e73-e97
CrossRef362
(2010) Section 13: Evaluation and Therapy for Heart Failure in the Setting of Ischemic Heart Disease. Journal of Cardiac Failure 16:6, e157-e165
CrossRef363
Ellen W Seely. (2010) Editorial overview. Current Opinion in Endocrinology, Diabetes and Obesity 17:3, 187
CrossRef364
Ronald Otto, Regina E. Roller, Bernhard Iglseder, Peter Dovjak, Monika Lechleitner, Ulrike Sommeregger, Ursula Benvenuti-Falger, Birgit Böhmdorfer, Markus Gosch. (2010) Komplikationen durch Diuretikatherapie bei geriatrischen Patienten. Wiener Medizinische Wochenschrift 160:11-12, 276-280
CrossRef365
F. Zannad, J. J. V. McMurray, H. Drexler, H. Krum, D. J. van Veldhuisen, K. Swedberg, H. Shi, J. Vincent, B. Pitt. (2010) Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS-HF). European Journal of Heart Failure 12:6, 617-622
CrossRef366
A. Tomaschitz, S. Pilz, E. Ritz, A. Meinitzer, B. O. Boehm, W. Marz. (2010) Plasma aldosterone levels are associated with increased cardiovascular mortality: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. European Heart Journal 31:10, 1237-1247
CrossRef367
E Marie Freel, John MC Connell. (2010) Primary aldosteronism: an update. Expert Review of Endocrinology & Metabolism 5:3, 389-402
CrossRef368
Andrea D Eckhart. (2010) Mineralocorticoid receptors, corticosteroids and the heart: where do we stand?. Journal of Hypertension 28:5, 889-891
CrossRef369
Isabelle Bourdel-Marchasson, Hamid Laksir, Emilie Puget. (2010) Interpreting routine biochemistry in those aged over 65 years: A time for change. Maturitas 66:1, 39-45
CrossRef370
Karen Jenkins, Mary Kirk. (2010) HEART FAILURE AND CHRONIC KIDNEY DISEASE: AN INTEGRATED CARE APPROACH. Journal of Renal Care 36, 127-135
CrossRef371
O. James Ekundayo, Chris Adamopoulos, Mustafa I. Ahmed, Bertram Pitt, James B. Young, Jerome L. Fleg, Thomas E. Love, Xuemei Sui, Gilbert J. Perry, David S. Siscovick, George Bakris, Ali Ahmed. (2010) Oral potassium supplement use and outcomes in chronic heart failure: A propensity-matched study. International Journal of Cardiology 141:2, 167-174
CrossRef372
Marie Briet, Ernesto L. Schiffrin. (2010) Aldosterone: effects on the kidney and cardiovascular system. Nature Reviews Nephrology 6:5, 261-273
CrossRef373
Bodh I Jugdutt. (2010) Heart failure in the elderly: advances and challenges. Expert Review of Cardiovascular Therapy 8:5, 695-715
CrossRef374
Dawood Darbar. (2010) Genomics, heart failure and sudden cardiac death. Heart Failure Reviews 15:3, 229-238
CrossRef375
Robert W. Schrier. (2010) Hyperkalemia: a threat to RAAS inhibition?. Nature Reviews Nephrology 6:5, 245-246
CrossRef376
So-Jung Park, Irina Kufareva, Ruben Abagyan. (2010) Improved docking, screening and selectivity prediction for small molecule nuclear receptor modulators using conformational ensembles. Journal of Computer-Aided Molecular Design 24:5, 459-471
CrossRef377
Ching Yan Goh, Claudio Ronco. (2010) CARDIO-RENAL SYNDROMES. Journal of Renal Care 36, 9-17
CrossRef378
Marco L. Alves, Robert D. Gaffin, Beata M. Wolska. (2010) Rescue of familial cardiomyopathies by modifications at the level of sarcomere and Ca2+ fluxes. Journal of Molecular and Cellular Cardiology 48:5, 834-842
CrossRef379
Wenxia Chai, Johannes Hofland, Pieter M Jansen, Ingrid M Garrelds, René de Vries, Antoon J van den Bogaerdt, Richard A Feelders, Frank H de Jong, AH Jan Danser. (2010) Steroidogenesis vs. steroid uptake in the heart: do corticosteroids mediate effects via cardiac mineralocorticoid receptors?. Journal of Hypertension 28:5, 1044-1053
CrossRef380
Bård Waldum, Arne S. Westheim, Leiv Sandvik, Berit Flønæs, Morten Grundtvig, Lars Gullestad, Torstein Hole, Ingrid Os. (2010) Renal Function in Outpatients With Chronic Heart Failure. Journal of Cardiac Failure 16:5, 374-380
CrossRef381
Jula K. Inrig. (2010) Antihypertensive Agents in Hemodialysis Patients: A Current Perspective. Seminars in Dialysis 23:3, 290-297
CrossRef382
Kursat Tigen, Tansu Karaahmet, Cevat Kirma, Cihan Dundar, Selcuk Pala, Iclal Isiklar, Cihan Cevik, Alev Kilicgedik, Yelda Basaran. (2010) Diffuse Late Gadolinium Enhancement by Cardiovascular Magnetic Resonance Predicts Significant Intraventricular Systolic Dyssynchrony in Patients With Non-Ischemic Dilated Cardiomyopathy. Journal of the American Society of Echocardiography 23:4, 416-422
CrossRef383
P. OVAERT, J. ELLIOTT, F. BERNAY, E. GUILLOT, T. BARDON. (2010) Aldosterone receptor antagonists - how cardiovascular actions may explain their beneficial effects in heart failure. Journal of Veterinary Pharmacology and Therapeutics 33:2, 109-117
CrossRef384
Kenji Oki, Kiminori Yamane, Kenichi Satoh, Shuhei Nakanishi, Hideya Yamamoto, Nobuoki Kohno. (2010) Aldosterone synthase (CYP11B2) C-344T polymorphism affects the association of age-related changes of the serum C-reactive protein. Hypertension Research 33:4, 326-330
CrossRef385
Alejandro Martinez-Aguayo, Cristian A. Carvajal, Carmen Campino, Marlene Aglony, Lillian Bolte, Hernán Garcia, Carlos E. Fardella. (2010) Primary Aldosteronism and its Impact on the Generation of Arterial Hypertension, Endothelial Injury and Oxidative Stress. Journal of Pediatric Endocrinology and Metabolism 23:4, 323-330
CrossRef386
Marsha A. Raebel, Colleen Ross, Stanley Xu, Douglas W. Roblin, Craig Cheetham, Christopher M. Blanchette, Gwyn Saylor, David H. Smith. (2010) Diabetes and Drug-Associated Hyperkalemia: Effect of Potassium Monitoring. Journal of General Internal Medicine 25:4, 326-333
CrossRef387
Anju Bhardwaj, Shafiq U. Rehman, Asim Mohammed, Aaron L. Baggish, Stephanie A. Moore, James L. Januzzi. (2010) Design and methods of the Pro-B Type Natriuretic Peptide Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study. American Heart Journal 159:4, 532-538.e1
CrossRef388
Brian L. Furman. 2010. Endocrine and Metabolic Agents. .
CrossRef389
Ross D. Feldman, Robert Gros. (2010) Rapid vascular effects of steroids – a question of balance?. Canadian Journal of Cardiology 26, 22A-26A
CrossRef390
John W. Funder. (2010) Aldosterone and Mineralocorticoid Receptors in the Cardiovascular System. Progress in Cardiovascular Diseases 52:5, 393-400
CrossRef391
Jason Pellman, Robert C. Lyon, Farah Sheikh. (2010) Extracellular matrix remodeling in atrial fibrosis: Mechanisms and implications in atrial fibrillation. Journal of Molecular and Cellular Cardiology 48:3, 461-467
CrossRef392
Hiroaki Kawano, Koichi Node. (2010) Medical agents acting on the renin–angiotensin–aldosterone axis for the treatment of heart failure. Hypertension Research 33:3, 192-193
CrossRef393
Ehab S El Desoky. (2010) Drug Therapy of Heart Failure: An Immunologic View. American Journal of Therapeutics1
CrossRef394
V.-P. Harjola, F. Follath, M. S. Nieminen, D. Brutsaert, K. Dickstein, H. Drexler, M. Hochadel, M. Komajda, J. L. Lopez-Sendon, P. Ponikowski, L. Tavazzi. (2010) Characteristics, outcomes, and predictors of mortality at 3 months and 1 year in patients hospitalized for acute heart failure. European Journal of Heart Failure 12:3, 239-248
CrossRef395
Jan Galle. (2010) Das kardiorenale Syndrom. Medizinische Klinik 105:3, 142-149
CrossRef396
Hannah Asghar, Peter S. Rahko. (2010) Quality of Heart Failure Management: A Comparison of Care Between a Comprehensive Heart Failure Program and a General Cardiology Practice. Congestive Heart Failure 16:2, 65-70
CrossRef397
Sibylle Wenzel, Ilhan Tastan, Yaser Abdallah, Rolf Schreckenberg, Klaus-Dieter Schlüter. (2010) Aldosterone improves contractile function of adult rat ventricular cardiomyocytes in a non-acute way: potential relationship to the calcium paradox of aldosteronism. Basic Research in Cardiology 105:2, 247-256
CrossRef398
OZLEM TIRYAKI, CELALETTIN USALAN, HAKAN BUYUKHATIPOGLU. (2010) Effect of combined angiotensin-converting enzyme and aldosterone inhibition on plasma plasminogen activator inhibitor type 1 levels in chronic hypertensive patients. Nephrology 15:2, 211-215
CrossRef399
Jane-Lise Samuel, Claude Delcayre. (2010) Heart failure: Aldosterone antagonists are underused by clinicians. Nature Reviews Cardiology 7:3, 125-127
CrossRef400
Pengxiang Huang, Vikas Chandra, Fraydoon Rastinejad. (2010) Structural Overview of the Nuclear Receptor Superfamily: Insights into Physiology and Therapeutics. Annual Review of Physiology 72:1, 247-272
CrossRef401
P. Schuetz, M. Batschwaroff, F. Dusemund, W. Albrich, U. Bürgi, M. Maurer, M. Brutsche, A. R. Huber, B. Müller. (2010) Effectiveness of a procalcitonin algorithm to guide antibiotic therapy in respiratory tract infections outside of study conditions: a post-study survey. European Journal of Clinical Microbiology & Infectious Diseases 29:3, 269-277
CrossRef402
E P Brass. (2010) The Gap Between Clinical Trials and Clinical Practice: The Use of Pragmatic Clinical Trials to Inform Regulatory Decision Making. Clinical Pharmacology & Therapeutics 87:3, 351-355
CrossRef403
Jennifer NA Silva, Charles E Canter. (2010) Current management of pediatric dilated cardiomyopathy. Current Opinion in Cardiology 25:2, 80-87
CrossRef404
Maartje CJ Slagman, Gerjan Navis, Gozewijn D Laverman. (2010) Dual blockade of the renin–angiotensin–aldosterone system in cardiac and renal disease. Current Opinion in Nephrology and Hypertension 19:2, 140-152
CrossRef405
G Arunagirinathan, G McKay, M Fisher. (2010) Spironolactone. Practical Diabetes International 27:2, 85-86
CrossRef406
Carlos M. Ferrario. (2010) Addressing the theoretical and clinical advantages of combination therapy with inhibitors of the renin–angiotensin–aldosterone system: Antihypertensive effects and benefits beyond BP control. Life Sciences 86:9-10, 289-299
CrossRef407
O M Dekkers, E v. Elm, A Algra, J A Romijn, J P Vandenbroucke. (2010) How to assess the external validity of therapeutic trials: a conceptual approach. International Journal of Epidemiology 39:1, 89-94
CrossRef408
C-K Wu, J-L Luo, C-T Tsai, Y-T Huang, C-L Cheng, J-K Lee, L-Y Lin, J-W Lin, J-J Hwang, F-T Chiang. (2010) Demonstrating the pharmacogenetic effects of angiotensin-converting enzyme inhibitors on long-term prognosis of diastolic heart failure. The Pharmacogenomics Journal 10:1, 46-53
CrossRef409
Charles R Salters, Alison L Bailey, Thomas F Whayne. (2010) Current treatment of heart failure in the USA. Expert Review of Cardiovascular Therapy 8:2, 279-290
CrossRef410
Muntaser D Musameh, Colin J Green, Brian E Mann, Roberto Motterlini, Barry J Fuller. (2010) CO Liberated From a Carbon Monoxide-Releasing Molecule Exerts a Positive Inotropic Effect in Doxorubicin-Induced Cardiomyopathy. Journal of Cardiovascular Pharmacology 55:2, 168-175
CrossRef411
Munir Pirmohamed. (2010) Drug-drug interactions and adverse drug reactions: separating the wheat from the chaff. Wiener klinische Wochenschrift 122:3-4, 62-64
CrossRef412
Michael Bader. (2010) Tissue Renin-Angiotensin-Aldosterone Systems: Targets for Pharmacological Therapy. Annual Review of Pharmacology and Toxicology 50:1, 439-465
CrossRef413
Oliver Vonend, Ivo Quack, Lars Christian Rump. (2010) Aldosteron und Hypertonie. Wiener klinische Wochenschrift 122:3-4, 65-74
CrossRef414
Mithilesh K Das, Douglas P Zipes. (2010) Antiarrhythmic and Nonantiarrhythmic Drugs for Sudden Cardiac Death Prevention. Journal of Cardiovascular Pharmacology1
CrossRef415
Osman Najam, Nizar Yonan, Simon G. Williams, Steven M. Shaw. (2010) The Usefulness of Chronic Heart Failure Treatments in Chronic Cardiac Graft Failure. Cardiovascular Therapeutics 28:1, 48-58
CrossRef416
Zefeng Zhang, Elizabeth M. Mahoney, Paul Kolm, John Spertus, Jaime Caro, Richard Willke, William S. Weintraub. (2010) Cost Effectiveness of Eplerenone in Patients with Heart Failure after Acute Myocardial Infarction Who were Taking Both ACE Inhibitors and β-Blockers. American Journal Cardiovascular Drugs 10:1, 55-63
CrossRef417
Hirofumi Ueno, Michihiro Yoshimura, Masafumi Nakayama, Megumi Yamamuro, Tsunenori Nishijima, Kenichi Kusuhara, Yasuhiro Nagayoshi, Sunao Kojima, Koichi Kaikita, Hitoshi Sumida. (2010) Clinical factors affecting serum potassium concentration in cardio-renal decompensation syndrome. International Journal of Cardiology 138:2, 174-181
CrossRef418
McMurray, John J.V., . (2010) Systolic Heart Failure. New England Journal of Medicine 362:3, 228-238
Full Text419
Roger Hullin. 2010. Treatment of Left Ventricular Failure. , 152-160.
CrossRef420
Mari Hosoda, Toshiharu Fujita, Masayuki Hashiguchi, Yosuke Fujii, Mayumi Mochizuki. (2010) A Pharmacologic Study on Risk Factors of Hyperkalaemia or Increased Blood Potassium Associated with ACE-Inhibitor Therapy. Japanese Journal of Pharmacoepidemiology/Yakuzai ekigaku 15:2, 49-59
CrossRef421
Larisa H Cavallari, Vicki L Groo, Marlos A. G Viana, Yang Dai, Shitalben R Patel, Thomas D Stamos. (2010) Association of Aldosterone Concentration and Mineralocorticoid Receptor Genotype with Potassium Response to Spironolactone in Patients with Heart Failure. Pharmacotherapy 30:1, 1-9
CrossRef422
Juan Pablo Kaski, Perry Elliott. 2010. Cardiomyopathies. , 1003-1034.
CrossRef423
Elisa Ruano Cea, Philippe Jouvet, Suzanne Vobecky, Aicha Merouani. (2010) Draining Fluids through a Peritoneal Catheter in Newborns after Cardiac Surgery Helps to Control Fluid Balance. Case Reports in Medicine 2010, 1-3
CrossRef424
Ralf Bauer, Alison Blain, Elizabeth Greally, Hanns Lochmüller, Kate Bushby, Guy A. MacGowan, Volker Straub. (2010) Attenuation of adverse cardiac effects in prednisolone-treated δ-sarcoglycan-deficient mice by mineralocorticoid-receptor-antagonism. Neuromuscular Disorders 20:1, 21-28
CrossRef425
Pei De-An, Li Li, Xu Zhi-Yun, Huang Jin-Yu, Xu Zheng-Ming, Wang Min, Yao Qiang, Huang Shi-eng. (2010) Increased Expression of Mineralocorticoid Receptor and 11β-Hydroxysteroid Dehydrogenase Type 2 in Human Atria During Atrial Fibrillation. Clinical Cardiology 33:1, 23-29
CrossRef426
Marsha A. Raebel, Colleen Ross, Craig Cheetham, Hans Petersen, Gwyn Saylor, David H. Smith, Leslie A. Wright, Douglas W. Roblin, Stanley Xu. (2010) Increasingly restrictive definitions of hyperkalemia outcomes in a database study: effect on incidence estimates. Pharmacoepidemiology and Drug Safety 19:1, 19-25
CrossRef427
Christian Gratzke, Javier Angulo, Kanchan Chitaley, Yu-tian Dai, Noel N. Kim, Jaw-Seung Paick, Ulf Simonsen, Stefan Ãckert, Eric Wespes, Karl E. Andersson, Tom F. Lue, Christian G. Stief. (2010) Anatomy, Physiology, and Pathophysiology of Erectile Dysfunction. Journal of Sexual Medicine 7:1pt2, 445-475
CrossRef428
Pawan D Patel, Rohit R Arora. (2010) Practical Implications of ACC/AHA 2007 Guidelines for the Management of Unstable Angina/Non-ST Elevation Myocardial Infarction. American Journal of Therapeutics 17:1, e24-e40
CrossRef429
Xiao-Jun Du, Ross A. D. Bathgate, Chrishan S. Samuel, Anthony M. Dart, Roger J. Summers. (2010) Cardiovascular effects of relaxin: from basic science to clinical therapy. Nature Reviews Cardiology 7:1, 48-58
CrossRef430
Anders Hovland, Anne Fagerheim, Randolf Hardersen, Erik Nielsen. (2010) Eldre mann med kjent hjertesvikt innlagt med kardiogent sjokk. Tidsskrift for Den norske legeforening 130:13, 1352-1354
CrossRef431
Robin A.P. Weir, Ashley M. Miller, Grace E.J. Murphy, Suzanne Clements, Tracey Steedman, John M.C. Connell, Iain B. McInnes, Henry J. Dargie, John J.V. McMurray. (2010) Serum Soluble ST2. Journal of the American College of Cardiology 55:3, 243-250
CrossRef432
Laura D. Kubzansky, Gail K. Adler. (2010) Aldosterone: A forgotten mediator of the relationship between psychological stress and heart disease. Neuroscience & Biobehavioral Reviews 34:1, 80-86
CrossRef433
Venkata M. Alla, Kishlay Anand, Mandeep Hundal, Aimin Chen, Showri Karnam, Tom Hee, Claire Hunter, Aryan N. Mooss, Dennis Esterbrooks, Syed M. Mohiuddin. (2010) Impact of Moderate to Severe Renal Impairment on Mortality and Appropriate Shocks in Patients with Implantable Cardioverter Defibrillators. Cardiology Research and Practice 2010, 1-6
CrossRef434
Clive Rosendorff. (2010) Spironolactone for all hypertensive patients?. Journal of Hypertension 28:1, 13-14
CrossRef435
Steven A Yarows. (2010) Aliskiren/valsartan combination for the treatment of cardiovascular and renal diseases. Expert Review of Cardiovascular Therapy 8:1, 19-33
CrossRef436
C. Ronco, P. McCullough, S. D. Anker, I. Anand, N. Aspromonte, S. M. Bagshaw, R. Bellomo, T. Berl, I. Bobek, D. N. Cruz, L. Daliento, A. Davenport, M. Haapio, H. Hillege, A. A. House, N. Katz, A. Maisel, S. Mankad, P. Zanco, A. Mebazaa, A. Palazzuoli, F. Ronco, A. Shaw, G. Sheinfeld, S. Soni, G. Vescovo, N. Zamperetti, P. Ponikowski, . (2009) Cardio-renal syndromes: report from the consensus conference of the Acute Dialysis Quality Initiative. European Heart Journal
CrossRef437
Slaughter, Mark S., Rogers, Joseph G., Milano, Carmelo A., Russell, Stuart D., Conte, John V., Feldman, David, Sun, Benjamin, Tatooles, Antone J., Delgado, Reynolds M. III, Long, James W., Wozniak, Thomas C., Ghumman, Waqas, Farrar, David J., Frazier, O. Howard, . (2009) Advanced Heart Failure Treated with Continuous-Flow Left Ventricular Assist Device. New England Journal of Medicine 361:23, 2241-2251
Full Text438
M.R. Davies, J. Cousins. (2009) Cardiomyopathy and anaesthesia. Continuing Education in Anaesthesia, Critical Care & Pain 9:6, 189-193
CrossRef439
Elizabeth M. Volz, G. Michael Felker. (2009) How to use diuretics in heart failure. Current Treatment Options in Cardiovascular Medicine 11:6, 426-432
CrossRef440
Bruno Vogt, Michel Burnier. (2009) Aldosterone and cardiovascular risk. Current Hypertension Reports 11:6, 450-455
CrossRef441
Manish M. Sood, Marisa Battistella, Charmaine E. Lok. (2009) Patterns of cardioprotective medication prescription in incident hemodialysis patients. International Urology and Nephrology 41:4, 1021-1027
CrossRef442
Farouk Mookadam, Sherif E. Moustafa. (2009) Prevention of late postmyocardial infarction left ventricular remodeling: An update. Current Heart Failure Reports 6:4, 245-253
CrossRef443
John G. Lainchbury, Richard W. Troughton, Kim M. Strangman, Christopher M. Frampton, Anna Pilbrow, Timothy G. Yandle, Amjad K. Hamid, M. Gary Nicholls, A. Mark Richards. (2009) N-Terminal Pro–B-Type Natriuretic Peptide-Guided Treatment for Chronic Heart Failure. Journal of the American College of Cardiology 55:1, 53-60
CrossRef444
Jane A Leopold. (2009) Rapid Aldosterone Signaling and Vascular Reactivity: Relax or Donʼt Do It. Journal of Cardiovascular Pharmacology 54:6, 465-467
CrossRef445
Anita D. Szady, James A. Hill. (2009) Diuretics in Heart Failure. Drugs 69:17, 2451-2461
CrossRef446
Rona Limor, Marielle Kaplan, Orly Sharon, Esther Knoll, Michal Naidich, Gary Weisinger, Shlomo Keidar, Naftali Stern. (2009) Aldosterone up-regulates 12- and 15-lipoxygenase expression and LDL oxidation in human vascular smooth muscle cells. Journal of Cellular Biochemistry 108:5, 1203-1210
CrossRef447
Young-Sin Kim, Barry Greenberg. (2009) Update on renin-angiotensin-aldosterone blockade in heart failure. Current Treatment Options in Cardiovascular Medicine 11:6, 455-466
CrossRef448
Bhoomika R Goyal, Nilay Solanki, Ramesh K Goyal, Anita A Mehta. (2009) Investigation Into the Cardiac Effects of Spironolactone in the Experimental Model of Type 1 Diabetes. Journal of Cardiovascular Pharmacology 54:6, 502-509
CrossRef449
Francesco Locatelli, Biff F. Palmer, Naoki Kashihara, Tevfik Ecder. (2009) Renal protective effect of RAAS blockade across the renal continuum, with a review of the efficacy and safety of valsartan. Current Medical Research and Opinion 25:12, 2933-2949
CrossRef450
Akshay S. Desai. (2009) Hyperkalemia in patients with heart failure: Incidence, prevalence, and management. Current Heart Failure Reports 6:4, 272-280
CrossRef451
Gaspare Parrinello, Pietro Di Pasquale, Giuseppe Licata, Daniele Torres, Marco Giammanco, Sergio Fasullo, Manuela Mezzero, Salvatore Paterna. (2009) Long-Term Effects of Dietary Sodium Intake on Cytokines and Neurohormonal Activation in Patients With Recently Compensated Congestive Heart Failure. Journal of Cardiac Failure 15:10, 864-873
CrossRef452
Daniel LaSala, Yasuhiko Shibanaka, Arco Y. Jeng. (2009) Coexpression of CYP11B2 or CYP11B1 with adrenodoxin and adrenodoxin reductase for assessing the potency and selectivity of aldosterone synthase inhibitors. Analytical Biochemistry 394:1, 56-61
CrossRef453
P. W.X. Foley, F. Leyva, M. P. Frenneaux. (2009) What is treatment success in cardiac resynchronization therapy?. Europace 11:Supplement 5, v58-v65
CrossRef454
Hoong Sern Lim, Roger Beadle, Michael Frenneaux. (2009) Death and Dying in Heart Failure With Normal Ejection Fraction. The American Journal of Cardiology 104:9, 1311-1314
CrossRef455
M. Khaled Shamseddin, Patrick S. Parfrey. (2009) Mechanisms of the cardiorenal syndromes. Nature Reviews Nephrology 5:11, 641-649
CrossRef456
Filippos Triposkiadis, George Karayannis, Grigorios Giamouzis, John Skoularigis, George Louridas, Javed Butler. (2009) The Sympathetic Nervous System in Heart Failure. Journal of the American College of Cardiology 54:19, 1747-1762
CrossRef457
F. Zannad, N. Agrinier, F. Alla. (2009) Heart failure burden and therapy. Europace 11:Supplement 5, v1-v9
CrossRef458
Sunjay Kaushal, Jeffrey Phillip Jacobs, Jeffrey G. Gossett, Ann Steele, Peter Steele, Craig R. Davis, Elfriede Pahl, Kalpana Vijayan, Alfred Asante-Korang, Robert J. Boucek, Carl L. Backer, Loren E. Wold. (2009) Innovation in Basic Science: Stem Cells and their role in the treatment of Paediatric Cardiac Failure – Opportunities and Challenges. Cardiology in the Young 19:S2, 74
CrossRef459
Tatsuhiko Mori, Daisuke Kurumazuka, Chika Matsumoto, Hisashi Shirakawa, Sayaka Kimura, Kento Kitada, Kana Kobayashi, Hirohisa Matsuda, Tetsuya Hayashi, Yasushi Kitaura, Yasuo Matsumura. (2009) Dietary salt restriction activates mineralocorticoid receptor signaling in volume-overloaded heart failure. European Journal of Pharmacology 623:1-3, 84-88
CrossRef460
Benjamin J Epstein, Steven M Smith, Rushab Choksi. (2009) Recent changes in the landscape of combination RAS blockade. Expert Review of Cardiovascular Therapy 7:11, 1373-1384
CrossRef461
Bertram Pitt. (2009) Pharmacotherapy: Cardiovascular effects of aldosterone blockade in CKD. Nature Reviews Cardiology 6:11, 679-680
CrossRef462
Eyal Leibovitz, Talin Ebrahimian, Pierre Paradis, Ernesto L Schiffrin. (2009) Aldosterone induces arterial stiffness in absence of oxidative stress and endothelial dysfunction. Journal of Hypertension 27:11, 2192-2200
CrossRef463
C. Adamopoulos, A. Ahmed, R. Fay, M. Angioi, G. Filippatos, J. Vincent, B. Pitt, F. Zannad, . (2009) Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHESUS trial. European Journal of Heart Failure 11:11, 1099-1105
CrossRef464
M. Klapholz, W. T. Abraham, J. K. Ghali, P. Ponikowski, S. D. Anker, B. Knusel, Y. Sun, S. M. Wasserman, D. J. van Veldhuisen. (2009) The safety and tolerability of darbepoetin alfa in patients with anaemia and symptomatic heart failure. European Journal of Heart Failure 11:11, 1071-1077
CrossRef465
Aaron M Tejani, Curt T Fowkes, Josh Batterink, Aaron M Tejani. 2009. Spironolactone for hypertension. .
CrossRef466
Brenda S. Thompson. (2009) Sudden Cardiac Death and Heart Failure. AACN Advanced Critical Care 20:4, 356-365
CrossRef467
Stefan Farese, Anja Kruse, Andreas Pasch, Bernhard Dick, Brigitte M Frey, Dominik E Uehlinger, Felix J Frey. (2009) Glycyrrhetinic acid food supplementation lowers serum potassium concentration in chronic hemodialysis patients. Kidney International 76:8, 877-884
CrossRef468
Noel S. Weiss. (2009) “Population-based outcome studies” of therapy: potentially useful, but not a panacea. Journal of Clinical Epidemiology 62:10, 1003-1005
CrossRef469
Ana R. Lehenbauer Ludke, Abd Al-Rahman S. Al-Shudiefat, Sanjiv Dhingra, Davinder S. Jassal, Pawan K. Singal. (2009) A concise description of cardioprotective strategies in doxorubicin-induced cardiotoxicityThis article is one of a selection of papers published in a special issue celebrating the 125th anniversary of the Faculty of Medicine at the University of Manitoba.. Canadian Journal of Physiology and Pharmacology 87:10, 756-763
CrossRef470
A. Hirata, N. Maeda, A. Hiuge, T. Hibuse, K. Fujita, T. Okada, S. Kihara, T. Funahashi, I. Shimomura. (2009) Blockade of mineralocorticoid receptor reverses adipocyte dysfunction and insulin resistance in obese mice. Cardiovascular Research 84:1, 164-172
CrossRef471
Shun Kohsaka, Shunichi Homma. (2009) Anticoagulation for heart failure: selecting the best therapy. Expert Review of Cardiovascular Therapy 7:10, 1209-1217
CrossRef472
Manouchehr Nakhjavani, Sepehr Hamidi, Alireza Esteghamati, Mehrshad Abbasi, Simindokht Nosratian-Jahromi, Parvin Pasalar. (2009) Short term effects of spironolactone on blood lipid profile: a 3-month study on a cohort of young women with hirsutism. British Journal of Clinical Pharmacology 68:4, 634-637
CrossRef473
Victor Soukoulis, Jamil B. Dihu, Michael Sole, Stefan D. Anker, John Cleland, Gregg C. Fonarow, Marco Metra, Evasio Pasini, Theresa Strzelczyk, Heinrich Taegtmeyer, Mihai Gheorghiade. (2009) Micronutrient Deficiencies. Journal of the American College of Cardiology 54:18, 1660-1673
CrossRef474
Andrew S. Bomback, Robert Toto. (2009) Dual Blockade of the Renin–Angiotensin–Aldosterone System: Beyond the ACE Inhibitor and Angiotensin-II Receptor Blocker Combination. American Journal of Hypertension 22:10, 1032-1040
CrossRef475
Travis J. McKenzie, Joseph B. Lillegard, William F. Young, Geoffrey B. Thompson. (2009) Aldosteronomas—State of the Art. Surgical Clinics of North America 89:5, 1241-1253
CrossRef476
Jonathan G. Howlett, O. Elizabeth Mann, Robert Baillie, Ronald Hatheway, Anna Svendsen, Rosalind Benoit, Carol Ferguson, Marlene Wheatley, David E. Johnstone, Jafna L. Cox. (2009) Heart failure clinics are associated with clinical benefit in both tertiary and community care settings: Data from the Improving Cardiovascular Outcomes in Nova Scotia (ICONS) registry. Canadian Journal of Cardiology 25:9, S306-S311
CrossRef477
Garrick C. Stewart, Kimberly Brooks, Parakash P. Pratibhu, Sui W. Tsang, Marc J. Semigran, Colleen M. Smith, Catherine Saniuk, Janice M. Camuso, James C. Fang, Gilbert H. Mudge, Gregory S. Couper, Kenneth L. Baughman, Lynne W. Stevenson. (2009) Thresholds of Physical Activity and Life Expectancy for Patients Considering Destination Ventricular Assist Devices. The Journal of Heart and Lung Transplantation 28:9, 863-869
CrossRef478
A. Brent Alper, Ruth C. Campbell, Stefan D. Anker, George Bakris, Christy Wahle, Thomas E. Love, L. Lee Hamm, Marjan Mujib, Ali Ahmed. (2009) A propensity-matched study of low serum potassium and mortality in older adults with chronic heart failure. International Journal of Cardiology 137:1, 1-8
CrossRef479
Kursat Tigen, Tansu Karaahmet, Emre Gurel, Cihan Cevik, Kenneth Nugent, Selcuk Pala, Ali Cevat Tanalp, Bulent Mutlu, Yelda Basaran. (2009) The utility of fragmented QRS complexes to predict significant intraventricular dyssynchrony in nonischemic dilated cardiomyopathy patients with a narrow QRS interval. Canadian Journal of Cardiology 25:9, 517-522
CrossRef480
E. Visús, E. Gargallo, P. Conthe. (2009) Novedades terapéuticas: estudio I-PRESERVE. Revista Clínica Española 209, 36-40
CrossRef481
R. Berger, A. Shankar, F. Fruhwald, A. Fahrleitner-Pammer, N. Freemantle, L. Tavazzi, J. G.F. Cleland, R. Pacher. (2009) Relationships between cardiac resynchronization therapy and N-terminal pro-brain natriuretic peptide in patients with heart failure and markers of cardiac dyssynchrony: an analysis from the Cardiac Resynchronization in Heart Failure (CARE-HF) study. European Heart Journal 30:17, 2109-2116
CrossRef482
Nona Sotoodehnia, Guo Li, Catherine O. Johnson, Rozenn N. Lemaitre, Kenneth M. Rice, Thomas D. Rea, David S. Siscovick. (2009) Genetic variation in angiotensin-converting enzyme–related pathways associated with sudden cardiac arrest risk. Heart Rhythm 6:9, 1306-1314
CrossRef483
Shweta Bansal, David Badesch, Todd Bull, Robert W. Schrier. (2009) Role of vasopressin and aldosterone in pulmonary arterial hypertension: A pilot study
. Contemporary Clinical Trials 30:5, 392-399
CrossRef484
Christina Ries, Simon Lucas, Ralf Heim, Barbara Birk, Rolf W. Hartmann. (2009) Selective aldosterone synthase inhibitors reduce aldosterone formation in vitro and in vivo. The Journal of Steroid Biochemistry and Molecular Biology 116:3-5, 121-126
CrossRef485
Parminder S. Chaggar, Chris J. Malkin, Steven M. Shaw, Simon G. Williams, Kevin S. Channer. (2009) Neuroendocrine Effects on the Heart and Targets for Therapeutic Manipulation in Heart Failure. Cardiovascular Therapeutics 27:3, 187-193
CrossRef486
J. Potratz, U. Wiegand. (2009) Kardiale Resynchronisationstherapie. Herzschrittmachertherapie + Elektrophysiologie 20:3, 99-102
CrossRef487
P.A. Mehta, S. McDonagh, J. Phillips, R. Grocott-Mason, S.W. Dubrey. (2009) Angiotensin Receptor Blocker Therapy for Heart Failure Patients: Is Combination Treatment a Feasible Prospect?. Clinical Cardiology 32:9, 513-518
CrossRef488
Alan H. Gradman. (2009) Role of Angiotensin II Type 1 Receptor Antagonists in the Treatment of Hypertension in Patients Aged ≥65 Years. Drugs & Aging 26:9, 751-767
CrossRef489
Sabine Oertelt-Prigione, Vera Regitz-Zagrosek. (2009) Gender Aspects in Cardiovascular Pharmacology. Journal of Cardiovascular Translational Research 2:3, 258-266
CrossRef490
J. Häggström, K. Höglund, M. Borgarelli. (2009) An update on treatment and prognostic indicators in canine myxomatous mitral valve disease. Journal of Small Animal Practice 50, 25-33
CrossRef491
Jill S. Burkiewicz, Kathy E. Komperda. (2009) An Elective Course on Landmark Trials to Improve Pharmacy Students' Literature Evaluation and Therapeutic Application Skills. American Journal of Pharmaceutical Education 73:2, 31
CrossRef492
Zian H. Tseng. (2009) Genetic association studies of sudden cardiac death/arrest: The importance of context. Heart Rhythm 6:9, 1315-1317
CrossRef493
C. Grossmann, M. Gekle. (2009) New aspects of rapid aldosterone signaling. Molecular and Cellular Endocrinology 308:1-2, 53-62
CrossRef494
AR Costa, LB Torres, E Medei, RA Ricardo, JP França, S Smaili, JHM Nascimento, MEM Oshiro, JWM Bassani, AT Ferreira, PJF Tucci. (2009) The negative inotropic action of canrenone is mediated by L-type calcium current blockade and reduced intracellular calcium transients. British Journal of Pharmacology 158:2, 580-587
CrossRef495
Chris Adamopoulos, Bertram Pitt, Xuemei Sui, Thomas E. Love, Faiez Zannad, Ali Ahmed. (2009) Low serum magnesium and cardiovascular mortality in chronic heart failure: A propensity-matched study
CrossRef496
Nicola C. Edwards, Richard P. Steeds, Paul M. Stewart, Charles J. Ferro, Jonathan N. Townend. (2009) Effect of Spironolactone on Left Ventricular Mass and Aortic Stiffness in Early-Stage Chronic Kidney DiseaseA Randomized Controlled Trial. Journal of the American College of Cardiology 54:6, 505-512
CrossRef497
Mohammad N. Jameel, Jianyi Zhang. (2009) Heart Failure Management: The Present and the Future. Antioxidants & Redox Signaling 11:8, 1989-2010
CrossRef498
William C. Little, Paul M. Kirkman. (2009) Moving Beyond Angiotensin II to Also Target Aldosterone?. Journal of the American College of Cardiology 54:6, 513-514
CrossRef499
Takayoshi Tsutamoto, Toshinari Tanaka, Keizo Nishiyama, Masayuki Yamaji, Chiho Kawahara, Masanori Fujii, Takashi Yamamoto, Minoru Horie. (2009) Long-term effect of efonidipine therapy on plasma aldosterone and left ventricular mass index in patients with essential hypertension. Hypertension Research 32:8, 670-674
CrossRef500
Junko Kurokawa, Hugues Abriel. (2009) Neurohormonal Regulation of Cardiac Ion Channels in Chronic Heart Failure. Journal of Cardiovascular Pharmacology 54:2, 98-105
CrossRef501
Takahiro Ohmine, Yoshikazu Miwa, Fumi Takahashi-Yanaga, Sachio Morimoto, Yoshihiko Maehara, Toshiyuki Sasaguri. (2009) The involvement of aldosterone in cyclic stretch-mediated activation of NADPH oxidase in vascular smooth muscle cells. Hypertension Research 32:8, 690-699
CrossRef502
Michael A. Chen. (2009) Heart Failure with Preserved Ejection Fraction in Older Adults. The American Journal of Medicine 122:8, 713-723
CrossRef503
Eileen M. Hsich, Ileana L. Piña. (2009) Heart Failure in Women. Journal of the American College of Cardiology 54:6, 491-498
CrossRef504
E. Ritz, A. Tomaschitz. (2009) Aldosterone, a vasculotoxic agent--novel functions for an old hormone. Nephrology Dialysis Transplantation 24:8, 2302-2305
CrossRef505
Miki Nagase, Toshiro Fujita. (2009) Mineralocorticoid receptor activation in obesity hypertension. Hypertension Research 32:8, 649-657
CrossRef506
B. A. Haynes, F. Mookadam. (2009) Male Gynecomastia. Mayo Clinic Proceedings 84:8, 672-672
CrossRef507
J. H. O'Keefe, M. D. Carter, C. J. Lavie. (2009) Primary and Secondary Prevention of Cardiovascular Diseases: A Practical Evidence-Based Approach. Mayo Clinic Proceedings 84:8, 741-757
CrossRef508
Sankar D Navaneethan, Sagar U Nigwekar, Ashwini R Sehgal, Giovanni FM Strippoli, Sankar D Navaneethan. 2009. Aldosterone antagonists for preventing the progression of chronic kidney disease. .
CrossRef509
Ralph AH Stewart. (2009) Clinical trials in heart valve disease. Current Opinion in Cardiology 24:4, 279-287
CrossRef510
Sarah J. Goodlin. (2009) Palliative Care in Congestive Heart Failure. Journal of the American College of Cardiology 54:5, 386-396
CrossRef511
Philip JW Koh, Audrey Koitka, Mark E Cooper, Terri J Allen. (2009) Eplerenone does not attenuate diabetes-associated atherosclerosis. Journal of Hypertension 27:7, 1431-1438
CrossRef512
Kevin T. Bain, Terri L. Maxwell, Scott A. Strassels, David J. Whellan. (2009) Hospice use among patients with heart failure. American Heart Journal 158:1, 118-125
CrossRef513
Makoto Kawai, Kenichi Hongo, Kimiaki Komukai, Satoshi Morimoto, Makoto Nagai, Shingo Seki, Ikuo Taniguchi, Seibu Mochizuki, Michihiro Yoshimura. (2009) Telmisartan predominantly suppresses cardiac fibrosis, rather than hypertrophy, in renovascular hypertensive rats. Hypertension Research 32:7, 604-610
CrossRef514
Guido Lastra-Lastra, James R. Sowers, Katherine Restrepo-Erazo, Camila Manrique-Acevedo, Guido Lastra-González. (2009) Role of aldosterone and angiotensin II in insulin resistance: an update. Clinical Endocrinology 71:1, 1-6
CrossRef515
Andrew D. Sumner, John P. Boehmer, Leslie A. Saxon, Peter Carson, Arthur M. Feldman, Elizabeth Galle, Michael R. Bristow. (2009) Statin Use Is Associated With Improved Survival in Patients With Advanced Heart Failure Receiving Resynchronization Therapy. Congestive Heart Failure 15:4, 159-164
CrossRef516
K. De Silva, R. Katbamna. (2009) Principles of heart failure. InnovAiT 2:7, 423-429
CrossRef517
Bertram Pitt, John Nicklas. (2009) Loop Diuretics in Patients With Heart Failure: Time to Change to Torsemide?. Journal of Cardiovascular Pharmacology 53:6, 435-437
CrossRef518
Bertram Pitt. (2009) Multiple renin-angiotensin-aldosterone-blocking agents in heart failure: How much is too much?. Current Heart Failure Reports 6:2, 112-116
CrossRef519
Robin A.P. Weir, Patrick B. Mark, Colin J. Petrie, Suzanne Clements, Tracey Steedman, Ian Ford, Leong L. Ng, Iain B. Squire, Galen S. Wagner, John J.V. McMurray. (2009) Left ventricular remodeling after acute myocardial infarction: Does eplerenone have an effect?. American Heart Journal 157:6, 1088-1096
CrossRef520
Veselin Mitrovic, Karl-Friedrich Appel, Nicolaos Proskynitopoulos, Seyfettin Dereli, Christian Wilhelm Hamm. (2009) Effects of candesartan cilexetil “add-on” treatment in congestive heart failure outpatients in daily practice. Clinical Research in Cardiology 98:6, 379-389
CrossRef521
Marcelle D. Smit, Isabelle C. Gelder, Michael Böhm, Hans-Ruprecht Neuberger, Dirk J. Veldhuisen. (2009) Should aldosterone blockade be used beyond current indications in heart failure?. Current Heart Failure Reports 6:2, 117-125
CrossRef522
Ken Harada, Hideo Izawa, Takao Nishizawa, Akihiro Hirashiki, Yosuke Murase, Masakazu Kobayashi, Satoshi Isobe, Xian Wu Cheng, Akiko Noda, Kohzo Nagata, Mitsuhiro Yokota, Toyoaki Murohara. (2009) Beneficial Effects of Torasemide on Systolic Wall Stress and Sympathetic Nervous Activity in Asymptomatic or Mildly Symptomatic Patients With Heart Failure: Comparison With Azosemide. Journal of Cardiovascular Pharmacology 53:6, 468-473
CrossRef523
Vivencio Barrios, Carlos Escobar. (2009) Hipertensión arterial refractaria. ¿Cuál es la mejor opción?. Revista Española de Cardiología 62:6, 711-712
CrossRef524
Praveen Kandula, Ravish Shah. (2009) Safety of Spironolactone Use in Ambulatory Heart Failure Patients. Clinical Cardiology 32:6, 347-348
CrossRef525
Gabriel Sayer, Yoshifumi Naka, Ulrich P. Jorde. (2009) Ventricular Assist Device Therapy. Cardiovascular Therapeutics 27:2, 140-150
CrossRef526
Michael R. MacDonald, Mark C. Petrie, Miles Fisher, John J. V. McMurray. (2009) Pharmacologic management of patients with both heart failure and diabetes. Current Heart Failure Reports 6:2, 126-132
CrossRef527
Michael Gekle, Claudia Grossmann. (2009) Actions of aldosterone in the cardiovascular system: the good, the bad, and the ugly?. Pflügers Archiv - European Journal of Physiology 458:2, 231-246
CrossRef528
Brett R. Cowan, Alistair A. Young. (2009) Left ventricular hypertrophy and renin-angiotensin system blockade. Current Hypertension Reports 11:3, 167-172
CrossRef529
Omalhassan Amir, Yahaya Hassan, Azmi Sarriff, Ahmed Awaisu, Noorizan Abd. Aziz, Omar Ismail. (2009) Incidence of risk factors for developing hyperkalemia when using ACE inhibitors in cardiovascular diseases. Pharmacy World & Science 31:3, 387-393
CrossRef530
Sarah J. Goodlin. (2009) End-of-life care in heart failure. Current Cardiology Reports 11:3, 184-191
CrossRef531
Dai Yumino, Hanqiao Wang, John S. Floras, Gary E. Newton, Susanna Mak, Pimon Ruttanaumpawan, John D. Parker, T. Douglas Bradley. (2009) Prevalence and Physiological Predictors of Sleep Apnea in Patients With Heart Failure and Systolic Dysfunction. Journal of Cardiac Failure 15:4, 279-285
CrossRef532
Krishna K. Gaddam, Anil Verma, Mark Thompson, Rohit Amin, Hector Ventura. (2009) Hypertension and Cardiac Failure in its Various Forms. Medical Clinics of North America 93:3, 665-680
CrossRef533
J. Fernández de Bobadilla, J. López-Sendón. (2009) Enfermedad renal: implicaciones terapéuticas en insuficiencia cardíaca y cardiopatía isquémica. Medicina Clínica 132, 48-54
CrossRef534
Matthew D Bacchetta, Arash Salemi, Federico Milla, Mun K Hong, Fermin Tio, Ying Zhou, Rong Chen, Edward Southard, Leonard Y Lee, Charles A Mack, Karl H Krieger, O Wayne Isom, Wilson Ko, Jeffrey S Borer, Daniel F Catanzaro. (2009) Low-Dose Spironolactone: Effects on Artery-to-Artery Vein Grafts and Percutaneous Coronary Intervention Sites. American Journal of Therapeutics 16:3, 204-214
CrossRef535
Zubin Eapen, Joseph G Rogers. (2009) Strategies to attenuate pathological remodeling in heart failure. Current Opinion in Cardiology 24:3, 223-229
CrossRef536
William B Lea, Eun Soo Kwak, James M Luther, Susan M Fowler, Zuofei Wang, Ji Ma, Agnes B Fogo, Nancy J Brown. (2009) Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt. Kidney International 75:9, 936-944
CrossRef537
Tomohito Ohtani, Toshiaki Mano, Shungo Hikoso, Yasushi Sakata, Mayu Nishio, Yasuharu Takeda, Kinya Otsu, Takeshi Miwa, Tohru Masuyama, Masatsugu Hori, Kazuhiro Yamamoto. (2009) Cardiac steroidogenesis and glucocorticoid in the development of cardiac hypertrophy during the progression to heart failure. Journal of Hypertension 27:5, 1074-1083
CrossRef538
Mohammed A. Rafey. (2009) Resistant Hypertension in the Elderly. Clinics in Geriatric Medicine 25:2, 289-301
CrossRef539
Camila Manrique, Guido Lastra, Michael Gardner, James R. Sowers. (2009) The Renin Angiotensin Aldosterone System in Hypertension: Roles of Insulin Resistance and Oxidative Stress. Medical Clinics of North America 93:3, 569-582
CrossRef540
H.-H. Parving, B. M. Brenner, John. J. V. McMurray, D. de Zeeuw, S. M. Haffner, S. D. Solomon, N. Chaturvedi, M. Ghadanfar, N. Weissbach, Z. Xiang, J. Armbrecht, M. A. Pfeffer. (2009) Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrology Dialysis Transplantation 24:5, 1663-1671
CrossRef541
Sarah M. Donlan, Erin Quattromani, Peter S. Pang, Mihai Gheorghiade. (2009) Therapy for acute heart failure syndromes. Current Cardiology Reports 11:3, 192-201
CrossRef542
Sankar D Navaneethan, Francesca Pansini, Vlado Perkovic, Carlo Manno, Fabio Pellegrini, David W Johnson, Jonathan C Craig, Giovanni FM Strippoli, Sankar D Navaneethan. 2009. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. .
CrossRef543
Waleed A. Ahmed, Phillip J. Tully, Robert A. Baker, John L. Knight. (2009) Survival After Isolated Coronary Artery Bypass Grafting in Patients With Severe Left Ventricular Dysfunction. The Annals of Thoracic Surgery 87:4, 1106-1112
CrossRef544
Rosemeire M. Kanashiro-Takeuchi, Bettina Heidecker, Guillaume Lamirault, Jennifer W. Dharamsi, Joshua M. Hare. (2009) Sex-Specific Impact of Aldosterone Receptor Antagonism on Ventricular Remodeling and Gene Expression after Myocardial Infarction. Clinical and Translational Science 2:2, 134-142
CrossRef545
H.J. Dargie. (2009) Current controversies in drug use. European Journal of Heart Failure Supplements 8:Supplement 1, i15-i20
CrossRef546
Colin D. Clyne, Ching-Yi Chang, Rachid Safi, Peter J. Fuller, Donald P. McDonnell, Morag J. Young. (2009) Purification and characterization of recombinant human mineralocorticoid receptor. Molecular and Cellular Endocrinology 302:1, 81-85
CrossRef547
Saraswathy Manickavasagam, Ramanna Merla, Michael M Koerner, Ken Fujise, Sanjay Kunapuli, Salvatore Rosanio, Alejandro Barbagelata. (2009) Management of hypertension in chronic heart failure. Expert Review of Cardiovascular Therapy 7:4, 423-433
CrossRef548
Jun Iwanami, Masaki Mogi, Masaru Iwai, Masatsugu Horiuchi. (2009) Inhibition of the renin–angiotensin system and target organ protection. Hypertension Research 32:4, 229-237
CrossRef549
Giorgio Costantino, Anna Maria Rusconi, Pier Giorgio Duca, Stefano Guzzetti, Ilaria Bossi, Marta Medico, Giuseppina Pisano, Mara Bulgheroni, Monica Solbiati, Raffaello Furlan, Nicola Montano. (2009) Eligibility criteria in heart failure randomized controlled trials: a gap between evidence and clinical practice. Internal and Emergency Medicine 4:2, 117-122
CrossRef550
Xiao-Jun Du, Qi Xu, Edna Lekgabe, Xiao-Ming Gao, Helen Kiriazis, Xiao-Lei Moore, Anthony M. Dart, Geoffrey W. Tregear, Ross A. D. Bathgate, Chrishan S. Samuel. (2009) Reversal of Cardiac Fibrosis and Related Dysfunction by Relaxin. Annals of the New York Academy of Sciences 1160:1, 278-284
CrossRef551
M. Komajda. (2009) Heart failure guidelines in North America and Europe: agreement or disagreement?. European Journal of Heart Failure Supplements 8:Supplement 1, i11-i14
CrossRef552
R. Kreutz. (2009) Besonderheiten der Pharmakotherapie beim älteren Hypertoniker. Der Internist 50:4, 442-454
CrossRef553
K. Swedberg. (2009) Tailoring therapy in chronic heart failure. European Journal of Heart Failure Supplements 8:Supplement 1, i25-i29
CrossRef554
Pieter M Jansen, AH Jan Danser, Ben P Imholz, Anton H van den Meiracker. (2009) Aldosterone-receptor antagonism in hypertension. Journal of Hypertension 27:4, 680-691
CrossRef555
Mariell Jessup, William T. Abraham, Donald E. Casey, Arthur M. Feldman, Gary S. Francis, Theodore G. Ganiats, Marvin A. Konstam, Donna M. Mancini, Peter S. Rahko, Marc A. Silver, Lynne Warner Stevenson, Clyde W. Yancy. (2009) 2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults. Journal of the American College of Cardiology 53:15, 1343-1382
CrossRef556
Sharon Ann Hunt, William T. Abraham, Marshall H. Chin, Arthur M. Feldman, Gary S. Francis, Theodore G. Ganiats, Mariell Jessup, Marvin A. Konstam, Donna M. Mancini, Keith Michl, John A. Oates, Peter S. Rahko, Marc A. Silver, Lynne Warner Stevenson, Clyde W. Yancy. (2009) 2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults. Journal of the American College of Cardiology 53:15, e1-e90
CrossRef557
C. D. Holloway, S. M. MacKenzie, R. Fraser, S. Miller, M. Barr, D. Wilkinson, G. H. Forbes, E. Friel, J. M. C. Connell, E. Davies. (2009) Effects of genetic variation in the aldosterone synthase ( CYP11B2 ) gene on enzyme function. Clinical Endocrinology 70:3, 363-371
CrossRef558
John W. Funder, Anastasia S. Mihailidou. (2009) Aldosterone and mineralocorticoid receptors: Clinical studies and basic biology. Molecular and Cellular Endocrinology 301:1-2, 2-6
CrossRef559
Ralph A.H. Stewart, Harvey D. White. (2009) Reply to: Role of aldosterone receptor antagonist eplerenone in aortic steroids. American Heart Journal 157:3, e17-e17
CrossRef560
Florence Wong. (2009) Cirrhotic cardiomyopathy. Hepatology International 3:1, 294-304
CrossRef561
Donah Zachariah, Philip A. Kalra, Paul R. Kalra. (2009) OPTIMAL MANAGEMENT OF CHRONIC HEART FAILURE IN PATIENTS WITH CHRONIC KIDNEY DISEASE. Journal of Renal Care 35:1, 2-10
CrossRef562
Theodore A. Kotchen, Jane M. Kotchen, Clarence E. Grim, Shanthi Krishnaswami, Srividya Kidambi. (2009) Aldosterone and Alterations of Hypertension-Related Vascular Function in African Americans. American Journal of Hypertension 22:3, 319-324
CrossRef563
Radhakrishnan Ramaraj. (2009) Role of aldosterone receptor antagonist eplerenone in aortic stenosis. American Heart Journal 157:3, e13-e13
CrossRef564
Eleanor Davies, Scott M. MacKenzie, E. Marie Freel, Samantha Alvarez-Madrazo, Robert Fraser, John M.C. Connell. (2009) Altered corticosteroid biosynthesis in essential hypertension: A digenic phenomenon. Molecular and Cellular Endocrinology 300:1-2, 185-191
CrossRef565
Patrick W.F. Hadoke, Javaid Iqbal, Brian R. Walker. (2009) Therapeutic manipulation of glucocorticoid metabolism in cardiovascular disease. British Journal of Pharmacology 156:5, 689-712
CrossRef566
Apurv Khanna, William B. White. (2009) The Management of Hyperkalemia in Patients with Cardiovascular Disease. The American Journal of Medicine 122:3, 215-221
CrossRef567
Kurt R. Daniel, Gretchen Wells, Kathryn Stewart, Brian Moore, Dalane W. Kitzman. (2009) Effect of Aldosterone Antagonism on Exercise Tolerance, Doppler Diastolic Function, and Quality of Life in Older Women With Diastolic Heart Failure. Congestive Heart Failure 15:2, 68-74
CrossRef568
Henry Krum, William T Abraham. (2009) Heart failure. The Lancet 373:9667, 941-955
CrossRef569
P.A. Mehta, S.W. Dubrey. (2009) High output heart failure. QJM 102:4, 235-241
CrossRef570
Douglas L. Mann. (2009) Molecular Imaging and the Failing HeartThrough the Looking Glass
CrossRef571
Cynthia A Sanoski. (2009) Aliskiren: An Oral Direct Renin Inhibitor for the Treatment of Hypertension. Pharmacotherapy 29:2, 193-212
CrossRef572
K GADDAM, E PIMENTA, S HUSAIN, D CALHOUN. (2009) Aldosterone and Cardiovascular Disease. Current Problems in Cardiology 34:2, 51-84
CrossRef573
Riccardo Lacchini, Maricene Sabha, Fernanda B Coeli, Fabrício F Favero, Juan Yugar-Toledo, Tatiane C Izidoro-Toledo, Valéria C Sandrim, José E Tanus-Santos, Maricilda P de Mello, Heitor Moreno. (2009) T allele of −344C/T polymorphism in aldosterone synthase gene is not associated with resistant hypertension. Hypertension Research 32:2, 159-162
CrossRef574
Murray Epstein. (2009) Hyperkalemia as a Constraint to Therapy With Combination Renin-Angiotensin System Blockade: The Elephant in the Room. The Journal of Clinical Hypertension 11:2, 55-60
CrossRef575
Ramesh C. Gupta, Sudhish Mishra, Mengjun Wang, Alice Jiang, Sharad Rastogi, Benny Rousso, Yuval Mika, Hani N. Sabbah. (2009) Cardiac Contractility Modulation Electrical Signals Normalize Activity, Expression, and Phosphorylation of the Na+-Ca2+ Exchanger in Heart Failure. Journal of Cardiac Failure 15:1, 48-56
CrossRef576
Susanne W.M. van den Borne, Satoshi Isobe, H. Reinier Zandbergen, Peng Li, Artiom Petrov, Nathan D. Wong, Shinichiro Fujimoto, Ai Fujimoto, Dagfinn Lovhaug, Jos F.M. Smits, Mat J.A.P. Daemen, W. Matthijs Blankesteijn, Chris Reutelingsperger, Faiez Zannad, Navneet Narula, Mani A. Vannan, Bertram Pitt, Leonard Hofstra, Jagat Narula. (2009) Molecular Imaging for Efficacy of Pharmacologic Intervention in Myocardial Remodeling. JACC: Cardiovascular Imaging 2:2, 187-198
CrossRef577
Martin Braun, Frank Edelmann, Markus Knapp, Steffen Schön, Carsten Schwencke, Gregor Simonis, Mathias Borst, Christof Weinbrenner, Ruth H. Strasser. (2009) The calcium channel blocker felodipine attenuates the positive hemodynamic effects of the β-blocker metoprolol in severe dilated cardiomyopathy — A prospective, randomized, double-blind and placebo-controlled study with invasive hemodynamic assessment. International Journal of Cardiology 132:2, 248-256
CrossRef578
Alex Odermatt, Atanas G. Atanasov. (2009) Mineralocorticoid receptors: Emerging complexity and functional diversity. Steroids 74:2, 163-171
CrossRef579
C WASYWICH, G WHALLEY, H WALSH, G GAMBLE, R DOUGHTY. (2009) Changes in Tissue-Doppler Echocardiographic Assessment of Left Ventricular Filling During NT-proBNP Guided Heart Failure Treatment Titration: A Pilot Study. Heart, Lung and Circulation 18:1, 38-44
CrossRef580
Kathy M Makkar, Cynthia A Sanoski, Sarah A Spinler. (2009) Role of Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Aldosterone Antagonists in the Prevention of Atrial and Ventricular Arrhythmias. Pharmacotherapy 29:1, 31-48
CrossRef581
Hiromi RAKUGI. (2009) Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics 40:2, 49S-50S
CrossRef582
Miyashita Yutaka, Mizuo Mifune, Eiji Kubota, Hiroshi Itoh, Ikuo Saito. (2009) Comparison of Effects of Low Dose of Spironolactone and a Thiazide Diuretic in Patients with Hypertension Treated with an Angiotensin-Converting Enzyme Inhibitor or an Angiotensin Type 1 Receptor Blocker. Clinical and Experimental Hypertension 31:8, 648-656
CrossRef583
P. de Groote, R. Isnard, P. Clerson, G. Jondeau, M. Galinier, P. Assyag, N. Demil, A. Ducardonnet, J.-F. Thebaut, M. Komajda. (2009) Improvement in the management of chronic heart failure since the publication of the updated guidelines of the European Society of Cardiology: The Impact-Reco Programme. European Journal of Heart Failure 11:1, 85-91
CrossRef584
Mark E Anderson, Peter J Mohler. (2009) Rescuing a failing heart: think globally, treat locally. Nature Medicine 15:1, 25-26
CrossRef585
William T. Mahle, Alicia Wang, Arshed A. Quyyumi, Michael E. McConnell, Wendy M. Book. (2009) Impact of Spironolactone on Endothelial Function in Patients with Single Ventricle Heart. Congenital Heart Disease 4:1, 12-16
CrossRef586
Nicola Acquarone, Cristoforo Castello, Giancarlo Antonucci, Sergio Lione, Paolo Bellotti. (2009) Pharmacologic therapy in patients with chronic heart failure and chronic kidney disease: a complex issue. Journal of Cardiovascular Medicine 10:1, 13-21
CrossRef587
Thomas E. Kottke, Dennis A. Faith, Courtney O. Jordan, Nicolaas P. Pronk, Randal J. Thomas, Simon Capewell. (2009) The Comparative Effectiveness of Heart Disease Prevention and Treatment Strategies. American Journal of Preventive Medicine 36:1, 82-88.e5
CrossRef588
Jong-Won Ha, Jae K. Oh. (2009) Therapeutic Strategies for Diastolic Dysfunction: A Clinical Perspective. Journal of Cardiovascular Ultrasound 17:3, 86
CrossRef589
Hiroko TANAKA, Kenichi WATANABE, Meilei HARIMA, Punniyakoti Veeraveedu THANIKACHALAM, Ken'ichi YAMAGUCHI, Hitoshi TACHIKAWA, Makoto KODAMA, Yoshifusa AIZAWA. (2009) Effects of Various Diuretics on Cardiac Function in Rats with Heart Failure. YAKUGAKU ZASSHI 129:7, 871-879
CrossRef590
Erkan Sengul, Tayfun Sahin, Erce Sevin, Ahmet Yilmaz. (2009) Effect of Spironolactone on Urinary Protein Excretion in Patients with Chronic Kidney Disease. Renal Failure 31:10, 928-932
CrossRef591
Anil Kumar, Wilbert S Aronow, Aniket Vadnerkar, Kasturi Sivan, Sanjay Mittal. (2009) Effects of Increased Dose of Diuretics on Symptoms, Weight, 6-Minute Walk Distance, and Echocardiographic Measurements of Left Ventricular Systolic and Diastolic Function in 51 Patients With Symptomatic Heart Failure Caused by Reduced Left Ventricular Ejection Fraction Treated With Beta Blockers and Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers. American Journal of Therapeutics 16:1, 5-7
CrossRef592
Tina H. Leetmaa, Henrik Villadsen, Kirsten V. Mikkelsen, Flemming Davidsen, Torben Haghfelt, Lars Videbæk. (2009) Are there long-term benefits in following stable heart failure patients in a heart failure clinic?. Scandinavian Cardiovascular Journal 43:3, 158-162
CrossRef593
Nabil El-Sherif, Abdullah Khan, Joseph Savarese, Gioia Turitto. (2009) Sudden Cardiac Death and Coronary Artery Disease-Pathophysiology and Risk Stratification. Journal of Arrhythmia 25:3, 122-129
CrossRef594
E. Born-Frontsberg, M. Quinkler. (2009) Conn-Syndrom. Der Internist 50:1, 17-26
CrossRef595
Juan M. Aranda, James W. Johnson, Jamie B. Conti. (2009) Current trends in heart failure readmission rates: analysis of medicare data. Clinical Cardiology 32:1, 47-52
CrossRef596
Paul Chacko, Shibu Philip. (2009) Emergency Department Presentation of Heart Transplant Recipients with Acute Heart Failure. Heart Failure Clinics 5:1, 129-143
CrossRef597
F. Orso, S. Baldasseroni, G. Fabbri, L. Gonzini, D. Lucci, C. D'Ambrosi, M. Gobbi, G. Lecchi, S. Randazzo, G. Masotti, L. Tavazzi, A. P. Maggioni, . (2009) Role of beta-blockers in patients admitted for worsening heart failure in a real world setting: data from the Italian Survey on Acute Heart Failure. European Journal of Heart Failure 11:1, 77-84
CrossRef598
J. Douglas Kirk, John T. Parissis, Gerasimos Filippatos. (2009) Pharmacologic Stabilization and Management of Acute Heart Failure Syndromes in the Emergency Department. Heart Failure Clinics 5:1, 43-54
CrossRef599
Philip E Brandish, Thomas W Forest, Hongxing Chen, Nicholas T Gatto, Sylvain Molon-Noblot, Izabela Zwierzynski, Peter Szczerba, Gary E Adamson, Bennett K Ma, Osvaldo A Flores, James C Hershey. (2009) Eplerenone Decreases Inflammatory Foci in Spontaneously Hypertensive Rat Hearts With Minimal Effects on Blood Pressure. Journal of Cardiovascular Pharmacology 53:1, 44-51
CrossRef600
A AHMED, F WAAGSTEIN, B PITT, M WHITE, F ZANNAD, J YOUNG, S RAHIMTOOLA. (2009) Effectiveness of Digoxin in Reducing One-Year Mortality in Chronic Heart Failure in the Digitalis Investigation Group Trial. The American Journal of Cardiology 103:1, 82-87
CrossRef601
Robert S McKelvie. (2009) The CHARM program: the effects of candesartan for the management of patients with chronic heart failure. Expert Review of Cardiovascular Therapy 7:1, 9-16
CrossRef602
Wilbert S. Aronow. (2009) Treating Hypertension in Older Adults. Drug Safety 32:2, 111-118
CrossRef603
Mei-Mei Kau, Shu-Fen Kan, Jiing-Rong Wang, Paulus S. Wang, Ying-Tung Lau, Shyi-Wu Wang. (2009) Acute effects of digoxin on plasma aldosterone and cortisol in monkeys. Metabolism 58:1, 55-61
CrossRef604
A. Boccanelli, G. F. Mureddu, G. Cacciatore, F. Clemenza, A. Di Lenarda, A. Gavazzi, M. Porcu, R. Latini, D. Lucci, A. P. Maggioni, S. Masson, M. Vanasia, G. de Simone, . (2009) Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results. European Journal of Heart Failure 11:1, 68-76
CrossRef605
Pramod Reddy, Arshag D Mooradian. (2009) Diuretics: An Update on the Pharmacology and Clinical Uses. American Journal of Therapeutics 16:1, 74-85
CrossRef606
Joel Menard. 2009. The History of the Renin–Angiotensin System. , 127-134.
CrossRef607
Rajesh Garg, Gail K. Adler. 2009. Aldosterone and its Cardiovascular Effects. , 349-359.
CrossRef608
John Coghlan, James F. Tait. 2009. Aldosterone: History and Introduction. , 309-327.
CrossRef609
William E. Rainey, Wendy B. Bollag, Carlos M. Isales. 2009. Regulation of Aldosterone Production. , 361-381.
CrossRef610
John C. Alexander, Daniel E. Salazar. 2009. Modern Drug Discovery and Development. , 361-380.
CrossRef611
Jason G. Umans, Edgardo J. Abalos, Marshall D. Lindheimer. 2009. Antihypertensive Treatment. , 369-387.
CrossRef612
Massie, Barry M., Carson, Peter E., McMurray, John J., Komajda, Michel, McKelvie, Robert, Zile, Michael R., Anderson, Susan, Donovan, Mark, Iverson, Erik, Staiger, Christoph, Ptaszynska, Agata, . (2008) Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction. New England Journal of Medicine 359:23, 2456-2467
Full Text613
M MIANA, D SANZROSA, N DELASHERAS, B MARTIN, V CACHOFEIRO, V LAHERA. (2008) Participación de los mineralocorticoides en la respuesta inflamatoria vascular asociada a la hipertensión
CrossRef614
(2008) Guía de práctica clínica de la Sociedad Europea de Cardiología (ESC) para el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica (2008). Revista Española de Cardiología 61:12, 1329.e1-1329.e70
CrossRef615
J. Paul Rocchiccioli, John J.V. McMurray. (2008) Medical management of advanced heart failure. Progress in Palliative Care 16:5, 229-240
CrossRef616
Michael D. Faulx, Gary S. Francis. (2008) Adverse Drug Reactions in Patients with Cardiovascular Disease. Current Problems in Cardiology 33:12, 703-768
CrossRef617
Juan Carlos Estrada, Dawood Darbar. (2008) Clinical use of and future perspectives on antiarrhythmic drugs. European Journal of Clinical Pharmacology 64:12, 1139-1146
CrossRef618
George V. Moukarbel, Scott D. Solomon. (2008) Treatment of asymptomatic left ventricular dysfunction. Current Treatment Options in Cardiovascular Medicine 10:6, 476-485
CrossRef619
Benjamin W Van Tassell, Przemyslaw Radwanski, Matthew Movsesian, Mark A Munger. (2008) Combination Therapy with β-Adrenergic Receptor Antagonists and Phosphodiesterase Inhibitors for Chronic Heart Failure. Pharmacotherapy 28:12, 1523-1530
CrossRef620
Yasutomo Hori, Akiko Katou, Mizuho Tsubaki, Kazutaka Kanai, Ruriko Nakao, Fumio Hoshi, Naoyuki Itoh, Sei-ichi Higuchi. (2008) Assessment of diuretic effects and changes in plasma aldosterone concentration following oral administration of a single dose of furosemide or azosemide in healthy dogs. American Journal of Veterinary Research 69:12, 1664-1669
CrossRef621
Beth D. Kaufman, Robert E. Shaddy, Girish S. Shirali, Ronn Tanel, Jeffrey A. Towbin. (2008) Assessment and management of the failing heart in children. Cardiology in the Young 18:S3, 63
CrossRef622
Bodh I. Jugdutt. (2008) Pleiotropic effects of cardiac drugs on healing post-MI. The good, bad, and ugly. Heart Failure Reviews 13:4, 439-452
CrossRef623
O.M. Dekkers, E. von Elm. (2008) Treating individuals: From study populations to individual patients. Preventive Medicine 47:6, 638-639
CrossRef624
Nicholas R. Banner, Chris A. Rogers, Robert S. Bonser. (2008) Effect of Heart Transplantation on Survival in Ambulatory and Decompensated Heart Failure. Transplantation 86:11, 1515-1522
CrossRef625
V. Regitz-Zagrosek, C. Schubert. (2008) Geschlechterunterschiede in der kardiovaskulären Pharmakotherapie. Der Internist 49:11, 1383-1390
CrossRef626
Jalal K. Ghali, S. William Tam, Michael L. Sabolinski, Anne L. Taylor, Joann Lindenfeld, Jay N. Cohn, Manuel Worcel. (2008) Exploring the Potential Synergistic Action of Spironolactone on Nitric Oxide–Enhancing Therapy: Insights From the African-American Heart Failure Trial. Journal of Cardiac Failure 14:9, 718-723
CrossRef627
Tariq Khan, J. Thomas Heywood. (2008) Inpatient management of patients with volume overload and high filling pressures. Journal of Hospital Medicine 3:S6, S25-S32
CrossRef628
F GOMEZSOTO, J PUERTO, J ANDREY, F FERNANDEZ, M ESCOBAR, A GARCIAEGIDO, S ROMERO, J BERNAL, F GOMEZ. (2008) Consultation between specialists in Internal Medicine and Family Medicine improves management and prognosis of heart failure. European Journal of Internal Medicine 19:7, 548-554
CrossRef629
Ricardo J. Lopes, Ana Patricia Lourenço, Joana Mascarenhas, Ana Azevedo, Paulo Bettencourt. (2008) Safety of Spironolactone Use in Ambulatory Heart Failure Patients. Clinical Cardiology 31:11, 509-513
CrossRef630
John P. Boehmer, Mark D. Carlson, Teresa Marco, Brian E. Jaski, Steven L. Higgins, Charles Kennergren, Andrew E. Epstein. (2008) Adjudication of mortality events in a heart failure–arrhythmia trial by a multiparameter descriptive method: Comparison with methods used in heart failure trials and methods used in arrhythmia trials. Journal of Interventional Cardiac Electrophysiology 23:2, 101-110
CrossRef631
Aarif Y Khakoo, Edward TH Yeh. (2008) Therapy Insight: management of cardiovascular disease in patients with cancer and cardiac complications of cancer therapy. Nature Clinical Practice Oncology 5:11, 655-667
CrossRef632
Jeanne Loughlin, John D. Seeger, P. Mona Eng, Marie Foegh, C. Robin Clifford, Jennifer Cutone, Alexander M. Walker. (2008) Risk of hyperkalemia in women taking ethinylestradiol/drospirenone and other oral contraceptives. Contraception 78:5, 377-383
CrossRef633
F GWADRYSRIDHAR, G GUYATT, B OBRIEN, J ARNOLD, S WALTER, E VINGILIS, L MACKEIGAN. (2008) TEACH: Trial of Education And Compliance in Heart dysfunction chronic disease and heart failure (HF) as an increasing problem. Contemporary Clinical Trials 29:6, 905-918
CrossRef634
Claudio Ronco, Mikko Haapio, Andrew A. House, Nagesh Anavekar, Rinaldo Bellomo. (2008) Cardiorenal Syndrome. Journal of the American College of Cardiology 52:19, 1527-1539
CrossRef635
Michael Wagner, Elena Rudakova, Tilmann Volk. (2008) Aldosterone-induced changes in the cardiac L-type Ca2+ current can be prevented by antioxidants in vitro and are absent in rats on low salt diet. Pflügers Archiv - European Journal of Physiology 457:2, 339-349
CrossRef636
Ron Blankstein, George L. Bakris. (2008) Changes in Kidney Function Following Heart Failure Treatment: Focus on Renin-Angiotensin System Blockade. Heart Failure Clinics 4:4, 425-438
CrossRef637
B URETSKY, K THYGESEN, J DAUBERT, E ERDMANN, N FREEMANTLE, D GRAS, L KAPPENBERGER, L TAVAZZI, J CLELAND. (2008) Predictors of Mortality From Pump Failure and Sudden Cardiac Death in Patients With Systolic Heart Failure and Left Ventricular Dyssynchrony: Results of the CARE-HF Trial. Journal of Cardiac Failure 14:8, 670-675
CrossRef638
Jeffrey J. Goldberger, Michael E. Cain, Stefan H. Hohnloser, Alan H. Kadish, Bradley P. Knight, Michael S. Lauer, Barry J. Maron, Richard L. Page, Rod S. Passman, David Siscovick, William G. Stevenson, Douglas P. Zipes. (2008) American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society Scientific Statement on Noninvasive Risk Stratification Techniques for Identifying Patients at Risk for Sudden Cardiac Death. Heart Rhythm 5:10, e1-e21
CrossRef639
Julian Segura, Luis M. Ruilope. (2008) Hyperkalemia Risk and Treatment of Heart Failure. Heart Failure Clinics 4:4, 455-464
CrossRef640
Hilde LE Smets, Johan FF De Haes, André De Swaef, Philippe G Jorens, Gert A Verpooten. (2008) Exposure of the elderly to potential nephrotoxic drug combinations in Belgium. Pharmacoepidemiology and Drug Safety 17:10, 1014-1019
CrossRef641
Frank Peters-Klimm, Thomas Müller-Tasch, Andrew Remppis, Joachim Szecsenyi, Dieter Schellberg. (2008) Improved guideline adherence to pharmacotherapy of chronic systolic heart failure in general practice - results from a cluster-randomized controlled trial of implementation of a clinical practice guideline. Journal of Evaluation in Clinical Practice 14:5, 823-829
CrossRef642
A ROCACUSACHSCOLL. (2008) Papel de los antialdosterónicos en el tratamiento de la hipertensión arterial refractaria. Medicina Clínica 131:11, 416-418
CrossRef643
, K. Dickstein, A. Cohen-Solal, G. Filippatos, J. J.V. McMurray, P. Ponikowski, P. A. Poole-Wilson, A. Stromberg, D. J. van Veldhuisen, D. Atar, A. W. Hoes, A. Keren, A. Mebazaa, M. Nieminen, S. G. Priori, K. Swedberg, , A. Vahanian, J. Camm, R. De Caterina, V. Dean, K. Dickstein, G. Filippatos, C. Funck-Brentano, I. Hellemans, S. D. Kristensen, K. McGregor, U. Sechtem, S. Silber, M. Tendera, P. Widimsky, J. L. Zamorano, , M. Tendera, A. Auricchio, J. Bax, M. Bohm, U. Corra, P. della Bella, P. M. Elliott, F. Follath, M. Gheorghiade, Y. Hasin, A. Hernborg, T. Jaarsma, M. Komajda, R. Kornowski, M. Piepoli, B. Prendergast, L. Tavazzi, J.-L. Vachiery, F. W. A. Verheugt, J. L. Zamorano, F. Zannad. (2008) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). European Heart Journal 29:19, 2388-2442
CrossRef644
Sana M. Al-Khatib, Gillian D. Sanders, Mark Carlson, Aida Cicic, Anne Curtis, Gregg C. Fonarow, Peter W. Groeneveld, David Hayes, Paul Heidenreich, Daniel Mark, Eric Peterson, Eric N. Prystowsky, Philip Sager, Marcel E. Salive, Kevin Thomas, Clyde W. Yancy, Wojciech Zareba, Douglas Zipes. (2008) Preventing tomorrow's sudden cardiac death today. American Heart Journal 156:4, 613-622
CrossRef645
John F. Boylan, Brian P. Kavanagh. (2008) The Name of the Game: No Transfusion (or Nontransfusion) by Cookbook. Anesthesiology 109:4, 745-746
CrossRef646
J. A. Ezekowitz, F. A. McAlister. (2008) Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials. European Heart Journal 30:4, 469-477
CrossRef647
Theresa A McDonagh. (2008) Challenges in advanced chronic heart failure: drug therapy. Future Cardiology 4:5, 517-525
CrossRef648
J.T. Kielstein, D. Fliser. (2008) Diuretika – tubuläre Wirkmechanismen und nephrologische Indikationen. Der Nephrologe 3:5, 384-393
CrossRef649
Alain Cohen-Solal, Florence Beauvais, Damien Logeart. (2008) Heart Failure and Diabetes Mellitus: Epidemiology and Management of an Alarming Association. Journal of Cardiac Failure 14:7, 615-625
CrossRef650
Jeffrey J. Goldberger, Michael E. Cain, Stefan H. Hohnloser, Alan H. Kadish, Bradley P. Knight, Michael S. Lauer, Barry J. Maron, Richard L. Page, Rod S. Passman, David Siscovick, William G. Stevenson, Douglas P. Zipes. (2008) American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society Scientific Statement on Noninvasive Risk Stratification Techniques for Identifying Patients at Risk for Sudden Cardiac Death. Journal of the American College of Cardiology 52:14, 1179-1199
CrossRef651
K.-D. Schlüter, S. Wenzel. (2008) Angiotensin II: A hormone involved in and contributing to pro-hypertrophic cardiac networks and target of anti-hypertrophic cross-talks. Pharmacology & Therapeutics 119:3, 311-325
CrossRef652
Oliviero Olivieri, Francesca Pizzolo, Alberto Ciacciarelli, Roberto Corrocher, Denise Signorelli, Salvatore Falcone, Gian S. Blengio. (2008) Menopause Not Aldosterone-to-Renin Ratio Predicts Blood Pressure Response to a Mineralocorticoid Receptor Antagonist in Primary Care Hypertensive Patients. American Journal of Hypertension 21:9, 976-982
CrossRef653
Daniel E. Forman. (2008) Heart failure in older adults. Current Cardiovascular Risk Reports 2:5, 390-397
CrossRef654
George Mak, Niamh F. Murphy, Akbar Ali, Alison Walsh, Christina O'loughlin, Carmel Conlon, Dermot McCaffrey, Mark Ledwidge, Kenneth McDonald. (2008) Multiple Neurohumoral Modulating Agents in Systolic Dysfunction Heart Failure: Are We Lowering Blood Pressure Too Much?. Journal of Cardiac Failure 14:7, 555-560
CrossRef655
U. Sester. (2008) Hyperkaliämie – ein nephrologischer Notfall. Der Nephrologe 3:5, 366-374
CrossRef656
Jason A. Goebel, Adrian B. Bakel. (2008) Rational use of diuretics in acute decompensated heart failure. Current Heart Failure Reports 5:3, 153-162
CrossRef657
Mª.T. Mories Álvarez. (2008) Protocolo de utilización de fármacos antialdosterónicos. Medicine - Programa de Formación Médica Continuada Acreditado 10:15, 1021-1023
CrossRef658
L. Paulis, J. Matuskova, M. Adamcova, V. Pelouch, J. Simko, K. Krajcirovicova, A. Potacova, I. Hulin, P. Janega, O. Pechanova, F. Simko. (2008) Regression of left ventricular hypertrophy and aortic remodelling in NO-deficient hypertensive rats: effect of l-arginine and spironolactone. Acta Physiologica 194:1, 45-55
CrossRef659
Siu-Sun Yao, Farooq A Chaudhry. (2008) Assessment of myocardial viability: an effective gatekeeper for coronary revascularization?. Future Cardiology 4:5, 443-447
CrossRef660
Helmy Siragy, Jiqian Huang, David C Lieb. (2008) The development of the direct renin inhibitor aliskiren: treating hypertension and beyond. Expert Opinion on Emerging Drugs 13:3, 417-430
CrossRef661
J.E. Pflumm, T. Pomykaj, M.P. Heintzen. (2008) Sekundärprävention nach Myokardinfarkt. Der Internist 49:9, 1052-1060
CrossRef662
Michael Kindermann, M. Bohm. (2008) Aktuelle konservative Therapie der chronischen Herzinsuffizienz. Zeitschrift für Herz-,Thorax- und Gefäßchirurgie 22:4, 184-196
CrossRef663
Marc A. Simon, John Watson, J. Timothy Baldwin, William R. Wagner, Harvey S. Borovetz. (2008) Current and Future Considerations in the Use of Mechanical Circulatory Support Devices*. Annual Review of Biomedical Engineering 10:1, 59-84
CrossRef664
Sonya Addison, Sameer Stas, Melvin R. Hayden, James R. Sowers. (2008) Insulin resistance and blood pressure. Current Hypertension Reports 10:4, 319-325
CrossRef665
Tatiana A.D. Theodoropoulos, Reinaldo B. Bestetti, Ana Paula Otaviano, José A. Cordeiro, Vanessa C. Rodrigues, Adriana C. Silva. (2008) Predictors of all-cause mortality in chronic Chagas' heart disease in the current era of heart failure therapy. International Journal of Cardiology 128:1, 22-29
CrossRef666
Feng J. He, Graham A. MacGregor. (2008) Beneficial effects of potassium on human health. Physiologia Plantarum 133:4, 725-735
CrossRef667
Sinem E. Gulmez, Annmarie T. Lassen, Claus Aalykke, Michael Dall, Alin Andries, Birthe S. Andersen, Jane M. Hansen, Morten Andersen, Jesper Hallas. (2008) Spironolactone use and the risk of upper gastrointestinal bleeding: a population-based case-control study. British Journal of Clinical Pharmacology 66:2, 294-299
CrossRef668
R. Mariotti, G. Borelli, M. Coceani, S. Zingaro, A. Barison, I. Morelli, L. Rondinini. (2008) Aldosterone receptor antagonism and heart failure: insights from an outpatient clinic. Journal of Clinical Pharmacy and Therapeutics 33:4, 349-356
CrossRef669
Miki Nagase, Toshiro Fujita. (2008) Aldosterone and glomerular podocyte injury. Clinical and Experimental Nephrology 12:4, 233-242
CrossRef670
M J Forrest, D Bloomfield, R J Briscoe, P N Brown, A-M Cumiskey, J Ehrhart, J C Hershey, W J Keller, X Ma, H E McPherson, E Messina, L B Peterson, W Sharif-Rodriguez, P K S Siegl, P J Sinclair, C P Sparrow, A S Stevenson, S-Y Sun, C Tsai, H Vargas, M Walker, S H West, V White, R F Woltmann. (2008) Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. British Journal of Pharmacology 154:7, 1465-1473
CrossRef671
S. Henz, M. T. Maeder, S. Huber, M. Schmid, M. Loher, T. Fehr. (2008) Influence of drugs and comorbidity on serum potassium in 15 000 consecutive hospital admissions. Nephrology Dialysis Transplantation 23:12, 3939-3945
CrossRef672
P. Mulder, V. Mellin, J. Favre, M. Vercauteren, I. Remy-Jouet, C. Monteil, V. Richard, S. Renet, J. P. Henry, A. Y. Jeng, R. L. Webb, C. Thuillez. (2008) Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone. European Heart Journal 29:17, 2171-2179
CrossRef673
Masateru Taira, Hiroe Toba, Masafumi Murakami, Ikumi Iga, Ryoko Serizawa, Shoko Murata, Miyuki Kobara, Tetsuo Nakata. (2008) Spironolactone exhibits direct renoprotective effects and inhibits renal renin–angiotensin–aldosterone system in diabetic rats. European Journal of Pharmacology 589:1-3, 264-271
CrossRef674
K Haynes, DF Heitjan, PA Kanetsky, S Hennessy. (2008) Declining Public Health Burden of Digoxin Toxicity From 1991 to 2004. Clinical Pharmacology & Therapeutics 84:1, 90-94
CrossRef675
Melvin R. Hayden, James R. Sowers. (2008) Treating hypertension while protecting the vulnerable islet in the cardiometabolic syndrome. Journal of the American Society of Hypertension 2:4, 239-266
CrossRef676
Nicholas B Norgard, Jennifer E Stark. (2008) Pharmacotherapy for Heart Failure with Left Ventricular Dysfunction: Beyond Angiotensin-Converting Enzyme Inhibitors and β-Blockers. Pharmacotherapy 28:7, 920-931
CrossRef677
Juan M. Aranda, Tomas D. Martin, Dana D. Leach, Charles T. Klodell. (2008) Reoperative Cardiac Surgery After Long-term Ventricular Support Therapy. The Journal of Heart and Lung Transplantation 27:7, 789-791
CrossRef678
ChunYuan Fan, Yasuyuki Kawai, Satoru Inaba, Kenichiro Arakawa, Masato Katsuyama, Kouji Kajinami, Toshihiro Yasuda, Chihiro Yabe-Nishimura, Tadashi Konoshita, Isamu Miyamori. (2008) Synergy of aldosterone and high salt induces vascular smooth muscle hypertrophy through up-regulation of NOX1. The Journal of Steroid Biochemistry and Molecular Biology 111:1-2, 29-36
CrossRef679
Michael Becker, Nora Erdmann, Emilia Stegemann, Dirk Benke, Patrick N. Schauerte, Wolfgang M. Schaefer, Ruediger Autschbach, Malte Kelm, Karl-Christian Koch. (2008) Survival and Quality of Life in Patients With Cardiac Resynchronization Therapy for Severe Heart Failure and in Heart Transplant Recipients Within a Contemporary Heart Failure Management Program. The Journal of Heart and Lung Transplantation 27:7, 746-752
CrossRef680
Virginie Médeau, François Moreau, Ludovic Trinquart, Maud Clemessy, Jean-Louis Wémeau, Marie Christine Vantyghem, Pierre-François Plouin, Yves Reznik. (2008) Clinical and biochemical characteristics of normotensive patients with primary aldosteronism: a comparison with hypertensive cases. Clinical Endocrinology 69:1, 20-28
CrossRef681
Ali Ahmed, Linda Jones, Clare I. Hays. (2008) DEFEAT Heart Failure: Assessment and Management of Heart Failure in Nursing Homes Made Easy. Journal of the American Medical Directors Association 9:6, 383-389
CrossRef682
William T. Abraham, Robin J. Trupp, Barbara Phillips, Robert C. Bourge, Susan M. Harding, Peter Schofield, Samantha Pilsworth, John M. Shneerson, Thomas Di Salvo, Janice Camuso, Douglas C. Johnson, Martin King. (2008) Effect of Treatment With Continuous Positive Airway Pressure or Oxygen on Sleep-Disordered Breathing in Patients With Heart Failure: Results of the Sleep Events, Arrhythmias, and Respiratory Analysis in Chronic Heart Failure (SEARCH) Study. Congestive Heart Failure 14:4, 197-201
CrossRef683
Anton H van den Meiracker, Wendy W Batenburg. (2008) Corticosteroid-dependent, aldosterone-independent mineralocorticoid-receptor activation in the heart. Journal of Hypertension 26:7, 1307-1309
CrossRef684
Masaki Tsukashita, Akira Marui, Takeshi Nishina, Eiji Yoshikawa, Hideo Kanemitsu, Jian Wang, Tadashi Ikeda, Masashi Komeda. (2008) Spironolactone alleviates late cardiac remodeling after left ventricular restoration surgery. The Journal of Thoracic and Cardiovascular Surgery 136:1, 58-64
CrossRef685
Hong Wang, Tatsuo Shimosawa, Hiromitsu Matsui, Tomoyo Kaneko, Sayoko Ogura, Yuzaburo Uetake, Katsu Takenaka, Yutaka Yatomi, Toshiro Fujita. (2008) Paradoxical mineralocorticoid receptor activation and left ventricular diastolic dysfunction under high oxidative stress conditions. Journal of Hypertension 26:7, 1453-1462
CrossRef686
Wilfried Mullens, Zuheir Abrahams, Gary S. Francis, Hadi N. Skouri, Randall C. Starling, James B. Young, David O. Taylor, W.H. Wilson Tang. (2008) Sodium Nitroprusside for Advanced Low-Output Heart Failure. Journal of the American College of Cardiology 52:3, 200-207
CrossRef687
F E Xavier, R Aras-López, I Arroyo-Villa, L del Campo, M Salaices, L V Rossoni, M Ferrer, G Balfagón. (2008) Aldosterone induces endothelial dysfunction in resistance arteries from normotensive and hypertensive rats by increasing thromboxane A 2 and prostacyclin. British Journal of Pharmacology 154:6, 1225-1235
CrossRef688
W. J. Remme, J. J.V. McMurray, F.D. R. Hobbs, A. Cohen-Solal, J. Lopez-Sendon, A. Boccanelli, F. Zannad, B. Rauch, K. Keukelaar, C. Macarie, W. Ruzyllo, C. Cline, . (2008) Awareness and perception of heart failure among European cardiologists, internists, geriatricians, and primary care physicians. European Heart Journal 29:14, 1739-1752
CrossRef689
Catherine A. Lemarié, Pierre Paradis, Ernesto L. Schiffrin. (2008) New insights on signaling cascades induced by cross-talk between angiotensin II and aldosterone. Journal of Molecular Medicine 86:6, 673-678
CrossRef690
Guido Lastra-Gonzalez, Camila Manrique-Acevedo, James R. Sowers. (2008) The role of aldosterone in cardiovascular disease in people with diabetes and hypertension: An update. Current Diabetes Reports 8:3, 203-207
CrossRef691
Shahriar Iravanian, Samuel C. Dudley. (2008) The renin-angiotensin-aldosterone system (RAAS) and cardiac arrhythmias. Heart Rhythm 5:6, S12-S17
CrossRef692
Alice Stanton. (2008) Now that we have a direct renin inhibitor, what should we do with it?. Current Hypertension Reports 10:3, 194-200
CrossRef693
Michael Bader, Detlev Ganten. (2008) Update on tissue renin–angiotensin systems. Journal of Molecular Medicine 86:6, 615-621
CrossRef694
Paulus Kirchhof, Lisa Fortmüller, Christoph Waldeyer, Günter Breithardt, Larissa Fabritz. (2008) Drugs that interact with cardiac electro-mechanics: Old and new targets for treatment. Progress in Biophysics and Molecular Biology 97:2-3, 497-512
CrossRef695
J. H. O’Keefe, H. Abuissa, B. Pitt. (2008) Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS. Diabetes, Obesity and Metabolism 10:6, 492-497
CrossRef696
Stephen G Oxberry, Miriam J Johnson. (2008) Review of the evidence for the management of dyspnoea in people with chronic heart failure. Current Opinion in Supportive and Palliative Care 2:2, 84-88
CrossRef697
Kathleen H. Berecek, Denise Kimbrough. (2008) Clinical trials report. Current Hypertension Reports 10:3, 211-212
CrossRef698
Alejandro de la Sierra, Manuel Gorostidi, Rafael Marín, Josep Redón, José R. Banegas, Pedro Armario, Juan García Puig, Julio Zarco, José L. Llisterri, Carlos Sanchís, Benjamín Abarca, Vicente Palomo, Ramón Gomis, Alfonso Otero, Fernando Villar, Jesús Honorato, Juan Tamargo, José M. Lobos, Juan Macías-Núñez, Antonio Sarría, Pedro Aranda, Luis M. Ruilope. (2008) Evaluación y tratamiento de la hipertensión arterial en España. Documento de consenso. Medicina Clínica 131:3, 104-116
CrossRef699
Hussam Abuissa, James O’Keefe. (2008) The role of renin–angiotensin–aldosterone system-based therapy in diabetes prevention and cardiovascular and renal protection. Diabetes, Obesity and Metabolism 0:0, 080520205432340-???
CrossRef700
B. R. Palmer, A. P. Pilbrow, C. M. Frampton, T. G. Yandle, L. Skelton, M. G. Nicholls, A. M. Richards. (2008) Plasma aldosterone levels during hospitalization are predictive of survival post-myocardial infarction. European Heart Journal 29:20, 2489-2496
CrossRef701
Stephanie Neuhold, Martin Hülsmann. (2008) Herzinsuffizienz. Wiener klinische Wochenschrift Education 3:1, 17-33
CrossRef702
Wilfried Mullens, Zuheir Abrahams, Hadi N. Skouri, David O. Taylor, Randall C. Starling, Gary S. Francis, James B. Young, W.H. Wilson Tang. (2008) Prognostic Evaluation of Ambulatory Patients With Advanced Heart Failure. The American Journal of Cardiology 101:9, 1297-1302
CrossRef703
Mori J. Krantz, Edward P. Havranek, Deborah K. Haynes, Inez Smith, Becki Bucher-Bartelson, Carlin S. Long. (2008) Inpatient Initiation of β-blockade Plus Nurse Management in Vulnerable Heart Failure Patients: A Randomized Study. Journal of Cardiac Failure 14:4, 303-309
CrossRef704
Antonio Russo, Mariangela Autelitano, Luigi Bisanti. (2008) Spironolactone and gastrointestinal bleeding: a population based study. Pharmacoepidemiology and Drug Safety 17:5, 495-500
CrossRef705
Wayne C. Levy, David T. Linker. (2008) Prediction of mortality in patients with heart failure and systolic dysfunction. Current Cardiology Reports 10:3, 198-205
CrossRef706
K ALBOUAINI, M EGRED, A RAO, A ALAHMAR, D WRIGHT. (2008) Cardiac resynchronisation therapy: Evidence based benefits and patient selection. European Journal of Internal Medicine 19:3, 165-172
CrossRef707
Aysha Arshad, Anisha Mandava, Ganesh Kamath, Dan Musat. (2008) Sudden Cardiac Death and the Role of Medical Therapy. Progress in Cardiovascular Diseases 50:6, 420-438
CrossRef708
K. Swaminathan, J. Davies, J. George, N. S. Rajendra, A. D. Morris, A. D. Struthers. (2008) Spironolactone for poorly controlled hypertension in type 2 diabetes: conflicting effects on blood pressure, endothelial function, glycaemic control and hormonal profiles. Diabetologia 51:5, 762-768
CrossRef709
Wayne L. Miller, Shaun Kurien, Karen T. Warfield, Christina M. Wood, Allan S. Jaffe. (2008) Lack of association between worsening renal function and mortality in heart failure patients treated with nesiritide. International Journal of Cardiology 126:2, 234-239
CrossRef710
M. Levi, G. K. Hovingh, S. C. Cannegieter, M. Vermeulen, H. R. Buller, F. R. Rosendaal. (2008) Bleeding in patients receiving vitamin K antagonists who would have been excluded from trials on which the indication for anticoagulation was based. Blood 111:9, 4471-4476
CrossRef711
Howard J. Eisen. (2008) Exercise Training and Myocardial Energetics in Patients With Heart Failure. Journal of the American College of Cardiology 51:19, 1892-1895
CrossRef712
Henry Greenberg. (2008) Sudden Cardiac Death. An Essay for 2008. Progress in Cardiovascular Diseases 50:6, 384-389
CrossRef713
Marmar Vaseghi, Kalyanam Shivkumar. (2008) The Role of the Autonomic Nervous System in Sudden Cardiac Death. Progress in Cardiovascular Diseases 50:6, 404-419
CrossRef714
Andreas Brieke, Joseph Cleveland, JoAnn Lindenfeld. (2008) Mechanical support in acute and chronic heart failure. Current Cardiology Reports 10:3, 168-175
CrossRef715
E. M. Freel, M. Ingram, A. M. Wallace, A. White, R. Fraser, E. Davies, J. M. C. Connell. (2008) Effect of variation in CYP11B1 and CYP11B2 on corticosteroid phenotype and hypothalamic–pituitary–adrenal axis activity in hypertensive and normotensive subjects. Clinical Endocrinology 68:5, 700-706
CrossRef716
A. Morton. (2008) Eplerenone in the treatment of Gitelman’s syndrome. Internal Medicine Journal 38:5, 377-377
CrossRef717
Vitantonio Di Bello. 2008. Use of Myocardial Imaging to Identify and Manage Subclinical Heart Disease in Thyroid and Other Endocrine Diseases. , 209-222.
CrossRef718
Gregory P. Arutyunov, Olga I. Kostyukevich, Roman A. Serov, Natalya V. Rylova, Nadezda A. Bylova. (2008) Collagen accumulation and dysfunctional mucosal barrier of the small intestine in patients with chronic heart failure. International Journal of Cardiology 125:2, 240-245
CrossRef719
Steven G. Chrysant, Alexander V. Murray, Uta C. Hoppe, Dan Dattani, Samir Patel, Huang Hsu, Jack Zhang. (2008) Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis. Current Medical Research and Opinion 24:4, 1039-1047
CrossRef720
F. Peters-Klimm, T. Müller-Tasch, D. Schellberg, A. Remppis, A. Barth, N. Holzapfel, J. Jünger, W. Herzog, J. Szecsenyi. (2008) Guideline adherence for pharmacotherapy of chronic systolic heart failure in general practice: a closer look on evidence-based therapy. Clinical Research in Cardiology 97:4, 244-252
CrossRef721
Osamu Akizuki, Atsushi Inayoshi, Tetsuya Kitayama, Kozo Yao, Shiro Shirakura, Katsutoshi Sasaki, Hideaki Kusaka, Masahiro Matsubara. (2008) Blockade of T-type voltage-dependent Ca2+ channels by benidipine, a dihydropyridine calcium channel blocker, inhibits aldosterone production in human adrenocortical cell line NCI-H295R. European Journal of Pharmacology 584:2-3, 424-434
CrossRef722
Allan Struthers, Henry Krum, Gordon H. Williams. (2008) A Comparison of the Aldosterone-blocking Agents Eplerenone and Spironolactone. Clinical Cardiology 31:4, 153-158
CrossRef723
Robert J. Goldberg, Rovshan M. Ismailov, Vishnu Patlolla, Darleen Lessard, Frederick A. Spencer. (2008) Therapies for Acute Heart Failure in Patients With Reduced Kidney Function: A Community-Based Perspective. American Journal of Kidney Diseases 51:4, 594-602
CrossRef724
Thomas Dieterle, Matthias Pfisterer, Hanspeter Brunner-La Rocca. (2008) Heart failure in the elderly. Aging Health 4:2, 137-155
CrossRef725
John W Funder. (2008) TRANSLATIONAL RESEARCH GOES BOTH WAYS: LESSONS FROM CLINICAL STUDIES. Clinical and Experimental Pharmacology and Physiology 35:4, 526-529
CrossRef726
Gian Paolo Rossi, Achille Cesare Pessina, Anthony M Heagerty. (2008) Primary aldosteronism: an update on screening, diagnosis and treatment. Journal of Hypertension 26:4, 613-621
CrossRef727
Jalal K Ghali, JoAnn Lindenfeld. (2008) Sex differences in response to chronic heart failure therapies. Expert Review of Cardiovascular Therapy 6:4, 555-565
CrossRef728
M. Yamada, M. Kushibiki, T. Osanai, H. Tomita, K. Okumura. (2008) Vasoconstrictor effect of aldosterone via angiotensin II type 1 (AT1) receptor: possible role of AT1 receptor dimerization. Cardiovascular Research 79:1, 169-178
CrossRef729
Christophe Tribouilloy, Dan Rusinaru, Laurent Leborgne, Marcel Peltier, Ziad Massy, Michel Slama. (2008) Prognostic Impact of Angiotensin-Converting Enzyme Inhibitor Therapy in Diastolic Heart Failure. The American Journal of Cardiology 101:5, 639-644
CrossRef730
Jay N. Cohn, Jesse M. Goldman. (2008) Establishing A New Option for Target-organ Protection: Rationale for ARB Plus ACE Inhibitor Combination Therapy. American Journal of Hypertension 21:3, 248-256
CrossRef731
Matthew T. Wheeler, Michael Ho, Joshua W. Knowles, Aleks Pavlovic, Euan A. Ashley. (2008) Pharmacogenetics of Heart Failure: Evidence, Opportunities, and Challenges for Cardiovascular Pharmacogenomics. Journal of Cardiovascular Translational Research 1:1, 25-36
CrossRef732
YELENA SELEKTOR, KARL T. WEBER. (2008) The Salt-Avid State of Congestive Heart Failure Revisited. The American Journal of the Medical Sciences 335:3, 209-218
CrossRef733
Robert C. Bourge, William T. Abraham, Philip B. Adamson, Mark F. Aaron, Juan M. Aranda, Anthony Magalski, Michael R. Zile, Andrew L. Smith, Frank W. Smart, Mark A. O’Shaughnessy, Mariell L. Jessup, Brandon Sparks, David L. Naftel, Lynne Warner Stevenson. (2008) Randomized Controlled Trial of an Implantable Continuous Hemodynamic Monitor in Patients With Advanced Heart Failure. Journal of the American College of Cardiology 51:11, 1073-1079
CrossRef734
Hind W. Rahmouni, James N. Kirkpatrick, Martin G. St. John Sutton. (2008) Effects of cardiac resynchronization therapy on ventricular remodeling. Current Heart Failure Reports 5:1, 25-30
CrossRef735
Morag J Young. (2008) Mechanisms of mineralocorticoid receptor-mediated cardiac fibrosis and vascular inflammation. Current Opinion in Nephrology and Hypertension 17:2, 174-180
CrossRef736
P BRANDISH, H CHEN, P SZCZERBA, J HERSHEY. (2008) Development of a simplified assay for determination of the antimineralocorticoid activity of compounds dosed in rats. Journal of Pharmacological and Toxicological Methods 57:2, 155-160
CrossRef737
D. W. Habicht, M. D. Witham, M. E. T. Mcmurdo. (2008) The under-representation of older people in clinical trials: Barriers and potential solutions. The Journal of Nutrition Health and Aging 12:3, 194-196
CrossRef738
James O. Mudd, David A. Kass. (2008) Tackling heart failure in the twenty-first century. Nature 451:7181, 919-928
CrossRef739
John A. McClung, Michele Nanna, Wilbert S. Aronow. 2008. Cardiomyopathies in the Elderly. , 493-516.
CrossRef740
A BOMBACK, A KSHIRSAGAR, M AMAMOO, P KLEMMER. (2008) Change in Proteinuria After Adding Aldosterone Blockers to ACE Inhibitors or Angiotensin Receptor Blockers in CKD: A Systematic Review. American Journal of Kidney Diseases 51:2, 199-211
CrossRef741
Giovanni Pedrazzini, Eugenio Santoro, Roberto Latini, Laurie Fromm, Maria Grazia Franzosi, Tiziano Mocetti, Lidia Staszewsky, Simona Barlera, Gianni Tognoni, Aldo P. Maggioni. (2008) Causes of death in patients with acute myocardial infarction treated with angiotensin-converting enzyme inhibitors: Findings from the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto (GISSI)–3 trial. American Heart Journal 155:2, 388-394
CrossRef742
Kapil Kumar, Kevin F. Kwaku, Richard L. Verrier. (2008) Treatment options for patients with coronary artery disease identified as high risk by T-wave alternans testing. Current Treatment Options in Cardiovascular Medicine 10:1, 39-48
CrossRef743
Jean-François Besançon, Laurence Lagarce, Bertrand Diquet, Pascale Lainé-Cessac. (2008) Study of the use of a spironolactone and angiotensin-converting enzyme inhibitor combination: a population-based analysis. Pharmacoepidemiology and Drug Safety 17:2, 172-179
CrossRef744
YELENA SELEKTOR, ROBERT A. AHOKAS, SYAMAL K. BHATTACHARYA, YAO SUN, IVAN C. GERLING, KARL T. WEBER. (2008) Cinacalcet and the Prevention of Secondary Hyperparathyroidism in Rats With Aldosteronism. The American Journal of the Medical Sciences 335:2, 105-110
CrossRef745
Paul J. Hauptman. (2008) Medication adherence in heart failure. Heart Failure Reviews 13:1, 99-106
CrossRef746
William H Frishman, Wilbert S Aronow, Angela Cheng-Lai. 2008. Cardiovascular Drug Therapy in the Elderly. , 99-136.
CrossRef747
Dalane W. Kitzman, Jerome L. Fleg. 2008. Heart Failure. , 542-576.
CrossRef748
Christine K Choy, Jo E Rodgers, Jean M Nappi, Stuart T Haines. (2008) Type 2 Diabetes Mellitus and Heart Failure. Pharmacotherapy 28:2, 170-192
CrossRef749
Akshay Desai. (2008) Current understanding of heart failure with preserved ejection fraction. Current Opinion in Internal Medicine 7:1, 1-8
CrossRef750
Renee Margossian. (2008) Contemporary management of pediatric heart failure. Expert Review of Cardiovascular Therapy 6:2, 187-197
CrossRef751
Robert E Shaddy, Gary Webb. (2008) Applying heart failure guidelines to adult congenital heart disease patients. Expert Review of Cardiovascular Therapy 6:2, 165-174
CrossRef752
A AHMED, B PITT, S RAHIMTOOLA, F WAAGSTEIN, M WHITE, T LOVE, E BRAUNWALD. (2008) Effects of digoxin at low serum concentrations on mortality and hospitalization in heart failure: A propensity-matched study of the DIG trial
CrossRef753
E GALVE. (2008) Fármacos antialdosterónicos: su papel en la insuficiencia cardíaca. Medicina Clínica 130:1, 30-34
CrossRef754
Ayten Ustundag, Armagan Tugrul, Sedat Ustundag, Necdet Sut, Bora Demirkan. (2008) The Effects of Spironolactone on Nephron Function in Patients with Diabetic Nephropathy. Renal Failure 30:10, 982-991
CrossRef755
Darcy A. Lamb, David F. Blackburn, Anne M. PausJenssen, William M. Semchuk, Patrick Robertson. (2008) Heart failure: Back to basics for pharmacists. Canadian Pharmacists Journal 141:1, 48-57
CrossRef756
BARRY A. BORLAUG, VOJTECH MELENOVSKY, DAVID A. KASS. 2008. Ventricular-Arterial Interaction in Patients with Heart Failure and a Preserved Ejection Fraction. , 403-412.
CrossRef757
Akshay Desai, James C. Fang. (2008) Heart Failure with Preserved Ejection Fraction: Hypertension, Diabetes, Obesity/Sleep Apnea, and Hypertrophic and Infiltrative Cardiomyopathy. Heart Failure Clinics 4:1, 87-97
CrossRef758
Norman K. Hollenberg. 2008. ACE Inhibitors, Angiotensin Receptor Blockers, Mineralocorticoid Receptor Antagonists, and Renin Antagonists. , 601-609.
CrossRef759
Sang Youl Rhee, Young Seol Kim. (2008) Evidence Based Medicine in Endocrinology. Journal of Korean Endocrine Society 23:6, 379
CrossRef760
Macaulay A.C. Onuigbo, Nnonyelum T.C. Onuigbo. (2008) Late Onset Azotemia from RAAS Blockade in CKD Patients with Normal Renal Arteries and No Precipitating Risk Factors. Renal Failure 30:1, 73-80
CrossRef761
Macaulay A. C. Onuigbo, Nnonyelum T. C. Onuigbo. (2008) Renal Failure and Concurrent RAAS Blockade in Older CKD Patients with Renal Artery Stenosis: An Extended Mayo Clinic Prospective 63-Month Experience. Renal Failure 30:4, 363-371
CrossRef762
Young Mee Park, Bong Hee Lim, Rhian M. Touyz, Jeong Bae Park. (2008) Expression of NAD(P)H Oxidase Subunits and Their Contribution to Cardiovascular Damage in Aldosterone/Salt-Induced Hypertensive Rat. Journal of Korean Medical Science 23:6, 1039
CrossRef763
Frances McManus, Gordon T McInnes, John MC Connell. (2008) Drug Insight: eplerenone, a mineralocorticoid-receptor antagonist. Nature Clinical Practice Endocrinology & Metabolism 4:1, 44-52
CrossRef764
Megumi Yamamuro, Michihiro Yoshimura, Masafumi Nakayama, Koji Abe, Hitoshi Sumida, Seigo Sugiyama, Yoshihiko Saito, Kazuwa Nakao, Hirofumi Yasue, Hisao Ogawa. (2008) Aldosterone, but Not Angiotensin II, Reduces Angiotensin Converting Enzyme 2 Gene Expression Levels in Cultured Neonatal Rat Cardiomyocytes. Circulation Journal 72:8, 1346-1350
CrossRef765
D SUSIC. (2008) Optimal Treatment of Hypertension with Diastolic Heart Failure. Heart Failure Clinics 4:1, 117-124
CrossRef766
Barry A. Borlaug, David A. Kass. (2008) Ventricular–Vascular Interaction in Heart Failure. Heart Failure Clinics 4:1, 23-36
CrossRef767
David J. Wang, Stephen S. Gottlieb. (2008) Diuretics: Still the mainstay of treatment. Critical Care Medicine 36:Suppl, S89-S94
CrossRef768
Frank Kramer, Peter Sandner, Martina Klein, Thomas Krahn. (2008) Plasma concentrations of matrix metalloproteinase-2, tissue inhibitor of metalloproteinase-1 and osteopontin reflect severity of heart failure in DOCA-salt hypertensive rat. Biomarkers 13:3, 270-281
CrossRef769
Matthijs L Becker, Loes E Visser, Teun van Gelder, Albert Hofman, Bruno H Ch Stricker. (2008) Increasing Exposure to Drug-Drug Interactions Between 1992 and 2005 in People Aged ≥55 Years. Drugs & Aging 25:2, 145-152
CrossRef770
Mark E Rea, Mark E Dunlap. (2008) Renal hemodynamics in heart failure: implications for treatment. Current Opinion in Nephrology and Hypertension 17:1, 87-92
CrossRef771
William B. White, Vladimir Hanes, Madhavi Mallareddy, Vijay Chauhan. (2008) Effects of the hormone therapy, drospirenone and 17-beta estradiol, on early morning blood pressure in postmenopausal women with hypertension. Journal of the American Society of Hypertension 2:1, 20-27
CrossRef772
Salpy V. Pamboukian, Imran Nisar, Sheetal Patel, Liping Gu, Mary McLeod, Maria Rosa Costanzo, Alain Heroux. (2008) Factors Associated with Non-adherence to Therapy with Warfarin in a Population of Chronic Heart Failure Patients. Clinical Cardiology 31:1, 30-34
CrossRef773
Arthur L. Riba. (2008) Evidence-Based Performance and Quality Improvement in the Acute Cardiac Care Setting. Critical Care Clinics 24:1, 201-229
CrossRef774
Shoichi Maruyama. (2008) Current and future medical therapies for CKD (chronic kidney disease). Folia Pharmacologica Japonica 132:3, 166-172
CrossRef775
J.-P. Emeriau, F. Lamouliatte. (2008) Gestione dell’insufficienza cardiaca delle persone anziane. EMC - AKOS - Trattato di Medicina 10:2, 1-10
CrossRef776
RICHARD W. TROUGHTON, JAY RITZEMA-CARTER, M. GARY NICHOLLS. 2008. Role of Neurohormones. , 345-366.
CrossRef777
Sharad Rastogi, Sudhish Mishra, Valerio Zacà, Issa Alesh, Ramesh C. Gupta, Sidney Goldstein, Hani N. Sabbah. (2007) Effect of Long-term Monotherapy with the Aldosterone Receptor Blocker Eplerenone on Cytoskeletal Proteins and Matrix Metalloproteinases in Dogs with Heart Failure. Cardiovascular Drugs and Therapy 21:6, 415-422
CrossRef778
Marcus Baumann, JJ Rob Hermans, Ben JA Janssen, Carine Peutz-Kootstra, Oliver Witzke, Uwe Heemann, Jos FM Smits, Harry AJ Struijker Boudier. (2007) Transient prehypertensive treatment in spontaneously hypertensive rats: a comparison of spironolactone and losartan regarding long-term blood pressure and target organ damage. Journal of Hypertension 25:12, 2504-2511
CrossRef779
Steven Sutcliffe, Charles Phillips, Des Watson, Chris Davidson. (2007) Trends in heart failure mortality in England and Wales since 1950. European Journal of Internal Medicine 18:8, 576-580
CrossRef780
E. M. Freel, M. Ingram, E. C. Friel, R. Fraser, M. Brown, N. J. Samani, M. Caulfield, P. Munroe, M. Farrall, J. Webster, D. Clayton, A. F. Dominiczak, E. Davies, J. M. C. Connell. (2007) Phenotypic consequences of variation across the aldosterone synthase and 11-beta hydroxylase locus in a hypertensive cohort: data from the MRC BRIGHT Study. Clinical Endocrinology 67:6, 832-838
CrossRef781
Anil Verma, Scott D. Solomon. (2007) Optimizing care of heart failure after acute MI with an aldosterone receptor antagonist. Current Heart Failure Reports 4:4, 183-189
CrossRef782
Masoor Kamalesh. (2007) Heart Failure in Diabetes and Related Conditions. Journal of Cardiac Failure 13:10, 861-873
CrossRef783
Monika M. Safford, Jeroan J. Allison, Catarina I. Kiefe. (2007) Patient Complexity: More Than Comorbidity. The Vector Model of Complexity. Journal of General Internal Medicine 22:S3, 382-390
CrossRef784
Chiung-Zuan Chiu, Jun-Jack Cheng. (2007) Congestive Heart Failure in the Elderly. International Journal of Gerontology 1:4, 143-152
CrossRef785
Giulio Molon, Edoardo Adamo, Gaetano M De Ferrari, Francesco Accardi, Eros Dalla Vecchia, Luciano Sallusti, Stefano Ciaffoni, Enrico Barbieri. (2007) Effects of cardiac resynchronization therapy on insulin-like growth factor-1 in patients with advanced heart failure. Journal of Cardiovascular Medicine 8:11, 917-922
CrossRef786
Akshay S. Desai, Karl Swedberg, John J.V. McMurray, Christopher B. Granger, Salim Yusuf, James B. Young, Mark E. Dunlap, Scott D. Solomon, James W. Hainer, Bertil Olofsson, Eric L. Michelson, Marc A. Pfeffer. (2007) Incidence and Predictors of Hyperkalemia in Patients With Heart Failure. Journal of the American College of Cardiology 50:20, 1959-1966
CrossRef787
Adem Ozkara, Faruk Turgut, Yusuf Selcoki, Aydin Karanfil, Melike Rusen Metin, Mehmet Kanbay, Oguz Tekin, Ali Akcay. (2007) Probrain Natriuretic Peptide for assessment of efficacy in heart failure treatment. Advances in Therapy 24:6, 1233-1239
CrossRef788
Lawrence R Krakoff. (2007) Is aldosterone a pro-arrhythmic hormone?. Journal of Hypertension 25:11, 2207-2208
CrossRef789
Olga Delgado Sánchez, Francesc Puigventós Latorre, Manel Pinteño Blanco, Pere Ventayol Bosch. (2007) Equivalencia terapéutica: concepto y niveles de evidencia. Medicina Clínica 129:19, 736-745
CrossRef790
Richard J. Auchus, Fiemu E. Nwariaku. (2007) Primary aldosteronism. Current Cardiology Reports 9:6, 447-452
CrossRef791
A. Fiebeler. (2007) Neues zu Aldosteron und dem Mineralokortikoidrezeptor. Der Nephrologe 2:6, 423-431
CrossRef792
Victoria McEneaney, Brian J. Harvey, Warren Thomas. (2007) Aldosterone rapidly activates protein kinase D via a mineralocorticoid receptor/EGFR trans-activation pathway in the M1 kidney CCD cell line. The Journal of Steroid Biochemistry and Molecular Biology 107:3-5, 180-190
CrossRef793
B. R. Walker. (2007) Glucocorticoids and Cardiovascular Disease. European Journal of Endocrinology 157:5, 545-559
CrossRef794
Nimit C Shah, Stuart D Pringle, Peter T Donnan, Allan D Struthers. (2007) Spironolactone has antiarrhythmic activity in ischaemic cardiac patients without cardiac failure. Journal of Hypertension 25:11, 2345-2351
CrossRef795
Massimiliano Maines, Domenico Catanzariti, Claudio Cemin, Chiara Vaccarini, Giuseppe Vergara. (2007) Usefulness of intrathoracic fluids accumulation monitoring with an implantable biventricular defibrillator in reducing hospitalizations in patients with heart failure: A case-control study. Journal of Interventional Cardiac Electrophysiology 19:3, 201-207
CrossRef796
A AHMED. (2007) DEFEAT Heart Failure: Clinical Manifestations, Diagnostic Assessment, and Etiology of Geriatric Heart Failure. Heart Failure Clinics 3:4, 389-402
CrossRef797
Claudia Grossmann, Michael Gekle. (2007) Non-classical actions of the mineralocorticoid receptor: Misuse of EGF receptors?. Molecular and Cellular Endocrinology 277:1-2, 6-12
CrossRef798
Dalane W. Kitzman, Kurt R. Daniel. (2007) Diastolic Heart Failure in the Elderly. Heart Failure Clinics 3:4, 437-453
CrossRef799
(2007) Guía de Práctica Clínica para el diagnóstico y tratamiento del síndrome coronario agudo sin elevación del segmento ST. Revista Española de Cardiología 60:10, 1070.e1-1070.e80
CrossRef800
Wilbert S. Aronow. (2007) Heart Failure–Complicating Acute Myocardial Infarction. Heart Failure Clinics 3:4, 465-475
CrossRef801
D SICA, T GEHR, W FRISHMAN. (2007) Use of Diuretics in the Treatment of Heart Failure in the Elderly. Heart Failure Clinics 3:4, 455-464
CrossRef802
Thanjavur KM Bragadeesh, Gaurav Mathur, Andrew L Clark, John GF Cleland. (2007) Novel cardiac myosin activators for acute heart failure. Expert Opinion on Investigational Drugs 16:10, 1541-1548
CrossRef803
A W Krug, K Vleugels, S Schinner, V Lamounier-Zepter, C G Ziegler, S R Bornstein, M Ehrhart-Bornstein. (2007) Human adipocytes induce an ERK1/2 MAP kinases-mediated upregulation of steroidogenic acute regulatory protein (StAR) and an angiotensin II — sensitization in human adrenocortical cells. International Journal of Obesity 31:10, 1605-1616
CrossRef804
Mara McAdams, Judy A. Staffa, Gerald J. Dal Pan. (2007) The concomitant prescribing of ethinyl estradiol/drospirenone and potentially interacting drugs. Contraception 76:4, 278-281
CrossRef805
Wilbert S. Aronow. (2007) Treatment of Heart Failure with Abnormal Left Ventricular Systolic Function in the Elderly. Heart Failure Clinics 3:4, 423-436
CrossRef806
Motoi Kushibiki, Masahiro Yamada, Koichi Oikawa, Hirofumi Tomita, Tomohiro Osanai, Ken Okumura. (2007) Aldosterone causes vasoconstriction in coronary arterioles of rats via angiotensin II type-1 receptor: Influence of hypertension. European Journal of Pharmacology 572:2-3, 182-188
CrossRef807
N DELASHERAS. (2007) Papel del factor de crecimiento de tejido conectivo en el daño vascular asociado a hipertensión en ratas. Interacción con la aldosterona
CrossRef808
James F. Neuenschwander, Ragavendra R. Baliga. (2007) Acute Decompensated Heart Failure. Critical Care Clinics 23:4, 737-758
CrossRef809
David Rosen, Matthew V. Decaro, Mark G. Graham. (2007) Evidence-based Treatment of Chronic Heart Failure. Comprehensive Therapy 33:1, 2-17
CrossRef810
Severa Bunda, Peter Liu, Yanting Wang, Kela Liu, Aleksander Hinek. (2007) Aldosterone Induces Elastin Production in Cardiac Fibroblasts through Activation of Insulin-Like Growth Factor-I Receptors in a Mineralocorticoid Receptor-Independent Manner. The American Journal of Pathology 171:3, 809-819
CrossRef811
Alessandro Boccanelli, Giuseppe Cacciatore, Gian Francesco Mureddu, Giovanni de Simone, Francesco Clemenza, Renata De Maria, Andrea Di Lenarda, Antonello Gavazzi, Roberto Latini, Serge Masson, Maurizio Porcu, Massimo Vanasia, Lucio Gonzini, Aldo Pietro Maggioni. (2007) Baseline characteristics of patients recruited in the AREA IN-CHF study (Antiremodelling Effect of Aldosterone Receptors Blockade with Canrenone in Mild Chronic Heart Failure). Journal of Cardiovascular Medicine 8:9, 683-691
CrossRef812
Larisa H. Cavallari, Vicki L. Groo, Kathryn M. Momary, Thomas D. Stamos, Paul T. Vaitkus. (2007) Markers of Cardiac Collagen Turnover Are Similar in Patients With Mild and More Severe Symptoms of Heart Failure. Congestive Heart Failure 13:5, 275-279
CrossRef813
Barbara J. Messinger-Rapport, John E. Morley, David R. Thomas, Julie K. Gammack. (2007) Intensive Session: New Approaches to Medical Issues in Long-Term Care. Journal of the American Medical Directors Association 8:7, 421-433
CrossRef814
B VOGT. (2007) The Association of Aldosterone With Obesity-Related Hypertension and the Metabolic Syndrome. Seminars in Nephrology 27:5, 529-537
CrossRef815
Andrew S Bomback, Philip J Klemmer. (2007) The incidence and implications of aldosterone breakthrough. Nature Clinical Practice Nephrology 3:9, 486-492
CrossRef816
U.C. Hoppe. (2007) Leitliniengerechte Therapie der chronischen Herzinsuffizienz. Der Internist 48:9, 929-937
CrossRef817
John L. Jefferies, Jack F. Price, Susan W. Denfield, Anthony C. Chang, William J. Dreyer, Colin J. McMahon, Michelle A. Grenier, Sarah K. Clunie, Anne Thomas, Brady S. Moffett, Tiffany S. Wann, E. O'Brian Smith, Jeffrey A. Towbin. (2007) Safety and Efficacy of Nesiritide in Pediatric Heart Failure. Journal of Cardiac Failure 13:7, 541-548
CrossRef818
Guido Lastra-Gonzalez, Camila Manrique-Acevedo, James R. Sowers. (2007) New Trends in Insulin Resistance: The Role of Mineralocorticoids. Journal of the CardioMetabolic Syndrome 2:4, 233-234
CrossRef819
Luc Roumen, Marijn P. A. Sanders, Koen Pieterse, Peter A. J. Hilbers, Ralf Plate, Erica Custers, Marcel Gooyer, Jos F. M. Smits, Ilona Beugels, Judith Emmen, Harry C. J. Ottenheijm, Dirk Leysen, J. J. R. Hermans. (2007) Construction of 3D models of the CYP11B family as a tool to predict ligand binding characteristics. Journal of Computer-Aided Molecular Design 21:8, 455-471
CrossRef820
Roger J.F. Baskett, Derek V. Exner, Gregory M. Hirsch, William A. Ghali. (2007) Mitral insufficiency and morbidity and mortality in left ventricular dysfunction. Canadian Journal of Cardiology 23:10, 797-800
CrossRef821
Jay N. Cohn. (2007) Myocardial Structural Effects of Aldosterone Receptor Antagonism in Heart Failure. Journal of the American College of Cardiology 50:7, 597-599
CrossRef822
Jeffrey L. Anderson, Cynthia D. Adams, Elliott M. Antman, Charles R. Bridges, Robert M. Califf, Donald E. Casey, William E. Chavey, Francis M. Fesmire, Judith S. Hochman, Thomas N. Levin, A. Michael Lincoff, Eric D. Peterson, Pierre Theroux, Nanette Kass Wenger, R. Scott Wright, Sidney C. Smith, Alice K. Jacobs, Cynthia D. Adams, Jeffrey L. Anderson, Elliott M. Antman, Jonathan L. Halperin, Sharon A. Hunt, Harlan M. Krumholz, Frederick G. Kushner, Bruce W. Lytle, Rick Nishimura, Joseph P. Ornato, Richard L. Page, Barbara Riegel. (2007) ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction. Journal of the American College of Cardiology 50:7, e1-e157
CrossRef823
Brandi J. Witt, Apoor S. Gami, Karla V. Ballman, Robert D. Brown, Ryan A. Meverden, Stephen J. Jacobsen, Véronique L. Roger. (2007) The Incidence of Ischemic Stroke in Chronic Heart Failure: A Meta-Analysis. Journal of Cardiac Failure 13:6, 489-496
CrossRef824
Jeffrey L. Anderson, Cynthia D. Adams, Elliott M. Antman, Charles R. Bridges, Robert M. Califf, Donald E. Casey, William E. Chavey, Francis M. Fesmire, Judith S. Hochman, Thomas N. Levin, A. Michael Lincoff, Eric D. Peterson, Pierre Theroux, Nanette Kass Wenger, R. Scott Wright, Sidney C. Smith, Alice K. Jacobs, Cynthia D. Adams, Jeffrey L. Anderson, Elliot M. Antman, Jonathan L. Halperin, Sharon A. Hunt, Harlan M. Krumholz, Frederick G. Kushner, Bruce W. Lytle, Rick Nishimura, Joseph P. Ornato, Richard L. Page, Barbara Riegel. (2007) ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction—Executive Summary. Journal of the American College of Cardiology 50:7, 652-726
CrossRef825
Jigar Patel, Michael Smith, J. Thomas Heywood. (2007) Optimal use of diuretics in patients with heart failure. Current Treatment Options in Cardiovascular Medicine 9:4, 332-342
CrossRef826
Manoel OC Rocha, Mauro M Teixeira, Antonio L Ribeiro. (2007) An update on the management of Chagas cardiomyopathy. Expert Review of Anti-infective Therapy 5:4, 727-743
CrossRef827
Anna K.Y. Chan, John E. Sanderson, Tian Wang, Wynnie Lam, Gabriel Yip, Mei Wang, Yat-Yin Lam, Yan Zhang, Leata Yeung, Eugene B. Wu, Wilson W.M. Chan, John T.H. Wong, Nina So, Cheuk-Man Yu. (2007) Aldosterone Receptor Antagonism Induces Reverse Remodeling When Added to Angiotensin Receptor Blockade in Chronic Heart Failure. Journal of the American College of Cardiology 50:7, 591-596
CrossRef828
M GUAZZI, R RAIMONDO, M VICENZI, R ARENA, C PROSERPIO, S SARZIBRAGA, R PEDRETTI. (2007) Exercise Oscillatory Ventilation May Predict Sudden Cardiac Death in Heart Failure Patients. Journal of the American College of Cardiology 50:4, 299-308
CrossRef829
Kyoe Tanaka, Naoto Ashizawa, Hiroaki Kawano, Osami Sato, Shinji Seto, Eijun Nishihara, Hideyuki Terazono, Shojiro Isomoto, Kazuyuki Shinohara, Katsusuke Yano. (2007) Aldosterone induces circadian gene expression of clock genes in H9c2 cardiomyoblasts. Heart and Vessels 22:4, 254-260
CrossRef830
Raymond Lee, Yiong-Huak Chan, Jennifer Wong, Diana Lau, Kenneth Ng. (2007) The 6-minute walk test predicts clinical outcome in Asian patients with chronic congestive heart failure on contemporary medical therapy: A study of the multiracial population in Singapore. International Journal of Cardiology 119:2, 168-175
CrossRef831
James N. Kirkpatrick, Mani A. Vannan, Jagat Narula, Roberto M. Lang. (2007) Echocardiography in Heart Failure. Journal of the American College of Cardiology 50:5, 381-396
CrossRef832
Gregg C. Fonarow, Clyde W. Yancy, Nancy M. Albert, Anne B. Curtis, Wendy Gattis Stough, Mihai Gheorghiade, J. Thomas Heywood, Mandeep Mehra, Christopher M. O'Connor, Dwight Reynolds, Mary Norine Walsh. (2007) Improving the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting: The IMPROVE HF performance improvement registry. American Heart Journal 154:1, 12-38
CrossRef833
Srinivasa R Kalidindi, WH Wilson Tang, Gary S Francis. (2007) Drug Insight: aldosterone-receptor antagonists in heart failure—the journey continues. Nature Clinical Practice Cardiovascular Medicine 4:7, 368-378
CrossRef834
Andreia Biolo, Tania Chao, Toni-Ann S. Duhaney, Eugene Kotlyar, Donald Allensworth-Davies, Joseph Loscalzo, Flora Sam. (2007) Usefulness of the Aldosterone Synthase Gene Polymorphism C-344-T to Predict Cardiac Remodeling in African-Americans Versus Non–African-Americans With Chronic Systolic Heart Failure. The American Journal of Cardiology 100:2, 285-290
CrossRef835
Wilbert S. Aronow, William H. Frishman, Angela Cheng-Lai. (2007) Cardiovascular Drug Therapy in the Elderly. Cardiology in Review 15:4, 195-215
CrossRef836
Kartikya Ahuja, Gregory A. Crooke, Eugene A. Grossi, Aubrey C. Galloway, Ulrich P. Jorde. (2007) Reversing Left Ventricular Remodeling in Chronic Heart Failure. Cardiology in Review 15:4, 184-190
CrossRef837
Martin Cadeiras, Manuel Prinz von Bayern, Mario C. Deng. (2007) Cardiac Transplantation: Any Role Left?. Heart Failure Clinics 3:3, 321-347
CrossRef838
Jun Iwanami, Masaki Mogi, Shoko Okamoto, Xin-Yu Gao, Jian-Mei Li, Li-Juan Min, Ayumi Ide, Kana Tsukuda, Masaru Iwai, Masatsugu Horiuchi. (2007) Pretreatment with eplerenone reduces stroke volume in mouse middle cerebral artery occlusion model. European Journal of Pharmacology 566:1-3, 153-159
CrossRef839
Adrian Covic, Paul Gusbeth-Tatomir, David J. A. Goldsmith. (2007) Current dilemmas in inhibiting the renin–angiotensin system: do not forget real life. International Urology and Nephrology 39:2, 571-576
CrossRef840
Srinivas Iyengar, William T. Abraham. (2007) Diuretics for the treatment of acute decompensated heart failure. Heart Failure Reviews 12:2, 125-130
CrossRef841
Anette Fiebeler, Dominik N Muller, Erdenechimeg Shagdarsuren, Friedrich C Luft. (2007) Aldosterone, mineralocorticoid receptors, and vascular inflammation. Current Opinion in Internal Medicine 6:3, 295-303
CrossRef842
G. William Dec. (2007) Management of Acute Decompensated Heart Failure. Current Problems in Cardiology 32:6, 321-366
CrossRef843
Jean-Pierre Monassier, Laurent Monassier. (2007) Prise en charge du post-infarctus. La Presse Médicale 36:6, 999-1006
CrossRef844
Larisa H Cavallari, Kathryn M Momary, Vicki L Groo, Marlos A. G Viana, Joseph R Camp, Thomas D Stamos. (2007) Association of β-Blocker Dose with Serum Procollagen Concentrations and Cardiac Response to Spironolactone in Patients with Heart Failure. Pharmacotherapy 27:6, 801-812
CrossRef845
Juan M. Aranda, Stephen E. McIntyre, Charles T. Klodell, Kaki M. York, Carl A. Dragstedt, Peter J. Chaille, Jamie B. Conti, Daniel F. Pauly, James A. Hill, Richard S. Schofield. (2007) Initial Heart Rate and Systolic Blood Pressure Predict Outcomes in Chronic Heart Failure Patients who are Evaluated for Cardiac Transplant. Clinical Cardiology 30:6, 282-287
CrossRef846
Hadi N. Skouri, W. H. Wilson Tang. (2007) The impact of diabetes on heart failure: Opportunities for intervention. Current Heart Failure Reports 4:2, 70-77
CrossRef847
Adrogué, Horacio J., Madias, Nicolaos E., . (2007) Sodium and Potassium in the Pathogenesis of Hypertension. New England Journal of Medicine 356:19, 1966-1978
Full Text848
Michael Gekle, Sigrid Mildenberger, Ruth Freudinger, Claudia Grossmann. (2007) Altered collagen homeostasis in human aortic smooth muscle cells (HAoSMCs) induced by aldosterone. Pflügers Archiv - European Journal of Physiology 454:3, 403-413
CrossRef849
(2007) Guías de práctica clínica sobre diabetes, prediabetes y enfermedades cardiovasculares: versión resumida. Revista Española de Cardiología 60:5, 525.e1-525.e64
CrossRef850
W. H. Wilson Tang. (2007) Glycemic control and treatment patterns in patients with heart failure. Current Cardiology Reports 9:3, 242-247
CrossRef851
James O Mudd, David A Kass. (2007) Reversing chronic remodeling in heart failure. Expert Review of Cardiovascular Therapy 5:3, 585-598
CrossRef852
Murray Epstein, David A. Calhoun. (2007) The role of aldosterone in resistant hypertension: Implications for pathogenesis and therapy. Current Hypertension Reports 9:2, 98-105
CrossRef853
Kamran Akram, Brian L. Pearlman. (2007) Congestive heart failure-related anemia and a role for erythropoietin. International Journal of Cardiology 117:3, 296-305
CrossRef854
Giuseppe Boriani, Cinzia Valzania, Igor Diemberger, Mauro Biffi, Cristian Martignani, Matteo Bertini, Matteo Ziacchi, Giulia Domenichini, Davide Saporito, Claudio Rapezzi, Angelo Branzi. (2007) Potential of non-antiarrhythmic drugs to provide an innovative upstream approach to the pharmacological prevention of sudden cardiac death. Expert Opinion on Investigational Drugs 16:5, 605-623
CrossRef855
Ana Martín, Alberto Cordero, Moisés Rodríguez. (2007) Importancia del estudio de la función renal en cardiología. Medicina Clínica 128:18, 705-710
CrossRef856
Christine' S. Rigsby, David M. Pollock, Anne M. Dorrance. (2007) Spironolactone improves structure and increases tone in the cerebral vasculature of male spontaneously hypertensive stroke-prone rats. Microvascular Research 73:3, 198-205
CrossRef857
Robert G. Dluhy. (2007) In the Literature: Prevalence and Conn-sequences of Primary Aldosteronism. American Journal of Kidney Diseases 49:5, 566-568
CrossRef858
E. M. Freel, M. Bernhardt, R. Ingram, A. M. Wallace, R. Fraser, E. Davies, J. M. C. Connell. (2007) Endogenous corticosteroid biosynthesis in subjects after bilateral adrenalectomy. Clinical Endocrinology 66:5, 659-665
CrossRef859
Richard A. Preston, Paul M. Norris, Alberto B. Alonso, Pingping Ni, Vladimir Hanes, Adel H. Karara. (2007) Randomized, placebo-controlled trial of the effects of drospirenone-estradiol on blood pressure and potassium balance in hypertensive postmenopausal women receiving hydrochlorothiazide. Menopause 14:3, 408-414
CrossRef860
Makoto Imai, Sharad Rastogi, Ramesh C. Gupta, Sudhish Mishra, Victor G. Sharov, William C. Stanley, Yuval Mika, Benny Rousso, Daniel Burkhoff, Shlomo Ben-Haim, Hani N. Sabbah. (2007) Therapy With Cardiac Contractility Modulation Electrical Signals Improves Left Ventricular Function and Remodeling in Dogs With Chronic Heart Failure. Journal of the American College of Cardiology 49:21, 2120-2128
CrossRef861
Heath E. Saltzman, Kumar Sharma, Paul J. Mather, Sharon Rubin, Suzanne Adams, David Joshua Whellan. (2007) Renal dysfunction in heart failure patients: what is the evidence?. Heart Failure Reviews 12:1, 37-47
CrossRef862
Mark E Dunlap. (2007) New Studies Influencing Treatment of Heart Failure: 2006 Update. Pharmacotherapy 27:4 Part 2, 3S-11S
CrossRef863
Nabil Uddin, J. Herbert Patterson. (2007) Current Guidelines for Treatment of Heart Failure: 2006 Update. Pharmacotherapy 27:4 Part 2, 12S-17S
CrossRef864
Clyde W. Yancy, Henry Krum, Barry M. Massie, Marc A. Silver, Lynne Warner Stevenson, Mei Cheng, Sun Sook Kim, Rosemary Evans. (2007) The Second Follow-up Serial Infusions of Nesiritide (FUSION II) trial for advanced heart failure: Study rationale and design. American Heart Journal 153:4, 478-484
CrossRef865
M OUZOUNIAN, A HASSAN, J COX, D JOHNSTONE, J HOWLETT. (2007) The Effect of Spironolactone Use on Heart Failure Mortality: A Population-Based Study. Journal of Cardiac Failure 13:3, 165-169
CrossRef866
Yuksel Cavusoglu. (2007) The use of levosimendan in comparison and in combination with dobutamine in the treatment of decompensated heart failure. Expert Opinion on Pharmacotherapy 8:5, 665-677
CrossRef867
Sorin V. Pusca, John D. Puskas. (2007) Revascularization in Heart Failure: Coronary Bypass or Percutaneous Coronary Intervention?. Heart Failure Clinics 3:2, 211-228
CrossRef868
Faiez Zannad. (2007) Aldosterone antagonist therapy in resistant hypertension. Journal of Hypertension 25:4, 747-750
CrossRef869
Iwan C. C. Horst, Adriaan A. Voors, Dirk J. Veldhuisen. (2007) Treatment of heart failure with ACE inhibitors and beta-blockers. Clinical Research in Cardiology 96:4, 193-195
CrossRef870
Deirdre A Lane, Sarah Shah, D Gareth Beevers. (2007) Low-dose spironolactone in the management of resistant hypertension: a surveillance study. Journal of Hypertension 25:4, 891-894
CrossRef871
Pim van der Harst, Gerrit van der Steege, Rudolf A. de Boer, Adriaan A. Voors, Alistair S. Hall, Marcel J. Mulder, Wiek H. van Gilst, Dirk J. van Veldhuisen. (2007) Telomere Length of Circulating Leukocytes Is Decreased in Patients With Chronic Heart Failure. Journal of the American College of Cardiology 49:13, 1459-1464
CrossRef872
Xiuren Gao, Longyun Peng, Chandra M. Adhikari, Jun Lin, Zhiyi Zuo. (2007) Spironolactone Reduced Arrhythmia and Maintained Magnesium Homeostasis in Patients With Congestive Heart Failure. Journal of Cardiac Failure 13:3, 170-177
CrossRef873
Sarah C. Huen, David S. Goldfarb. (2007) Adverse Metabolic Side Effects of Thiazides: Implications for Patients With Calcium Nephrolithiasis. The Journal of Urology 177:4, 1238-1243
CrossRef874
Camille G. Frazier, Karen P. Alexander, L. Kristin Newby, Susan Anderson, Erik Iverson, Milton Packer, Jay Cohn, Sidney Goldstein, Pamela S. Douglas. (2007) Associations of Gender and Etiology With Outcomes in Heart Failure With Systolic Dysfunction. Journal of the American College of Cardiology 49:13, 1450-1458
CrossRef875
H. S. Hwang, G. Cirrincione, D. P. Thomas, R. J. McCormick, M. O. Boluyt. (2007) Aldosterone Antagonism Fails to Attenuate Age-Associated Left Ventricular Fibrosis. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 62:4, 382-388
CrossRef876
Neubauer, Stefan, . (2007) The Failing Heart — An Engine Out of Fuel. New England Journal of Medicine 356:11, 1140-1151
Full Text877
Hari Krishnan Parthasarathy, Thomas M. MacDonald. (2007) Mineralocorticoid receptor antagonists. Current Hypertension Reports 9:1, 45-52
CrossRef878
John M. Davis, Hilal Maradit Kremers, Cynthia S. Crowson, Paulo J. Nicola, Karla V. Ballman, Terry M. Therneau, Véronique L. Roger, Sherine E. Gabriel. (2007) Glucocorticoids and cardiovascular events in rheumatoid arthritis: A population-based cohort study. Arthritis & Rheumatism 56:3, 820-830
CrossRef879
Pietro Di Pasquale, Filippo M. Sarullo, Salvatorew Paterna. (2007) Novel Strategies: Challenge Loop Diuretics and Sodium Management in Heart Failure?Part I. Congestive Heart Failure 13:2, 93-98
CrossRef880
Yohannes Gebreegziabher, Amgad N Makaryus, John N Makaryus, Samy I McFarlane. (2007) Heart failure: metabolic derangements and therapeutic rationale. Expert Review of Cardiovascular Therapy 5:2, 331-343
CrossRef881
Katherine T. Murray, Lisa C. Mace, Zhenjiang Yang. (2007) Nonantiarrhythmic drug therapy for atrial fibrillation. Heart Rhythm 4:3, S88-S90
CrossRef882
Caroline Schirpenbach, Martin Reincke. (2007) Primary aldosteronism: current knowledge and controversies in Conn's syndrome. Nature Clinical Practice Endocrinology & Metabolism 3:3, 220-227
CrossRef883
Olivier Muller, Sylvain Pradervand, Stefan Berger, Gabriel Centeno, Aude Milet, Pascal Nicod, Thierry Pedrazzini, François Tronche, Günter Schütz, Kenneth Chien, Bernard C. Rossier, Dmitri Firsov. (2007) Identification of corticosteroid-regulated genes in cardiomyocytes by serial analysis of gene expression. Genomics 89:3, 370-377
CrossRef884
Shoaib Alam, Harold I. Palevsky. (2007) Standard Therapies for Pulmonary Arterial Hypertension. Clinics in Chest Medicine 28:1, 91-115
CrossRef885
T.-Y. Yang, N.-J. Cheng, Y.-S. Ko, C.-T. Kuo. (2007) QT interval is prolonged but QT dispersion is maintained in patients with primary aldosteronism. International Journal of Clinical Practice 61:3, 392-396
CrossRef886
Christian Butter, Ernst Wellnhofer, Michael Schlegl, Georgia Winbeck, Eckart Fleck, Hani N. Sabbah. (2007) Enhanced Inotropic State of the Failing Left Ventricle by Cardiac Contractility Modulation Electrical Signals Is Not Associated With Increased Myocardial Oxygen Consumption. Journal of Cardiac Failure 13:2, 137-142
CrossRef887
Zafar H Israili, Rafael Hern??ndez-Hern??ndez, Manuel Valasco. (2007) The Future of Antihypertensive Treatment. American Journal of Therapeutics 14:2, 121-134
CrossRef888
T CONNOLLY, A SHARAFKHANEH. (2007) Sleep-Related Breathing Disorder and Heart Disease—Central Sleep Apnea. Sleep Medicine Clinics 2:1, 107-117
CrossRef889
A AHMED, M ZILE, M RICH, J FLEG, K ADAMSJR, T LOVE, J YOUNG, W ARONOW, D KITZMAN, M GHEORGHIADE. (2007) Hospitalizations Due to Unstable Angina Pectoris in Diastolic and Systolic Heart Failure. The American Journal of Cardiology 99:4, 460-464
CrossRef890
David M. Kaye, Henry Krum. (2007) Drug discovery for heart failure: a new era or the end of the pipeline?. Nature Reviews Drug Discovery 6:2, 127-139
CrossRef891
Wilbert S. Aronow. (2007) Treatment of Heart Failure with Abnormal Left Ventricular Systolic Function in the Elderly. Clinics in Geriatric Medicine 23:1, 61-81
CrossRef892
D SICA. (2007) Use of Diuretics in the Treatment of Heart Failure in the Elderly. Clinics in Geriatric Medicine 23:1, 107-121
CrossRef893
B. Pitt. (2007) Drug safety: who is responsible?. International Journal of Clinical Practice 61:2, 182-184
CrossRef894
Dalane W. Kitzman, Kurt R. Daniel. (2007) Diastolic Heart Failure in the Elderly. Clinics in Geriatric Medicine 23:1, 83-106
CrossRef895
Frederick A. Masoudi, Silvio E. Inzucchi. (2007) Diabetes Mellitus and Heart Failure: Epidemiology, Mechanisms, and Pharmacotherapy. The American Journal of Cardiology 99:4, 113-132
CrossRef896
Patricia Mona Eng, John D. Seeger, Jeanne Loughlin, Kelly Oh, Alexander M. Walker. (2007) Serum potassium monitoring for users of ethinyl estradiol/drospirenone taking medications predisposing to hyperkalemia: physician compliance and survey of knowledge and attitudes. Contraception 75:2, 101-107
CrossRef897
M. B. Yilmaz, M. Refiker, Y. Guray, U. Guray, H. Altay, B. Demirkan, V. Caldir, S. Korkmaz. (2007) Prescription patterns in patients with systolic heart failure at hospital discharge: why beta blockers are underprescribed or prescribed at low dose in real life?. International Journal of Clinical Practice 61:2, 225-230
CrossRef898
A AHMED. (2007) Clinical Manifestations, Diagnostic Assessment, and Etiology of Heart Failure in Older Adults. Clinics in Geriatric Medicine 23:1, 11-30
CrossRef899
Rony L. Shammas, Nazim Uddin Azam Khan, Rajasekar Nekkanti, Assad Movahed. (2007) Diastolic heart failure and left ventricular diastolic dysfunction: What we know, and what we don't know!. International Journal of Cardiology 115:3, 284-292
CrossRef900
Wilbert S. Aronow. (2007) Heart-Failure–Complicating Acute Myocardial Infarction. Clinics in Geriatric Medicine 23:1, 123-139
CrossRef901
Oliver Zolk, Johannes Jacobi, Andreas Pahl, Martin F. Fromm, Roland E. Schmieder. (2007) MDR1 genotype-dependent regulation of the aldosterone system in humans. Pharmacogenetics and Genomics 17:2, 137-144
CrossRef902
A AURICCHIO, M METRA, M GASPARINI, B LAMP, C KLERSY, A CURNIS, C FANTONI, E GRONDA, J VOGT. (2007) Long-Term Survival of Patients With Heart Failure and Ventricular Conduction Delay Treated With Cardiac Resynchronization Therapy. The American Journal of Cardiology 99:2, 232-238
CrossRef903
Anja Pfau, Claudia Grossmann, Ruth Freudinger, Sigrid Mildenberger, Andreas Benesic, Michael Gekle. (2007) Ca2+ but not H2O2 modulates GRE-element activation by the human mineralocorticoid receptor in HEK cells. Molecular and Cellular Endocrinology 264:1-2, 35-43
CrossRef904
Eman Hamad, Paul J Mather, Siva Srinivasan, Sharon Rubin, David J Whellan, Arthur M Feldman. (2007) Pharmacologic Therapy of Chronic Heart Failure. American Journal of Cardiovascular Drugs 7:4, 235-248
CrossRef905
Lucia Del Vecchio, Mirella Procaccio, Sara Viganò, Daniele Cusi. (2007) Mechanisms of Disease: the role of aldosterone in kidney damage and clinical benefits of its blockade. Nature Clinical Practice Nephrology 3:1, 42-49
CrossRef906
Tsuyoshi Shiga, Hiroshi Kasanuki. (2007) Drug Therapy for Ventricular Tachyarrhythmia in Heart Failure. Circulation Journal 71:SupplementA, A90-A96
CrossRef907
T. Rau, T. Eschenhagen. (2007) Aldosteron und Aldosteronrezeptorantagonisten in der Herzinsuffizienztherapie. Clinical Research in Cardiology Supplements 2:1, 55-64
CrossRef908
Masahiro Akishita. (2007) Medical treatment of cardiovascular disease in the elderly. Nippon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics 44:6, 708-710
CrossRef909
Soon Jib Yoo. (2007) Aldosterone as a Cardiovascular Risk Factor. Journal of Korean Endocrine Society 22:1, 8
CrossRef910
Apurva Motivala, Bertram Pitt. (2007) Drospirenone for Oral Contraception and Hormone Replacement Therapy. Drugs 67:5, 647-655
CrossRef911
Roman M. Sniecinski, Susan Wright, Jerrold H. Levy. 2007. Cardiovascular Pharmacology. , 33-52.
CrossRef912
Razi Khan. (2007) Examining Potential Therapies Targeting Myocardial Fibrosis through the Inhibition of Transforming Growth Factor-Beta 1. Cardiology 108:4, 368-380
CrossRef913
John W Funder. (2007) The Role of Aldosterone and Mineralocorticoid Receptors in Cardiovascular Disease. American Journal of Cardiovascular Drugs 7:3, 151-157
CrossRef914
Michael Stowasser, Francesco Fallo, Albertina So, Yvette Jeske, Livia Kelemen, Catia Pilon, Richard Gordon. (2007) Genetic Forms of Primary Aldosteronism. High Blood Pressure & Cardiovascular Prevention 14:2, 75-81
CrossRef915
Céline Onno, Héléna Rémignon, Laurence Lagarce, Corinne Bruhat, Yves Tourmen, Jean-François Subra, Pascale Lainé-Cessac. (2007) Étude prospective observationnelle des hyperkaliémies médicamenteuses chez des adultes non dialysés hospitalisés. Thérapie 62:1, 55-60
CrossRef916
Gregor Leibundgut, Matthias Pfisterer, Hans-Peter Brunner-La Rocca. (2007) Drug Treatment of Chronic Heart Failure in the Elderly. Drugs & Aging 24:12, 991-1006
CrossRef917
Pradipta Bhakta, Binay K Biswas, Basudeb Banerjee. (2007) Peripartum Cardiomyopathy: Review of the Literature. Yonsei Medical Journal 48:5, 731
CrossRef918
J CAMBOU, E VICAUT, A PAPADOPOULOSDEGRANDSART, N DANCHIN. (2007) Prise en charge thérapeutique de l'insuffisance cardiaque et de la dysfonction ventriculaire gauche post-infarctus du myocarde dans les unités de soins intensifs en cardiologie française. Annales de Cardiologie et d'Angéiologie 56:1, 36-41
CrossRef919
Stephen Scheidt, Nanette K. Wenger, Michael Weber. (2007) Denial of Standard Treatment to the Elderly: Why?. The American Journal of Geriatric Cardiology 16:1, 5-7
CrossRef920
Akira NISHIYAMA, Takashi KUSAKA, Hiroyuki KITAJIMA. (2007) Role of Aldosterone in Oxidative Stress and Renal Injury. YAKUGAKU ZASSHI 127:9, 1331-1337
CrossRef921
Daisuke NAGATA, Yasunobu HIRATA. (2007) Molecular Mechanism of Cardiovascular Damage Induced by Aldosterone. YAKUGAKU ZASSHI 127:9, 1339-1346
CrossRef922
The J-MELODIC Program Committee. (2007) Rationale and Design of a Randomized Trial to Assess the Effects of Diuretics in Heart Failure. Circulation Journal 71:7, 1137-1140
CrossRef923
Alfonso Carvajal, Diego Macias, Ang??lica Guti??rrez, Sara Ortega, Mar??a S??inz, Luis H Mart??n Arias, Alfonso Velasco. (2007) Gynaecomastia Associated with Proton Pump Inhibitors. Drug Safety 30:6, 527-531
CrossRef924
Takao Nakahara, Yoshifumi Takata, Yoji Hirayama, Kihiro Asano, Hirotaka Adachi, Genzo Shiokawa, Teijin Sumi, Takashi Ogawa, Akira Yamashina. (2007) Left Ventricular Hypertrophy and Geometry in Untreated Essential Hypertension is Associated With Blood Levels of Aldosterone and Procollagen Type III Amino-Terminal Peptide. Circulation Journal 71:5, 716-721
CrossRef925
Maya Guglin, Khaled Esmaeel Awad, Latha Polavaram, Hema Vankayala. (2007) Aldosterone Antagonists. American Journal of Cardiovascular Drugs 7:1, 75-79
CrossRef926
Marvin J Meyers, Xiao Hu. (2007) Non-steroidal mineralocorticoid receptor antagonists. Expert Opinion on Therapeutic Patents 17:1, 17-23
CrossRef927
Manfred Hauben, Lester Reich, Charles M Gerrits, David Madigan. (2007) Detection of Spironolactone-Associated Hyperkalaemia Following the Randomized Aldactone Evaluation Study (RALES). Drug Safety 30:12, 1143-1149
CrossRef928
Henry Krum, Richard E Gilbert. (2007) Novel therapies blocking the renin–angiotensin–aldosterone system in the management of hypertension and related disorders. Journal of Hypertension 25:1, 25-35
CrossRef929
Nichole M. McMullen, Kishore B.S. Pasumarthi. (2007) Donor cell transplantation for myocardial disease: does it complement current pharmacological therapies?This paper is one of a selection of papers published in this Special Issue, entitled Young Investigators' Forum.. Canadian Journal of Physiology and Pharmacology 85:1, 1-15
CrossRef930
J ABBOTT. 2007. Canine Myocardial Disease. , 107-117.
CrossRef931
J ABBOTT. 2007. Management of Heart Failure. , 81-92.
CrossRef932
Bruno Laviolle, Danielle Pape, Bruno Turlin, Eric Bellissant. (2006) Direct Effects of 3 Combinations of Enalapril, Metoprolol, and Spironolactone on Cardiac Remodeling in Dilated Cardiomyopathic Hamsters. Journal of Cardiac Failure 12:9, 752-758
CrossRef933
V CARVALHANA, L BURRY, S LAPINSKY. (2006) Management of severe hyperkalemia without hemodialysis: Case report and literature review. Journal of Critical Care 21:4, 316-321
CrossRef934
Sachiko Matsumoto, Kohzo Takebayashi, Yoshimasa Aso. (2006) The effect of spironolactone on circulating adipocytokines in patients with type 2 diabetes mellitus complicated by diabetic nephropathy. Metabolism 55:12, 1645-1652
CrossRef935
Jill M. Gelow, James C. Fang. (2006) Update in the Approach to and Management of Heart Failure. Southern Medical Journal 99:12, 1346-1355
CrossRef936
R MA Van de Wal, A A Voors, R T Gansevoort. (2006) Urinary albumin excretion and the renin–angiotensin system in cardiovascular risk management. Expert Opinion on Pharmacotherapy 7:18, 2505-2520
CrossRef937
, G. Breithardt. (2006) Empfehlungen zur Diagnostik und Behandlung von Patienten mit koronarer Herzkrankheit und Niereninsuffizienz. Clinical Research in Cardiology Supplements 1:2, 103-117
CrossRef938
John D. Harding, Mariell Jessup. (2006) New Directions in the Medical Management of Heart Failure. Seminars in Thoracic and Cardiovascular Surgery 17:4, 334-342
CrossRef939
Simona Maule, Paolo Mulatero, Alberto Milan, Giannina Leotta, Mimma Caserta, Chiara Bertello, Franco Rabbia, Franco Veglio. (2006) QT interval in patients with primary aldosteronism and low-renin essential hypertension. Journal of Hypertension 24:12, 2459-2464
CrossRef940
Roberto Latini, Serge Masson, Lidia Staszewsky, Simona Barlera. (2006) Neurohormonal modulation in heart failure of ischemic etiology: Correlates with left ventricular remodeling. Current Heart Failure Reports 3:4, 157-163
CrossRef941
Toni L Ripley, Jennifer S Chonlahan, Robin E Germany. (2006) Candesartan in heart failure. Clinical Interventions in Aging 1:4, 357-366
CrossRef942
Maximiliano Arroyo, Stephen P. Laguardia, Syamal K. Bhattacharya, Maeda D. Nelson, Patti L. Johnson, Laura D. Carbone, Kevin P. Newman, Karl T. Weber. (2006) Micronutrients in African-Americans with decompensated and compensated heart failure. Translational Research 148:6, 301-308
CrossRef943
M H Weinberger, F C Luft. (2006) Comprehensive suppression of the renin–angiotensin–aldosterone system in chronic kidney disease: Covering all of the bases. Kidney International 70:12, 2051-2053
CrossRef944
Adnan Siddiqui, Peter R Kowey. (2006) Sudden death secondary to cardiac arrhythmias: mechanisms and treatment strategies. Current Opinion in Internal Medicine 5:6, 544-552
CrossRef945
Micheline Monteiro de Resende, Alison Jessica Kriegel, Andrew Seth Greene. (2006) Combined Effects of Low-Dose Spironolactone and Captopril Therapy in a Rat Model of Genetic Hypertrophic Cardiomyopathy. Journal of Cardiovascular Pharmacology 48:6, 265-273
CrossRef946
Wilbert S. Aronow. (2006) Treatment of heart failure with decreased left ventricular ejection fraction. Comprehensive Therapy 32:4, 218-225
CrossRef947
Wenxia Chai, A. H. Jan Danser. (2006) Why are mineralocorticoid receptor antagonists cardioprotective?. Naunyn-Schmiedeberg's Archives of Pharmacology 374:3, 153-162
CrossRef948
K. A. Pöschel, G. Wolf. (2006) Das Renin-Angiotensin-Aldosteron-System als Zentraler Mediator der Progression der Niereninsuffizienz. Der Nephrologe 1:4, 233-240
CrossRef949
Dan R. Berlowitz, Donald R. Miller, Susan A. Oliveria, Fran Cunningham, Andres Gomez-Caminero, James A. Rothendler. (2006) Differential associations of beta-blockers with hemorrhagic events for chronic heart failure patients on warfarin. Pharmacoepidemiology and Drug Safety 15:11, 799-807
CrossRef950
Manfred Hauben, Lester Reich, Charles M. Gerrits. (2006) Reports of hyperkalemia after publication of RALES—a pharmacovigilance study. Pharmacoepidemiology and Drug Safety 15:11, 775-783
CrossRef951
Reem H. Elbekai, Ayman O.S. El-Kadi. (2006) Cytochrome P450 enzymes: Central players in cardiovascular health and disease. Pharmacology & Therapeutics 112:2, 564-587
CrossRef952
Anne Miternique-Grosse, Christophe Griffon, Luz Siegel, Agnès Neuville, Denis Weltin, Dominique Stephan. (2006) Antiangiogenic effects of spironolactone and other potassium-sparing diuretics in human umbilical vein endothelial cells and in fibrin gel chambers implanted in rats. Journal of Hypertension 24:11, 2207-2213
CrossRef953
Jacob A Udell, Joel G Ray. (2006) Primary and secondary prevention of heart failure with statins. Expert Review of Cardiovascular Therapy 4:6, 917-926
CrossRef954
P Gosse, R J Macfadyen. (2006) Does eplerenone have a future in the management of hypertension in Europe?. Journal of Human Hypertension 20:11, 829-832
CrossRef955
N Khalifeh, A Vychytil, W H Hörl. (2006) The role of peritoneal dialysis in the management of treatment-resistant congestive heart failure: A European perspective. Kidney International 70, S72-S75
CrossRef956
Steven M. Schwartz, David L. Wessel. (2006) Medical cardiovascular support in acute viral myocarditis in children. Pediatric Critical Care Medicine 7:Supplement, S12-S16
CrossRef957
(2006) Biventricular Pacing. New England Journal of Medicine 355:16, 1738-1739
Full Text958
2006. Chronic Low Back Pain. .
CrossRef959
Estêvão Lanna Figueiredo, Fabiana Vieira Garcia Leão, Lílian Vaz De Oliveira, Maria Da Consolação Vieira Moreira, Amintas Fabiano De Souza Figueiredo. (2006) The Amidase Activity of Human Tissue Kallikrein Is Significantly Lower in the Urine of Patients With Systolic Heart Failure. Journal of Cardiac Failure 12:8, 653-658
CrossRef960
Randy S. Hebert, Richard Schulz. (2006) Caregiving at the End of Life. Journal of Palliative Medicine 9:5, 1174-1187
CrossRef961
Nicolas W Shammas. 2006. Congestive Heart Failure: Epidemiology, Pathophysiology, and Current Therapies. , 525-544.
CrossRef962
Robert S McKelvie. (2006) Candesartan for the management of heart failure: more than an alternative. Expert Opinion on Pharmacotherapy 7:14, 1945-1956
CrossRef963
YOSHIO HORITA, KOUICHI TAURA, TAKASHI TAGUCHI, AKIRA FURUSU, SHIGERU KOHNO. (2006) Aldosterone breakthrough during therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in proteinuric patients with immunoglobulin A nephropathy. Nephrology 11:5, 462-466
CrossRef964
Bertram Pitt, Roberto Ferrari, Mihai Gheorghiade, Dirk J. van Veldhuisen, Henry Krum, John McMurray, Jose Lopez-Sendon. (2006) Aldosterone blockade in post-acute myocardial infarction heart failure. Clinical Cardiology 29:10, 434-438
CrossRef965
Leanne Groban, John Butterworth. (2006) Perioperative Management of Chronic Heart Failure. Anesthesia & Analgesia 103:3, 557-575
CrossRef966
Kyung W Park. (2006) Angiotensin-Converting Enzyme Inhibitors, AG Receptor Blockers, and Aldosterone Receptor Antagonists. International Anesthesiology Clinics 43:2, 23-37
CrossRef967
Ihsan Dursun, Mahmut Sahin. (2006) Difficulties in maintaining potassium homeostasis in patients with heart failure. Clinical Cardiology 29:9, 388-392
CrossRef968
Dennis M. McNamara, S. William Tam, Michael L. Sabolinski, Page Tobelmann, Karen Janosko, Anne L. Taylor, Jay N. Cohn, Arthur M. Feldman, Manuel Worcel. (2006) Aldosterone Synthase Promoter Polymorphism Predicts Outcome in African Americans With Heart Failure. Journal of the American College of Cardiology 48:6, 1277-1282
CrossRef969
Caroline Schirpenbach, Martin Reincke. (2006) Screening for primary aldosteronism. Best Practice & Research Clinical Endocrinology & Metabolism 20:3, 369-384
CrossRef970
Veronica Franco, Yiu-Fai Chen, Ji A Feng, Peng Li, Dajun Wang, Erum Hasan, Suzanne Oparil, Gilbert J Perry. (2006) EPLERENONE PREVENTS ADVERSE CARDIAC REMODELLING INDUCED BY PRESSURE OVERLOAD IN ATRIAL NATRIURETIC PEPTIDE-NULL MICE. Clinical and Experimental Pharmacology and Physiology 33:9, 773-779
CrossRef971
, G. Breithardt. (2006) Empfehlungen zur Diagnostik und Behandlung von Patienten mit koronarer Herzkrankheit und Niereninsuffizienz. Clinical Research in Cardiology Supplements 1:1, 8-30
CrossRef972
John W Funder. (2006) Eplerenone: hypertension, heart failure and the importance of mineralocorticoid receptor blockade. Future Cardiology 2:5, 535-541
CrossRef973
Friedrich C. Luft. (2006) The serum- and glucocorticoid-induced kinase in DOCA–salt hypertension. Journal of Molecular Medicine 84:9, 709-711
CrossRef974
Fabian Hammer, Paul M. Stewart. (2006) Cortisol metabolism in hypertension. Best Practice & Research Clinical Endocrinology & Metabolism 20:3, 337-353
CrossRef975
M. Quinkler, M. Reincke. (2006) Moderne pharmakologische Aspekte der Therapie des Aldosteronismus. Der Internist 47:9, 953-959
CrossRef976
Michael W. Rich. (2006) Heart Failure in Older Adults. Medical Clinics of North America 90:5, 863-885
CrossRef977
Christopher B. Granger, John J.V. McMurray. (2006) Using Measures of Disease Progression to Determine Therapeutic Effect. Journal of the American College of Cardiology 48:3, 434-437
CrossRef978
Navindra Persaud, Muhammad M. Mamdani. (2006) External validity: the neglected dimension in evidence ranking. Journal of Evaluation in Clinical Practice 12:4, 450-453
CrossRef979
Ole Skøtt, Torben R. Uhrenholt, Jeppe Schjerning, Pernille B.L. Hansen, Lasse E. Rasmussen, Boye L. Jensen. (2006) Rapid actions of aldosterone in vascular health and disease—friend or foe?. Pharmacology & Therapeutics 111:2, 495-507
CrossRef980
Kayla D. Goodwin, Robert A. Ahokas, Syamal K. Bhattacharya, Yao Sun, Ivan C. Gerling, Karl T. Weber. (2006) Preventing Oxidative Stress in Rats with Aldosteronism by Calcitriol and Dietary Calcium and Magnesium Supplements. The American Journal of the Medical Sciences 332:2, 73-78
CrossRef981
Isao Nishi, Satoru Kawano, Masako Misaki, Tomoya Hoshi, Tomoko Masumi, Keiji Iida, Shigeyuki Watanabe, Iwao Yamaguchi. (2006) Addition of spironolactone to an angiotensin-converting enzyme inhibitor decreases lung congestion and edema in Dahl hypertensive rats. Heart and Vessels 21:4, 251-255
CrossRef982
Tarek Hakki, Rita Bernhardt. (2006) CYP17- and CYP11B-dependent steroid hydroxylases as drug development targets. Pharmacology & Therapeutics 111:1, 27-52
CrossRef983
W. Frank Peacock, Alex Harrison, Alan S. Maisel. (2006) The Utility of Heart Sounds and Systolic Intervals Across the Care Continuum. Congestive Heart Failure 12:s4, 2-7
CrossRef984
Ralf Goebel, Martin Schulz. (2006) Klinisch-pharmazeutische Beratung bei der Diuretikatherapie: Beitrag der Apotheke. Pharmazie in unserer Zeit 35:4, 354-363
CrossRef985
Bodo Cremers, Michael Böhm. (2006) Diuretika bei Hypertonie und Herzinsuffizienz: Wirkmechanismen und Therapieschemata. Pharmazie in unserer Zeit 35:4, 322-332
CrossRef986
David H Birnie, Michael Gollob, Jeffrey S Healey. (2006) Clinical trials, the renin angiotensin system and atrial fibrillation. Current Opinion in Cardiology 21:4, 368-375
CrossRef987
Douglas S. Lee, Ramachandran S. Vasan. (2006) Goals and guidelines for treating hypertension in a patient with heart failure. Current Treatment Options in Cardiovascular Medicine 8:4, 334-344
CrossRef988
Martin MacKinnon, Sabin Shurraw, Ayub Akbari, Greg A. Knoll, James Jaffey, Heather D. Clark. (2006) Combination Therapy With an Angiotensin Receptor Blocker and an ACE Inhibitor in Proteinuric Renal Disease: A Systematic Review of the Efficacy and Safety Data. American Journal of Kidney Diseases 48:1, 8-20
CrossRef989
Larisa H. Cavallari, Vicki L. Groo, Kathryn M. Momary, Deidra Fontana, Marlos A.G. Viana, Paul Vaitkus. (2006) Racial Differences in Potassium Response to Spironolactone in Heart Failure. Congestive Heart Failure 12:4, 200-205
CrossRef990
KNUT T. LAPPEGARD, HANNE BJORNSTAD. (2006) Anti-Inflammatory Effect of Cardiac Resynchronization Therapy. Pacing and Clinical Electrophysiology 29:7, 753-758
CrossRef991
Sabu Thomas, Edward Geltman. (2006) What is the Optimal Angiotensin-Converting Enzyme Inhibitor Dose in Heart Failure?. Congestive Heart Failure 12:4, 213-218
CrossRef992
W. Frank Peacock, Alex Harrison, Alan S. Maisel. (2006) The Utility of Heart Sounds and Systolic Intervals Across the Care Continuum. Congestive Heart Failure 12, 2-7
CrossRef993
Domenic A. Sica. (2006) Spironolactone: An Old Friend Rediscovered. The Journal of Clinical Hypertension 8:7, 467-469
CrossRef994
O Pechanova, J Matuskova, D Capikova, L Jendekova, L Paulis, F Simko. (2006) Effect of spironolactone and captopril on nitric oxide and S-nitrosothiol formation in kidney of L-NAME-treated rats. Kidney International 70:1, 170-176
CrossRef995
Michael A. Crouch. (2006) Pharmacotherapy Implications of Revised Chronic Heart Failure Guidelines. The Consultant Pharmacist 21:7, 576-582
CrossRef996
K. ODEDRA, A. FERRO. (2006) Neurohormones and heart failure: the importance of aldosterone. International Journal of Clinical Practice 60:7, 835-846
CrossRef997
Brian R Dulin, Henry Krum. (2006) Drug therapy of chronic heart failure in the elderly: the current state of clinical-trial evidence. Current Opinion in Cardiology 21:4, 393-399
CrossRef998
Susanne Böhmer, Christine Carapito, Britta Wilzewski, Emmanuelle Leize, Alain Van Dorsselaer, Rita Bernhardt. (2006) Analysis of aldosterone-induced differential receptor-independent protein patterns using 2D-electrophoresis and mass spectrometry. Biological Chemistry 387:7, 917-929
CrossRef999
Dawood Darbar, Dan M Roden. (2006) Future of antiarrhythmic drugs. Current Opinion in Cardiology 21:4, 361-367
CrossRef1000
Andreas Brunschweiger, Christa Müller. (2006) Medizinische Chemie der Diuretika: Entwicklung einer erfolgreichen Wirkstoffgruppe. Pharmazie in unserer Zeit 35:4, 310-320
CrossRef1001
María G. Crespo Leiro, María J. Paniagua Martín. (2006) Insuficiencia cardiaca. ¿Son diferentes las mujeres?. Revista Española de Cardiología 59:7, 725-735
CrossRef1002
Myrielle Mathieu, Sophie Motte, Lynn Ray, Anne Pensis, Pascale Jespers, Serge Brimioulle, Valérie Laroute, Robert Naeije, Kathleen Mc Entee. (2006) Effects of ramipril on renal function during progressive overpacing-induced heart failure in dogs. American Journal of Veterinary Research 67:7, 1236-1243
CrossRef1003
Nadia Aspromonte, Mauro Feola, Angela Beatrice Scardovi, Claudio Coletta, Alessandra DʼEri, Prospero Giovinazzo, Alessandro Carunchio, Antonella Chiera, Renato Fanelli, Tiziana Di Giacomo, Roberto Ricci, Vincenzo Ceci, Loredano Milani, Roberto Valle. (2006) Early diagnosis of congestive heart failure: clinical utility of B-type natriuretic peptide testing associated with Doppler echocardiography. Journal of Cardiovascular Medicine 7:6, 406-413
CrossRef1004
Zainal Hussain, Jason Swindle, Paul J. Hauptman. (2006) Digoxin Use and Digoxin Toxicity in the Post-DIG Trial Era. Journal of Cardiac Failure 12:5, 343-346
CrossRef1005
Joël Ménard, Leigh Pascoe. (2006) Can the dextroenantiomer of the aromatase inhibitor fadrozole be useful for clinical investigation of aldosterone-synthase inhibition?. Journal of Hypertension 24:6, 993-997
CrossRef1006
Douglas B. Sawyer, Martha Skinner. (2006) Cardiac amyloidosis: Shifting our impressions to hopeful. Current Heart Failure Reports 3:2, 64-71
CrossRef1007
Lee A. Biblo, Johan Aasbo. (2006) To catch a moving target. Heart Rhythm 3:6, 638-639
CrossRef1008
Bertram Pitt. (2006) Whither Withering? The Role of Digoxin in Patients With Heart Failure Due to Systolic Left Ventricular Dysfunction in Sinus Rhythm. Journal of Cardiac Failure 12:5, 347-348
CrossRef1009
Serge Masson, Roberto Latini, Inder S. Anand, Simona Barlera, Dianne Judd, Monica Salio, Francesco Perticone, Giampaolo Perini, Gianni Tognoni, Jay N. Cohn. (2006) The Prognostic Value of Big Endothelin-1 in More Than 2,300 Patients With Heart Failure Enrolled in the Valsartan Heart Failure Trial (Val-HeFT). Journal of Cardiac Failure 12:5, 375-380
CrossRef1010
Michael Domanski, Xin Tian, Mark Haigney, Bertram Pitt. (2006) Diuretic Use, Progressive Heart Failure, and Death in Patients in the DIG Study. Journal of Cardiac Failure 12:5, 327-332
CrossRef1011
Kathleen M. Knights, Arduino A. Mangoni, John O. Miners. (2006) Non-selective nonsteroidal anti-inflammatory drugs and cardiovascular events: is aldosterone the silent partner in crime?. British Journal of Clinical Pharmacology 61:6, 738-740
CrossRef1012
Rachele Adorisio, Leonardo De Luca, Joseph Rossi, Mihai Gheorghiade. (2006) Pharmacological treatment of chronic heart failure. Heart Failure Reviews 11:2, 109-123
CrossRef1013
Scott M. MacKenzie, John M. C. Connell. (2006) Hypertension and the expanding role of aldosterone. Current Hypertension Reports 8:3, 255-261
CrossRef1014
Kevin A. Courville, Hector O. Ventura. (2006) Hypertension and heart failure: Diagnosis and management. Current Hypertension Reports 8:3, 185-190
CrossRef1015
Markus Flesch, Erland Erdmann. (2006) The problem of polypharmacy in heart failure. Current Cardiology Reports 8:3, 217-225
CrossRef1016
Jay N. Cohn, Peter E. Carson, Christopher O'Connor, Cristina Opasich, Ileana L. Piña, Marino Scherillo, Gianfranco Sinagra, Lynne Warner-Stevenson, Felix E. Tristani, Alberto Volpi. (2006) Prognosis and Mechanism of Death in Treated Heart Failure: Data From the Placebo Arm of Val-HeFT. Congestive Heart Failure 12:3, 127-131
CrossRef1017
Micheline Monteiro de Resende, Katalin Kauser, José Geraldo Mill. (2006) Regulation of cardiac and renal mineralocorticoid receptor expression by captopril following myocardial infarction in rats. Life Sciences 78:26, 3066-3073
CrossRef1018
SUNIL C. SHROFF, KYUNGMOO RYU, NICHOLE L. MARTOVITZ, BRIAN D. HOIT, BRUCE S. STAMBLER. (2006) Selective Aldosterone Blockade Suppresses Atrial Tachyarrhythmias in Heart Failure. Journal of Cardiovascular Electrophysiology 17:5, 534-541
CrossRef1019
Yiming Z Lit, Timothy Meyer. (2006) Managing diabetic nephropathy: recent studies. Current Opinion in Internal Medicine 5:3, 239-244
CrossRef1020
Susumu Ogawa, Kazuhisa Takeuchi, Takefumi Mori, Kazuhiro Nako, Sadayoshi Ito. (2006) SPIRONOLACTONE FURTHER REDUCES URINARY ALBUMIN EXCRETION AND PLASMA B-TYPE NATRIURETIC PEPTIDE LEVLES IN HYPERTENSIVE TYPE II DIABETES TREATED WITH ANGIOTENSIN-CONVERTING ENZYME INHIBITOR. Clinical and Experimental Pharmacology and Physiology 33:5-6, 477-479
CrossRef1021
Gian Paolo Rossi. (2006) Aldosterone breakthrough during ras blockade: A role for endothelins and their antagonists?. Current Hypertension Reports 8:3, 262-268
CrossRef1022
E Ann Tallant, Carlos M Ferrario, Patricia E Gallagher. (2006) Cardioprotective role for angiotensin-(1-7) and angiotensin converting enzyme 2 in the heart. Future Cardiology 2:3, 335-342
CrossRef1023
E. M. L. Wong, E. B. Wu, W. W. M. Chan, C. M. Yu. (2006) A review of the management of patients after percutaneous coronary intervention. International Journal of Clinical Practice 60:5, 582-589
CrossRef1024
Søren Ulrik Salling Sønder, Marianne Mikkelsen, Klaus Rieneck, Chris Juul Hedegaard, Klaus Bendtzen. (2006) Effects of spironolactone on human blood mononuclear cells: mineralocorticoid receptor independent effects on gene expression and late apoptosis induction. British Journal of Pharmacology 148:1, 46-53
CrossRef1025
Ragavendra R. Baliga, Prathiba Ranganna, Bertram Pitt, Todd M. Koelling. (2006) Spironolactone Treatment and Clinical Outcomes in Patients With Systolic Dysfunction and Mild Heart Failure Symptoms: A Retrospective Analysis. Journal of Cardiac Failure 12:4, 250-256
CrossRef1026
Monica Colvin Adams, Syed Sohail Ali. (2006) Who should pay for home monitoring of heart failure?. Current Cardiology Reports 8:3, 191-197
CrossRef1027
Patricia A. Howard. (2006) Cardiovascular Therapeutics - Hyperkalemia with Combined Aldosterone and Angiotensin Blockade in Patients with Heart Failure. Hospital Pharmacy 41:5, 414-418
CrossRef1028
Wilbert S. Aronow. (2006) Epidemiology, Pathophysiology, Prognosis, and Treatment of Systolic and Diastolic Heart Failure. Cardiology in Review 14:3, 108-124
CrossRef1029
Judy W.M. Cheng. (2006) A review of isosorbide dinitrate and hydralazine in the management of heart failure in black patients, with a focus on a new fixed-dose combination. Clinical Therapeutics 28:5, 666-678
CrossRef1030
David A. Cesario, G. William Dec. (2006) Implantable Cardioverter- Defibrillator Therapy in Clinical Practice. Journal of the American College of Cardiology 47:8, 1507-1517
CrossRef1031
M. Böhm, N. Werner, M. Kindermann. (2006) Stand der medikamentösen Therapie bei chronischer Herzinsuffizienz. Clinical Research in Cardiology 95:S4, 36-56
CrossRef1032
Gastone Sabbadini, Marco Metra, Andrea Di Lenarda, Savina Nodari, Gianfranco Sinagra, Livio Dei Cas. (2006) Managing heart failure in the very old. Aging Health 2:2, 253-275
CrossRef1033
Hoang M. Thai, Bao Q. Do, Trung D. Tran, Mohamed A. Gaballa, Steven Goldman. (2006) Aldosterone Antagonism Improves Endothelial-Dependent Vasorelaxation in Heart Failure via Upregulation of Endothelial Nitric Oxide Synthase Production. Journal of Cardiac Failure 12:3, 240-245
CrossRef1034
Susanne E. Rising, Justin M. Welch, Ji M. Koo. (2006) Association of Mortality Risk with High Serum Digoxin Concentrations. Hospital Pharmacy 41:4, 343-347
CrossRef1035
Shuji Arima. (2006) Aldosterone and the kidney: Rapid regulation of renal microcirculation. Steroids 71:4, 281-285
CrossRef1036
Srinivas Iyengar, William T. Abraham. (2006) Diuretic resistance in heart failure. Current Heart Failure Reports 3:1, 41-45
CrossRef1037
Dennis T. Ko, David N. Juurlink, Muhammad M. Mamdani, John J. You, Julie T. Wang, Linda R. Donovan, Jack V. Tu. (2006) Appropriateness of Spironolactone Prescribing in Heart Failure Patients: A Population-Based Study. Journal of Cardiac Failure 12:3, 205-210
CrossRef1038
Christine Z Guo, Smita Kherde, Gail K Adler. (2006) Role of mineralocorticoid receptor in diabetic vascular disease. Current Opinion in Endocrinology & Diabetes 13:2, 127-134
CrossRef1039
Osamu Tsukamoto, Tetsuo Minamino, Shoji Sanada, Ken-ichiro Okada, Akio Hirata, Masashi Fujita, Yasunori Shintani, Liao Yulin, Yoshihiro Asano, Seiji Takashima, Satoru Yamasaki, Hitonobu Tomoike, Masatsugu Hori, Masafumi Kitakaze. (2006) The Antagonism of Aldosterone Receptor Prevents the Development of Hypertensive Heart Failure Induced by Chronic Inhibition of Nitric Oxide Synthesis in Rats. Cardiovascular Drugs and Therapy 20:2, 93-102
CrossRef1040
Hani N. Sabbah, Ramesh C. Gupta, Sharad Rastogi, Sudhish Mishra, Yuval Mika, Daniel Burkhoff. (2006) Treating heart failure with cardiac contractility modulation electrical signals. Current Heart Failure Reports 3:1, 21-24
CrossRef1041
Salim Janmohamed, Pierre-Marc G Bouloux. (2006) The pharmacological treatment of primary aldosteronism. Expert Opinion on Pharmacotherapy 7:5, 563-573
CrossRef1042
Yuko Hashikabe, Kunihiro Suzuki, Teruo Jojima, Kohsuke Uchida, Yoshiyuki Hattori. (2006) Aldosterone Impairs Vascular Endothelial Cell Function. Journal of Cardiovascular Pharmacology 47:4, 609-613
CrossRef1043
Eric M. Williams, Richard E. Katholi, Marcey R. Karambelas. (2006) Use and side-effect profile of spironolactone in a private cardiologist's practice. Clinical Cardiology 29:4, 149-153
CrossRef1044
S. Ellery, T. Pakrashi, V. Paul, S. Sack, . (2006) Predicting mortality and rehospitalization in heart failure patients with Home Monitoring—. Clinical Research in Cardiology 95:S3, iii29-iii35
CrossRef1045
Lawrence R Krakoff. (2006) Screening for primary aldosteronism: progress and frustration. Journal of Hypertension 24:4, 635-637
CrossRef1046
Bodh I Jugdutt. (2006) Valsartan in the treatment of heart attack survivors. Vascular Health and Risk Management 2:2, 125-138
CrossRef1047
Eldrin F. Lewis, Carol M. Flavell. 2006. Prognosis Assessment and End of Life Issues. , 531-546.
CrossRef1048
Ulrich P. Jorde. (2006) Suppression of the Renin???Angiotensin???Aldosterone System in Chronic Heart Failure. Cardiology in Review 14:2, 81-87
CrossRef1049
Jens Gaedeke, Hans-H Neumayer, Harm Peters. (2006) Pharmacological management of renal fibrotic disease. Expert Opinion on Pharmacotherapy 7:4, 377-386
CrossRef1050
Sabine Strassburg, Stefan D. Anker. (2006) Metabolic and immunologic derangements in cardiac cachexia: where to from here?. Heart Failure Reviews 11:1, 57-64
CrossRef1051
Eugene Kotlyar, Joseph A. Vita, Michael R. Winter, Eric H. Awtry, Deborah A. Siwik, John F. Keaney, Douglas B. Sawyer, L. Adrienne Cupples, Wilson S. Colucci, Flora Sam. (2006) The Relationship Between Aldosterone, Oxidative Stress, and Inflammation in Chronic, Stable Human Heart Failure. Journal of Cardiac Failure 12:2, 122-127
CrossRef1052
Usha B. Tedrow, William G. Stevenson. 2006. Management of Ventricular Arrhythmias in Heart Failure. , 183-202.
CrossRef1053
David J. Rozansky. (2006) The Role of Aldosterone in Renal Sodium Transport. Seminars in Nephrology 26:2, 173-181
CrossRef1054
J Ma, A Weisberg, J P Griffin, D E Vaughan, A B Fogo, N J Brown. (2006) Plasminogen activator inhibitor-1 deficiency protects against aldosterone-induced glomerular injury. Kidney International 69:6, 1064-1072
CrossRef1055
Stuart D. Russell. 2006. Acute Heart Failure. , 203-226.
CrossRef1056
Rona K. Reibis, C. Dovifat, R. Dissmann, B. Ehrlich, S. Schulz, K. Stolze, K. Wegscheider, H. Völler. (2006) Implementation of evidence–based therapy in patients with systolic heart failure from 1998–2000. Clinical Research in Cardiology 95:3, 154-161
CrossRef1057
Anthony SL Tang, Kenneth A Ellenbogen. (2006) A futuristic perspective on clinical studies of cardiac resynchronization therapy for heart failure patients. Current Opinion in Cardiology 21:2, 78-82
CrossRef1058
Ilan S. Wittstein. 2006. Diuretics. , 71-98.
CrossRef1059
Aruna D Pradhan, Michael M Givertz, Kenneth L Baughman. 2006. Heart Failure and Obesity: The Risk of Development and the Treatment of Heart Failure in Obese Patients. , 403-428.
CrossRef1060
Michael M. Givertz. 2006. Diet, Metabolic Syndrome, and Obesity. , 37-58.
CrossRef1061
Jan B Östergren. (2006) Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure — Assessment of Reduction in Mortality and morbidity (CHARM) programme. Journal of Hypertension 24:Suppl 1, S3-S7
CrossRef1062
Syamal K. Bhattacharya, Robert A. Ahokas, Laura D. Carbone, Kevin P. Newman, Ivan C. Gerling, Yao Sun, Karl T. Weber. (2006) Macro- and micronutrients in African-Americans with heart failure. Heart Failure Reviews 11:1, 45-55
CrossRef1063
C. Maciá-Bobes, A. Ronzón-Fernández, G. Castaño-Fernández, P. Botas-Cervero. (2006) Hiperaldosteronismo primario: ¿debemos plantearnos su detección sistemática en los centros de salud?. Atención Primaria 37:2, 104-107
CrossRef1064
Luis A. Pires. (2006) Implantable devices for management of chronic heart failure: defibrillators and biventricular pacing therapy. Current Opinion in Anaesthesiology 19:1, 69-74
CrossRef1065
Robert Fraser. (2006) To stimulate or not to stimulate: the differential diagnosis of aldosteronism revisited. Journal of Hypertension 24:2, 285-286
CrossRef1066
Heart Failure Society of America. (2006) Section 13: Evaluation and Therapy for Heart Failure in the Setting of Ischemic Heart Disease. Journal of Cardiac Failure 12:1, e104-e111
CrossRef1067
S. Heindl, J. Holzschneider, A. Hinz, F. Sayk, H. L. Fehm, C. Dodt. (2006) Acute Effects of Aldosterone on the Autonomic Nervous System and the Baroreflex Function in Healthy Humans. Journal of Neuroendocrinology 18:2, 115-121
CrossRef1068
Heart Failure Society of America. (2006) Section 7: Heart Failure in Patients With Left Ventricular Systolic Dysfunction. Journal of Cardiac Failure 12:1, e38-e57
CrossRef1069
Jeffrey J. Teuteberg, Eldrin F. Lewis, Anju Nohria, Sui W. Tsang, James C. Fang, Michael M. Givertz, John A. Jarcho, Gilbert H. Mudge, Kenneth L. Baughman, Lynne W. Stevenson. (2006) Characteristics of Patients Who Die With Heart Failure and a Low Ejection Fraction in the New Millennium. Journal of Cardiac Failure 12:1, 47-53
CrossRef1070
Angelo Capricchione, Nathaniel Winer, James R. Sowers. (2006) Adrenocortical hypertension. Current Urology Reports 7:1, 73-79
CrossRef1071
Raymond Ng, Nathan Better, Michael D. Green. (2006) Anticancer Agents and Cardiotoxicity. Seminars in Oncology 33:1, 2-14
CrossRef1072
A JAVIERTRUJILLOSANTOS. (2006) Indicadores de calidad relacionados con el reingreso y la muerte precoces tras la hospitalización por insuficiencia cardíaca. Medicina Clínica 126:5, 165-169
CrossRef1073
Rajaa F Faris, Marcus Flather, H Purcell, PA Poole-Wilson, Andrew JS Coats, Rajaa F Faris. 2006. Diuretics for heart failure. .
CrossRef1074
2006. Diuretics. , 1152-1169.
CrossRef1075
Wilbert S. Aronow. (2006) Treatment of Systolic and Diastolic Heart Failure in the Elderly. Journal of the American Medical Directors Association 7:1, 29-36
CrossRef1076
Clyde W. Yancy, Margarita Lopatin, Lynne Warner Stevenson, Teresa De Marco, Gregg C. Fonarow. (2006) Clinical Presentation, Management, and In-Hospital Outcomes of Patients Admitted With Acute Decompensated Heart Failure With Preserved Systolic Function. Journal of the American College of Cardiology 47:1, 76-84
CrossRef1077
Yoshihisa Matsumura, Jun Takata, Hiroaki Kitaoka, Toru Kubo, Yuichi Baba, Eri Hoshikawa, Tomoyuki Hamada, Makoto Okawa, Nobuhiko Hitomi, Kyoko Sato, Naohito Yamasaki, Toshikazu Yabe, Takashi Furuno, Masanori Nishinaga, Yoshinori Doi. (2006) Long-Term Prognosis of Dilated Cardiomyopathy Revisited. Circulation Journal 70:4, 376-383
CrossRef1078
Michael J Lipinski, George W Vetrovec. (2006) Medical Treatment of Patients with Heart Failure or Left Ventricular Dysfunction Undergoing Percutaneous Coronary Intervention. American Journal of Cardiovascular Drugs 6:5, 313-325
CrossRef1079
Miguel A. Gómez Sánchez, Camino Bañuelos de Lucas, José M. Ribera Casado, Feliciano Pérez Casar. (2006) Avances en cardiología geriátrica. Revista Española de Cardiología 59, 105-109
CrossRef1080
Akira Nishiyama, Youichi Abe. (2006) Molecular Mechanisms and Therapeutic Strategies of Chronic Renal Injury: Renoprotective Effects of Aldosterone Blockade. Journal of Pharmacological Sciences 100:1, 9-16
CrossRef1081
Bernhard Straubhaar, Stephan Kr??henb??hl, Raymond G Schlienger. (2006) The Prevalence of Potential Drug-Drug Interactions in Patients with Heart Failure at Hospital Discharge. Drug Safety 29:1, 79-90
CrossRef1082
J. Malcolm O. Arnold, Peter Liu, Catherine Demers, Paul Dorian, Nadia Giannetti, Haissam Haddad, George A. Heckman, Jonathan G. Howlett, Andrew Ignaszewski, David E. Johnstone, Philip Jong, Robert S. McKelvie, Gordon W. Moe, John D. Parker, Vivek Rao, Heather J. Ross, Errol J. Sequeira, Anna M. Svendsen, Koon Teo, Ross T. Tsuyuki, Michel White. (2006) Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: Diagnosis and management. Canadian Journal of Cardiology 22:1, 23-45
CrossRef1083
Maria M J van der Vorst, Joana E Kist, Albert J van der Heijden, Jacobus Burggraaf. (2006) Diuretics in Pediatrics. Pediatric Drugs 8:4, 245-264
CrossRef1084
Ernst R Schwarz, Pramod Sanghi. (2006) Conivaptan: a selective vasopressin antagonist for the treatment of heart failure. Expert Review of Cardiovascular Therapy 4:1, 17-23
CrossRef1085
Robert W. Schrier. (2006) Role of Diminished Renal Function in Cardiovascular Mortality. Journal of the American College of Cardiology 47:1, 1-8
CrossRef1086
Gunnar H. Gislason, Niels Gadsboll, Miguel A. Quinones, Lars Kober, Marie Seibaek, Hans Burchardt, Christian Torp-Pedersen. (2006) The Reliability of Echocardiographic Left Ventricular Wall Motion Index to Identify High-Risk Patients for Multicenter Studies. Echocardiography 23:1, 1-6
CrossRef1087
2006. Spironolactone. , 3176-3180.
CrossRef1088
Mustafa Gullulu, Ibrahim Akdag, Serdar Kahvecioglu, Gülaydan Filiz, Vahide Savci. (2006) Aldosterone Blockage in Proliferative Glomerulonephritis Prevents Not Only Fibrosis, but Proliferation as Well. Renal Failure 28:6, 509-514
CrossRef1089
Paul A Gould, Justin A Mariani, David M Kaye. (2006) Biventricular pacing in heart failure: a review. Expert Review of Cardiovascular Therapy 4:1, 97-109
CrossRef1090
John D. Bonagura, Linda B. Lehmkuhl, Helio Autran de Morais. 2006. Fluid and Diuretic Therapy in Heart Failure. , 490-518.
CrossRef1091
Elijah Sounders. (2006) Building on the Specialist's Antihypertensive Treatment Recommendation: It's Just the Beginning. The Journal of Clinical Hypertension 8:s1, 31-39
CrossRef1092
Michael H Gollob. (2006) Genetic profiling as a marker for risk of sudden cardiac death. Current Opinion in Cardiology 21:1, 42-46
CrossRef1093
Ashwani Kumar, Gary Meyerrose, Vineeta Sood, Chanwit Roongsritong. (2006) Diastolic Heart Failure in the Elderly and the Potential Role of Aldosterone Antagonists. Drugs & Aging 23:4, 299-308
CrossRef1094
EIICHI WATANABE. (2006) Nihon Naika Gakkai Zasshi 95:2, 261-270
CrossRef1095
Gregg C. Fonarow. (2006) Hospital protocols and evidence-based therapies: The importance of integrating aldosterone blockade into the management of patients with post-acute myocardial infarction heart failure. Clinical Cardiology 29:1, 4-8
CrossRef1096
Ikuo Taniguchi, Makoto Kawai, Taro Date, Satoru Yoshida, Shingo Seki, Masayuki Taniguchi, Mitsuyuki Shimizu, Seibu Mochizuki. (2006) Effects of Spironolactone During an Angiotensin II Receptor Blocker Treatment on the Left Ventricular Mass Reduction in Hypertensive Patients With Concentric Left Ventricular Hypertrophy. Circulation Journal 70:8, 995-1000
CrossRef1097
Takuya Okada, Makoto Nagai, Ikuo Taniguchi, Mamoru Kuno, Satoshi Imamoto, Shingo Seki, Masayuki Taniguchi, Seibu Mochizuki. (2006) Combined Treatment With Valsartan and Spironolactone Prevents Cardiovascular Remodeling in Renovascular Hypertensive Rats. International Heart Journal 47:5, 783-793
CrossRef1098
Sarah Ulmschneider, Matthias Negri, Marieke Voets, Rolf W. Hartmann. (2006) Development and evaluation of a pharmacophore model for inhibitors of aldosterone synthase (CYP11B2). Bioorganic & Medicinal Chemistry Letters 16:1, 25-30
CrossRef1099
Michele Borgarelli, Roberto A. Santilli, David Chiavegato, Gino D'Agnolo, Renato Zanatta, Alessandro Mannelli, Alberto Tarducci. (2006) Prognostic Indicators for Dogs with Dilated Cardiomyopathy. Journal of Veterinary Internal Medicine 20:1, 104-110
CrossRef1100
Mohamed A. Bayorh, Garrett Mann, Marcus Walton, Danita Eatman. (2006) Effects of Enalapril, Tempol, and Eplerenone on Salt-Induced Hypertension in Dahl Salt-Sensitive Rats. Clinical and Experimental Hypertension 28:2, 121-132
CrossRef1101
Randall E. Williams. (2006) The effect of neurohormonal antagonists in reducing heart failure hospitalizations. Current Medical Research and Opinion 22:1, 139-150
CrossRef1102
E. C. Miner, W. L. Miller. (2006) A Look Between the Cardiomyocytes: The Extracellular Matrix in Heart Failure. Mayo Clinic Proceedings 81:1, 71-76
CrossRef1103
Katrine Jordan Schjoedt, Kasper Rossing, Tina Ragnholm Juhl, Frans Boomsma, Peter Rossing, Lise Tarnow, Hans-Henrik Parving. (2005) Beneficial impact of spironolactone in diabetic nephropathy. Kidney International 68:6, 2829-2836
CrossRef1104
A. Benetos, J. P. Gardner, M. Kimura, C. Labat, R. Nzietchueng, B. Dousset, F. Zannad, P. Lacolley, A. Aviv. (2005) Aldosterone and Telomere Length in White Blood Cells. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 60:12, 1593-1596
CrossRef1105
Kevin L. Thomas, Eric J. Velazquez. (2005) Therapies to prevent heart failure post-myocardial infarction. Current Heart Failure Reports 2:4, 174-182
CrossRef1106
Peter Carson, Inder Anand, Christopher O’Connor, Brian Jaski, Jonathan Steinberg, Amy Lwin, JoAnn Lindenfeld, Jalil Ghali, Jodi H. Barnet, Arthur M. Feldman, Michael R. Bristow. (2005) Mode of Death in Advanced Heart Failure. Journal of the American College of Cardiology 46:12, 2329-2334
CrossRef1107
M. Saito, M. Takada, K. Hirooka, F. Isobe, Y. Yasumura. (2005) Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil. Journal of Clinical Pharmacy and Therapeutics 30:6, 603-610
CrossRef1108
Adam Whaley-Connell, John Palmer, James R Sowers. (2005) Can drospirenone with 17-β estradiol safely reduce blood pressure in hypertensive postmenopausal women?. Nature Clinical Practice Endocrinology & Metabolism 1:2, 72-73
CrossRef1109
José A. Tallaj, Verónica Franco, Barry K. Rayburn, Laura Pinderski, Raymond L. Benza, Salpy Pamboukian, Brian Foley, Robert C. Bourge. (2005) Response of Doxorubicin-induced Cardiomyopathy to the Current Management Strategy of Heart Failure. The Journal of Heart and Lung Transplantation 24:12, 2196-2201
CrossRef1110
ANTONIO DE SISTI, JEAN-FRANCOIS TOUSSAINT, THOMAS LAVERGNE, JACKY OLLITRAULT, ERIC ABERGEL, OLIVIER PAZIAUD, MINA AIT SAID, RAIF SADER, JEAN-YVES LE HEUZEY, LOUIS GUIZE. (2005) Determinants of Mortality in Patients Undergoing Cardiac Resynchronization Therapy: Baseline Clinical, Echocardiographic, and Angioscintigraphic Evaluation Prior to Resynchronization. Pacing and Clinical Electrophysiology 28:12, 1260-1270
CrossRef1111
Ulf Landmesser, Helmut Drexler. (2005) Chronic heart failure: an overview of conventional treatment versus novel approaches. Nature Clinical Practice Cardiovascular Medicine 2:12, 628-638
CrossRef1112
John R. Bullinga, Rami Alharethi, Mark S. Schram, Michael R. Bristow, Edward M. Gilbert. (2005) Changes in Heart Rate Variability Are Correlated to Hemodynamic Improvement With Chronic CARVEDILOL Therapy in Heart Failure. Journal of Cardiac Failure 11:9, 693-699
CrossRef1113
Dennis A Revicki, Clark Paramore, Anne M Rentz. (2005) Incorporating pharmacoeconomic and health outcomes into randomized clinical trials. Expert Review of Pharmacoeconomics & Outcomes Research 5:6, 695-703
CrossRef1114
Vijay K Verma, Steven M Hollenberg. (2005) Update on acute coronary syndromes and ST-elevation myocardial infarction. Current Opinion in Internal Medicine 4:6, 614-618
CrossRef1115
MANUEL PRAGA. (2005) Therapeutic measures in proteinuric nephropathy. Kidney International 68, S137-S141
CrossRef1116
W. S. Aronow. (2005) Drug Treatment of Systolic and of Diastolic Heart Failure in Elderly Persons. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 60:12, 1597-1605
CrossRef1117
W. H. W. Tang, A. C. Parameswaran, A. P. Maroo, G. S. Francis. (2005) Aldosterone Receptor Antagonists in the Medical Management of Chronic Heart Failure. Mayo Clinic Proceedings 80:12, 1623-1630
CrossRef1118
Bradley, T. Douglas, Logan, Alexander G., Kimoff, R. John, Sériès, Frédéric, Morrison, Debra, Ferguson, Kathleen, Belenkie, Israel, Pfeifer, Michael, Fleetham, John, Hanly, Patrick, Smilovitch, Mark, Tomlinson, George, Floras, John S., . (2005) Continuous Positive Airway Pressure for Central Sleep Apnea and Heart Failure. New England Journal of Medicine 353:19, 2025-2033
Full Text1119
D. Gütlich, M. Hochscherf, H.-B. Hopf. (2005) Erfolgreiche Reanimation einer Patientin mit hyperkaliämischem Herzstillstand durch notfallmäßige Hämodiafiltration. Der Anaesthesist 54:11, 1100-1104
CrossRef1120
T.S. Dharmarajan, Tuan Nguyen, Robin O. Russell. (2005) Life-Threatening, Preventable Hyperkalemia in a Nursing Home Resident: Case Report and Literature Review. Journal of the American Medical Directors Association 6:6, 400-405
CrossRef1121
John W Funder. (2005) Mineralocorticoid-receptor blockade, hypertension and heart failure. Nature Clinical Practice Endocrinology & Metabolism 1:1, 4-5
CrossRef1122
G. de Gevigney, S. Fol, F. Delahaye. (2005) Données physiopathologiques et implications thérapeutiques au cours de l'insuffisance cardiaque gauche. La Revue de Médecine Interne 26:11, 874-884
CrossRef1123
Natale G. De Santo, Massimo Cirillo, Alessandra Perna, Rosa Maria Pollastro, Annamaria Frangiosa, Enzo Di Stazio, Luigi Iorio, Vito Andrea Di Leo, Pietro Anastasio. (2005) The Kidney in Heart Failure. Seminars in Nephrology 25:6, 404-407
CrossRef1124
Rebecca S. Boxer, Mark E. Dunlap. (2005) Aldosterone antagonists in the treatment and prevention of heart failure. Current Treatment Options in Cardiovascular Medicine 7:6, 431-436
CrossRef1125
Robert D. Toto. (2005) Heart Disease in Diabetic Patients. Seminars in Nephrology 25:6, 372-378
CrossRef1126
A. Sánchez Rodríguez, M. Sánchez Ledesma, I. Cruz González. (2005) Hipertensión arterial. Relevancia epidemiológica. Tratamiento farmacológico. Indicaciones. Criterios de respuesta. Asociaciones. Efectos secundarios. Interacciones. Situaciones de especial relevancia. Medicine - Programa de Formación Médica Continuada Acreditado 9:46, 3050-3061
CrossRef1127
Robert Berkowitz, Lenore J. Blank, Suzanne K. Powell. (2005) Strategies to Reduce Hospitalization in the Management of Heart Failure. Lippincott's Case Management 10:Supplement, S1???S15
CrossRef1128
Simona Bruno, Dario Cattaneo, Norberto Perico, Giuseppe Remuzzi. (2005) Emerging drugs for diabetic nephropathy. Expert Opinion on Emerging Drugs 10:4, 747-771
CrossRef1129
Jonathan Sackner-Bernstein. (2005) Reducing the risks of sudden death and heart failure post myocardial infarction: Utility of optimized pharmacotherapy. Clinical Cardiology 28:S1, 19-27
CrossRef1130
H. A. Dieterich, C. Wendt, F. Saborowski. (2005) Cardioprotection by Aldosterone Receptor Antagonism in Heart Failure: 1. The Role of Aldosterone in Heart Failure. Human Physiology 31:6, 706-714
CrossRef1131
Vishal Bhatia, Ruchi Bhatia, Boban Mathew. (2005) Angiotensin Receptor Blockers in Congestive Heart Failure. Cardiology in Review 13:6, 297-303
CrossRef1132
Michelle M Kittleson, Joshua M Hare. (2005) Molecular signature analysis: the potential of gene-expression analysis in cardiomyopathy. Future Cardiology 1:6, 793-808
CrossRef1133
Karl T. Weber. (2005) The Proinflammatory Heart Failure Phenotype: A Case of Integrative Physiology. The American Journal of the Medical Sciences 330:5, 219-226
CrossRef1134
Todd J. Rudo, Peter R. Kowey. (2005) Real-world algorithms for the optimal use of drugs and devices in the patient post myocardial infarction and the future of post myocardial infarction management. Clinical Cardiology 28:S1, 58-63
CrossRef1135
James A. Reiffel. (2005) Practical algorithms for pharmacologic management of the post myocardial infarction patient. Clinical Cardiology 28:S1, 28-37
CrossRef1136
Iain Squire. (2005) Neurohormonal Intervention to Reduce Sudden Cardiac Death in Heart Failure: What is the Optimal Pharmacologic Strategy?. Heart Failure Reviews 9:4, 337-345
CrossRef1137
Alfred W. H. Stanley, Constantine L. Athanasuleas, Gerald D. Buckberg, . (2005) Heart Failure Following Anterior Myocardial Infarction: An Indication for Ventricular Restoration, a Surgical Method to Reverse Post-Infarction Remodeling. Heart Failure Reviews 9:4, 241-254
CrossRef1138
Constantine L. Athanasuleas, Gerald D. Buckberg, Alfred W. H. Stanley, William Siler, Vincent Dor, Marisa Di Donato, Lorenzo Menicanti, Sergio Almeida Oliveira, Friedhelm Beyersdorf, Irving L. Kron, Hisayoshi Suma, Nicholas T. Kouchoukos, Wistar Moore, Patrick M. McCarthy, Mehmet C. Oz, Francis Fontan, Meredith L. Scott, Kevin A. Accola, . (2005) Surgical Ventricular Restoration: The RESTORE Group Experience. Heart Failure Reviews 9:4, 287-297
CrossRef1139
Lisa Mielniczuk, Lynne Warner Stevenson. (2005) Angiotensin-converting enzyme inhibitors and angiotensin II type I receptor blockers in the management of congestive heart failure patients: what have we learned from recent clinical trials?. Current Opinion in Internal Medicine 4:5, 529-534
CrossRef1140
JOHN J V MCMURRAY. (2005) Chronic kidney disease in patients with cardiac disease: A review of evidence-based treatment. Kidney International 68:4, 1419-1426
CrossRef1141
I. A. Scott, P. B. Greenberg. (2005) Cautionary tales in the clinical interpretation of therapeutic trial reports. Internal Medicine Journal 35:10, 611-621
CrossRef1142
Juan Fernández-Yáñez, Jesús Palomo, Esteban G. Torrecilla, David Pascual, Gregorio Garrido, José J. Gómez de Diego, Marta Domínguez, Jesús Almendral. (2005) Pronóstico de una población inicialmente candidata a trasplante cardíaco controlada con tratamiento médico. Revista Española de Cardiología 58:10, 1162-1170
CrossRef1143
MARCUS STAHLBERG, FRIEDER BRAUNSCHWEIG, FREDRIK GADLER, HELENA KARLSSON, CECILIA LINDE. (2005) Three Year Outcome of Cardiac Resynchronization Therapy: A Single Center Evaluation. Pacing and Clinical Electrophysiology 28:10, 1013-1017
CrossRef1144
LORENZO A CALÒ, DECIO ARMANINI. (2005) Aldosterone-mediated endothelial remodeling and oxidative stress. Kidney International 68:4, 1899-1899
CrossRef1145
Steven G. Coca, Mark A. Perazella. (2005) The Role of Aldosterone Blockers in the Management of Chronic Heart Failure. The American Journal of the Medical Sciences 330:4, 176-183
CrossRef1146
Toru Sugiyama, Takanobu Yoshimoto, Yuki Hirono, Noriko Suzuki, Maya Sakurada, Kyoichiro Tsuchiya, Isao Minami, Fumiko Iwashima, Haruna Sakai, Toru Tateno, Ryuji Sato, Yukio Hirata. (2005) Aldosterone increases osteopontin gene expression in rat endothelial cells. Biochemical and Biophysical Research Communications 336:1, 163-167
CrossRef1147
Christianne L. Roumie, Patrick G. Arbogast, Edward F. Mitchel, Marie R. Griffin. (2005) Prescriptions for Chronic High-Dose Cyclooxygenase-2 Inhibitors are Often Inappropriate and Potentially Dangerous. Journal of General Internal Medicine 20:10, 879-883
CrossRef1148
Dee Ann Rivera, Michael R. Bristow. (2005) Cardiac Resynchronization-A Heart Failure Perspective. Annals of Noninvasive Electrocardiology 10:s4, 16-23
CrossRef1149
Clyde W. Yancy. (2005) Heart Failure in African Americans. The American Journal of Cardiology 96:7, 3-12
CrossRef1150
Harlan M. Krumholz. (2005) The Year in Epidemiology, Health Services, and Outcomes Research. Journal of the American College of Cardiology 46:7, 1362-1370
CrossRef1151
Pravin Singhal, Joseph Mattana, Hitesh Shah. 2005. Diuretics. , 305-315.
CrossRef1152
(2005) Guías de Práctica Clínica sobre el diagnóstico y tratamiento de la insuficiencia cardíaca crónica. Versión resumida (actualización 2005). Revista Española de Cardiología 58:9, 1062-1092
CrossRef1153
John V Terrovitis, Maria I Anastasiou-Nana, John N Nanas. (2005) Out-patient management of chronic heart failure. Expert Opinion on Pharmacotherapy 6:11, 1857-1881
CrossRef1154
Frank A. Cuoco, Steven N. Singh. (2005) Nonsustained ventricular tachycardia in dilated cardiomyopathy. Current Cardiology Reports 7:5, 368-375
CrossRef1155
Philip B. Adamson. (2005) Ambulatory Hemodynamics in Patients With Chronic Heart Failure: Implications for Volume Management in Elderly Patients. The American Journal of Geriatric Cardiology 14:5, 236-241
CrossRef1156
Srinivas Iyengar, William T Abraham. (2005) Role of medical therapy in the device era for the treatment of heart failure. Expert Review of Cardiovascular Therapy 3:5, 783-785
CrossRef1157
S KINGUE, A DZUDIE, A MENANGA, M AKONO, M OUANKOU, W MUNA. (2005) Nouveau regard sur l'insuffisance cardiaque chronique de l'adulte en Afrique à l'ère de l'échocardiographie Doppler : expérience du service de médecine de l'Hôpital Général de Yaoundé. Annales de Cardiologie et d'Angéiologie 54:5, 276-283
CrossRef1158
Hector F. Lozano, Cesar A. Conde, Todd Florin, Gervasio A. Lamas. (2005) Treatment and prevention of atrial fibrillation with nonantiarrhythmic pharmacologic therapy. Heart Rhythm 2:9, 1000-1007
CrossRef1159
Michael A. Crouch. (2005) Chronic Heart Failure: Developments and Perspectives. The Consultant Pharmacist 20:9, 751-765
CrossRef1160
Sharon Ann Hunt, William T. Abraham, Marshall H. Chin, Arthur M. Feldman, Gary S. Francis, Theodore G. Ganiats, Mariell Jessup, Marvin A. Konstam, Donna M. Mancini, Keith Michl, John A. Oates, Peter S. Rahko, Marc A. Silver, Lynne Warner Stevenson, Clyde W. Yancy, Elliott M. Antman, Sidney C. Smith, Cynthia D. Adams, Jeffrey L. Anderson, David P. Faxon, Valentin Fuster, Jonathan L. Halperin, Loren F. Hiratzka, Sharon Ann Hunt, Alice K. Jacobs, Rick Nishimura, Joseph P. Ornato, Richard L. Page, Barbara Riegel. (2005) ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult—Summary Article. Journal of the American College of Cardiology 46:6, 1116-1143
CrossRef1161
Ricardo Gómez, Lucía Núñez, Ricardo Caballero, Miguel Vaquero, Juan Tamargo, Eva Delpón. (2005) Spironolactone and its main metabolite canrenoic acid block hKv1.5, Kv4.3 and Kv7.1+minK channels. British Journal of Pharmacology 146:1, 146-161
CrossRef1162
Heyman Luckraz, Linda D. Sharples, Susan C. Charman, Steven S.L. Tsui, John Wallwork, Jayan Parameshwar, Stephen R. Large. (2005) Does Heart Transplantation Confer Survival Benefit in All Risk Groups?. The Journal of Heart and Lung Transplantation 24:9, 1231-1234
CrossRef1163
Keyur B. Shah, Krishnamurti Rao, Robert Sawyer, Stephen S. Gottlieb. (2005) The Adequacy of Laboratory Monitoring in Patients Treated With Spironolactone for Congestive Heart Failure. Journal of the American College of Cardiology 46:5, 845-849
CrossRef1164
Arantxa González, Begoña López, Javier Díez. (2005) New directions in the assessment and treatment of hypertensive heart disease. Current Opinion in Nephrology and Hypertension 14:5, 428-434
CrossRef1165
Sharon Ann Hunt. (2005) ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult. Journal of the American College of Cardiology 46:6, e1-e82
CrossRef1166
Nigel J. Dagenais, Fakhreddin Jamali. (2005) Protective Effects of Angiotensin II Interruption: Evidence for Antiinflammatory Actions. Pharmacotherapy 25:9, 1213-1229
CrossRef1167
Daniel J. Garry, Sean C. Goetsch, Amanda J. McGrath, Pradeep P.A. Mammen. (2005) Alternative Therapies for Orthotopic Heart Transplantation. The American Journal of the Medical Sciences 330:2, 88-101
CrossRef1168
Douglas L. Jennings, James S. Kalus, Kate M. O'Dell. (2005) Aldosterone Receptor Antagonism in Heart Failure. Pharmacotherapy 25:8, 1126-1133
CrossRef1169
Hiromitsu Miyamoto, Hisashi Kai, Hiroyuki Nakaura, Katsunori Osada, Yoshihiko Mizuta, Akira Matsumoto, Tsutomu Imaizumi. (2005) Safety and Efficacy of Repeated Sauna Bathing in Patients With Chronic Systolic Heart Failure: A Preliminary Report. Journal of Cardiac Failure 11:6, 432-436
CrossRef1170
Sandeep A. Kamath, Clyde W. Yancy. (2005) Treatment of the african-american patient with congestive heart failure. Current Treatment Options in Cardiovascular Medicine 7:4, 307-315
CrossRef1171
Nancy J Brown. (2005) Aldosterone and end-organ damage. Current Opinion in Internal Medicine 4:4, 381-387
CrossRef1172
C. Richard Conti. (2005) Heart failure after acute ST-segment elevation myocardial infarction: What should we do about it?. Clinical Cardiology 28:8, 360-361
CrossRef1173
Shyam Bhakta, Mark E. Dunlap. (2005) Treatment of heart failure with a normal ejection fraction. Current Treatment Options in Cardiovascular Medicine 7:4, 317-325
CrossRef1174
Frank Bogun, Subramaniam Krishnan, Mukarram Siddiqui, Eric Good, Joseph E. Marine, Claudio Schuger, Hakan Oral, Aman Chugh, Frank Pelosi, Fred Morady. (2005) Electrogram Characteristics in Postinfarction Ventricular Tachycardia. Journal of the American College of Cardiology 46:4, 667-674
CrossRef1175
John L. Jefferies, Anthony C. Chang. (2005) The neurohormonal axis and biochemical markers of heart failure. Cardiology in the Young 15:4, 333-344
CrossRef1176
Ursula Müller-Vieira, Marc Angotti, Rolf W. Hartmann. (2005) The adrenocortical tumor cell line NCI-H295R as an in vitro screening system for the evaluation of CYP11B2 (aldosterone synthase) and CYP11B1 (steroid-11β-hydroxylase) inhibitors. The Journal of Steroid Biochemistry and Molecular Biology 96:3-4, 259-270
CrossRef1177
Evan Gross, Marcos Rothstein, Susan Dombek, Henrikas Irmantas Juknis. (2005) Effect of Spironolactone on Blood Pressure and the Renin-Angiotensin-Aldosterone System in Oligo-Anuric Hemodialysis Patients. American Journal of Kidney Diseases 46:1, 94-101
CrossRef1178
Xiaobing Guo, Harjot K Saini, Jingwei Wang, Suresh K Gupta, Ramesh K Goyal, Naranjan S Dhalla. (2005) Prevention of remodeling in congestive heart failure due to myocardial infarction by blockade of the renin–angiotensin system. Expert Review of Cardiovascular Therapy 3:4, 717-732
CrossRef1179
Frederick A. Spencer, Theo Meyer. (2005) Heart failure and shock complicating acute coronary syndromes. Current Cardiology Reports 7:4, 276-282
CrossRef1180
Kenneth L. Choi, George L. Bakris. (2005) Hypertension Treatment Guidelines: Practical Implications. Seminars in Nephrology 25:4, 198-209
CrossRef1181
Franz H. Messerli, Ehud Grossman. (2005) Therapeutic Controversies in Hypertension. Seminars in Nephrology 25:4, 227-235
CrossRef1182
Wenxia Chai, Ingrid M Garrelds, Udayasankar Arulmani, Regien G Schoemaker, Jos M J Lamers, A H Jan Danser. (2005) Genomic and nongenomic effects of aldosterone in the rat heart: why is spironolactone cardioprotective?. British Journal of Pharmacology 145:5, 664-671
CrossRef1183
Edward D Frohlich. (2005) Recent advances in hypertension, stroke, and cardiorenal disease. Current Opinion in Cardiology 20:4, 258-263
CrossRef1184
Stefano Bianchi, Roberto Bigazzi, Vito M. Campese. (2005) Antagonists of Aldosterone and Proteinuria in Patients With CKD: An Uncontrolled Pilot Study. American Journal of Kidney Diseases 46:1, 45-51
CrossRef1185
Constança S Cruz, Luzia S Cruz, Gustavo S Domingues, Carlos A Marcílio de Souza. (2005) New strategies for treatment of heart failure with aldosterone antagonists and the risk of hyperkalaemia. Expert Opinion on Drug Safety 4:4, 677-688
CrossRef1186
Tae-Yon Chun, J. Howard Pratt. (2005) Aldosterone increases plasminogen activator inhibitor-1 synthesis in rat cardiomyocytes. Molecular and Cellular Endocrinology 239:1-2, 55-61
CrossRef1187
Aliye L. Runyan, Vikram S. Chhokar, Yao Sun, Syamal K. Bhattacharya, John W. Runyan, Karl T. Weber. (2005) Bone Loss in Rats with Aldosteronism. The American Journal of the Medical Sciences 330:1, 1-7
CrossRef1188
John W Funder. (2005) Cardiac synthesis of aldosterone: con. Current Opinion in Endocrinology & Diabetes 12:3, 215-218
CrossRef1189
Roy S. Gardner, Kwok S. Chong, James J. Morton, Theresa A. Mcdonagh. (2005) N-Terminal Brain Natriuretic Peptide, But Not Anemia, Is a Powerful Predictor of Mortality in Advanced Heart Failure. Journal of Cardiac Failure 11:5, S47-S53
CrossRef1190
Rafael Marín, Álex de la Sierra, Pedro Armario, Carlos Campo, José R. Banegas, Manuel Gorostidi. (2005) Guía sobre el diagnóstico y tratamiento de la hipertensión arterial en España 2005. Medicina Clínica 125:1, 24-34
CrossRef1191
Reinhard Rychlik, Hanna Rulhoff. (2005) Socioeconomic relevance of selected treatment strategies in patients with chronic heart failure. Expert Review of Pharmacoeconomics & Outcomes Research 5:3, 277-286
CrossRef1192
Domenic A. Sica. (2005) The risks and benefits of aldosterone antagonists. Current Heart Failure Reports 2:2, 65-71
CrossRef1193
Mary Rose Fabi, John R. Teerlink. (2005) The addition of angiotensin receptor blockers to angiotens-inconverting enzyme inhibitors—What has time told us?. Current Heart Failure Reports 2:2, 59-64
CrossRef1194
Mako Isaji, Tomoatsu Mune, Nobuki Takada, Yoritsuna Yamamoto, Tetsuya Suwa, Hiroyuki Morita, Jun Takeda, Perrin C White. (2005) Correlation between left ventricular mass and urinary sodium excretion in specific genotypes of CYP11B2. Journal of Hypertension 23:6, 1149-1157
CrossRef1195
Ariel J. Reyes, William P. Leary, Giuseppe Crippa, Mário F.C. Maranhão, Rafael Hernández-Hernández. (2005) The aldosterone antagonist and facultative diuretic eplerenone: A critical review. European Journal of Internal Medicine 16:3, 145-153
CrossRef1196
Gregg C. Fonarow. (2005) When to initiate beta-blockers in heart failure: Is it ever too early?. Current Heart Failure Reports 2:2, 94-99
CrossRef1197
Osama A. Ibrahim, Mark E. Dunlap. (2005) Combination pharmacologic therapies for heart failure: What next after angiotensin-converting enzyme inhibitors and beta-blockers?. Current Heart Failure Reports 2:2, 89-93
CrossRef1198
Martin Wehling. (2005) Cardiac and vascular synthesis of aldosterone: yes, but???. Current Opinion in Endocrinology & Diabetes 12:3, 211-214
CrossRef1199
Paolo Magni, Marcella Motta. (2005) Aldosterone receptor antagonists: Biology and novel therapeutic applications. Current Hypertension Reports 7:3, 206-211
CrossRef1200
I.P. Garrido Bravo, J.Á. Rodríguez Fernández, J. García de Lara, A. Castro Beiras. (2005) Tratamiento de la insuficiencia cardíaca crónica. Medicine - Programa de Formación Médica Continuada Acreditado 9:35, 2318-2326
CrossRef1201
T. Jared Bunch, Stephen C. Hammill, Roger D. White. (2005) Outcomes After Ventricular Fibrillation Out-of-Hospital Cardiac Arrest: Expanding the Chain of Survival. Mayo Clinic Proceedings 80:6, 774-782
CrossRef1202
Mary Norine Walsh. (2005) Advanced heart failure and transplantation in women. Current Cardiology Reports 7:3, 184-189
CrossRef1203
Paul R. Conlin. (2005) Interactions of High Salt Intake and the Response of the Cardiovascular System to Aldosterone. Cardiology in Review 13:3, 118-124
CrossRef1204
M. Cabré Roure. (2005) Tratamiento de la insuficiencia cardíaca en fase muy avanzada. FMC - Formación Médica Continuada en Atención Primaria 12:5, 315-324
CrossRef1205
L. R. Erhardt. (2005) A review of the current evidence for the use of angiotensin-receptor blockers in chronic heart failure. International Journal of Clinical Practice 59:5, 571-578
CrossRef1206
U. Wenzel, G. Wolf. (2005) Blutdruckunabhängige Wirkungen von Antihypertensiva. Der Internist 46:5, 548-556
CrossRef1207
Ileana L. Piña. (2005) Clinical trials report. Current Cardiology Reports 7:3, 155-158
CrossRef1208
John JV McMurray, Marc A Pfeffer. (2005) Heart failure. The Lancet 365:9474, 1877-1889
CrossRef1209
Michele Senni, Renata De Maria, Dario Gregori, Lucio Gonzini, Marco Gorini, Giuseppe Cacciatore, Antonello Gavazzi, Giovanni Pulignano, Maurizio Porcu, Aldo P. Maggioni. (2005) Temporal Trends in Survival and Hospitalizations in Outpatients With Chronic Systolic Heart Failure in 1995 and 1999. Journal of Cardiac Failure 11:4, 270-278
CrossRef1210
T. Barry Levine, Arlene B. Levine. (2005) Rationale for the use of angiotensin ii receptor blockers in patients with left ventricular dysfunction (part I of II). Clinical Cardiology 28:5, 215-218
CrossRef1211
David S. Geller. (2005) Mineralocorticoid resistance. Clinical Endocrinology 62:5, 513-520
CrossRef1212
J. Davies, A. Gavin, M. Band, A. Morris, A. Struthers. (2005) Spironolactone reduces brachial pulse wave velocity and PIIINP levels in hypertensive diabetic patients. British Journal of Clinical Pharmacology 59:5, 520-523
CrossRef1213
Steven Gabardi, Stuart Abramson. (2005) Drug Dosing in Chronic Kidney Disease. Medical Clinics of North America 89:3, 649-687
CrossRef1214
Wendy M. Book. (2005) Heart Failure in the Adult Patient with Congenital Heart Disease. Journal of Cardiac Failure 11:4, 306-312
CrossRef1215
David A. Neel, Matthew L. Brown, Peter A. Lander, Timothy A. Grese, Jean M. Defauw, Robert A. Doti, Todd Fields, Sally Ann Kelley, Stephon Smith, Karen M. Zimmerman, Mitchell I. Steinberg, Prabhakar K. Jadhav. (2005) 3,3-Bisaryloxindoles as mineralocorticoid receptor antagonists. Bioorganic & Medicinal Chemistry Letters 15:10, 2553-2557
CrossRef1216
Steven G Coca, Mark A Perazella. (2005) Adverse cardiorenal effects of aldosterone: is aldosterone antagonism beneficial?. Expert Review of Cardiovascular Therapy 3:3, 497-512
CrossRef1217
Michael W. Rich. (2005) Heart Failure in the Oldest Patients: The Impact of Comorbid Conditions. The American Journal of Geriatric Cardiology 14:3, 134-141
CrossRef1218
Nancy J Brown. (2005) Aldosterone and end-organ damage. Current Opinion in Nephrology and Hypertension 14:3, 235-241
CrossRef1219
Cleland, John G.F., Daubert, Jean-Claude, Erdmann, Erland, Freemantle, Nick, Gras, Daniel, Kappenberger, Lukas, Tavazzi, Luigi, . (2005) The Effect of Cardiac Resynchronization on Morbidity and Mortality in Heart Failure. New England Journal of Medicine 352:15, 1539-1549
Full Text1220
E. Erdmann. (2005) Effekte der RALE-Studie. Der Internist 46:4, 466-468
CrossRef1221
Paul Milliez, Xavier Girerd, Pierre-François Plouin, Jacques Blacher, Michel E. Safar, Jean-Jacques Mourad. (2005) Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. Journal of the American College of Cardiology 45:8, 1243-1248
CrossRef1222
GianPaolo Rossi, Marco Boscaro, Vanessa Ronconi, John W. Funder. (2005) Aldosterone as a cardiovascular risk factor. Trends in Endocrinology & Metabolism 16:3, 104-107
CrossRef1223
A MUNOZGARCIA. (2005) Aplicabilidad de los resultados de los ensayos clínicos de insuficiencia cardíaca a los pacientes mayores. Medicina Clínica 124:14, 558-558
CrossRef1224
J DIEZMANGLANO. (2005) Análisis coste-efectividad y coste-beneficio del tratamiento con bloqueadores beta de la insuficiencia cardíaca congestiva en España. Revista Clínica Española 205:4, 149-156
CrossRef1225
Richard D. Gordon, John H. Laragh, John W. Funder. (2005) Low renin hypertensive states: perspectives, unsolved problems, future research. Trends in Endocrinology & Metabolism 16:3, 108-113
CrossRef1226
Gary S. Francis, W.H. Wilson Tang. (2005) Should we consider aldosterone as the primary screening target for preventing cardiovascular events?**Editorials published in the Journal of American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.. Journal of the American College of Cardiology 45:8, 1249-1250
CrossRef1227
Lilian Grigorian Shamagian, Alfonso Varela Román, Alejandro Virgos Lamela, Pedro Rigueiro Veloso, José M. García Acuña, José R. González-Juanatey. (2005) Evolución a largo plazo de la prescripción de fármacos en pacientes hospitalizados por insuficiencia cardíaca congestiva. Influencia del patrón de disfunción. Revista Española de Cardiología 58:4, 381-388
CrossRef1228
Eyal Herzog, Cathleen Varley, Marrick Kukin. (2005) Pathway for the Management of Acute Heart Failure. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 4:1, 37-42
CrossRef1229
Kurt Banz. (2005) Cardiac Resynchronization Therapy (CRT) in Heart Failure—A Model to Assess the Economic Value of this New Medical Technology. Value in Health 8:2, 128-139
CrossRef1230
M. Block, J. Br
msen. (2005) Effekt von CRT auf Morbidit
CrossRef1231
Cherry L Wainwright. (2005) Targets for immunomodulation in cardiovascular disease – where are we now?. Future Cardiology 1:2, 177-189
CrossRef1232
Eva Delpón, Ricardo Caballero, Ricardo Gómez, Lucía Núñez, Juan Tamargo. (2005) Angiotensin II, angiotensin II antagonists and spironolactone and their modulation of cardiac repolarization. Trends in Pharmacological Sciences 26:3, 155-161
CrossRef1233
Audrey H. Wu, Keith D. Aaronson, Steven F. Bolling, Francis D. Pagani, Kathy Welch, Todd M. Koelling. (2005) Impact of mitral valve annuloplasty on mortality risk in patients with mitral regurgitation and left ventricular systolic dysfunction. Journal of the American College of Cardiology 45:3, 381-387
CrossRef1234
Bertram Pitt. (2005) Should chronic heart failure patients with reduced left-ventricular ejection fraction receive angiotensin-receptor blockers?. Nature Clinical Practice Cardiovascular Medicine 2:2, 70-71
CrossRef1235
Steven G. Coca, Mark A. Perazella, Gregory K. Buller. (2005) The cardiovascular implications of hypokalemia. American Journal of Kidney Diseases 45:2, 233-247
CrossRef1236
John W. Funder. (2005) RALES, EPHESUS and redox. The Journal of Steroid Biochemistry and Molecular Biology 93:2-5, 121-125
CrossRef1237
Alessandro Pingitore, Patrizia Landi, Maria Chiara Taddei, Andrea Ripoli, Antonio L’Abbate, Giorgio Iervasi. (2005) Triiodothyronine levels for risk stratification of patients with chronic heart failure. The American Journal of Medicine 118:2, 132-136
CrossRef1238
Kazuki Fukuchi, Hideyuki Sasaki, Takahiro Yokoya, Teruo Noguchi, Yoichi Goto, Kohei Hayashida, Yoshio Ishida. (2005) Ga-67 Citrate and F-18 FDG Uptake in Spironolactone-Induced Gynecomastia. Clinical Nuclear Medicine 30:2, 105-106
CrossRef1239
R. Dale Brown, S. Kelly Ambler, M. Darren Mitchell, Carlin S. Long. (2005) THE CARDIAC FIBROBLAST: Therapeutic Target in Myocardial Remodeling and Failure. Annual Review of Pharmacology and Toxicology 45:1, 657-687
CrossRef1240
Craig M. Pratt. (2005) Three decades of clinical trials with beta-blockers. Journal of the American College of Cardiology 45:4, 531-532
CrossRef1241
P. Roman-Sanchez, P. Conthe, J. Garcia-Alegria, J. Forteza-Rey, M. Montero, C. Montoto, . (2005) Factors influencing medical treatment of heart failure patients in Spanish internal medicine departments: a national survey. QJM 98:2, 127-138
CrossRef1242
Gordon H. Williams. (2005) Aldosterone and Heart Failure: The Rest of the Story. Heart Failure Reviews 10:1, 5-6
CrossRef1243
Masahiro Yoshida, Jun Ma, Tsutomu Tomita, Norihiro Morikawa, Nobuyoshi Tanaka, Katsuhiko Masamura, Yasuyuki Kawai, Isamu Miyamori. (2005) Mineralocorticoid Receptor Is Overexpressed in Cardiomyocytes of Patients With Congestive Heart Failure. Congestive Heart Failure 11:1, 12-16
CrossRef1244
Michihiro Yoshimura. (2005) Folia Pharmacologica Japonica 126:6, 377-380
CrossRef1245
Nagahiro Nishikawa, Kazuhiro Yamamoto, Yasushi Sakata, Toshiaki Mano, Junichi Yoshida, Seiko Umekawa1, Masatsugu Hori, Yuki Yasuhara, Teruyuki Sonoyama, Akimitsu Harada, Tohru Masuyama. (2005) Long-Term Effect of Spironolactone on Cardiac Structure as Assessed by Analysis of Ultrasonic Radio-Frequency Signals in Patients With Ventricular Hypertrophy. Circulation Journal 69:11, 1394-1400
CrossRef1246
Mir Imam Ibne Wahed, Kenichi Watanabe, Meilei Ma, Kenichi Yamaguchi, Toshihiro Takahashi, Hitoshi Tachikawa, Makoto Kodama, Yushifusa Aizawa. (2005) Effects of Eplerenone, a Selective Aldosterone Blocker, on the Progression of Left Ventricular Dysfunction and Remodeling in Rats with Dilated Cardiomyopathy. Pharmacology 73:2, 81-88
CrossRef1247
Domenic A. Sica. (2005) Pharmacokinetics and Pharmacodynamics of Mineralocorticoid Blocking Agents and their Effects on Potassium Homeostasis. Heart Failure Reviews 10:1, 23-29
CrossRef1248
Xiaoyan Zhou, Edward D. Frohlich. (2005) Differential Effects of Antihypertensive Drugs on Renal and Glomerular Hemodynamics and Injury in the Chronic Nitric-Oxide-Suppressed Rat. American Journal of Nephrology 25:2, 138-152
CrossRef1249
Katherine F Croom, Caroline M Perry. (2005) Eplerenone. American Journal of Cardiovascular Drugs 5:1, 51-69
CrossRef1250
Gurbir Bhatia, Michael Sosin, John F Leahy, Derek L Connolly, Russell C Davis, Gregory YH Lip. (2005) Hibernating myocardium in heart failure. Expert Review of Cardiovascular Therapy 3:1, 111-122
CrossRef1251
John W. Funder. (2005) Mineralocorticoid Receptors: Distribution and Activation. Heart Failure Reviews 10:1, 15-22
CrossRef1252
Fumihiko Yasuma. (2005) Cheyne-Stokes Respiration in Congestive Heart Failure: Continuous Positive Airway Pressure of 5–8 cm H<sub>2</sub>O for 1 Year in Five Cases. Respiration 72:2, 198-201
CrossRef1253
T. S. Dharmarajan, Tuan Nguyen, Robin O. Russell. (2005) Life-Threatening, Preventable Hyperkalemia in a Nursing Home Resident. Journal of the American Medical Directors Association 6:6, 400???405
CrossRef1254
Sandeep A. Kamath, S. Raja Laskar, Clyde W. Yancy. (2005) Novel Therapies for Heart Failure: Vasopressin and Selective Aldosterone Antagonists. Congestive Heart Failure 11:1, 21-29
CrossRef1255
Hylton V. Joffe, Gail K. Adler. (2005) Effect of Aldosterone and Mineralocorticoid Receptor Blockade on Vascular Inflammation. Heart Failure Reviews 10:1, 31-37
CrossRef1256
C. Leclercq. (2005) La resynchronisation cardiaque : quel type d’appareil utiliser ?. Annales de Cardiologie et d Angéiologie 54:1, 12
CrossRef1257
John W. Funder. (2005) ACE inhibitors and mineralocorticoid receptor blockade in patients with congestive heart failure. Current Diabetes Reports 5:1, 36-40
CrossRef1258
Christian J.F. Holubarsch. (2005) Evidenz-basierte Medizin mit Wei
CrossRef1259
Justine I. Davies, Miles D. Witham, Allan D. Struthers. (2005) Autonomic Effects of Spironolactone and MR Blockers in Heart Failure. Heart Failure Reviews 10:1, 63-69
CrossRef1260
Michael Domanski, Eliot Peyster. (2005) Heart failure with preserved systolic function. Current Treatment Options in Cardiovascular Medicine 7:1, 55-59
CrossRef1261
Olaf Hedrich, Richard D. Patten, David Nofrio. (2005) Current treatment options for CHF management: Focus on the renin-angiotensin-aldosterone system. Current Treatment Options in Cardiovascular Medicine 7:1, 3-13
CrossRef1262
Alexandra E R??tz Bravo, Lydia Tchambaz, Anita Kr??henb??hl-Melcher, Lorenzo Hess, Raymond G Schlienger, Stephan Kr??henb??hl. (2005) Prevalence of Potentially Severe Drug-Drug Interactions in Ambulatory Patients with Dyslipidaemia Receiving HMG-CoA Reductase Inhibitor Therapy. Drug Safety 28:3, 263-275
CrossRef1263
Bertram Pitt. (2005) The Role of Aldosterone Blockade in Patients with Heart Failure. Heart Failure Reviews 10:1, 79-83
CrossRef1264
Andrew J. Burger. (2005) A Review of the Renal and Neurohormonal Effects of B-Type Natriuretic Peptide. Congestive Heart Failure 11:1, 30-38
CrossRef1265
Charles T. Stier, Ricardo Rocha, Praveen N. Chander. (2005) Effect of Aldosterone and MR Blockade on the Brain and the Kidney. Heart Failure Reviews 10:1, 53-62
CrossRef1266
Goran Milasinovic, Vera Jelic, Milan Petrovic, Zarko Calovic, Dragutin Savic, Sinisa Pavlovic, Mirjana Zivkovic, Vladimir Kanjuh. (2005) Resynchronisation therapy in patients with heart failure: Our results. Srpski arhiv za celokupno lekarstvo 133:5-6, 237-241
CrossRef1267
Faiez Zannad, Anca Radauceanu. (2005) Effect of MR Blockade on Collagen Formation and Cardiovascular Disease with a Specific Emphasis on Heart Failure. Heart Failure Reviews 10:1, 71-78
CrossRef1268
Sergio Richter, Gabor Duray, Gerian Grönefeld, Carsten W Israel, Stefan H Hohnloser. (2005) Prevention of Sudden Cardiac Death. Circulation Journal 69:6, 625-629
CrossRef1269
Arduino A Mangoni. (2005) Cardiovascular Drug Therapy in Elderly Patients. Drugs & Aging 22:11, 913-941
CrossRef1270
Gillian A Whalley, Cara A Wasywich, Helen Walsh, Robert N Doughty. (2005) Role of echocardiography in the contemporary management of chronic heart failure. Expert Review of Cardiovascular Therapy 3:1, 51-70
CrossRef1271
Kevin D. O'Brien, Daniel P. Fishbein. (2005) Mitral valve abnormalities in congestive heart failure. Journal of the American College of Cardiology 45:1, 62-64
CrossRef1272
(2004) Hyperkalemia after the Publication of RALES. New England Journal of Medicine 351:23, 2448-2450
Full Text1273
RICHARD L. KRAVITZ, NAIHUA DUAN, JOEL BRASLOW. (2004) Evidence-Based Medicine, Heterogeneity of Treatment Effects, and the Trouble with Averages. The Milbank Quarterly 82:4, 661-687
CrossRef1274
David Rosenthal, Maryanne R.K. Chrisant, Erik Edens, Lynn Mahony, Charles Canter, Steven Colan, Anne Dubin, Jacque Lamour, Robert Ross, Robert Shaddy, Linda Addonizio, Lee Beerman, Stuart Berger, Daniel Bernstein, Elizabeth Blume, Mark Boucek, Paul Checchia, Anne Dipchand, Jonathan Drummond-Webb, Jay Fricker, Richard Friedman, Sara Hallowell, Robert Jaquiss, Seema Mital, Elfriede Pahl, Bennett Pearce, Larry Rhodes, Kathy Rotondo, Paolo Rusconi, Janet Scheel, Tajinder Pal Singh, Jeffrey Towbin. (2004) International Society for Heart and Lung Transplantation: Practice guidelines for management of heart failure in children. The Journal of Heart and Lung Transplantation 23:12, 1313-1333
CrossRef1275
Allan D. Struthers. (2004) Aldosterone in heart failure: Pathophysiology and treatment. Current Heart Failure Reports 1:4, 171-175
CrossRef1276
Ronald Van Beneden, Olivier Gurné, Philippe L. Selvais, Sylvie A. Ahn, Annie R. Robert, Jean-marie Ketelslegers, Hubert G. Pouleur, Michel F. Rousseau. (2004) Superiority of big endothelin-1 and endothelin-1 over natriuretic peptides in predicting survival in severe congestive heart failure: a 7-year follow-up study. Journal of Cardiac Failure 10:6, 490-495
CrossRef1277
Andrew Boyle, Monica Colvin-Adams. (2004) Recipient selection and management. Seminars in Thoracic and Cardiovascular Surgery 16:4, 358-363
CrossRef1278
Juan M. Aranda, Jamie B. Conti, James W. Johnson, Susan Petersen-Stejskal, Anne B. Curtis. (2004) Cardiac resynchronization therapy in patients with heart failure and conduction abnormalities other than left bundle-branch block: Analysis of the multicenter insync randomized clinical evaluation (MIRACLE). Clinical Cardiology 27:12, 678-682
CrossRef1279
Jay N. Cohn. (2004) New therapeutic strategies for heart failure: left ventricular remodeling as a target. Journal of Cardiac Failure 10:6, S200-S201
CrossRef1280
Keyur B. Shah, Stephen S. Gottlieb. (2004) Current concepts for the neurohormonal management of left ventricular dysfunction after myocardial infarction. Current Heart Failure Reports 1:4, 161-167
CrossRef1281
Eileen O’Meara, Clare Murphy, John J. V. McMurray. (2004) Anemia and heart failure. Current Heart Failure Reports 1:4, 176-182
CrossRef1282
Ellen Burgess. (2004) Eplerenone in hypertension. Expert Opinion on Pharmacotherapy 5:12, 2573-2581
CrossRef1283
P. Cía Gómez, A. Martínez Berganza, J.I. Pérez Calvo. (2004) Tratamiento farmacológico de la hipertensión arterial. Medicine - Programa de Formación Médica Continuada Acreditado 9:23, 1481-1493
CrossRef1284
(2004) Aldosterone Revisited. New England Journal of Medicine 351:20, 2131-2133
Full Text1285
Srinivas Iyengar, William T. Abraham. (2004) Pharmacogenomics and Heart Failure: Tailor-Made Therapy?. Congestive Heart Failure 10:6, 273-288
CrossRef1286
Ivar K Eide, Peter A Torjesen, Anders Drolsum, Almira Babovic, Nils P Lilledahl. (2004) Low-renin status in therapy-resistant hypertension. Journal of Hypertension 22:11, 2217-2226
CrossRef1287
John C Somberg, Janos Molnar. (2004) The Pharmacologic Treatment of Heart Failure. American Journal of Therapeutics 11:6, 480-488
CrossRef1288
PIERRE BORDACHAR, STEPHANE LAFITTE, SYLVAIN REUTER, STEPHANE GARRIGUE, PRASHANTHAN SANDERS, RAYMOND ROUDAUT, PIERRE JAIS, MICHEL HAISSAGUERRE, JACQUES CLEMENTY. (2004) Biventricular Pacing and Left Ventricular Pacing in Heart Failure:. Similar Hemodynamic Improvement Despite Marked Electromechanical Differences. Journal of Cardiovascular Electrophysiology 15:12, 1342-1347
CrossRef1289
Kamyar Kalantar-Zadeh, Rajnish Mehrotra, Denis Fouque, Joel D. Kopple. (2004) POOR NUTRITIONAL STATUS AND INFLAMMATION: Metabolic Acidosis and Malnutrition-Inflammation Complex Syndrome in Chronic Renal Failure. Seminars in Dialysis 17:6, 455-465
CrossRef1290
Robert M. Lobel, Daniel L. Lustgarten. (2004) Treatment of arrhythmias in patients with congestive heart failure. Current Treatment Options in Cardiovascular Medicine 6:6, 519-529
CrossRef1291
Miles D. Witham, Neil D. Gillespie, Allan D Struthers. (2004) Tolerability of spironolactone in patients with chronic heart failure - a cautionary message. British Journal of Clinical Pharmacology 58:5, 554-557
CrossRef1292
Robert E Hobbs. (2004) Guidelines for the Diagnosis and Management of Heart Failure. American Journal of Therapeutics 11:6, 467-472
CrossRef1293
Angie Veverka, Jamie L Jolly. (2004) Recent advances in the secondary prevention of coronary heart disease. Expert Review of Cardiovascular Therapy 2:6, 877-889
CrossRef1294
John IP, Sricharan Kantipudi, Atul Khasnis, Anand Cholia, Michael Dickinson. (2004) Statin Therapy Is Associated With Improved Survival in Ischemic and Non-Ischemic Heart Failure. Rates of Hyperkalemia After Publication of the Randomized Aldactone Evaluation Study. Congestive Heart Failure 10:6, 313-315
CrossRef1295
Sabrina D. Phillips, Carole A. Warnes. (2004) Peripartum cardiomyopathy: Current therapeutic perspectives. Current Treatment Options in Cardiovascular Medicine 6:6, 481-488
CrossRef1296
Mary Clare Derfler, Mark Jacob, Robert E. Wolf, Frank Bleyer, Paul J. Hauptman. (2004) Mode of Death From Congestive Heart Failure: Implications for Clinical Management. The American Journal of Geriatric Cardiology 13:6, 299-304
CrossRef1297
A. Kay Williams. (2004) Gynecomastia. AJN, American Journal of Nursing 104:11, 72AA-72GG
CrossRef1298
Myron H. Weinberger. (2004) The Use of Aldosterone Receptor Blockers in the Treatment of Hypertension. The Journal of Clinical Hypertension 6:11, 632-635
CrossRef1299
van de Wal Rma, Voors AA, Plokker HWM, van Gilst WH, van Veldhuisen DJ. (2004) New Pharmacological Strategies in Chronic Heart Failure. Cardiovascular Drugs and Therapy 18:6, 491-501
CrossRef1300
Allison M. Pritchett, Douglas L. Mann. (2004) Neurohormonal therapy for congestive heart failure. Current Treatment Options in Cardiovascular Medicine 6:6, 499-507
CrossRef1301
HOWARD TRACHTMAN, ADAM C. WEISER, ELSA VALDERRAMA, MARIA MORGADO, LANE S. PALMER. (2004) PREVENTION OF RENAL FIBROSIS BY SPIRONOLACTONE IN MICE WITH COMPLETE UNILATERAL URETERAL OBSTRUCTION. The Journal of Urology 172:4, 1590-1594
CrossRef1302
PETER GROSS. (2004) Renal transport proteins in excreted urine: Gold mine or gold dust?. Kidney International 66:4, 1707-1708
CrossRef1303
Constantine L. Athanasuleas, Gerald D. Buckberg, Alfred W.H. Stanley, William Siler, Vincent Dor, Marisa Di Donato, Lorenzo Menicanti, Sergio Almeida de Oliveira, Friedhelm Beyersdorf, Irving L. Kron, Hisayoshi Suma, Nicholas T. Kouchoukos, Wistar Moore, Patrick M. McCarthy, Mehmet C. Oz, Francis Fontan, Meredith L. Scott, Kevin A. Accola. (2004) Surgical ventricular restoration in the treatment of congestive heart failure due to post-infarction ventricular dilation. Journal of the American College of Cardiology 44:7, 1439-1445
CrossRef1304
Serge Masson, Lidia Staszewsky, Giorgio Annoni, Eleonora Carlo, Beatrice Arosio, Antonio Bai, Carmen Calabresi, Elena Martinoli, Monica Salio, Fabio Fiordaliso, Eugenio Scanziani, Amy E. Rudolph, Roberto Latini. (2004) Eplerenone, a selective aldosterone blocker, improves diastolic function in aged rats with small-to-moderate myocardial infarction. Journal of Cardiac Failure 10:5, 433-441
CrossRef1305
Fraser M Rogerson, Yizhou Yao, Brian J Smith, Peter J Fuller. (2004) Differences in the determinants of eplerenone, spironolactone and aldosterone binding to the mineralocorticoid receptor*. Clinical and Experimental Pharmacology and Physiology 31:10, 704-709
CrossRef1306
J. Bauersachs. (2004) Aldosterone antagonism in heart failure: improvement of cardiac remodelling, endothelial dysfunction and platelet activation. European Journal of Clinical Investigation 34:10, 649-652
CrossRef1307
Steven N. Singh, Jonathan Patrick. (2004) Antiarrhythmic drugs. Current Treatment Options in Cardiovascular Medicine 6:5, 357-364
CrossRef1308
J. I. Davies, M. Band, A. Morris, A. D. Struthers. (2004) Spironolactone impairs endothelial function and heart rate variability in patients with Type 2 diabetes. Diabetologia 47:10, 1687-1694
CrossRef1309
Ian Balfour. (2004) Management of chronic congestive heart failure in children. Current Treatment Options in Cardiovascular Medicine 6:5, 407-416
CrossRef1310
Ji-Guang Wang, Lifang Liu, Laura Zagato, Jinxiang Xie, Robert Fagard, Kugen Jin, Jinxiang Wang, Yan Li, Giuseppe Bianchi, Jan A. Staessen, Lisheng Liu. (2004) Renal function in relation to three candidate genes in a Chinese population. Journal of Molecular Medicine 82:10, 715-722
CrossRef1311
Mauro Di Bari, Claudia Pozzi, Maria Chiara Cavallini, Francesca Innocenti, Giorgio Baldereschi, Walter De Alfieri, Enrico Antonini, Riccardo Pini, Giulio Masotti, Niccolò Marchionni. (2004) The diagnosis of heart failure in the community. Journal of the American College of Cardiology 44:8, 1601-1608
CrossRef1312
H.-P. Hermann, G. Hasenfuss. (2004) Therapie der Herzinsuffizienz. Intensivmedizin und Notfallmedizin 41:7, 451-464
CrossRef1313
Victor N. Uebele, Cindy E. Nuss, John J. Renger, Thomas M. Connolly. (2004) Role of voltage-gated calcium channels in potassium-stimulated aldosterone secretion from rat adrenal zona glomerulosa cells. The Journal of Steroid Biochemistry and Molecular Biology 92:3, 209-218
CrossRef1314
Aurigemma, Gerard P., Gaasch, William H., . (2004) Diastolic Heart Failure. New England Journal of Medicine 351:11, 1097-1105
Full Text1315
Michael Stowasser, Richard D. Gordon. (2004) The Aldosterone???Renin Ratio in Screening for Primary Aldosteronism. The Endocrinologist 14:5, 267-276
CrossRef1316
Jocelyn D. Jones, Keecia D. King, Frank S. Emanuel. (2004) Hypertension: A Clinical Pharmacist's Synopsis of JNC 7. American Journal of Pharmaceutical Education 68:3, 71
CrossRef1317
Karl T. Weber. (2004) Furosemide in the long-term management of heart failure. Journal of the American College of Cardiology 44:6, 1308-1310
CrossRef1318
John M. McCurley, Stephen U. Hanlon, Shao-kui Wei, Erich F. Wedam, Michael Michalski, Mark C. Haigney. (2004) Furosemide and the progression of left ventricular dysfunction in experimental heart failure. Journal of the American College of Cardiology 44:6, 1301-1307
CrossRef1319
Clyde W. Yancy. (2004) The prevention of heart failure in minority communities and discrepancies in health care delivery systems. Medical Clinics of North America 88:5, 1347-1368
CrossRef1320
Domenic A. Sica, Michael Hess. (2004) Aldosterone Receptor Antagonism: Interface With Hyperkalemia in Heart Failure. Congestive Heart Failure 10:5, 259-264
CrossRef1321
M AMBROISINE, P MILLIEZ, J NEHME, A PASQUIER, N DEANGELIS, P MANSIER, B SWYNGHEDAUW, C DELCAYRE. (2004) Aldosterone and anti-aldosterone effects in cardiovascular diseases and diabetic nephropathy. Diabetes & Metabolism 30:4, 311-318
CrossRef1322
Marc A. Silver, Alan Maisel, Clyde W. Yancy, Peter A. McCullough, John C. Burnett, Gary S. Francis, Mandeep R. Mehra, Gregg Fonarow, W. Brian Gibler, David A. Morrow, Judd Hollander. (2004) BNP Consensus Panel 2004: A Clinical Approach for the Diagnostic, Prognostic, Screening, Treatment Monitoring, and Therapeutic Roles of Natriuretic Peptides in Cardiovascular Diseases. Congestive Heart Failure 10:s5, 1-30
CrossRef1323
Liviu Klein, Mihai Gheorghiade. (2004) Coronary artery disease and prevention of heart failure. Medical Clinics of North America 88:5, 1209-1235
CrossRef1324
Leonard I. Ganz. (2004) Primary prevention of sudden cardiac death. Current Cardiology Reports 6:5, 339-347
CrossRef1325
Makoto Nagai, Kazuaki Horikoshi, Takehiko Izumi, Shingo Seki, Masayuki Taniguchi, Ikuo Taniguchi, Seibu Mochizuki. (2004) Cardioprotective Action of Perindopril versus Candesartan in Renovascular Hypertensive Rats. Cardiovascular Drugs and Therapy 18:5, 353-362
CrossRef1326
Flávio Danni Fuchs. (2004) Blood pressure-lowering drugs: essential therapy for some patients with normal blood pressure. Expert Review of Cardiovascular Therapy 2:5, 771-775
CrossRef1327
Jeanne Y Wei. (2004) Understanding the aging cardiovascular system. Geriatrics and Gerontology International 4:s1, S298-S303
CrossRef1328
Guillermo Torre-Amione, François Sestier, Branislav Radovancevic, James Young. (2004) Effects of a novel immune modulation therapy in patients with advanced chronic heart failure. Journal of the American College of Cardiology 44:6, 1181-1186
CrossRef1329
Myron H. Weinberger. (2004) The use of selective aldosterone antagonists. Current Hypertension Reports 6:5, 342-345
CrossRef1330
Lars H. Lund, Donna Mancini. (2004) Heart failure in women. Medical Clinics of North America 88:5, 1321-1345
CrossRef1331
Guido Boerrigter, John C. Burnett. (2004) Cardiorenal syndrome in decompensated heart failure: Prognostic and therapeutic implications. Current Heart Failure Reports 1:3, 113-120
CrossRef1332
Sidney Goldstein. (2004) The changing epidemiology of sudden death in heart failure. Current Heart Failure Reports 1:3, 93-97
CrossRef1333
Steven Kang, David S. Cannom. (2004) Current role of device therapy to reduce sudden cardiac death in heart failure. Current Heart Failure Reports 1:3, 104-110
CrossRef1334
P. Gross. (2004) Hyperkalaemia: again. Nephrology Dialysis Transplantation 19:9, 2163-2166
CrossRef1335
Palmer, Biff F., . (2004) Managing Hyperkalemia Caused by Inhibitors of the Renin–Angiotensin–Aldosterone System. New England Journal of Medicine 351:6, 585-592
Full Text1336
Juurlink, David N., Mamdani, Muhammad M., Lee, Douglas S., Kopp, Alexander, Austin, Peter C., Laupacis, Andreas, Redelmeier, Donald A., . (2004) Rates of Hyperkalemia after Publication of the Randomized Aldactone Evaluation Study. New England Journal of Medicine 351:6, 543-551
Full Text1337
McMurray, John J.V., O'Meara, Eileen, . (2004) Treatment of Heart Failure with Spironolactone — Trial and Tribulations. New England Journal of Medicine 351:6, 526-528
Full Text1338
Ari Mosenkis, Raymond R. Townsend. (2004) Gynecomastia and Antihypertensive Therapy. The Journal of Clinical Hypertension 6:8, 122-130
CrossRef1339
Anita Deswal, David Yao. (2004) Aldosterone receptor blockers in the treatment of heart failure. Current Treatment Options in Cardiovascular Medicine 6:4, 327-334
CrossRef1340
Olaf Hedrich, Mark Jacob, Paul J. Hauptman. (2004) Progression of coronary artery disease in non-ischemic dilated cardiomyopathy. Coronary Artery Disease 15:5, 291-297
CrossRef1341
Morten Svensson, Finn Gustafsson, SØren Galatius, Per R Hildebrandt, Dan Atar. (2004) How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure?. Journal of Cardiac Failure 10:4, 297-303
CrossRef1342
Richard D. Patten, Prem Soman. (2004) Prevention and reversal of LV remodeling with neurohormonal inhibitors. Current Treatment Options in Cardiovascular Medicine 6:4, 313-325
CrossRef1343
C Sierra, Luis M Ruilope. (2004) Novel antihypertensive agents. Expert Opinion on Investigational Drugs 13:8, 987-998
CrossRef1344
Y.H Liang, J.M Wang, Y Zhou, X.J Jiang, H Jiang, C.X Huang. (2004) Additive effects of combined valsartan and spironolactone on cardiac aldosterone escape in spontaneously hypertensive rats. Life Sciences 75:15, 1871-1878
CrossRef1345
Elliott M. Antman, Daniel T. Anbe, Paul Wayne Armstrong, Eric R. Bates, Lee A. Green, Mary Hand, Judith S. Hochman, Harlan M. Krumholz, Frederick G. Kushner, Gervasio A. Lamas, Charles J. Mullany, Joseph P. Ornato, David L. Pearle, Michael A. Sloan, Sidney C. Smith, Elliott M. Antman, Sidney C. Smith, Joseph S. Alpert, Jeffrey L. Anderson, David P. Faxon, Valentin Fuster, Raymond J. Gibbons, Gabriel Gregoratos, Jonathan L. Halperin, Loren F. Hiratzka, Sharon Ann Hunt, Alice K. Jacobs, Joseph P. Ornato. (2004) ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction—Executive Summary. Journal of the American College of Cardiology 44:3, 671-719
CrossRef1346
Mihir Prakash Pandia, Parmod Kumar Bithal, Meenu Gupta. (2004) Life-Threatening Hyperkalemia In the Intraoperative Period. Journal of Neurosurgical Anesthesiology 16:3, 263
CrossRef1347
Felix J Frey, A Odermatt, Brigitte M Frey. (2004) Glucocorticoid-mediated mineralocorticoid receptor activation and hypertension. Current Opinion in Nephrology and Hypertension 13:4, 451-458
CrossRef1348
Jan Östergren. (2004) Candesartan for the treatment of hypertension and heart failure. Expert Opinion on Pharmacotherapy 5:7, 1589-1597
CrossRef1349
Bertram Pitt. (2004) Generic drugs in cardiology: will they reduce health care costs?. Journal of the American College of Cardiology 44:1, 10-13
CrossRef1350
W.H Wilson Tang, Anjli Maroo, James B Young. (2004) Ischemic heart disease and congestive heart failure in diabetic patients. Medical Clinics of North America 88:4, 1037-1061
CrossRef1351
Bradley P Knight, Aseem Desai, James Coman, Mitchell Faddis, Patrick Yong. (2004) Long-term retention of cardiac resynchronization therapy. Journal of the American College of Cardiology 44:1, 72-77
CrossRef1352
C LECLERCQ. (2004) Comparative effects of ventricular resynchronization therapy in heart failure patients with or without coronary artery disease. Annales de Cardiologie et d?Ang
CrossRef1353
Olga Gumieniak, Gordon H. Williams. (2004) Mineralocorticoid receptor antagonists and hypertension: Is there a rationale?. Current Hypertension Reports 6:4, 279-287
CrossRef1354
Vinay Thohan, Guillermo Torre-Amione, Micheal M Koerner. (2004) Aldosterone antagonism and congestive heart failure: a new look at an old therapy. Current Opinion in Cardiology 19:4, 301-308
CrossRef1355
Joanne Moncrieff, M Mitchell Lindsay, Francis G Dunn. (2004) Hypertensive heart disease and fibrosis. Current Opinion in Cardiology 19:4, 326-331
CrossRef1356
C. Pedone, M. Pahor, L. Carosella, R. Bernabei, P. Carbonin, for the GIFA Investigators. (2004) Use of Angiotensin-Converting Enzyme Inhibitors in Elderly People With Heart Failure: Prevalence and Outcomes. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 59:7, M716-M721
CrossRef1357
Brian F. McBride, C. Michael White. (2004) Anemia Management in Heart Failure: A Thick Review of Thin Data. Pharmacotherapy 24:6, 757-767
CrossRef1358
Steven R. Goldsmith. (2004) Interactions between the sympathetic nervous system and the RAAS in heart failure. Current Heart Failure Reports 1:2, 45-50
CrossRef1359
Michele Emdin, Claudio Passino, Concetta Prontera, Annalisa Iervasi, Andrea Ripoli, Silvano Masini, Gian Carlo Zucchelli, Aldo Clerico. (2004) Cardiac natriuretic hormones, neuro-hormones, thyroid hormones and cytokines in normal subjects and patients with heart failure. Clinical Chemistry and Laboratory Medicine 42:6, 627-636
CrossRef1360
Katsuya Onishi, Kaoru Dohi, Takafumi Koji, Kaoru Funabiki, Tetsuya Kitamura, Kyoko Imanaka-Yoshida, Masaaki Ito, Tsutomu Nobori, Takeshi Nakano. (2004) Candesartan Prevents Myocardial Fibrosis during Progression of Congestive Heart Failure. Journal of Cardiovascular Pharmacology 43:6, 860-867
CrossRef1361
Pablo Navarro, Robert Moskowitz, Thierry H. Le Jemtel. (2004) Inhibition of RAAS—When is it too much?. Current Heart Failure Reports 1:2, 57-64
CrossRef1362
Zaid Abassi, Tony Karram, Samer Ellaham, Joseph Winaver, Aaron Hoffman. (2004) Implications of the natriuretic peptide system in the pathogenesis of heart failure: diagnostic and therapeutic importance. Pharmacology & Therapeutics 102:3, 223-241
CrossRef1363
R. Buchhorn. (2004) Medikamentöse Therapie der Herzinsuffizienz im Kindesalter. Monatsschrift Kinderheilkunde 152:6, 659-665
CrossRef1364
Lawrence Baruch, Prabhakara Kunamneni. (2004) Beta-blockers in heart failure: Is more better?. Current Heart Failure Reports 1:2, 77-81
CrossRef1365
Monica R Shah, Lynne W Stevenson. (2004) Searching for evidence: refractory questions in advanced heart failure. Journal of Cardiac Failure 10:3, 210-218
CrossRef1366
Karl T. Weber. (2004) Efficacy of aldosterone receptor antagonism in heart failure: Potential mechanisms. Current Heart Failure Reports 1:2, 51-56
CrossRef1367
Larisa H. Cavallari, Lucy A. Fashingbauer, Amber L. Beitelshees, Vicki L. Groo, Mary R. Southworth, Marlos A. G. Viana, Randall E. Williams, Stephanie H. Dunlap. (2004) Racial Differences in Patients’ Potassium Concentrations During Spironolactone Therapy for Heart Failure. Pharmacotherapy 24:6, 750-756
CrossRef1368
Carl V. Leier. (2004) Advanced Heart Failure: A Practical Management Algorithm and Therapeutic Options. The American Heart Hospital Journal 2:3, 142-148
CrossRef1369
Kadish, Alan, Dyer, Alan, Daubert, James P., Quigg, Rebecca, Estes, N.A. Mark, Anderson, Kelley P., Calkins, Hugh, Hoch, David, Goldberger, Jeffrey, Shalaby, Alaa, Sanders, William E., Schaechter, Andi, Levine, Joseph H., . (2004) Prophylactic Defibrillator Implantation in Patients with Nonischemic Dilated Cardiomyopathy. New England Journal of Medicine 350:21, 2151-2158
Full Text1370
Angelo Capricchione, Nathaniel Winer, James R. Sowers. (2004) Adrenocortical hypertension. Current Hypertension Reports 6:3, 224-229
CrossRef1371
Mariell Jessup, Ileana L Piña. (2004) Is it important to examine gender differences in the epidemiology and outcome of severe heart failure?. The Journal of Thoracic and Cardiovascular Surgery 127:5, 1247-1252
CrossRef1372
Rigobert Lapu-Bula, Elizabeth Ofili. (2004) Diastolic heart failure: The forgotten manifestation of hypertensive heart disease. Current Hypertension Reports 6:3, 164-170
CrossRef1373
John W. Funder. (2004) Is aldosterone bad for the heart?. Trends in Endocrinology & Metabolism 15:4, 139-142
CrossRef1374
Akiyo Tanabe, Mitsuhide Naruse, Yoshiko Hara, Atsuhisa Sato, Ken Tsuchiya, Toshio Nishikawa, Toshihiro Imaki, Kazue Takano. (2004) Aldosterone antagonist facilitates the cardioprotective effects of angiotensin receptor blockers in hypertensive rats. Journal of Hypertension 22:5, 1017-1023
CrossRef1375
Rachel Hughes-Doichev, Mark E. Dunlap. (2004) Is heart failure different on the two continents (North America and Europe)?. Current Cardiology Reports 6:3, 182-188
CrossRef1376
W.H. Wilson Tang, Gary S. Francis. (2004) Evolving concepts in left ventricular systolic and diastolic remodeling: Implications for therapy. Current Cardiology Reports 6:3, 200-204
CrossRef1377
(2004) References. American Journal of Kidney Diseases 43, 268-290
CrossRef1378
R. Rachmani, I. Slavachevsky, M. Amit, Z. Levi, Y. Kedar, M. Berla, M. Ravid. (2004) The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study. Diabetic Medicine 21:5, 471-475
CrossRef1379
Michael L. Hess, Denise L. Hurst. (2004) Right Ventricular Function: A Stepchild in the Management of Congestive Heart Failure. Congestive Heart Failure 10:3, 152-153
CrossRef1380
Thiemo Pfab, Berthold Hocher. (2004) Tranilast and hypertensive heart disease. Journal of Hypertension 22:5, 883-886
CrossRef1381
Peter J. Fuller. (2004) Aldosterone and DNA: the 50th anniversary. Trends in Endocrinology & Metabolism 15:4, 143-146
CrossRef1382
J.R Payne, S.S Dhamrait, I.S Toor, J Cooper, A Jones, G.J Miller, S.E Humphries, H.E Montgomery. (2004) The −344T>C promoter variant of the gene for aldosterone synthase (CYP11B2) is not associated with cardiovascular risk in a prospective study of UK healthy men. Atherosclerosis 174:1, 81-86
CrossRef1383
Maylene Wong, Luigi Tavazzi. (2004) Effect of Drug Therapy for Heart Failure on Quality of Life. The Journal of Clinical Hypertension 6:5, 256-261
CrossRef1384
Kathleen H. Berecek, Amal Farag, Gul Bahtiyar, Jeffery Rothman, Samy I. McFarlane. (2004) Clinical trials report. Current Hypertension Reports 6:3, 211-214
CrossRef1385
Sumit R Majumdar, Finlay A McAlister, Marilyn Cree, Wei-Ching Chang, Milton Packer, Paul W Armstrong. (2004) Do evidence-based treatments provide incremental benefits to patients with congestive heart failure already receiving angiotensin-converting enzyme inhibitors? A secondary analysis of one-year outcomes from the assessment of treatment with lisinopril and survival (ATLAS) study. Clinical Therapeutics 26:5, 694-703
CrossRef1386
Henry Krum, Danny Liew. (2004) Eplerenone in the treatment of chronic heart failure. Expert Review of Cardiovascular Therapy 2:3, 315-320
CrossRef1387
Inder S. Anand. (2004) Is too much neurohormonal blockade harmful?. Current Cardiology Reports 6:3, 169-175
CrossRef1388
William B Hood, Jr., Antonio L Dans, Gordon H Guyatt, Roman Jaeschke, John JV McMurray, William B Hood, Jr.. 2004. Digitalis for treatment of congestive heart failure in patients in sinus rhythm. .
CrossRef1389
Karen A. Griffin, Anil K. Bidani. (2004) Hypertensive renal damage: Insights from animal models and clinical relevance. Current Hypertension Reports 6:2, 145-153
CrossRef1390
Janine Fletcher, Ashesh N Buch, Helen C Routledge, Saqib Chowdhary, John H Coote, Jonathan N Townend. (2004) Acute aldosterone antagonism improves cardiac vagal control in humans. Journal of the American College of Cardiology 43:7, 1270-1275
CrossRef1391
William B. Hood, Antonio L. Dans, Gordon H. Guyatt, Roman Jaeschke, John J.V. McMurray. (2004) Digitalis for treatment of congestive heart failure in patients in sinus rhythm: a systematic review and meta-analysis. Journal of Cardiac Failure 10:2, 155-164
CrossRef1392
C. Schirpenbach, L. Seiler, F. Beuschlein, M. Reincke. (2004) Primary aldosteronism: Diagnosis and differential diagnosis / Primärer Hyperaldosteronismus: Diagnose und Differentialdiagnose. LaboratoriumsMedizin 28:2, 135-143
CrossRef1393
Horng H Chen, Margaret M Redfield, Lynda J Nordstrom, Darlene P Horton, John C Burnett. (2004) Subcutaneous administration of the cardiac hormone BNP in symptomatic human heart failure. Journal of Cardiac Failure 10:2, 115-119
CrossRef1394
J. M. Trujillo, M. J. Gonyeau, M. V. DiVall, S. L. Alexander. (2004) Spironolactone use in patients with heart failure. Journal of Clinical Pharmacy and Therapeutics 29:2, 165-170
CrossRef1395
Joël Ménard. (2004) The 45-year story of the development of an anti-aldosterone more specific than spironolactone. Molecular and Cellular Endocrinology 217:1-2, 45-52
CrossRef1396
Michael Stowasser, Richard D Gordon. (2004) Primary aldosteronism—careful investigation is essential and rewarding. Molecular and Cellular Endocrinology 217:1-2, 33-39
CrossRef1397
Damien Le Menuet, Say Viengchareun, Martine Muffat-Joly, Maria-Christina Zennaro, Marc Lombès. (2004) Expression and function of the human mineralocorticoid receptor: lessons from transgenic mouse models. Molecular and Cellular Endocrinology 217:1-2, 127-136
CrossRef1398
Emma J. Birks, Magdi H. Yacoub, Nicholas R. Banner, Asghar Khaghani. (2004) The role of bridge to transplantation: should LVAD patients be transplanted?. Current Opinion in Cardiology 19:2, 148-153
CrossRef1399
John M.C Connell, Robert Fraser, Scott M MacKenzie, Elaine C Friel, Mary C Ingram, Christine D Holloway, Eleanor Davies. (2004) The impact of polymorphisms in the gene encoding aldosterone synthase (CYP11B2) on steroid synthesis and blood pressure regulation. Molecular and Cellular Endocrinology 217:1-2, 243-247
CrossRef1400
William T. Abraham. (2004) Overview. Coronary Artery Disease 15:2, 77-79
CrossRef1401
Elise P Gomez-Sanchez. (2004) Brain mineralocorticoid receptors: orchestrators of hypertension and end-organ disease. Current Opinion in Nephrology and Hypertension 13:2, 191-196
CrossRef1402
John D Baxter, John W Funder, James W Apriletti, Paul Webb. (2004) Towards selectively modulating mineralocorticoid receptor function: lessons from other systems. Molecular and Cellular Endocrinology 217:1-2, 151-165
CrossRef1403
Ralf Lösel, Armin Schultz, Martin Wehling. (2004) A quick glance at rapid aldosterone action. Molecular and Cellular Endocrinology 217:1-2, 137-141
CrossRef1404
Amy E. Rudolph, Ricardo Rocha, Ellen G. McMahon. (2004) Aldosterone target organ protection by eplerenone. Molecular and Cellular Endocrinology 217:1-2, 229-238
CrossRef1405
Melyssa R Bratton, Elise P Gomez-Sanchez, Celso E Gomez-Sanchez, Jose S Subauste. (2004) The myosin binding protein is a novel mineralocorticoid receptor binding partner. Molecular and Cellular Endocrinology 217:1-2, 221-227
CrossRef1406
Eldrin F. Lewis, Sui W. Tsang, James C. Fang, Gilbert H. Mudge, John A. Jarcho, Carol M. Flavell, Anju Nohria, Michael M. Givertz, Gregory S. Couper, John G. Byrne, Lynne Warner Stevenson. (2004) Frequency and impact of delayed decisions regarding heart transplantation on long-term outcomes in patients with advanced heart failure. Journal of the American College of Cardiology 43:5, 794-802
CrossRef1407
C Heymes, A Garnier, S Fuchs, J.K Bendall, J Nehme, M.L Ambroisine, E Robidel, B Swynghedauw, P Milliez, C Delcayre. (2004) Aldosterone-synthase overexpression in heart: a tool to explore aldosterone’s effects. Molecular and Cellular Endocrinology 217:1-2, 213-219
CrossRef1408
Norman Sharpe. (2004) Pharmacologic effects on cardiac remodeling. Current Heart Failure Reports 1:1, 9-13
CrossRef1409
Bertram Pitt. (2004) Effect of aldosterone blockade in patients with systolic left ventricular dysfunction: implications of the RALES and EPHESUS studies. Molecular and Cellular Endocrinology 217:1-2, 53-58
CrossRef1410
Neil Goldfarb, Christine Weston, Christine W. Hartmann, Mirko Sikirica, Albert Crawford, Hope He, Jamie Howell, Vittorio Maio, Janice Clarke, Bhaskar Nuthulaganti, Nicole Cobb. (2004) Impact of Appropriate Pharmaceutical Therapy for Chronic Conditions on Direct Medical Costs and Workplace Productivity: A Review of the Literature. Disease Management 7:1, 61-75
CrossRef1411
Matthias Bureik, Katja Hübel, Calin-Aurel Dragan, Jochen Scher, Hans Becker, Natalie Lenz, Rita Bernhardt. (2004) Development of test systems for the discovery of selective human aldosterone synthase (CYP11B2) and 11β-hydroxylase (CYP11B1) inhibitors.. Molecular and Cellular Endocrinology 217:1-2, 249-254
CrossRef1412
Javed Butler, Ghazanfar Khadim, Kimberly M. Paul, Stacy F. Davis, Marvin W. Kronenberg, Don B. Chomsky, Richard N. Pierson, John R. Wilson. (2004) Selection of patients for heart transplantationin the current era of heart failure therapy. Journal of the American College of Cardiology 43:5, 787-793
CrossRef1413
Susan M Garthwaite, Ellen G McMahon. (2004) The evolution of aldosterone antagonists. Molecular and Cellular Endocrinology 217:1-2, 27-31
CrossRef1414
Robin L. Smith, Sandhya Pruthi, Lorraine A. Fitzpatrick. (2004) Evaluation and Management of Breast Pain. Mayo Clinic Proceedings 79:3, 353-372
CrossRef1415
R GORMAN, B JACKSON, J GORMANIII. (2004) The potential role of ventricular compressive therapy. Surgical Clinics of North America 84:1, 45-59
CrossRef1416
G.William Dec. (2004) Management of heart failure: crossing boundary over to the surgical country. Surgical Clinics of North America 84:1, 1-25
CrossRef1417
Gian Paolo Rossi. (2004) Primary aldosteronism: A needle in a haystack or a yellow cab on fifth avenue?. Current Hypertension Reports 6:1, 1-4
CrossRef1418
L EDMUNDSJR. (2004) Reading tarot cards. Surgical Clinics of North America 84:1, 323-331
CrossRef1419
Dahai Wang, Yun-He Liu, Xiao-Ping Yang, Nour-Eddine Rhaleb, Jiang Xu, Edward Peterson, Amy E Rudolph, Oscar A Carretero. (2004) Role of a selective aldosterone blocker in mice with chronic heart failure. Journal of Cardiac Failure 10:1, 67-73
CrossRef1420
S WESTABY. (2004) Coronary revascularization in ischemic cardiomyopathy. Surgical Clinics of North America 84:1, 179-199
CrossRef1421
Yoshihiko Seino. (2004) Back to the Future: Pathophysiology and Therapeutic Strategies in Heart Failure. Journal of Nippon Medical School 71:6, 421-425
CrossRef1422
Satoru Komura, Masaomi Chinushi, Michiko Kudo, Takashi Saikawa, Yasutaka Tanabe, Hiroshi Furushima, Takashi Washizuka, Makoto Kodama, Hirotaka Oda, Seiichi Miyajima, Fumiaki Masani, Yutaka Igarashi, Minoru Murata, Yoshifusa Aizawa. (2004) Potential Candidates for Cardiac Resynchronization Therapy in Japanese Patients With Idiopathic Dilated Cardiomyopathy. Circulation Journal 68:12, 1104-1109
CrossRef1423
Atsushi Sugiyama, Yoshioki Satoh, Akira Takahara, Kentaro Ando, Kai Wang, Sachiko Honsho, Yuji Nakamura, Keitaro Hashimoto. (2004) Electropharmacological Effects of a Spironolactone Derivative, Potassium Canrenoate, Assessed in the Halothane-Anesthetized Canine Model. Journal of Pharmacological Sciences 96:4, 436-443
CrossRef1424
Rosemary S. Bubien, Elizabeth A. Ching, G. Neal Kay. (2004) Cardiac Defibrillation and Resynchronization Therapies. AACN Clinical Issues: Advanced Practice in Acute and Critical Care 15:3, 340-361
CrossRef1425
Gillian M Keating, Greg L Plosker. (2004) Eplerenone. Drugs 64:23, 2689-2707
CrossRef1426
Takayoshi TSUTAMOTO. (2004) Mineralocorticoid receptor antagonist spironolactone improves left ventricular remodeling in patients with congestive heart failure and acute myocardial infarction. Folia Pharmacologica Japonica 124:2, 90-100
CrossRef1427
Atsuhisa SATO, Takao SARUTA. (2004) Aldosterone-Induced Organ Damage: Plasma Aldosterone Level and Inappropriate Salt Status. Hypertension Research 27:5, 303-310
CrossRef1428
Sushma A Mengi, Naranjan S Dhalla. (2004) Carnitine Palmitoyltransferase-I, a New Target for the Treatment of Heart Failure. American Journal of Cardiovascular Drugs 4:4, 201-209
CrossRef1429
Adelle Dawson, Justine I Davies, Allan D Struthers. (2004) The role of aldosterone in heart failure and the clinical benefits of aldosterone blockade. Expert Review of Cardiovascular Therapy 2:1, 29-36
CrossRef1430
Sandra L. Lowery, Regina Massaro, Clyde W. Yancy,. (2004) Advances in the Management of Acute and Chronic Decompensated Heart Failure. Lippincott's Case Management 9:1, 4-18
CrossRef1431
Young-Sam Lee, Jeong-A Kim, Koung Li Kim, Hyung-Suk Jang, Jeong-Min Kim, Jae-Young Lee, In-Soon Shin, Jung-Sun Lee, Wonhee Suh, Jin-Ho Choi, Eun-Seok Jeon, Jonghoe Byun, Duk-Kyung Kim. (2004) Aldosterone Upregulates Connective Tissue Growth Factor Gene Expression via p38 MAPK Pathway and Mineralocorticoid Receptor in Ventricular Myocytes. Journal of Korean Medical Science 19:6, 805
CrossRef1432
ANNE S. KANDERIAN, AJAY BHARGAVA, GARY S. FRANCIS. 2004. General Treatment of Diastolic Heart Failure. , 415-427.
CrossRef1433
Masaki ASAI, Toshiaki MONKAWA, Takeshi MARUMO, Seiichi FUKUDA, Mihoko TSUJI, Jun YOSHINO, Hiroshi KAWACHI, Fujio SHIMIZU, Matsuhiko HAYASHI, Takao SARUTA. (2004) Spironolactone in Combination with Cilazapril Ameliorates Proteinuria and Renal Interstitial Fibrosis in Rats with Anti-Thy-1 Irreversible Nephritis. Hypertension Research 27:12, 971-978
CrossRef1434
Sandra L. Lowery, Regina Massaro, Clyde W. Yancy. (2004) Advances in the Management of Acute and Chronic Decompensated Heart Failure. Lippincott's Case Management 9:Supplement, S1-S15
CrossRef1435
John E. Macdonald, Allan D. Struthers. (2004) What is the optimal serum potassium level in cardiovascular patients?. Journal of the American College of Cardiology 43:2, 155-161
CrossRef1436
Minoru YOSHIYAMA, Takashi OMURA, Jyunichi YOSHIKAWA. (2004) Additive improvement of left ventricular remodeling by aldosterone receptor blockade with eplerenone and angiotensin II type 1 receptor antagonist in rats with myocardial infarction. Folia Pharmacologica Japonica 124:2, 83-89
CrossRef1437
Massimo Volpe. (2004) Evidence-Based Indications in Hypertensive Patients. High Blood Pressure & Cardiovascular Prevention 11:1, 1-7
CrossRef1438
C. E. Mogensen, M. E. Cooper. (2004) Diabetic renal disease: from recent studies to improved clinical practice. Diabetic Medicine 21:1, 4-17
CrossRef1439
Riccardo Sarzani, Paolo Dess??-Fulgheri, Alessandro Rappelli. (2004) Angiotensin Receptor Blockers and Target-Organ Protection Beyond Blood Pressure Control. High Blood Pressure & Cardiovascular Prevention 11:2, 65-73
CrossRef1440
Norifumi Hirao, Taisei Mikami, Hisao Onozuka, Satoshi Yamada, Kaoru Komuro, Sanae Kaga, Mamiko Inoue, Hiroshi Okamoto, Akira Kitabatake. (2004) Prognostic Significance of Left Ventricular Diastolic Dysfunction Assessed by Color M-mode Doppler Echocardiography in Patients With Chronic Left Ventricular Systolic Dysfunction. Journal of Echocardiography 2:3, 68-77
CrossRef1441
Paola Stella, Giada Bigatti, Laura Tizzoni, Cristina Barlassina, Chiara Lanzani, Giuseppe Bianchi, Daniele Cusi. (2004) Association between aldosterone synthase (CYP11B2) polymorphism and left ventricular mass in human essential hypertension. Journal of the American College of Cardiology 43:2, 265-270
CrossRef1442
Yoshiyu TAKEDA. (2004) Pleiotropic Actions of Aldosterone and the Effects of Eplerenone, a Selective Mineralocorticoid Receptor Antagonist. Hypertension Research 27:11, 781-789
CrossRef1443
Hugues Bader, Stephane Garrigue, Stephane Lafitte, Sylvain Reuter, Pierre Jaïs, Michel Haïssaguerre, Jacques Bonnet, Jacques Clementy, Raymond Roudaut. (2004) Intra-left ventricular electromechanical asynchrony. Journal of the American College of Cardiology 43:2, 248-256
CrossRef1444
Nicholas L M Cruden, David E Newby. (2004) Angiotensin Antagonism in Patients with Heart Failure. American Journal of Cardiovascular Drugs 4:6, 345-353
CrossRef1445
Ileana L Piña. (2003) A better survival for women with heart failure? it's not so simple…. Journal of the American College of Cardiology 42:12, 2135-2138
CrossRef1446
Anthony N DeMaria, Ori Ben-Yehuda, Daniel Berman, Gregory K Feld, Barry H Greenberg, James D Knoke, Kirk U Knowlton, Wilbur Y.W Lew, Sotirios Tsimikas. (2003) Highlights of the year in JACC 2003. Journal of the American College of Cardiology 42:12, 2156-2166
CrossRef1447
Yasunori Ohbayashi, Takayoshi Tsutamoto, Tomoko Sakaguchi, Toshinari Tanaka, Toshiyuki Kanamori, Hiroshi Yokohama, Gensyo Sichiri, Daisuke Hukai, Tabito Okabayashi, Tomoya Ozawa, Chitose Ishii, Takashi Tsutsui, Keijin Ohno, Masato Ohnishi, Atsuyuki Wada. (2003) Effect of an Angiotensin II Type 1 Receptor Blocker, Valsartan, on Neurohumoral Factors in Patients with Hypertension: Comparison with a Long-Acting Calcium Channel Antagonist, Amlodipine. Journal of Cardiovascular Pharmacology 42, S71-S74
CrossRef1448
DAN M. RODEN. (2003) Antiarrhythmic Drugs:. Pacing and Clinical Electrophysiology 26:12, 2340-2348
CrossRef1449
Karin Malmqvist, K. Peter ??hman, Lars Lind, Fredrik Nystr??m, Thomas Kahan. (2003) Long-Term Effects of Irbesartan and Atenolol on the Renin-Angiotensin-Aldosterone System in Human Primary Hypertension. Journal of Cardiovascular Pharmacology 42:6, 719-726
CrossRef1450
Angelo Auricchio, Christoph Stellbrink, Christian Butter, Stefan Sack, Jürgen Vogt, Anand Ramdat Misier, Dirk Böcker, Michael Block, Johannes H Kirkels, Andrew Kramer, Etienne Huvelle. (2003) Clinical efficacy of cardiac resynchronization therapy using left ventricular pacing in heart failure patients stratified by severity of ventricular conduction delay. Journal of the American College of Cardiology 42:12, 2109-2116
CrossRef1451
Luigi Sacca, Raffaele Napoli, Antonio Cittadini. (2003) Growth hormone, acromegaly, and heart failure: an intricate triangulation. Clinical Endocrinology 59:6, 660-671
CrossRef1452
Rajan Krishnamani, Mohamad El-Zaru, David DeNofrio. (2003) Contemporary medical, surgical, and device therapies for end-stage heart failure. Current Treatment Options in Cardiovascular Medicine 5:6, 487-499
CrossRef1453
Arthur M Feldman. (2003) The emerging role of pharmacogenomics in the treatment of patients with heart failure. The Annals of Thoracic Surgery 76:6, S2246-S2253
CrossRef1454
Elizabeth Bisinov, James H Mitchell, Craig T January. (2003) Potassium andlong QT syndrome. Journal of the American College of Cardiology 42:10, 1783-1784
CrossRef1455
Sheila A Doggrell. (2003) Are implantable cardioverter-defribrillators always superior to amiodarone?. Expert Opinion on Pharmacotherapy 4:11, 2111-2114
CrossRef1456
Scott D. Solomon, Marc A. Pfeffer. (2003) Aldosterone antagonism and myocardial infarction. Journal of the American College of Cardiology 42:9, 1674-1676
CrossRef1457
Stefan Viktor Vormfelde, Gerhard Burckhardt, Alexandra Zirk, Leszek Wojnowski, Jürgen Brockmöller. (2003) Pharmacogenomics of diuretic drugs: data on rare monogenic disorders and on polymorphisms and requirements for further research. Pharmacogenomics 4:6, 701-734
CrossRef1458
MG Gama, G Rocha. (2003) The CHARM programme. The Lancet 362:9396, 1676
CrossRef1459
Kelli L. Davis, Jean M. Nappi. (2003) The cardiovascular effects of eplerenone, a selective aldosterone-receptor antagonist. Clinical Therapeutics 25:11, 2647-2668
CrossRef1460
David Joyce, Matthias Loebe, George P. Noon, Susan McRee, Robert Southard, Larry Thompson, Christian Skrabal, Keith Youker, Guillermo Torre-Amione. (2003) Revascularization and ventricular restoration in patients with ischemic heart failure: the STICH trial. Current Opinion in Cardiology 18:6, 454-457
CrossRef1461
Ole Dyg Pedersen, Bente Brendorp, Lars Køber, Christian Torp-Pedersen. (2003) Prevalence, Prognostic Significance, and Treatment of Atrial Fibrillation in Congestive Heart Failure With Particular Reference to the DIAMOND-CHF Study. Congestive Heart Failure 9:6, 333-340
CrossRef1462
Michael Stowasser, Richard D Gordon, Thanuja G Gunasekera, Diane C Cowley, Gregory Ward, Colin Archibald, B Mark Smithers. (2003) High rate of detection of primary aldosteronism, including surgically treatable forms, after ???non-selective??? screening of hypertensive patients. Journal of Hypertension 21:11, 2149-2157
CrossRef1463
Daniela Fraccarollo, Paolo Galuppo, Steven Hildemann, Michael Christ, Georg Ertl, Johann Bauersachs. (2003) Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction. Journal of the American College of Cardiology 42:9, 1666-1673
CrossRef1464
Daniel E. Forman, Michael W. Rich. (2003) Heart Failure in the Elderly. Congestive Heart Failure 9:6, 311-323
CrossRef1465
WH Wilson Tang, Gary S Francis. (2003) Novel pharmacological treatments for heart failure. Expert Opinion on Investigational Drugs 12:11, 1791-1801
CrossRef1466
John JV McMurray, Marc A Pfeffer, Karl Swedberg, Christopher B Granger, Salim Yusuf. (2003) The CHARM programme. The Lancet 362:9396, 1678-1679
CrossRef1467
(2003) 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. Journal of Hypertension 21:11, 1983-1992
CrossRef1468
NABIL EL-SHERIF, GIOIA TURITTO. (2003) Risk Stratification and Management of Sudden Cardiac Death:. Journal of Cardiovascular Electrophysiology 14:10, 1113-1119
CrossRef1469
Markus Kellner, Angela Peiter, Mathias Hafner, Martin Feuring, Michael Christ, Martin Wehling, Elisabeth Falkenstein, Ralf Losel. (2003) Early aldosterone up-regulated genes: New pathways for renal disease?. Kidney International 64:4, 1199-1207
CrossRef1470
Linda R Peterson, Kenneth B Schechtman, Gregory A Ewald, Edward M Geltman, Lisa de las Fuentes, Timothy Meyer, Pamela Krekeler, Martha L Moore, Joseph G Rogers. (2003) Timing of cardiac transplantation in patients with heart failure receiving β-adrenergic blockers. The Journal of Heart and Lung Transplantation 22:10, 1141-1148
CrossRef1471
Jose Geraldo Mill, Maria da Conceicao Milanez, Micheline Monteiro de Resende, Maria da Gloria S Gomes, Claudia Mendes Leite. (2003) Spironolactone prevents cardiac collagen proliferation after myocardial infarction in rats. Clinical and Experimental Pharmacology and Physiology 30:10, 739-744
CrossRef1472
Michiel J. Janse. (2003) A brief history of sudden cardiac death and its therapy. Pharmacology & Therapeutics 100:1, 89-99
CrossRef1473
Veronique Sebille, Eric Bellissant. (2003) Sequential methods and group sequential designs for comparative clinical trials. Fundamental and Clinical Pharmacology 17:5, 505-516
CrossRef1474
Issam Zineh, Richard S. Schofield, Julie A. Johnson. (2003) The Evolving Role of Nesiritide in Advanced or Decompensated Heart Failure. Pharmacotherapy 23:10, 1266-1280
CrossRef1475
Jay Lakkis, Wei X. Lu, Matthew R. Weir. (2003) RAAS escape: A real clinical entity that may be important in the progression of cardiovascular and renal disease. Current Hypertension Reports 5:5, 408-417
CrossRef1476
K. BENDTZEN, P. R. HANSEN, K. RIENECK, . (2003) Spironolactone inhibits production of proinflammatory cytokines, including tumour necrosis factor-alpha and interferon-gamma, and has potential in the treatment of arthritis. Clinical and Experimental Immunology 134:1, 151-158
CrossRef1477
Ellen D. Burgess, Yves Lacourciére, Luis M. Ruilope-Urioste, Suzanne Oparil, Jay H. Kleiman, Scott Krause, Barbara Roniker, Clement Maurath. (2003) Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension. Clinical Therapeutics 25:9, 2388-2404
CrossRef1478
Sheila Doggrell. (2003) Should the aldosterone-receptor antagonist – eplerenone – be used after acute myocardial infarction with left ventricular dysfunction?. Expert Opinion on Pharmacotherapy 4:9, 1605-1607
CrossRef1479
Fabiana Roveda, Holly R Middlekauff, Maria Urbana P.B Rondon, Soraya F Reis, Márcio Souza, Luciano Nastari, Antonio Carlos P Barretto, Eduardo M Krieger, Carlos Eduardo Negrão. (2003) The effects of exercise training on sympathetic neural activation in advanced heart failure. Journal of the American College of Cardiology 42:5, 854-860
CrossRef1480
Annie Rochetaing, Catherine Chapon, Laurent Marescaux, Anne Le Bouil, Alain Furber, Paul Kreher. (2003) Potential beneficial as well as detrimental effects of chronic treatment with lisinopril and (or) spironolactone on isolated hearts following low-flow ischemia in normal and infarcted rats. Canadian Journal of Physiology and Pharmacology 81:9, 864-872
CrossRef1481
Tera D. Moore, James J. Nawarskas, Joe R. Anderson. (2003) Eplerenone. Heart Disease 5:5, 354-363
CrossRef1482
Marc A Pfeffer, Karl Swedberg, Christopher B Granger, Peter Held, John JV McMurray, Eric L Michelson, Bertil Olofsson, Jan Östergren, Salim Yusuf. (2003) Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. The Lancet 362:9386, 759-766
CrossRef1483
R. S Fredericks, N. L Constantino. (2003) Skeletal Mineralization: Understood as the Integration of Proximate and Ultimate Causation. The Endocrinologist 13:5, 381-393
CrossRef1484
William E. Chavey, Barry E. Bleske, John M. Nicklas. (2003) Controversies in the Use of Beta Blockers in Heart Failure. Congestive Heart Failure 9:5, 255-262
CrossRef1485
Michael Stowasser, Richard D Gordon. (2003) Primary aldosteronism: from genesis to genetics. Trends in Endocrinology & Metabolism 14:7, 310-317
CrossRef1486
Patrick M McCarthy. (2003) Ventricular aneurysms, shock, and late follow-up in patients with heart failure. The Journal of Thoracic and Cardiovascular Surgery 126:2, 323-325
CrossRef1487
Adrian F Hernandez, Christopher M O'Connor. (2003) Sparing a little may save a lot. Journal of the American College of Cardiology 42:4, 709-711
CrossRef1488
W YOUNG. (2003) Primary aldosteronism ? treatment options. Growth Hormone & IGF Research 13, S102-S108
CrossRef1489
C. Anton, A. R. Cox, R. D. S. Watson, R. E. Ferner. (2003) The safety of spironolactone treatment in patients with heart failure. Journal of Clinical Pharmacy and Therapeutics 28:4, 285-287
CrossRef1490
Brian F. McBride, C. Michael White. (2003) Acute Decompensated Heart Failure: A Contemporary Approach to Pharmacotherapeutic Management. Pharmacotherapy 23:8, 997-1020
CrossRef1491
Nathalie Thilly, Serge Briancon, Yves Juilliere, Edith Dufay, Faiez Zannad. (2003) Improving ACE inhibitor use in patients hospitalized with systolic heart failure: a cluster randomized controlled trial of clinical practice guideline development and use. Journal of Evaluation in Clinical Practice 9:3, 373-382
CrossRef1492
Steven J. Hussein, John R. Teerlink. (2003) Novel pharmacologic therapy of heart failure. Current Treatment Options in Cardiovascular Medicine 5:4, 321-335
CrossRef1493
Richard F. Wright. (2003) Therapies for preventing heart failure. Current Treatment Options in Cardiovascular Medicine 5:4, 337-343
CrossRef1494
Michael Domanski, James Norman, Bertram Pitt, Mark Haigney, Stephen Hanlon, Eliot Peyster. (2003) Diuretic use, progressive heart failure, and death in patients in the studies of left ventricular dysfunction (SOLVD). Journal of the American College of Cardiology 42:4, 705-708
CrossRef1495
Bente Brendorp, Ole Dyg Pedersen, Hanne Elming, Lars Køber, Christian Torp-Pedersen. (2003) Can antiarrhythmic drugs save lives in patients with congestive heart failure?. Expert Review of Cardiovascular Therapy 1:2, 191-202
CrossRef1496
Amar Mohammad Salam. (2003) Selective aldosterone blockade with eplerenone in patients with congestive heart failure. Expert Opinion on Investigational Drugs 12:8, 1423-1427
CrossRef1497
R. E. Gilbert, H. Krum, J. Wilkinson-Berka, D. J. Kelly. (2003) The renin-angiotensin system and the long-term complications of diabetes: pathophysiological and therapeutic considerations. Diabetic Medicine 20:8, 607-621
CrossRef1498
(2003) Eplerenone in Patients with Left Ventricular Dysfunction. New England Journal of Medicine 349:1, 88-89
Full Text1499
Robert L. Scott. (2003) Is Heart Failure in African Americans a Distinct Entity?. Congestive Heart Failure 9:4, 193-196
CrossRef1500
Philip Hansten. (2003) Reply. Journal of the American College of Cardiology 42:2, 397-398
CrossRef1501
Rubin Zhang, Judy Crump, Efrain Reisin. (2003) Regression of left ventricular hypertrophy is a key goal of hypertension management. Current Hypertension Reports 5:4, 301-308
CrossRef1502
Wilbert S. Aronow. (2003) Epidemiology, Pathophysiology, Prognosis, and Treatment of Systolic and Diastolic Heart Failure in Elderly Patients. Heart Disease 5:4, 279-294
CrossRef1503
Domemic A. Sica, Todd W.B. Gehr, Clyde Yancy. (2003) Hyperkalemia, Congestive Heart Failure, and Aldosterone Receptor Antagonism. Congestive Heart Failure 9:4, 224-229
CrossRef1504
Eleanor Davies, Scott M MacKenzie. (2003) Extra-adrenal production of corticosteroids. Clinical and Experimental Pharmacology and Physiology 30:7, 437-445
CrossRef1505
Ursula C. Brewster, John F. Setaro, Mark A. Perazella. (2003) The Renin-Angiotensin-Aldosterone System: Cardiorenal Effects and Implications for Renal and Cardiovascular Disease States. The American Journal of the Medical Sciences 326:1, 15-24
CrossRef1506
Antonio Pacifico, Philip D. Henry. (2003) Structural Pathways and Prevention of Heart Failure and Sudden Death. Journal of Cardiovascular Electrophysiology 14:7, 764-774
CrossRef1507
WALTER F. KERWIN, OFFIR PAZ. (2003) Cardiac Resynchronization Therapy: Overcoming Ventricular Dyssynchrony in Dilated Heart Failure. Cardiology in Review 11:4, 221-239
CrossRef1508
Rosaire P. Gray, John S. Yudkin. 2003. Clinical Features and Treatment of Coronary Heart Disease in Diabetes. .
CrossRef1509
Michael W. Rich. (2003) Drug Therapy Of Heart Failure in the Elderly. The American Journal of Geriatric Cardiology 12:4, 235-242
CrossRef1510
Michel F Rossier, Olivier Lesouhaitier, Emeline Perrier, Liliane Bockhorn, Alberto Chiappe, Nathalie Lalevée. (2003) Aldosterone regulation of T-type calcium channels. The Journal of Steroid Biochemistry and Molecular Biology 85:2-5, 383-388
CrossRef1511
Todd S. Perlstein, Eveline M. Oestreicher, Gail K. Adler. (2003) Role for aldosterone in cardiovascular injury. Current Opinion in Endocrinology and Diabetes 10:3, 191-196
CrossRef1512
Atsushi Kambara, Bethany J. Holycross, Peter Wung, Brandon Schanbacher, Sarbani Ghosh, Sylvia A. McCune, John A. Bauer, Pawel Kwiatkowski. (2003) Combined Effects of Low-dose Oral Spironolactone and Captopril Therapy in a Rat Model of Spontaneous Hypertension and Heart Failure. Journal of Cardiovascular Pharmacology 41:6, 830-837
CrossRef1513
Maryanne Crowther. (2003) Optimal Management of Outpatients With Heart Failure Using Advanced Practice Nurses in a Hospital-Based Heart Failure Center. Journal of the American Academy of Nurse Practitioners 15:6, 260-265
CrossRef1514
Shlomo Keidar, Tony Hayek, Marielle Kaplan, Elsa Pavlotzky, Shadi Hamoud, Raymond Coleman, Michael Aviram. (2003) Effect of Eplerenone, a Selective Aldosterone Blocker, on Blood Pressure, Serum and Macrophage Oxidative Stress, and Atherosclerosis in Apolipoprotein E–Deficient Mice. Journal of Cardiovascular Pharmacology 41:6, 955-963
CrossRef1515
Bruce W. Lytle. (2003) The role of coronary revascularization in the treatment of ischemic cardiomyopathy. The Annals of Thoracic Surgery 75:6, S2-S5
CrossRef1516
David S. Geller. (2003) Activating and inactivating mutations of the human mineralocorticoid receptor. Current Opinion in Endocrinology and Diabetes 10:3, 186-190
CrossRef1517
Michelle Kittleson, Shelley Hurwitz, Monica R Shah, Anju Nohria, Eldrin Lewis, Michael Givertz, James Fang, John Jarcho, Gilbert Mudge, Lynne W Stevenson. (2003) Development of circulatory-renal limitations to angiotensin-converting enzyme inhibitors identifies patients with severe heart failure and early mortality. Journal of the American College of Cardiology 41:11, 2029-2035
CrossRef1518
F Mouquet, S Susen, E Van Belle, C Bauters, B Jude. (2003) Thérapie cellulaire et insuffisance cardiaque. La Revue de Médecine Interne 24:6, 401-404
CrossRef1519
L Tilson, B McGowan, M Ryan, M Barry. (2003) Cost-effectiveness of spironolactone in patients with severe heart failure. Irish Journal of Medical Science 172:2, 70-72
CrossRef1520
Keith D Aaronson, Himanshu Patel, Francis D Pagani. (2003) Patient selection for left ventricular assist device therapy. The Annals of Thoracic Surgery 75:6, S29-S35
CrossRef1521
S. Fenwick. (2003) Aldactone therapy in a peritoneal dialysis patient. Nephrology Dialysis Transplantation 18:6, 1232-1232
CrossRef1522
M. J. Hausmann. (2003) Reply. Nephrology Dialysis Transplantation 18:6, 1232-b-1233
CrossRef1523
Jessup, Mariell, Brozena, Susan, . (2003) Heart Failure. New England Journal of Medicine 348:20, 2007-2018
Full Text1524
Wilbert S. Aronow. (2003) Treatment of Heart Failure in Older Persons.. Congestive Heart Failure 9:3, 142-147
CrossRef1525
S. Raja Laskar, Daniel L. Dries. (2003) The prognostic significance of renal dysfunction in patients with chronic systolic heart failure. Current Cardiology Reports 5:3, 205-210
CrossRef1526
Keith Norris, Charles Vaughn. (2003) The role of renin–angiotensin– aldosterone system inhibition in chronic kidney disease. Expert Review of Cardiovascular Therapy 1:1, 51-63
CrossRef1527
Ali Ahmed. (2003) Use of spironolactone in heart failure patients receiving angiotensin-converting enzyme inhibitors and beta-blockers. Journal of the American College of Cardiology 41:10, 1851-1852
CrossRef1528
Subodh Verma, Violet G Yuen, Mitesh Badiwala, Todd J Anderson, John H McNeill. (2003) Working heart function in diabetes is not improved by spironolactone treatment. Canadian Journal of Physiology and Pharmacology 81:5, 493-496
CrossRef1529
Mitja Lainscak, Alojz Horvat, Irena Keber. (2003) The management of patients with heart failure in a Slovenian community hospital: What has changed between 1997 and 2000?. Wiener Klinische Wochenschrift 115:10, 334-339
CrossRef1530
Henry Krum, Danny Liew. (2003) New developments in the pharmacological treatment of chronic heart failure. Expert Opinion on Investigational Drugs 12:5, 751-757
CrossRef1531
Jan A Staessen, Jiguang Wang, Giuseppe Bianchi, Willem H Birkenhäger. (2003) Essential hypertension. The Lancet 361:9369, 1629-1641
CrossRef1532
Anupama Mohanram, Robert D Toto. (2003) Outcome studies in diabetic nephropathy. Seminars in Nephrology 23:3, 255-271
CrossRef1533
S.Adam Strickberger, John D Hummel, Thomas G Bartlett, Howard I Frumin, Claudio D Schuger, Scott L Beau, Cynthia Bitar, Fred Morady. (2003) Amiodarone versus implantable cardioverter-defibrillator:randomized trial in patients with nonischemicdilated cardiomyopathy and asymptomaticnonsustained ventricular tachycardia—AMIOVIRT. Journal of the American College of Cardiology 41:10, 1707-1712
CrossRef1534
Soccorso Capomolla. (2003) Reply. Journal of the American College of Cardiology 41:10, 1850-1851
CrossRef1535
Bobbi L. Hoppe, Denise D. Hermann. (2003) Sex differences in the causes and natural history of heart failure. Current Cardiology Reports 5:3, 193-199
CrossRef1536
Masao Endoh. (2003) The therapeutic potential of novel cardiotonic agents. Expert Opinion on Investigational Drugs 12:5, 735-750
CrossRef1537
Andrew D. Feingold, David DeNofrio. (2003) Management issues for patients with coronary artery disease and heart failure. Current Cardiology Reports 5:3, 216-222
CrossRef1538
Mandeep R Mehra, Patricia A Uber, Gary S Francis. (2003) Heart failure therapy at a crossroad: are there limits to the neurohormonal model?. Journal of the American College of Cardiology 41:9, 1606-1610
CrossRef1539
Pitt, Bertram, Remme, Willem, Zannad, Faiez, Neaton, James, Martinez, Felipe, Roniker, Barbara, Bittman, Richard, Hurley, Steve, Kleiman, Jay, Gatlin, Marjorie, . (2003) Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction. New England Journal of Medicine 348:14, 1309-1321
Full Text1540
Jessup, Mariell, . (2003) Aldosterone Blockade and Heart Failure. New England Journal of Medicine 348:14, 1380-1382
Full Text1541
Emmanuel L. Bravo. (2003) Aldosterone and specific aldosterone receptor antagonists in hypertension and cardiovascular disease. Current Hypertension Reports 5:2, 122-125
CrossRef1542
Jay H. Kleiman. (2003) Drug Development and the Heart Hospital. The American Heart Hospital Journal 1:2, 188-191
CrossRef1543
John M Flack, Suzanne Oparil, J.Howard Pratt, Barbara Roniker, Susan Garthwaite, Jay H Kleiman, Yonghong Yang, Scott L Krause, Diane Workman, Elijah Saunders. (2003) Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. Journal of the American College of Cardiology 41:7, 1148-1155
CrossRef1544
M. W. S. Martin. (2003) Treatment of congestive heart failure - a neuroendocrine disorder. Journal of Small Animal Practice 44:4, 154-160
CrossRef1545
Lisa C Costello-Boerrigter, Guido Boerrigter, John C Burnett. (2003) Revisiting salt and water retention: new diuretics, aquaretics, and natriuretics. Medical Clinics of North America 87:2, 475-491
CrossRef1546
Richard J. Auchus. (2003) Aldo is back: recent advances and unresolved controversies in hyperaldosteronism. Current Opinion in Nephrology and Hypertension 12:2, 153-158
CrossRef1547
Arnold M Katz. (2003) Pathophysiology of heart failure: identifying targets for pharmacotherapy. Medical Clinics of North America 87:2, 303-316
CrossRef1548
Charles T. Stier, Seth Koenig, Davis Y. Lee, Mohit Chawla, William H. Frishman. (2003) Aldosterone and Aldosterone Antagonism in Cardiovascular Disease. Heart Disease 5:2, 102-118
CrossRef1549
S RAJAGOPALAN, B PITT. (2003) Aldosterone as a target in congestive heart failure. Medical Clinics of North America 87:2, 441-457
CrossRef1550
G.Michael Felker, Raymond L Benza, A.Bleakley Chandler, Jeffrey D Leimberger, Michael S Cuffe, Robert M Califf, Mihai Gheorghiade, Christopher M O’Connor. (2003) Heart failure etiology and response tomilrinone in decompensated heart failure. Journal of the American College of Cardiology 41:6, 997-1003
CrossRef1551
Hassan N. Ibrahim, Thomas H. Hostetter. (2003) Aldosterone in renal disease. Current Opinion in Nephrology and Hypertension 12:2, 159-164
CrossRef1552
James H. O’Keefe, Jared T. Lurk, Ravindra C. Kahatapitiya, Janet A. Haskin. (2003) The renin-angiotensin-aldosterone system as a target in coronary disease. Current Atherosclerosis Reports 5:2, 124-130
CrossRef1553
Domenic A. Sica. (2003) Aldosterone Receptor Blockade: A Therapy Resurrected. Heart Disease 5:2, 85-88
CrossRef1554
John G.F Cleland. (2003) β-Blockers for heart failure: why, which, when, and where. Medical Clinics of North America 87:2, 339-371
CrossRef1555
Philip A Poole-Wilson. (2003) ACE inhibitors and ARBs in chronic heart failure: the established, the expected, and the pragmatic. Medical Clinics of North America 87:2, 373-389
CrossRef1556
Gian Paolo Rossi. (2003) Dual ACE and NEP Inhibitors: A Review of the Pharmacological Properties of MDL 100,240. Cardiovascular Drug Reviews 21:1, 51-66
CrossRef1557
Ragavendra R Baliga, Jagat Narula. (2003) Pharmacogenomics of congestive heart failure. Medical Clinics of North America 87:2, 569-578
CrossRef1558
Chetan Varma, Sanjay Sharma, Sam Firoozi, William J McKenna, Jean-Claude Daubert. (2003) Atriobiventricular pacing improves exercise capacity in patients with heart failure and intraventricular conduction delay. Journal of the American College of Cardiology 41:4, 582-588
CrossRef1559
Grant Howard, Murray Barclay, Chris Florkowski, Grant Moore, Anne Roche. (2003) Lack of Clinically Significant Interference by Spironolactone With the AxSym Digoxin II Assay. Therapeutic Drug Monitoring 25:1, 112-113
CrossRef1560
Shu Kasama, Takuji Toyama, Hisao Kumakura, Yoshiaki Takayama, Shuichi Ichikawa, Tadashi Suzuki, Masahiko Kurabayashi. (2003) Effect of spironolactone on cardiacsympathetic nerve activity and left ventricular remodeling in patients with dilated cardiomyopathy. Journal of the American College of Cardiology 41:4, 574-581
CrossRef1561
Anthony F. Jerant, Rahman Azari, Carmen Martinez, Thomas S. Nesbitt. (2003) A Randomized Trial of Telenursing to Reduce Hospitalization for Heart Failure: Patient-Centered Outcomes and Nursing Indicators. Home Health Care Services Quarterly 22:1, 1-20
CrossRef1562
J WLODARCZYK, A KEOGH, K SMITH, C MCCOSKER. (2003) CHART: Congestive cardiac failure in hospitals, an Australian review of treatment. Heart, Lung and Circulation 12:2, 94-102
CrossRef1563
Takashi Satoh, Haruka Munakata, Ken-ichi Fujita, Shinji Itoh, Shungo Itoh, Tetsuya Kamataki, Itsuo Yoshizawa. (2003) Studies on the Interactions between Drug and Estrogen. II. On the Inhibitory Effect of 29 Drugs Reported to Induce Gynecomastia on the Oxidation of Estradiol at C-2 or C-17. Biological & Pharmaceutical Bulletin 26:5, 695-700
CrossRef1564
Biykem Bozkurt, Ildiko Agoston, A.A Knowlton. (2003) Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines. Journal of the American College of Cardiology 41:2, 211-214
CrossRef1565
Mariell Jessup. (2003) The less familiar face of heart failure. Journal of the American College of Cardiology 41:2, 224-226
CrossRef1566
Sonia Goineau, Danielle Pape, Pascal Guillo, Marie-Paule Ramée, Eric Bellissant. (2003) Combined Effects of Enalapril and Spironolactone in Hamsters With Dilated Cardiomyopathy. Journal of Cardiovascular Pharmacology 41:1, 49-59
CrossRef1567
Robert E. Lamb, Jon Folstad. (2003) Aldosterone Receptor Antagonists: Focus on Eplerenone. Progress in Cardiovascular Nursing 18:1, 54-59
CrossRef1568
Elijah Saunders, James R. Gavin. (2003) Blockade of the Renin-Angiotensin System in African Americans With Hypertension and Cardiovascular Disease. The Journal of Clinical Hypertension 5:1, 12-17
CrossRef1569
Carlos Alberto Mandarim-de-Lacerda, Leila Maria Meirelles Pereira. (2003) The effects of spironolactone monotherapy on blood pressure and myocardial remodeling in spontaneously hypertensive rats: A stereological study. Journal of Biomedical Science 10:1, 50-57
CrossRef1570
Stuart D. Russell, Tracy DeWald. (2003) Vasopressin Receptor Antagonists. American Journal of Cardiovascular Drugs 3:1, 13-20
CrossRef1571
Nicholas D Palmer, Barbara Appleton, Erwin A Rodrigues. (2003) Specialist Nurse-Led Intervention in Outpatients with Congestive Heart Failure. Disease Management & Health Outcomes 11:11, 693-698
CrossRef1572
W.H.Wilson Tang, Gary S. Francis. (2003) Spironolactone inchronic heart failure:all’s well that ends well**Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.. Journal of the American College of Cardiology 41:2, 215-216
CrossRef1573
Ali Ahmed. (2003) American College of Cardiology/American Heart Association Chronic Heart Failure Evaluation and Management Guidelines: Relevance to the Geriatric Practice. Journal of the American Geriatrics Society 51:1, 123-126
CrossRef1574
Masaki Yamato, Tatsuya Sasaki, Kaduo Honda, Masayuki Fukuda, Osamu Akutagawa, Masakuni Okamoto, Takaharu Hayashi. (2003) Effects of Torasemide on Left Ventricular Function and Neurohumoral Factors in Patients With Chronic Heart Failure. Circulation Journal 67:5, 384-390
CrossRef1575
A. M. Katz. (2003) Heart failure: a hemodynamic disorder complicated by maladaptive proliferative responses. Journal of Cellular and Molecular Medicine 7:1, 1-10
CrossRef1576
Amy E. Rudolph, Ricardo Rocha, Ellen G. McMahon. 2003. Eplerenone, Pharmacological Effects of. , 556-561.
CrossRef1577
Alice Stanton. (2003) Therapeutic Potential of Renin Inhibitors in the Management of Cardiovascular Disorders. American Journal of Cardiovascular Drugs 3:6, 389-394
CrossRef1578
Toshio OGIHARA, Kunio HIWADA, Shigeto MORIMOTO, Hiroaki MATSUOKA, Masayuki MATSUMOTO, Shuichi TAKISHITA, Kazuaki SHIMAMOTO, Kazuyuki SHIMADA, Isao ABE, Yasuyoshi OUCHI, Hisaichiro TSUKIYAMA, Shigehiro KATAYAMA, Yutaka IMAI, Hiromichi SUZUKI, Katsuhiko KOHARA, Kohya OKAISHI, Hiroshi MIKAMI. (2003) Guidelines for Treatment of Hypertension in the Elderly. 2002 Revised Version.. Hypertension Research 26:1, 1-36
CrossRef1579
Danny Liew, Henry Krum. (2003) Aldosterone Receptor Antagonists for Hypertension. Drugs 63:19, 1963-1972
CrossRef1580
ALI ERDOGAN, SEBASTIAN RUECKLEBEN, HARALD H. TILLMANNS, BERND WALDECKER. (2003) Proportion of Candidates for Cardiac Resynchronization Therapy. Pacing and Clinical Electrophysiology 26:1p2, 152-154
CrossRef1581
Elizabeth A. McGlynn. (2003) An Evidence-Based National Quality Measurement and Reporting System. Medical Care 41:Supplement, I-8-I-15
CrossRef1582
Iris Feria, Israel Pichardo, Patricia Juárez, Victoria Ramírez, Marco A González, Norma Uribe, Romeo García-Torres, Fernando López-Casillas, Gerardo Gamba, Norma A Bobadilla. (2003) Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity. Kidney International 63:1, 43-52
CrossRef1583
Gillian M Keating, Blair Jarvis. (2003) Carvedilol. Drugs 63:16, 1697-1741
CrossRef1584
Mehmet Akbulut, Yilmaz Özbay, Erdogan Ilkay, Ilgin Karaca, Nadi Arslan. (2003) Effects of Spironolactone and Metoprolol on QT Dispersion in Heart Failere. Japanese Heart Journal 44:5, 681-392
CrossRef1585
Ralf Lösel, Martin Feuring, Martin Wehling. (2002) Non-genomic aldosterone action: from the cell membrane to human physiology. The Journal of Steroid Biochemistry and Molecular Biology 83:1-5, 167-171
CrossRef1586
Mark T Kearney, Keith A.A Fox, Amanda J Lee, Robin J Prescott, Ajay M Shah, Philip D Batin, Wazir Baig, Stephen Lindsay, Timothy S Callahan, William E Shell, Dwain L Eckberg, Azfar G Zaman, Simon Williams, James M.M Neilson, James Nolan. (2002) Predicting death due to progressive heart failure in patients with mild-to-moderate chronic heart failure. Journal of the American College of Cardiology 40:10, 1801-1808
CrossRef1587
Joseph H. Flaherty, John E. Morley, Donald J. Murphy, Michael R. Wasserman. (2002) The Development of Outpatient Clinical Glidepathsâ¢. Journal of the American Geriatrics Society 50:11, 1886-1901
CrossRef1588
Paul A Gould, David M Kaye. (2002) Clinical treatment regimens for chronic heart failure: a review. Expert Opinion on Pharmacotherapy 3:11, 1569-1576
CrossRef1589
Lwin Lwin Tin, D. Gareth Beevers, Gregory Y. H. Lip. (2002) Hypertension, left ventricular hypertrophy, and sudden death. Current Cardiology Reports 4:6, 449-457
CrossRef1590
Mandeep R. Mehra, Patricia A. Uber, Srinivasa Potluri. (2002) Renin Angiotensin Aldosterone and Adrenergic Modulation in Chronic Heart Failure: Contemporary Concepts. The American Journal of the Medical Sciences 324:5, 267-275
CrossRef1591
Edward P. Havranek, Frederick A. Masoudi, Debra L. Ralston, Nancy J. Susman, Harlan M. Krumholz, Jane P. Taylor. (2002) Future Challenges in Quality Improvement in Heart Failure. Congestive Heart Failure 8:6, 342-345
CrossRef1592
Domenic A. Sica. (2002) Eplerenone: A New Aldosterone Receptor Antagonist-Are the FDA's Restrictions Appropriate?. The Journal of Clinical Hypertension 4:6, 441-445
CrossRef1593
Michel F Rousseau, Olivier Gurné, Daniel Duprez, Walter Van Mieghem, Annie Robert, Sylvie Ahn, Laurence Galanti, Jean-Marie Ketelslegers. (2002) Beneficial neurohormonal profile of spironolactone in severe congestive heart failure. Journal of the American College of Cardiology 40:9, 1596-1601
CrossRef1594
Sara Paul. (2002) Balancing Diuretic Therapy in Heart Failure: Loop Diuretics, Thiazides, and Aldosterone Antagonists. Congestive Heart Failure 8:6, 307-312
CrossRef1595
Mohamad El-Zaru, David Nofrio. (2002) End-stage heart failure: Surgical therapy and implantable devices. Current Treatment Options in Cardiovascular Medicine 4:6, 511-520
CrossRef1596
Levy, Daniel, Kenchaiah, Satish, Larson, Martin G., Benjamin, Emelia J., Kupka, Michelle J., Ho, Kalon K.L., Murabito, Joanne M., Vasan, Ramachandran S., . (2002) Long-Term Trends in the Incidence of and Survival with Heart Failure. New England Journal of Medicine 347:18, 1397-1402
Full Text1597
Sonia Goineau, Danielle Pape, Pascal Guillo, Marie-Paule Ramée, Eric Bellissant. (2002) Combined Effects of Metoprolol and Spironolactone in Dilated Cardiomyopathic Hamsters. Journal of Cardiovascular Pharmacology 40:4, 543-553
CrossRef1598
Jens Gaedeke, Nancy A. Noble, Wayne A. Border. (2002) Angiotensin II and progressive renal insufficiency. Current Hypertension Reports 4:5, 403-407
CrossRef1599
M. Bureik, M. Lisurek, R. Bernhardt. (2002) The Human Steroid Hydroxylases CYP11B1 and CYP11B2. Biological Chemistry 383:10, 1537-1551
CrossRef1600
Amy E Rudolph, Ellen G McMahon. (2002) Emerging therapies for heart failure. Expert Opinion on Emerging Drugs 7:2, 247-258
CrossRef1601
Mário L de Lemos. (2002) How to survive the survival plots. The Lancet 360:9337, 954
CrossRef1602
Eugene S. Smith, Suzanne Trussell, Laura J. Mencer. (2002) Prevention of heart failure. Current Opinion in Cardiology 17:5, 512-517
CrossRef1603
B DEWAZIERES, C CAROL, J VERNAZ, B LEDESERT, A LEPAPE, C JEANDEL, J FOURCADE. (2002) Analyse de la prescription médicamenteuse chez les plus de 65 ans en Languedoc-RoussillonStudy of drug prescribing in patients older than 65 in Languedoc-Roussillon. La Revue de Médecine Interne 23:9, 745-750
CrossRef1604
Silke Isabelle Trautmann, Michael Kloss, Angelo Auricchio. (2002) Cardiac resynchronization therapy. Current Cardiology Reports 4:5, 371-378
CrossRef1605
John W. Funder. (2002) Central effects of mineralocorticoids on blood pressure: new answers, new questions. Journal of Hypertension 20:9, 1715-1716
CrossRef1606
Eric Lim, Stephen Large, John Wallwork, Jayan Parameshwar. (2002) Candidate selection for heart transplantation in the 21st Century. Current Opinion in Organ Transplantation 7:3, 221-225
CrossRef1607
Sonia Goineau, Sophie Nisse-Durgeat, Danielle Pape, Pascal Guillo, Marie-Paule Ramée, Eric Bellissant. (2002) Systemic and Regional Hemodynamic and Cardiac Remodeling Effects of Candesartan in Dilated Cardiomyopathic Hamsters With Advanced Congestive Heart Failure. Journal of Cardiovascular Pharmacology 40:2, 189-200
CrossRef1608
Tae-Yon Chun, Laura Bloem, J.Howard Pratt. (2002) Spironolactone increases integrin β3 gene expression in kidney and heart muscle cells. Molecular and Cellular Endocrinology 194:1-2, 175-182
CrossRef1609
Edward Lakatos. (2002) Designing complex group sequential survival trials. Statistics in Medicine 21:14, 1969-1989
CrossRef1610
Mariantonietta Cicoira, Luisa Zanolla, Andrea Rossi, Giorgio Golia, Lorenzo Franceschini, Giovanna Brighetti, Paolo Marino, Piero Zardini. (2002) Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure. Journal of the American College of Cardiology 40:2, 304-310
CrossRef1611
Yuwen Hu, Jeffrey P. Carpenter, Albert T. Cheung. (2002) Life-Threatening Hyperkalemia: A Complication of Spironolactone for Heart Failure in a Patient with Renal Insufficiency. Anesthesia & Analgesia 95:1, 39-41
CrossRef1612
Lindsay Brown, Sheila A Doggrell. (2002) Present and future pharmacotherapy for heart failure. Expert Opinion on Pharmacotherapy 3:7, 915-930
CrossRef1613
Cecilia Linde, Christophe Leclercq, Steve Rex, Stephane Garrigue, Thomas Lavergne, Serge Cazeau, William McKenna, Melissa Fitzgerald, Jean-Claude Deharo, Christine Alonso, Stuart Walker, Frieder Braunschweig, Christophe Bailleul, Jean-Claude Daubert. (2002) Long-term benefits of biventricular pacing in congestive heart failure: results from the MUltisite STimulation in cardiomyopathy (MUSTIC) study. Journal of the American College of Cardiology 40:1, 111-118
CrossRef1614
Hare, Joshua M., . (2002) Cardiac-Resynchronization Therapy for Heart Failure. New England Journal of Medicine 346:24, 1902-1905
Full Text1615
Peter B Ehmer, Matthias Bureik, Rita Bernhardt, Ursula Müller, Rolf W Hartmann. (2002) Development of a test system for inhibitors of human aldosterone synthase (CYP11B2): screening in fission yeast and evaluation of selectivity in V79 cells. The Journal of Steroid Biochemistry and Molecular Biology 81:2, 173-179
CrossRef1616
A CLARK. (2002) What's new in& Heart failure. Medicine 30:6, 1-4
CrossRef1617
Malcolm Man-Son-Hing, Andreas Laupacis, Keith O'Rourke, Frank J. Molnar, Jeffery Mahon, Karen B. Y. Chan, George Wells. (2002) Determination of the Clinical Importance of Study Results. A Review. Journal of General Internal Medicine 17:6, 469-476
CrossRef1618
Chyung S. Cook, Liming Zhang. (2002) Interconversion pharmacokinetics of eplerenone, a selective aldosterone blocker, and its lactone-ring open form. Journal of Pharmaceutical Sciences 91:6, 1383-1389
CrossRef1619
Eberhard Ritz, Ralf Dikow, Marcin Adamzcak, Martin Zeier. (2002) Congestive Heart Failure Due to Systolic Dysfunction: The Cinderella of Cardiovascular Management in Dialysis Patients. Seminars in Dialysis 15:3, 135-140
CrossRef1620
S Stewart. (2002) The current cost of heart failure to the National Health Service in the UK. European Journal of Heart Failure 4:3, 361-371
CrossRef1621
A CLARK. (2002) Investigation and Treatment of Heart Failure. Medicine 30:5, 98-103
CrossRef1622
Rajesh Sharma, Madalyn N. Davidoff. (2002) Oxidative Stress and Endothelial Dysfunction in Heart Failure. Congestive Heart Failure 8:3, 165-172
CrossRef1623
Paul J. Hauptman, Daniel Woods, Marc R. Pritzker. (2002) Novel use of a short-acting intravenous beta blocker in combination with inotropic therapy as a bridge to chronic oral beta blockade in patients with advanced heart failure. Clinical Cardiology 25:5, 247-249
CrossRef1624
Judy W.M. Cheng. (2002) Nesiritide: Review of Clinical Pharmacology and Role in Heart Failure Management. Heart Disease 4:3, 199-203
CrossRef1625
R. L. Grant, G. M. Batty, R. Aggarwal, D. Lowe, J. M. Potter, M. G. Pearson, A. Oborne, S. H. D. Jackson. (2002) National sentinel clinical audit of evidence-based prescribing for older people: methodology and development. Journal of Evaluation in Clinical Practice 8:2, 189-198
CrossRef1626
Wendy M. Book. (2002) Carvedilol: A Nonselective ? Blocking Agent With Antioxidant Properties. Congestive Heart Failure 8:3, 173-190
CrossRef1627
Gourang P. Patel, Jennifer B. Kasiar. (2002) Syndrome of Inappropriate Antidiuretic Hormone–Induced Hyponatremia Associated with Amiodarone. Pharmacotherapy 22:5, 649-651
CrossRef1628
Bernard Swynghedauw. (2002) Myocardial remodelling: pharmacological targets. Expert Opinion on Investigational Drugs 11:5, 661-674
CrossRef1629
Ralf M. Lösel, Martin Feuring, Elisabeth Falkenstein, Martin Wehling. (2002) Nongenomic effects of aldosterone: cellular aspects and clinical implications. Steroids 67:6, 493-498
CrossRef1630
Masafumi Kitakaze, Tetsuo Minamino. (2002) Cellular mechanisms for the treatment of chronic heart failure: the nitric oxide- and adenosine-dependent pathways. Expert Opinion on Emerging Drugs 7:1, 99-110
CrossRef1631
A.Mark Richards, John G Lainchbury, M.Gary Nicholls, Richard W Troughton, Timothy G Yandle. (2002) BNP in hormone-guided treatment of heart failure. Trends in Endocrinology & Metabolism 13:4, 151-155
CrossRef1632
D Collette, Petra A Thürmann. (2002) Angiotensin II Type 1 receptor antagonists in chronic heart failure. Expert Opinion on Investigational Drugs 11:5, 705-716
CrossRef1633
Kevin C Allman, Leslee J Shaw, Rory Hachamovitch, James E Udelson. (2002) Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. Journal of the American College of Cardiology 39:7, 1151-1158
CrossRef1634
Martin St. John Sutton, Victor A. Ferrari. (2002) Prevention of left ventricular remodeling after myocardial infarction. Current Treatment Options in Cardiovascular Medicine 4:2, 97-108
CrossRef1635
Berthold Hocher, Michael Godes, Jan Olivier, Joachim Weil, Thomas Eschenhagen, Torsten Slowinski, Hans-H. Neumayer, Christian Bauer, Martin Paul, Yigal M. Pinto. (2002) Inhibition of left ventricular fibrosis by tranilast in rats with renovascular hypertension. Journal of Hypertension 20:4, 745-751
CrossRef1636
Deepak R. Talreja, Gregory W. Barsness. (2002) Endocrine heart disease. Current Treatment Options in Cardiovascular Medicine 4:2, 181-192
CrossRef1637
H. C. Routledge, S. Chowdhary, J. N. Townend. (2002) Heart rate variability - a therapeutic target?. Journal of Clinical Pharmacy and Therapeutics 27:2, 85-92
CrossRef1638
(2002) Left Ventricular Assist Device. New England Journal of Medicine 346:13, 1023-1025
Full Text1639
(2002) Sudden Death Due to Cardiac Arrhythmias. New England Journal of Medicine 346:12, 946-947
Full Text1640
Chyung S. Cook, Liming Zhang. (2002) Atypical dose-route-dependent food effects of eplerenone in the dog: Presence of food effects following intravenous dosing and lack of food effects of following oral dosing. Journal of Pharmaceutical Sciences 91:3, 607-614
CrossRef1641
M. C. Deng, J. M. A. Smits, M. Packer. (2002) Selecting patients for heart transplantation: which patients are too well for transplant?. Current Opinion in Cardiology 17:2, 137-144
CrossRef1642
Susan L. Ravnan, Marcus C. Ravnan, Prakash C. Deedwania. (2002) Diuretic Resistance and Strategies to Overcome Resistance in Patients With Congestive Heart Failure. Congestive Heart Failure 8:2, 80-85
CrossRef1643
CHARLES T. STIER, PRAVEEN N. CHANDER, RICARDO ROCHA. (2002) Aldosterone as a Mediator in Cardiovascular Injury. Cardiology in Review 10:2, 97-107
CrossRef1644
(2002) Spironolactone and ACE Inhibition in Chronic Renal Failure. New England Journal of Medicine 346:6, 456-457
Full Text1645
Douglas L. Mann, Anita Deswal, Biykem Bozkurt, Guillermo Torre-Amione. (2002) N
EW THERAPEUTICS FOR CHRONIC HEART FAILURE . Annual Review of Medicine 53:1, 59-74
CrossRef1646
David Hürlimann, Frank Enseleit, Georg Noll, Thomas F. Lüscher, Frank Ruschitzka. (2002) Endothelin antagonists and heart failure. Current Hypertension Reports 4:1, 85-92
CrossRef1647
Andrey K. Gurevich, Sandor A. Falk, Raphael A. Nemenoff, Howard D. Weinberger, Sandra N. Summer, Mona Rizeq, Patricia E. Gengaro, Martin P. Bedigian, Robert W. Schrier. (2002) Effects of Angiotensin Receptor Blockade on Haemodynamics and Gene Expression after Myocardial Infarction. Drugs in R & D 3:4, 239-249
CrossRef1648
Anil K. Bidani, Karen A. Griffin. (2002) Long-term renal consequences of hypertension for normal and diseased kidneys. Current Opinion in Nephrology and Hypertension 11:1, 73-80
CrossRef1649
W.H Wilson Tang, Randall H Vagelos, Yin-Gail Yee, Claude R Benedict, Kathy Willson, Charles L Liss, Patrice LaBelle, Michael B Fowler. (2002) Neurohormonal and clinical responses to high- versus low-dose enalapril therapy in chronic heart failure. Journal of the American College of Cardiology 39:1, 70-78
CrossRef1650
Kanu Chatterjee. (2002) Congestive Heart Failure. American Journal of Cardiovascular Drugs 2:1, 1-6
CrossRef1651
Ayan R. Patel, Marvin A. Konstam. (2002) Recent Advances in the Treatment of Heart Failure. Circulation Journal 66:2, 117-117
CrossRef1652
Leila Maria Meirelles Pereira, C.A. Mandarim-de-Lacerda. (2002) Myocardial changes after spironolactone in spontaneous hypertensive rats. A laser scanning confocal microscopy study. Journal of Cellular and Molecular Medicine 6:1, 49-57
CrossRef1653
Patricia A. Howard, Marvin I. Dunn. (2002) Severe Heart Failure in the Elderly. Drugs & Aging 19:4, 249-256
CrossRef1654
Andrew Owen. (2002) Optimising the Use of ??-Blockers in Older Patients with Heart Failure. Drugs & Aging 19:9, 671-684
CrossRef1655
Christophe Leclercq, David A. Kass. (2002) Retiming the failing heart: principles and current clinical status of cardiac resynchronization. Journal of the American College of Cardiology 39:2, 194-201
CrossRef1656
Karlheinz Seidl, Monika Rameken, Margit Vater, Jochen Senges. (2002) Cardiac Resynchronization Therapy in Patients with Chronic Heart Failure. American Journal of Cardiovascular Drugs 2:4, 219-226
CrossRef1657
Arnold M Katz. (2002) Proliferative Signaling and Disease Progression in Heart Failure. Circulation Journal 66:3, 225-225
CrossRef1658
Yoshio IWASHIMA, Takeshi HORIO, Setsuko KURODA, Shuichi TAKISHITA, Yuhei KAWANO. (2002) Influence of Plasma Aldosterone on Left Ventricular Geometry and Diastolic Function in Treated Essential Hypertension. Hypertension Research 25:1, 49-56
CrossRef1659
Luke A. Bruns, Charles E. Canter. (2002) Should ??-Blockers be Used for the Treatment of Pediatric Patients with Chronic Heart Failure?. Pediatric Drugs 4:12, 771-778
CrossRef1660
Johann Bauersachs, Marina Heck, Daniela Fraccarollo, Steven K Hildemann, Georg Ertl, Martin Wehling, Michael Christ. (2002) Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction. Journal of the American College of Cardiology 39:2, 351-358
CrossRef1661
Pierre Corvol, Pierre-Francois Plouin. (2002) Antagonistes des r??cepteurs de l???angiotensine II. Drugs 62:Special Issue 1, 53-64
CrossRef1662
Robert Kelly, Anthony Staines, Ron MacWalter, Peter Stonebridge, Hugh Tunstall-Pedoe, Allan D Struthers. (2002) The prevalence of treatable left ventricular systolic dysfunction in patients who present with noncardiac vascular episodes. Journal of the American College of Cardiology 39:2, 219-224
CrossRef1663
Rakesh Sharma, Stefan D. Anker. (2002) Immune and Neurohormonal Pathways in Chronic Heart Failure. Congestive Heart Failure 8:1, 23-48
CrossRef1664
Emile Levy, Pierre Levy. (2002) Pharmacoeconomic Considerations in Assessing and Selecting Congestive Heart Failure Therapies. PharmacoEconomics 20:14, 963-977
CrossRef1665
Ricardo Rocha, Gordon H. Williams. (2002) Rationale for the Use of Aldosterone Antagonists in Congestive Heart Failure. Drugs 62:5, 723-731
CrossRef1666
Atsuhisa SATO, Matsuhiko HAYASHI, Takao SARUTA. (2002) Relative Long-Term Effects of Spironolactone in Conjunction with an Angiotensin-Converting Enzyme Inhibitor on Left Ventricular Mass and Diastolic Function in Patients with Essential Hypertension.. Hypertension Research 25:6, 837-842
CrossRef1667
Andrew R. Houghton. (2002) Angiotensin II Receptor Antagonists in Chronic Heart Failure. Drugs 62:10, 1433-1440
CrossRef1668
Barry M Massie. (2002) Neurohormonal blockade in chronic heart failure. Journal of the American College of Cardiology 39:1, 79-82
CrossRef1669
Steven J. Lavine, Steven D. Gellman. (2002) Treatment of Heart Failure in Patients with Diabetes Mellitus. Drugs 62:2, 285-307
CrossRef1670
Weber, Karl T., . (2001) Aldosterone in Congestive Heart Failure. New England Journal of Medicine 345:23, 1689-1697
Full Text1671
Cohn, Jay N., Tognoni, Gianni, . (2001) A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure. New England Journal of Medicine 345:23, 1667-1675
Full Text1672
John Funder. (2001) MINERALOCORTICOIDS AND CARDIAC FIBROSIS: THE DECADE IN REVIEW. Clinical and Experimental Pharmacology and Physiology 28:12, 1002-1006
CrossRef1673
Paul R. Kalra, Rakesh Sharma. (2001) Absolute, not relative, changes are important when interpreting trial data. Journal of the American College of Cardiology 38:7, 2132
CrossRef1674
Susanne Trost, Martin LeWinter. (2001) Diabetic cardiomyopathy. Current Treatment Options in Cardiovascular Medicine 3:6, 481-492
CrossRef1675
P Duc. (2001) Insuffisance cardiaque du sujet âgéCongestive heart failure in the elderly. Annales de Cardiologie et d'Angéiologie 50:7-8, 426-433
CrossRef1676
Kevin F Fox. (2001) A critical evaluation of the NICE guidelines for post-myocardial infarction prophylaxis. Expert Opinion on Pharmacotherapy 2:12, 2079-2084
CrossRef1677
JoAnn Lindenfeld. (2001) Management of Congestive Heart Failure. Primary Care Case Reviews 4:4, 161-170
CrossRef1678
Susan Ammon. (2001) Managing Patients with Heart Failure. American Journal of Nursing 101:12, 34-40
CrossRef1679
William L. Lombardi, Edward M. Gilbert. (2001) Carvedilol in the failing heart. Clinical Cardiology 24:12, 757-766
CrossRef1680
Carl V. Leier. (2001) Dilated cardiomyopathy. Current Treatment Options in Cardiovascular Medicine 3:6, 451-462
CrossRef1681
Janis Carelock, Angela P. Clark. (2001) Heart Failure: Pathophysiologic Mechanisms. American Journal of Nursing 101:12, 26-33
CrossRef1682
J L Blackshea, G L Schwartz. (2001) Step care therapy for hypertension in diabetic patients.. Mayo Clinic Proceedings 76:12, 1266-1274
CrossRef1683
Andreas Kjaer, Birger Hesse. (2001) Heart failure and neuroendocrine activation: diagnostic, prognostic and therapeutic perspectives. Clinical Physiology 21:6, 661-672
CrossRef1684
STEVEN E. LIPSHULTZ, STACY D. FISHER, WYMAN W. LAI, TRACIE L. MILLER. (2001) Cardiovascular Monitoring and Therapy for HIV-Infected Patients. Annals of the New York Academy of Sciences 946:1, 236-273
CrossRef1685
Salmaan Kanji, John W. Devlin, Krista A. Piekos, Eric Racine. (2001) Recombinant Human Activated Protein C, Drotrecogin Alfa (activated): A Novel Therapy for Severe Sepsis. Pharmacotherapy 21:11, 1389-1402
CrossRef1686
Antonis A. Armoundas, Richard Wu, George Juang, Eduardo Marbán, Gordon F. Tomaselli. (2001) Electrical and structural remodeling of the failing ventricle. Pharmacology & Therapeutics 92:2-3, 213-230
CrossRef1687
Thomas D. Giles, Gary E. Sander. (2001) Beyond the Usual Strategies for Blood Pressure Reduction: Therapeutic Considerations and Combination Therapies. The Journal of Clinical Hypertension 3:6, 346-353
CrossRef1688
Philip A. Poole-Wilson. (2001) Implications of recent heart failure trials for patients with hypertension. Current Cardiology Reports 3:6, 504-510
CrossRef1689
Barry Greenberg. (2001) Treatment of Heart Failure: State of the Art and Prospectives. Journal of Cardiovascular Pharmacology 38, S59-S63
CrossRef1690
Masaru Hayashi, Takayoshi Tsutamoto, Atsuyuki Wada, Keiko Maeda, Naoko Mabuchi, Takashi Tsutsui, Toshiki Matsui, Masanori Fujii, Takehiro Matsumoto, Takashi Yamamoto, Hajime Horie, Masato Ohnishi, Masahiko Kinoshita. (2001) Relationship between transcardiac extraction of aldosterone and left ventricular remodeling in patients with first acute myocardial infarction: extracting aldosterone through the heart promotes ventricular remodeling after acute myocardial infarction. Journal of the American College of Cardiology 38:5, 1375-1382
CrossRef1691
Kathleen M. Parker, Nancy Houston Miller, Robert F. DeBusk. (2001) Optimal Use of Spironolactone for Treatment of Heart Failure. Congestive Heart Failure 7:6, 315-318
CrossRef1692
C McMurray. (2001) Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone. The American Journal of Medicine 111:7, 587
CrossRef1693
Gian Paolo Rossi, Martina Cavallin, Gastone G Nussdorfer, Achille C Pessina. (2001) The Endothelin-Aldosterone Axis and Cardiovascular Diseases. Journal of Cardiovascular Pharmacology 38, S49-S52
CrossRef1694
Anthony F. Jerant, Rahman Azari, Thomas S. Nesbitt. (2001) Reducing the Cost of Frequent Hospital Admissions for Congestive Heart Failure. Medical Care 39:11, 1234-1245
CrossRef1695
Jasmina Varagic, Dinko Susic, Edward D. Frohlich. (2001) Heart, aging, and hypertension. Current Opinion in Cardiology 16:6, 336-341
CrossRef1696
R Faris, MD Flather, H Purcell, MY Heinan, P Poole-Wilson, AJS Coats, Rajaa Faris. 2001. Diuretics for heart failure. .
CrossRef1697
Robert E. Shaddy. (2001) Optimizing treatment for chronic congestive heart failure in children. Critical Care Medicine 29:Supplement, S237-S240
CrossRef1698
A Al-Ahmad. (2001) Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. Journal of the American College of Cardiology 38:4, 955-962
CrossRef1699
Michael Stowasser. (2001) New Perspectives On The Role Of Aldosterone Excess In Cardiovascular Disease. Clinical and Experimental Pharmacology and Physiology 28:10, 783-791
CrossRef1700
G Michaud. (2001) Should an abnormal serum potassium concentration be considered a correctable cause of cardiac arrest?. Journal of the American College of Cardiology 38:4, 1224-1225
CrossRef1701
E Rashba. (2001) Temporal decline in defibrillation thresholds with an active pectoral lead system. Journal of the American College of Cardiology 38:4, 1150-1155
CrossRef1702
(2001) Effects of Beta-Blocker Therapy in Severe Chronic Heart Failure. New England Journal of Medicine 345:13, 998-999
Full Text1703
Chrysostomou, Anastasia, Becker, Gavin, . (2001) Spironolactone in Addition to ACE Inhibition to Reduce Proteinuria in Patients with Chronic Renal Disease. New England Journal of Medicine 345:12, 925-926
Full Text1704
Burkhard Hornig, Helmut Drexler. (2001) Reversal of endothelial dysfunction in humans. Coronary Artery Disease 12:6, 463-473
CrossRef1705
David S. Geller. (2001) A mineralocorticoid receptor mutation causing human hypertension. Current Opinion in Nephrology and Hypertension 10:5, 661-665
CrossRef1706
Howard H. Weitz. (2001) PERIOPERATIVE CARDIAC COMPLICATIONS. Medical Clinics of North America 85:5, 1151-1169
CrossRef1707
John A. Delyani, Ricardo Rocha, Chyung S. Cook, Dwain S. Tolbert, Stuart Levin, Barbara Roniker, Diane L. Workman, Yuen-lung L. Sing, Brian Whelihan. (2001) Eplerenone: A Selective Aldosterone Receptor Antagonist (SARA). Cardiovascular Drug Reviews 19:3, 185-200
CrossRef1708
Ricardo Rocha, Charles T Stier. (2001) Pathophysiological effects of aldosterone in cardiovascular tissues. Trends in Endocrinology & Metabolism 12:7, 308-314
CrossRef1709
Nathaniel Winer, Michael A. Weber, James R. Sowers. (2001) The effect of antihypertensive drugs on vascular compliance. Current Hypertension Reports 3:4, 297-304
CrossRef1710
Christian Delles, Roland E. Schmieder. (2001) The Kidney in Congestive Heart Failure: Renal Adverse Event Rate of Treatment. Journal of Cardiovascular Pharmacology 38:1, 99-107
CrossRef1711
. (2001) De behandeling van decompensatio cordis: toevoeging van spironolacton. Medisch-Farmaceutische Mededelingen 39:7, 141-142
CrossRef1712
. (2001) Het effect van spironolacton op morbiditeit en mortaliteit bij patiënten met ernstig hartfalen. Medisch-Farmaceutische Mededelingen 39:7, 137-138
CrossRef1713
Anders Albåge, Jan van der Linden, Lars Bengtsson, Dan Lindblom, Göran Kennebäck, Hans Berglund. (2001) Elevations in antidiuretic hormone and aldosterone as possible causes of fluid retention in the Maze procedure. The Annals of Thoracic Surgery 72:1, 58-64
CrossRef1714
Kok-Meng Yee, Stuart D Pringle, Allan D Struthers. (2001) Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure. Journal of the American College of Cardiology 37:7, 1800-1807
CrossRef1715
ROBERT B. FELDER, JOSEPH FRANCIS, ROBERT M. WEISS, ZHI-HUA ZHANG, SHUN-GUANG WEI, ALAN KIM JOHNSON. (2001) Neurohumoral Regulation in Ischemia-Induced Heart Failure. Annals of the New York Academy of Sciences 940:1, 444-453
CrossRef1716
Celso E. Gomez-Sanchez, Elise P. Gomez-Sanchez. (2001) Role of central mineralocorticoid receptors in cardiovascular disease. Current Hypertension Reports 3:3, 263-269
CrossRef1717
Lynn Fletcher, Debera Thomas. (2001) Congestive Heart Failure: Understanding the Pathophysiology and Management. Journal of the American Academy of Nurse Practitioners 13:6, 249-257
CrossRef1718
Timothy J. Cole, David Pearce. (2001) Mineralocorticoid target genes. Current Opinion in Endocrinology & Diabetes 8:3, 118-123
CrossRef1719
Mariantonietta Cicoira, Luisa Zanolla, Andrea Rossi, Giorgio Golia, Lorenzo Franceschini, Giulio Cabrini, Alberto Bonizzato, Maristella Graziani, Stefan D Anker, Andrew J.S Coats, Piero Zardini. (2001) Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype. Journal of the American College of Cardiology 37:7, 1808-1812
CrossRef1720
Sanjay Rajagopalan, Bertram Pitt. (2001) Aldosterone antagonists in the treatment of hypertension and target organ damage. Current Hypertension Reports 3:3, 240-248
CrossRef1721
Masaru Hayashi, Takayoshi Tsutamoto, Atsuyuki Wada, Keiko Maeda, Naoko Mabuchi, Takashi Tsutsui, Hajime Horie, Masato Ohnishi, Masahiko Kinoshita. (2001) Intravenous atrial natriuretic peptide prevents left ventricular remodeling in patients with first anterior acute myocardial infarction. Journal of the American College of Cardiology 37:7, 1820-1826
CrossRef1722
Packer, Milton, Coats, Andrew J.S., Fowler, Michael B., Katus, Hugo A., Krum, Henry, Mohacsi, Paul, Rouleau, Jean L., Tendera, Michal, Castaigne, Alain, Roecker, Ellen B., Schultz, Melissa K., Staiger, Christoph, Curtin, Ellen L., DeMets, David L., . (2001) Effect of Carvedilol on Survival in Severe Chronic Heart Failure. New England Journal of Medicine 344:22, 1651-1658
Full Text1723
WB Hood, AL Dans, GH Guyatt, R Jaeschke, JJV McMurray. 2001. Digitalis for treatment of congestive heart failure in patients in sinus rhythm. .
CrossRef1724
Neville Suskin, Tej Sheth, Abdissa Negassa, Salim Yusuf. (2001) Relationship of current and past smoking to mortality and morbidity in patients with left ventricular dysfunction. Journal of the American College of Cardiology 37:6, 1677-1682
CrossRef1725
Thomas D. Giles, Gary E. Sander. (2001) Reawakening of Interest in Aldosterone and Aldosterone Antagonists: Implications for Treatment of Cardiovascular Disease. The American Journal of Geriatric Cardiology 10:3, 166-169
CrossRef1726
Sheila A Doggrell, Lindsay Brown. (2001) The spironolactone renaissance. Expert Opinion on Investigational Drugs 10:5, 943-954
CrossRef1727
Murray Epstein. (2001) Aldosterone and the hypertensive kidney: its emerging role as a mediator of progressive renal dysfunction: a paradigm shift. Journal of Hypertension 19:5, 829-842
CrossRef1728
Roopal B. Thakkar, Suzanne Oparil. (2001) Primary Aldosteronism: A Practical Approach to Diagnosis and Treatment. The Journal of Clinical Hypertension 3:3, 189-195
CrossRef1729
Gabriella Cargnelli, Lucia Trevisi, Patrizia Debetto, Sisto Luciani, Sergio Bova. (2001) Effects of Canrenone on Aorta and Right Ventricle of the Rat. Journal of Cardiovascular Pharmacology 37:5, 540-547
CrossRef1730
Pasi Tavi, Mika Laine, Matti Weckström, Heikki Ruskoaho. (2001) Cardiac mechanotransduction: from sensing to disease and treatment. Trends in Pharmacological Sciences 22:5, 254-260
CrossRef1731
James Lightwood, Kirsten E Fleischmann, Stanton A Glantz. (2001) Smoking cessation in heart failure: it is never too late. Journal of the American College of Cardiology 37:6, 1683-1684
CrossRef1732
Wolfgang Kiowski, Gabor Sütsch. (2001) The role of endothelin receptor antagonists in the treatment of chronic heart failure. Current Cardiology Reports 3:3, 232-240
CrossRef1733
Sheila A Doggrell. (2001) Carvedilol versus other β-blockers in heart failure. Expert Opinion on Investigational Drugs 10:5, 971-980
CrossRef1734
A Bouzamondo, J S Hulot, P Sanchez, M Cucherat, P Lechat. (2001) Beta-blocker treatment in heart failure. Fundamental and Clinical Pharmacology 15:2, 95-109
CrossRef1735
E McMahon. (2001) Recent studies with eplerenone, a novel selective aldosterone receptor antagonist. Current Opinion in Pharmacology 1:2, 190-196
CrossRef1736
Takayoshi Tsutamoto, Atsuyuki Wada, Keiko Maeda, Naoko Mabuchi, Masaru Hayashi, Takashi Tsutsui, Masato Ohnishi, Masahide Sawaki, Masanori Fujii, Takehiro Matsumoto, Toshiki Matsui, Masahiko Kinoshita. (2001) Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. Journal of the American College of Cardiology 37:5, 1228-1233
CrossRef1737
Murray Epstein. (2001) Aldosterone as a mediator of progressive renal disease: Pathogenetic and clinical implications. American Journal of Kidney Diseases 37:4, 677-688
CrossRef1738
Chetan Varma, AJ Camm. (2001) Pacing for heart failure. The Lancet 357:9264, 1277-1283
CrossRef1739
A. M. Katz. (2001) Crossovers between functional and proliferative signaling: key to understanding the pathophysiology and management of heart failure. Journal of Cellular and Molecular Medicine 5:2, 125-131
CrossRef1740
R. W. Troughton, A. M. Richards, M. G. Nicholls. (2001) Individualized treatment of heart failure. Internal Medicine Journal 31:3, 138-141
CrossRef1741
H Krum. (2001) New and emerging pharmacological strategies in the management of chronic heart failure. Current Opinion in Pharmacology 1:2, 126-133
CrossRef1742
Cazeau, Serge, Leclercq, Christophe, Lavergne, Thomas, Walker, Stuart, Varma, Chetan, Linde, Cecilia, Garrigue, Stéphane, Kappenberger, Lukas, Haywood, Guy A., Santini, Massimo, Bailleul, Christophe, Mabo, Philippe, Lazarus, Arnaud, Ritter, Philippe, Levy, Terry, McKenna, William, Daubert, Jean-Claude, . (2001) Effects of Multisite Biventricular Pacing in Patients with Heart Failure and Intraventricular Conduction Delay. New England Journal of Medicine 344:12, 873-880
Full Text1743
Todd W.B. Gehr, Domenic A. Sica. (2001) Hyperkalemia in Congestive Heart Failure. Congestive Heart Failure 7:2, 97-100
CrossRef1744
T. Barry Levine, Arlene B. Levine, William G. Elliott, Barbara Narins, Robert J. Stomel. (2001) Dobutamine as bridge to angiotensin-converting enzyme inhibitor-nitrate therapy in endstage heart failure. Clinical Cardiology 24:3, 231-236
CrossRef1745
Omar Ali, Hector O. Ventura. (2001) Raison d'
CrossRef1746
Pitt O. Lim, William F. Young, Thomas M. MacDonald. (2001) A review of the medical treatment of primary aldosteronism. Journal of Hypertension 19:3, 353-361
CrossRef1747
M. W. Rich. (2001) Heart Failure in the 21st Century: A Cardiogeriatric Syndrome. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 56:2, M88-M96
CrossRef1748
Thomas H. Hostetter, Mark E. Rosenberg, Hassan N. Ibrahim, Irmantas Juknevicius. (2001) Aldosterone in renal disease. Current Opinion in Nephrology and Hypertension 10:1, 105-110
CrossRef1749
M Gary Nicholls, John G Lainchbury, A Mark Richards, Richard W Troughton, Timothy G Yandle. (2001) Brain natriuretic peptide-guided therapy for heart failure. Annals of Medicine 33:6, 422-427
CrossRef1750
Jose L. Merino. (2001) Mechanisms Underlying Ventricular Arrhythmias in Idiopathic Dilated Cardiomyopathy. American Journal of Cardiovascular Drugs 1:2, 105-118
CrossRef1751
J. C. Somberg. (2001) Clinical Therapeutic Conference: Congestive Heart Failure Therapy. American Journal of Therapeutics 8:1, 65-72
CrossRef1752
Japanese Society of Hypertension Gu. (2001) Guidelines for the Management of Hypertension for General Practitioners.. Hypertension Research 24:6, 613-634
CrossRef1753
R. Isnard. (2001) Le traitement médical de l'insuffisance cardiaque chronique. Annales de Cardiologie et d Angéiologie 50:1, 30
CrossRef1754
Atsuhisa SATO, Hiroshi TAKANE, Takao SARUTA. (2001) High Serum Level of Procollagen Type III Amino-Terminal Peptide Contributes to the Efficacy of Spironolactone and Angiotensin-Converting Enzyme Inhibitor Therapy on Left Ventricular Hypertrophy in Essential Hypertensive Patients.. Hypertension Research 24:2, 99-104
CrossRef1755
Arvo Haenni, Richard Reneland, Lars Lind, Hans Lithell. (2001) Serum aldosterone changes during hyperinsulinemia are correlated to body mass index and insulin sensitivity in patients with essential hypertension. Journal of Hypertension 19:1, 107-112
CrossRef1756
Lena Brynne, John L. McNay, Hans G. Schaefer, Karl Swedberg, Curtis G. Wiltse, Mats O. Karlsson. (2001) Pharmacodynamic models for the cardiovascular effects of moxonidine in patients with congestive heart failure. British Journal of Clinical Pharmacology 51:1, 35-43
CrossRef1757
Hideaki KIDO, Yutaka OHTAKI. (2001) Torasemide (LUPRAC): A review of its pharmacological and clinical profile.. Folia Pharmacologica Japonica 118:2, 97-105
CrossRef1758
Melissa Young, Greg L. Plosker. (2001) Torasemide. PharmacoEconomics 19:6, 679-703
CrossRef1759
G. Roul, P. Bareiss. (2001) Les facteurs pronostiques de l'insuffisance cardiaque chronique. Annales de Cardiologie et d Angéiologie 50:1, 21
CrossRef1760
D Logeart. (2001) Perspectives médicamenteuses dans le traitement de l'insuffisance cardiaque. Annales de Cardiologie et d Angéiologie 50:1, 38
CrossRef1761
K. Gregory Pugh, Jeanne Y. Wei. (2001) Clinical Implications of Physiological Changes in the Aging Heart*. Drugs & Aging 18:4, 263-276
CrossRef1762
Janet Wittes. (2000) EDITORIAL. Evidence-based Cardiovascular Medicine 4:4, 79-81
CrossRef1763
Tarik M. Ramahi, Marcella D. Longo, Kate Rohlfs, Natalie Sheynberg. (2000) Effect of Heart Failure Program on Cardiovascular Drug Utilization and Dosage in Patients with Chronic Heart Failure. Clinical Cardiology 23:12, 909-914
CrossRef1764
Anis Rassi Jr, Anis Rassi, William C. Little. (2000) Chagas' Heart Disease. Clinical Cardiology 23:12, 883-889
CrossRef1765
O. Franklin, M. Burch. (2000) Applied physiology: understanding cardiac failure. Current Paediatrics 10:4, 284-288
CrossRef1766
Allan D. Struthers. (2000) Pathophysiology of aldosterone and its antagonists. Fundamental & Clinical Pharmacology 14:6, 549-552
CrossRef1767
Hector O. Ventura, Ileana L. Piña. (2000) The AHF SCENE II Preceptorship Program: Rationale and Design of an Educational Program to Optimize Management of Advanced Heart Failure. Congestive Heart Failure 6:6, 319-324
CrossRef1768
Jo E. Rodgers, J. Herbert Patterson. (2000) The Role of the Renin-Angiotensin-Aldosterone System in the Management of Heart Failure. Pharmacotherapy 20:11 Part 2, 368S-378S
CrossRef1769
Wendy A. Gattis. (2000) Practical Issues in the Treatment of Patients with Heart Failure. Pharmacotherapy 20:11 Part 2, 385S-391S
CrossRef1770
Luis M Ruilope, Vivencio Barrios, Massimo Volpe. (2000) Renal implications of the renin–angiotensin–aldosterone system blockade in heart failure. Journal of Hypertension 18:11, 1545-1551
CrossRef1771
B. McGowan, A. Heerey, M. Ryan, M. Barry. (2000) Cost of treating heart failure in an Irish teaching hospital. Irish Journal of Medical Science 169:4, 241-244
CrossRef1772
Henry Krum. (2000) New and emerging pharmacologic strategies in the management of chronic heart failure. Clinical Cardiology 23:10, 724-730
CrossRef1773
Steven R. Kayser. (2000) Spironolactone in the Management of Congestive Heart Failure. Progress in Cardiovascular Nursing 15:4, 145-148
CrossRef1774
Stein Ørn, Kenneth Dickstein. (2000) Pharmacotherapy following myocardial infarction - a review of current treatment practices. Expert Opinion on Pharmacotherapy 1:6, 1105-1116
CrossRef1775
Judith E. Soberman, Karl T. Weber. (2000) Spironolactone in congestive heart failure. Current Hypertension Reports 2:5, 451-456
CrossRef1776
Amy J. Cha, Susan E. Malecha, Kevin W. Judge. (2000) Aldosterone, a New Appreciation of Its Role in Heart Failure. Pharmacotherapy 20:9, 1107-1115
CrossRef1777
Takayoshi Tsutamoto, Atsuyuki Wada, Keiko Maeda, Naoko Mabuchi, Masaru Hayashi, Takashi Tsutsui, Masato Ohnishi, Masahide Sawaki, Masanori Fujii, Takehiro Matsumoto, Hajime Horie, Yoshihisa Sugimoto, Masahiko Kinoshita. (2000) Spironolactone inhibits the transcardiac extraction of aldosterone in patients with congestive heart failure. Journal of the American College of Cardiology 36:3, 838-844
CrossRef1778
Morag Young, John W Funder. (2000) Aldosterone and the Heart. Trends in Endocrinology & Metabolism 11:6, 224-226
CrossRef1779
James C. Sisson. (2000) Radiopharmaceuticals for Nuclear Endocrinology at the University of Michigan. Cancer Biotherapy & Radiopharmaceuticals 15:4, 305-318
CrossRef1780
H. Krum. (2000) Recent advances in the management of chronic heart failure. Australian and New Zealand Journal of Medicine 30:4, 475-482
CrossRef1781
Nancy M. Albert. (2000) Implementation Strategies to Manage Heart Failure Outcomes. AACN Clinical Issues: Advanced Practice in Acute & Critical Care 11:3, 396-411
CrossRef1782
C.-H. Hui, P-K Das, N. Horvath. (2000) Spironolactone and agranulocytosis. Australian and New Zealand Journal of Medicine 30:4, 515-515
CrossRef1783
F López-Jiménez. (2000) Update in Internal Medicine. Archives of Medical Research 31:4, 329-352
CrossRef1784
D Dostal. (2000) The cardiac renin–angiotensin system: novel signaling mechanisms related to cardiac growth and function. Regulatory Peptides 91:1-3, 1-11
CrossRef1785
Paul S Watson, Gregory M Scalia, Andrew Galbraith, Darryl J Burstow, Nicholas Bett, Constantine N Aroney. (2000) Reply. Journal of the American College of Cardiology 36:1, 305
CrossRef1786
Michael J. Domanski. (2000) Prevention of sudden cardiac death: management considerations. Current Opinion in Cardiology 15:4, 304-308
CrossRef1787
Gary S. Francis. (2000) Can we prevent congestive heart failure? Excerpts from a Symposium. Clinical Cardiology 23:S4, IV-1-IV-3
CrossRef1788
Richard D. Patten, Marvin A. Konstam. (2000) Ventricular Remodeling and the Renin Angiotensin Aldosterone System. Congestive Heart Failure 6:4, 187-192
CrossRef1789
Adam S. Betkowski, Paul J. Hauptman. (2000) Update on recent clinical trials in congestive heart failure. Current Opinion in Cardiology 15:4, 293-303
CrossRef1790
Maryann Z. Skrabal, Julie A. Stading, Kathryn A. Behmer-Miller, Daniel E. Hilleman. (2000) Advances in the Treatment of Congestive Heart Failure: New Approaches for an Old Disease. Pharmacotherapy 20:7, 787-804
CrossRef1791
Asim Hameedi, Hal L. Chadow. (2000) The promise of selective aldosterone receptor antagonists for the treatment of hypertension and congestive heart failure. Current Hypertension Reports 2:4, 378-383
CrossRef1792
Willem J. Remme. (2000) Overview of the relationship between ischemia and congestive heart failure. Clinical Cardiology 23:S4, IV-4-IV-8
CrossRef1793
John M. Nicklas, Jay N. Cohn, Bertram Pitt. (2000) What does atlas really tell us about “High” dose angiotensin-converting enzyme inhibition in heart failure?. Journal of Cardiac Failure 6:2, 165-168
CrossRef1794
Ronnie Willenhemer, Karl Swedberg. (2000) Dressing heart-failure patients on Savile Row—tailored treatment?. The Lancet 355:9220, 2012-2013
CrossRef1795
T. Barry Levine, Arlene B. Levine, Patricia Kaminski, Robert J. Stomel. (2000) Reversal of Heart Failure Remodeling in Women. Journal of Women's Health & Gender-Based Medicine 9:5, 513-519
CrossRef1796
John W. Funder. (2000) Eplerenone, a new mineralocorticoid antagonist:in vitro and in vivo studies. Current Opinion in Endocrinology & Diabetes 7:3, 138-142
CrossRef1797
Thierry H. Jemtel. (2000) Management of heart failure. Current Cardiology Reports 2:3, 221-224
CrossRef1798
Michael M. Koerner, Jean-Bernard Durand, Javier A Lafuente, George P. Noon, Guillermo Torre-Amione. (2000) Cardiac transplantation: the final therapeutic option for the treatment of heart failure. Current Opinion in Cardiology 15:3, 178-182
CrossRef1799
Kevin T. Stroupe, Melissa M. Forthofer, D. Craig Brater, Michael D. Murray. (2000) Healthcare Costs of Patients with Heart Failure Treated with Torasemide or Furosemide. PharmacoEconomics 17:5, 429-440
CrossRef1800
Kirkwood F. Adams, Kenneth L. Baughman, William G. Dec, Uri Elkayam, Alan D. Forker, Mihai Gheorghiade, Denise Hermann, Marvin A. Konstam, Peter Liu, Barry M. Massie, J. Herbert Patterson, Marc A. Silver, Lynne Warner Stevenson, Arthur M. Feldman, Jay N. Cohn, Gary S. Francis, Barry Greenberg, Marvin A. Konstam, Carl Leier, Beverly H. Lorell, Milton Packer, Bertram Pitt, Marc A. Silver, Edmund Sonnenblick, John Strobeck, Richard Walsh, Salim Yusuf. (2000) HFSA Guidelines for Management of Patients With Heart Failure Caused by Left Ventricular Systolic Dysfunction—Pharmacological Approaches. Pharmacotherapy 20:5, 495-522
CrossRef1801
Richard W Troughton, Christopher M Frampton, Timothy G Yandle, Eric A Espine, M Gary Nicholls, A Mark Richards. (2000) Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. The Lancet 355:9210, 1126-1130
CrossRef1802
John A Delyani. (2000) Mineralocorticoid receptor antagonists: The evolution of utility and pharmacology. Kidney International 57:4, 1408-1411
CrossRef1803
Dave J. van Kraaij, Rene W. Jansen, Frank W. Gribnau, Willibrord H. Hoefnagels. (2000) Diuretic Therapy in Elderly Heart Failure Patients With and Without Left Ventricular Systolic Dysfunction. Drugs & Aging 16:4, 289-300
CrossRef1804
Leslie A. Saxon, Uday N. Kumar, Teresa Marco. (2000) Heart Failure and Cardiac Resynchronization Therapies: U.S. Experience in the Year 2000. Annals of Noninvasive Electrocardiology 5:2, 188-194
CrossRef1805
Robert W Schrier, Joseph G Abdallah, Howard H D Weinberger, William T Abraham. (2000) Therapy of heart failure. Kidney International 57:4, 1418-1425
CrossRef1806
Benoît Georges, Claire Beguin, Michel Jadoul. (2000) Spironolactone and congestive heart-failure. The Lancet 355:9212, 1369-1370
CrossRef1807
Khalid Muhammad, Hector O. Ventura, Dwight D. Stapleton, Frank W. Smart. (2000) Difficult Cases in Heart Failure Marc A. Silver, MD Hector O. Ventura, MD Editors. Beneficial Effects of Aldosterone Blockade in Heart Failure. Congestive Heart Failure 6:2, 115-117
CrossRef1808
Kerryn L. Simpson, Karen J. McClellan. (2000) Losartan. Drugs & Aging 16:3, 227-250
CrossRef1809
Gunter Wolf. (2000) Free radical production and angiotensin. Current Hypertension Reports 2:2, 167-173
CrossRef1810
Marrick L. Kukin. (2000) Beta-blockers and spironolactone in heart failure. Current Cardiology Reports 2:2, 87-89
CrossRef1811
Jonathan D. Sackner-Bernstein. (2000) The myocardial matrix and the development and progression of ventricular remodeling. Current Cardiology Reports 2:2, 112-119
CrossRef1812
Lawrence Baruch, Tariq Jamil. (2000) The Role of Angiotensin Receptor Blockers in Heart Failure. Congestive Heart Failure 6:2, 103-109
CrossRef1813
Dorothea McAreavey, Derek V Exner, Ellen Leigh Curtin, Michael J Domanski. (2000) β-blockers in heart failure: recently completed and ongoing clinical trials. Expert Opinion on Investigational Drugs 9:2, 415-428
CrossRef1814
C.Allyson Walker, Fred A. Crawford, Francis G. Spinale. (2000) Myocyte contractile dysfunction with hypertrophy and failure: Relevance to cardiac surgery. The Journal of Thoracic and Cardiovascular Surgery 119:2, 388-400
CrossRef1815
William A Ghali, Jacques Cornuz. (2000) Early uptake of research findings after fast-track publication. The Lancet 355:9203, 579-580
CrossRef1816
Francis, Gary S., . (2000) ACE Inhibition in Cardiovascular Disease. New England Journal of Medicine 342:3, 201-202
Full Text1817
(2000) Spironolactone in Patients with Heart Failure. New England Journal of Medicine 342:2, 132-134
Full Text1818
Altaf Rasool, Paul M. Palevsky. (2000) Treatment of Edematous Disorders with Diuretics. The American Journal of the Medical Sciences 319:1, 25
CrossRef1819
(2000) Poster-Abstracts1. LaboratoriumsMedizin 24:10, 455-494
CrossRef1820
W BRAUN. 2000. Cardiovascular and Other Noninfectious Complications after Renal Transplantation in Adults. , 1009-1033.
CrossRef1821
Wendy Gattis, Christopher M. O??Connor. (2000) Utilisation des inhibiteurs calciques dans le traitement de l??insuffisance cardiaque. Drugs 59:Special Issue 2, 17-24
CrossRef1822
Michael Kim, Marrick Kukin. (2000) New advances in the pharmacological management of chronic heart failure. Expert Opinion on Pharmacotherapy 1:2, 261-269
CrossRef1823
Jonathan A. Abbott. 2000. Canine Dilated Cardiomyopathy. , 230-237.
CrossRef1824
Jonathan A. Abbott. 2000. Management of Chronic Congestive Heart Failure. , 170-178.
CrossRef1825
W W Parmley. (2000) Surviving heart failure: Robert L. Frye lecture.. Mayo Clinic Proceedings 75:1, 111-118
CrossRef1826
Heart Failure Society Of America. (1999) HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction—pharmacological approaches. Journal of Cardiac Failure 5:4, 357-382
CrossRef1827
Weber, Karl T., . (1999) Aldosterone and Spironolactone in Heart Failure. New England Journal of Medicine 341:10, 753-755
Full Text1828
A Mark Richards, M Gary Nicholls. (1999) Aldosterone antagonism in heart failure. The Lancet 354:9181, 789-790
CrossRef
- Letters
